<SEC-DOCUMENT>0001274737-21-000094.txt : 20210809
<SEC-HEADER>0001274737-21-000094.hdr.sgml : 20210809
<ACCEPTANCE-DATETIME>20210809171721
ACCESSION NUMBER:		0001274737-21-000094
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210809
DATE AS OF CHANGE:		20210809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXAGEN INC.
		CENTRAL INDEX KEY:			0001274737
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39049
		FILM NUMBER:		211157467

	BUSINESS ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081
		BUSINESS PHONE:		(760) 560-1501

	MAIL ADDRESS:	
		STREET 1:		1261 LIBERTY WAY
		CITY:			VISTA
		STATE:			CA
		ZIP:			92081

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXAGEN DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20031230
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exdx-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:6018f8ea-fa05-452a-adea-254786192c77,g:68b7dde8-2230-495d-984a-015fcac6c60d,d:90dcb240c7c649938129ef90b5941787--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:exdx="http://www.exagen.com/20210630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exdx-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF8zLTEtMS0xLTA_3d1bef73-1b1e-4919-9392-501582bf9a15">0001274737</ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF80LTEtMS0xLTA_55190894-0dca-4489-b287-f38736d4a691">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF81LTEtMS0xLTA_9df5b06d-bcf9-4b36-8a27-32bd0f7cddcd">2021</ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF82LTEtMS0xLTA_535e728b-6bf1-4c0d-9380-2e2accaa5619">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF83LTEtMS0xLTA_a66bf16f-e2f7-46f3-a4cd-cc0ea3df8d2c">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="idd6b73e6480747b0a96c555a0607e176_D20191101-20191130" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTExOQ_db518ce5-2992-4221-8603-2271ebaa5ba5">P24M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exdx-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i814429626dec4826a699d35e97d00de2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5780fca0aaf34dcfab553f2efb981de5_I20210806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8717a2bf86c340c089d364c29e6c135d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec6a7c2a312487caf8734b58f397e25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i366fa7cf9c3940e884aa8c8619173cc2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5150cd684b0d46ccba522709fba131b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758a0d891e3e480d95465ccb025f61f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0deb0612dda8455fad61349cd2e577de_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac5881792a74f33ac659f8310bbcd0b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72ebe96bf2e14fb788d101048eba37f6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8061b34d637b4709a07e120a85126e27_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d3c385b85e3496db450da0807647ad7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8df4d4a6e90f495da04464f80d6009ec_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0791f27cac87465e9a64cc86bd068ff1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74f91780daf468f8527681009a493cc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib27834d9ecc64761948dc8797f616336_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65e7ef5eaa61480cadeee7d277e565f2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac674a12b624346ba69c6d4c91a087c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552bc21453cb4af5b990c1672758ce50_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1218833ece7f47b482280689d529b3c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d1a0041a2247299991bb0eb2225c05_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec65931f2bd14b39bad0fda30bdea3c0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6548eab8e25b4293949c913d7e33574c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0db198013004fa19cd45a4eae00b98c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e69de6aff041908d22b9baeecf3fc3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f77899e7cb54d408a8f6746c4d36b03_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b56bc7f626845b48cb17da5717ddb00_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i979494764014402c94c0b5072500a2d6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i507cf8c3a86c47eeaa37f1c4799aabe0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb73f35a6dbe4685b6581455ef8c5cd3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd12ee06e3146ee848bb4b240212ea1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34270509c6ec4547a8c0584c3edda583_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id102a5b2a4f048f8b4f9ce799a943014_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b86b21740cf4825b079ffee255e0a30_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717e3a6bdd9d4ede925668cdc7aa8187_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib4abda3c45354b949166899b405e3a62_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dced9e9019345d899c2982db367d60d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a9723325ae40058c158c22778b76a5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic10ddfd5136e4061b9973d178e27ba18_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea277eb7cbf4254adf6026f29375664_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d8f685d9b944f60b9103e1913818ac9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6abedb7e04b40e8aeec6aa02680f33b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7128036de6754666b5f3a81736dcc5fa_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2586bfebd6614d1488d082744fec8ef5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ee787030d814685ab554a163cf5e574_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb609bc49d8411aacdd2e672d62eb26_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453f98cffb604fd48828fd1e8ee2d430_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibac162d49bd04ab38540f0d788ab7b01_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i835d56825d0a476da36bc88326650f02_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3751d07906149e5b585fd8950ac1b5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifde0bcda7e7545ae9ff38a215ba73eca_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40dd1efb9e15401da3f592bff24d5574_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68cb5038c4e341a8bb7e0d23eae19b25_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998b7cab204741c28fcd51dd94bad45f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a803537d6434bee8f5afde8a4ef80c5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic48e64747d464d9bbd1afc1bf9d6cc47_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f9aedf4a1c437d845bc8e10b3515a0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ca528d80c5424f812a294764c8b9e7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e927f12ecfb4ca884308d22fe725b51_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf77992ac8849b0b8f3496176757612_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7885defdea48b79ac4c92e06b53809_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie91517e9ab974cbd90efe111ae240752_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e0cc5e4bba4bedb4ecef0c7823eed5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i568a53683fbf488c94e44430a6963b63_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a58092b38ba40109a35c69dca20121f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if21a06f4627b43ad9babcc317f3f97d2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7956a164bef94499b35cc310c4dfa294_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871675045d654924b72a5dff008b67ed_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9092bb8a26fc4e91aaa2cd450c799ddd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a3b44a9c5c04e059b0deb00b7ec0856_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9891076fa8c64cd7a563f92569372319_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e7a7a50804f4d55974db533637b345c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0caa9d180cf9428e911a0e8958c06187_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic92986ea9525425a99124a727802cafa_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec98ad996148414b982b48ce1fb97499_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b2e1719a224e7e80ad848e2e398f17_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba69b5a6c3564f0f80195f7298100232_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcd4bbc200954114b1e61bdcf69d26ef_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ca735999a14a46b0051553431233d7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e011876b544007978e81d4e8a12381_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c5a5ab8a2e4bf7895c99d6d53c706e_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0e4213bad142eaa4399139407152d9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia28be9a1944346ff97180e2bd48e846e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af77a6c91de42baa701376938862bef_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0c42e21a78482eb4842f031387a636_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i355e8ad01573466884248e15012957d3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i997cfa266cc049a8a0eb6ce9d22ce202_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i095b975d91e844528a4ecbc0d02226ab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b212ea1c94f44ddb43e8958f910b803_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6d296eb29947729818846e34e334fe_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:JanssenPromotionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df835bc9321482ea1c21e97a45b2b46_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5cf118bed6843c49e51e3a063b2f215_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa166a05412145609609afa9045b6c36_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ab5400a6d1441c989c0987429f31c5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d57b7de558142c282a4c8a44d661825_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0ebbe6307b48fd8165e0d875dba99a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260acc2d1e664219932adbe50ba9b56c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie43b2c29a3af401db0f76f11da748e11_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i727eef9b6d6841bfafb949eedc04adc6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3bfc019a3043dfa65e9ab76ebb83ba_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748aa018ed14456e8bbd6fefdb2bb343_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0062233c30074ba2a141cbf88bac2dfc_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb7f37a50b544479a5a49d2f8a7f1de1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cbe68f2531c41b2ac7307191c02d60f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1de1f702c3940caa18e3c855c718b6f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70cd681b7da54b718ba2a94de49fe566_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee2c605c05b4d7184eee467043f7f7b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521d00286bef46b8988c748f9b09da38_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c88be424ba4421b0681115a0468ff6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3dc1550c49342788746509b902551e3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21b606f430d94e608359e908e5675881_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ebe85cfda44056a48e8c86297ff80d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4ce2fdc8a245879ca524ab3fef616f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50fdc73457e64ff58b4af00e94a3d47a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exdx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i019b55474b03417188ce0a6599b09a06_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48774ed5d6c94ea395c2ad9d1ab2ce4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf9a3c919134b408f3367b2f162100b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91228be59b0d4bbbb6dd3e4e3b5aa38f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f0253166e9425b97baa1464c6dadd8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0936318fe184480caddef482306a6003_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac65fe1c3e84b0088c92074e306b603_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdcf495c5bbc4290af9da6a68df65ef8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6b0b82d0abe422985b1fc6559a21381_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i838a40fa91e847cf8a46ed8a5c4fd73a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878741a4ebe5465789238ff029c6bb05_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b05cb96f9b4ad39ce807d4c92ff525_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3aeb264ea9c49aaa65800b5d232f669_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a352deb17e46e3a01049447545824a_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cae1ab4f7684fc9984e25a56c343ce2_D20181207-20181207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-07</xbrli:startDate><xbrli:endDate>2018-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieced59f9bfea440b98b881cd100be221_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i363ecec2e07a4f4f9429105336138bb9_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6b73e6480747b0a96c555a0607e176_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i051865121b864843a7aa6d0196c1ce5d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1bf67b90be54de7a4cb661c84afb134_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5205c3992de49bd94179b9de9cea768_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13bd35b84c84c08b97cf25c25447a01_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33be34133ab34424a1d393162ac35351_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586ccca64fab4ff3922bd68ad5ab7254_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic125d46c253c46218b4ff1c223808e5f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64e5fa2583514a499a2c2e814b73a55f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca6b551f41048dbac2cc2f24a067a81_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ce02fbc4e20421e91f360d2257a0bdf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i176ded5488ca41bf8f320b2151888cff_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4f0c91b62b144c98930aada725aeb5f_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib81bf8c979f84fd29d5b105929b0d3ce_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6063862f0049ad920ccdded39326b3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17ac12b6a47847b39613a583f3715e22_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie918642c1b394009ad0b69833a6119be_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d194d9380fc4177be4de2c4474844a3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239c9597bcdc4b76b9572e7dc62e7793_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88553bc1fc4946cfacf88eb4b595623d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21c725659c554256894e6753bca963bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9801f382d4c346349a3739ac75eb6c29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2a0e15468d14f1d800e862e526e0bd8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad87945e18794ca292bc45b973f89c11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045a54532883447b9ba4d8e5b2a6eae3_D20201110-20201110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-10</xbrli:startDate><xbrli:endDate>2020-11-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie922f6d9a6124200b1afa6562935970c_D20210325-20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15d6bb2bda3454aac07113283b3188f_I20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9460ad066b9b478eab9cd1f7a6a40ac1_D20210622-20210622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-22</xbrli:startDate><xbrli:endDate>2021-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f2162308c734d97b338ad4453278bb5_I20210622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492e5c40d7034eaf962d0469c7c795cf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071b488b09a1417c91811e6d8f3d29b3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ee8d512a0840b190f350455a2ed1a9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5761e4153746f5a98d6355c0258668_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51452bd995b44c0083d3c57b6f6acef2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9815b27e2974facbe3b603ea097a3f5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i380b31af79e04aba8a6b53172095dbb6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82819fc6d4c4f04baba439733edc724_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0298f7cc8a044f3ea0148fea59992a10_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ffae978ff094b5595bb90b4291d7670_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac35630d5b74bbdb0694e77844fc22f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0759ea92cd33439d8ee655337f3ca564_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809b83fd5e2949e98dfca51a6405bc5e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2f240e32a94e0091882c0f86aec9c2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i053c7646827546d5980da48ba6995176_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddcb859bbff74e819108a02b2f35c671_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f749fcc65a465494ce02dd6f69461e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaddaedafdc194a299eae12d2f0b746f8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c18c0730b4c4c2f89587dfd06467595_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id749abe27a0440ca809efd67793994ed_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd31cf38fcb436d84f561912752611e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53db86996c4a4b2aa8810e431ba1895c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fd1752efb344048b8a02fcfe6fb0f95_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5ea1131c9af47dd8588756554e13957_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3f62783fe24bacb1e4a648e4847e70_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9415ee637f114999b6d5d2f67f7050fa_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3f26179ffa4405bc060edb0ba198b2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia27e8ea51bc64e348a17908196ce969c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6de0d2e713746bb9c050c4ab98f4f51_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2835a9642ebd49899501526ee781c908_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2bebf6fe6604b9cac9e5fcd8f81e01b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0827b20b427b4e6ab8c7d6c7c4a5ba90_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i504e664134704f5a90ec38a184fa703b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i344fc6213f364bd0844d383c9bdfc785_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574d92d10a8b47df85aa14649bb3aa66_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7156ce287e04be6adfdde022fd8dc7f_D20200416-20200416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001274737</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-16</xbrli:startDate><xbrli:endDate>2020-04-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i90dcb240c7c649938129ef90b5941787_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y184NA_84e7fd69-c362-4489-9768-f9caa1b0ad71">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Mark One) </span></div><div><span style="font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:115%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:2.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.026%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6YmIyZGQ4MjdiN2I3NDhhYTk3MTVkMzdkYzViZjc3YmEvdGFibGVyYW5nZTpiYjJkZDgyN2I3Yjc0OGFhOTcxNWQzN2RjNWJmNzdiYV8wLTAtMS0xLTA_ded014f4-49e9-4375-bcb5-2c609c6cee09">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the quarterly period ended <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6YmIyZGQ4MjdiN2I3NDhhYTk3MTVkMzdkYzViZjc3YmEvdGFibGVyYW5nZTpiYjJkZDgyN2I3Yjc0OGFhOTcxNWQzN2RjNWJmNzdiYV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjpiYmU4ZTk3MmI0NWI0ZGRkODUyODg5MDBhMDYzMTNiMV8zNg_8ad192cc-0fbf-4f22-9a03-4454b5ddefc8">June&#160;30, 2021</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6YmIyZGQ4MjdiN2I3NDhhYTk3MTVkMzdkYzViZjc3YmEvdGFibGVyYW5nZTpiYjJkZDgyN2I3Yjc0OGFhOTcxNWQzN2RjNWJmNzdiYV8yLTAtMS0xLTA_f587bfde-b6b3-485e-8043-deab17ae0617">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Commission File Number: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xMjk_4bd25d56-1e21-424d-8717-beecce60d427">001-39049</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xMzM_35ce1c67-2ff7-401a-86fc-b298d1dba204">EXAGEN INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:0.1%"></td><td style="width:1.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV8wLTAtMS0xLTA_9a70cc21-5afc-46ad-850a-1ce3cc5b3b85">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV8wLTYtMS0xLTA_ce1524e9-48a3-40a7-a559-7345c2ef764e">20-0434866</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV8zLTEtMS0xLTA_949f4aae-4134-4c2e-8ce2-12aafa413d94">1261 Liberty Way</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV80LTEtMS0xLTA_ba761a3f-4708-4cda-a902-6d89ad77272d">Vista,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV80LTItMS0xLTA_f7df520f-dbe1-4f7c-b3bd-3e3b9fcd2e3f">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV80LTYtMS0xLTA_329a0939-bf05-49f7-a076-fa7529500291">92081</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.766%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDEyZDRkOGRiZjBkNDVlODhmNDc0NzE2MmQwY2FlODEvdGFibGVyYW5nZTowMTJkNGQ4ZGJmMGQ0NWU4OGY0NzQ3MTYyZDBjYWU4MV8wLTAtMS0xLTA_34b18666-46cb-4c60-8a41-7a92d884b370">(760)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDEyZDRkOGRiZjBkNDVlODhmNDc0NzE2MmQwY2FlODEvdGFibGVyYW5nZTowMTJkNGQ4ZGJmMGQ0NWU4OGY0NzQ3MTYyZDBjYWU4MV8wLTEtMS0xLTA_ec185350-8425-4b82-bedf-1fb04acbc4c8">560-1501</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant's Telephone Number, Including Area Code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6OGNiYTdjMDBhMzM3NDAzY2JiMjUxY2I3ZGVmOTFlYjQvdGFibGVyYW5nZTo4Y2JhN2MwMGEzMzc0MDNjYmIyNTFjYjdkZWY5MWViNF8xLTAtMS0xLTA_705ceb4a-1d45-4a00-a9df-204f4f0e07fc">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6OGNiYTdjMDBhMzM3NDAzY2JiMjUxY2I3ZGVmOTFlYjQvdGFibGVyYW5nZTo4Y2JhN2MwMGEzMzc0MDNjYmIyNTFjYjdkZWY5MWViNF8xLTItMS0xLTA_8f050bdb-f2d8-4d38-ac2b-47f735b91e69">XGN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6OGNiYTdjMDBhMzM3NDAzY2JiMjUxY2I3ZGVmOTFlYjQvdGFibGVyYW5nZTo4Y2JhN2MwMGEzMzc0MDNjYmIyNTFjYjdkZWY5MWViNF8xLTQtMS0xLTA_6034e390-4deb-4602-b13b-f9211dc83f09">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y181OTk_2ea96a0b-f938-42d4-b0b3-cbfcb2be202c">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y185MDE_39d7de99-9290-4fa6-b949-fe62d35ee2d9">Yes</ix:nonNumeric> &#9746; No &#9744; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Securities Exchange Act of 1934. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6M2ZhMTEyMDVlMGFkNDUwOThiNWM2MDc1ZTExNGJiY2EvdGFibGVyYW5nZTozZmExMTIwNWUwYWQ0NTA5OGI1YzYwNzVlMTE0YmJjYV8yLTAtMS0xLTA_eb895149-6241-4e2f-8cf0-e23ca94b0745">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6M2ZhMTEyMDVlMGFkNDUwOThiNWM2MDc1ZTExNGJiY2EvdGFibGVyYW5nZTozZmExMTIwNWUwYWQ0NTA5OGI1YzYwNzVlMTE0YmJjYV8yLTQtMS0xLTA_5b300d2b-ed94-45b8-946f-9576b929228b">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6M2ZhMTEyMDVlMGFkNDUwOThiNWM2MDc1ZTExNGJiY2EvdGFibGVyYW5nZTozZmExMTIwNWUwYWQ0NTA5OGI1YzYwNzVlMTE0YmJjYV80LTQtMS0xLTA_fa2c37ab-db38-451a-9ebf-3037254ca8a3">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Securities Act&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xNTM0_40f0dfce-49f1-45c1-b27e-6a7895bce586">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xNjU0_cbd3db40-08d5-42f3-89b2-8a791251e4ec">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total shares of common stock outstanding as of the close of business on August&#160;6, 2021 was <ix:nonFraction unitRef="shares" contextRef="i5780fca0aaf34dcfab553f2efb981de5_I20210806" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xNzQx_ce51f91c-ca52-4b2c-a584-e8d7090821a6">16,126,784</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_13">Condensed Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_16">Condensed Balance Sheets as of June 30, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_19">Condensed Statements of Operations for the Three and Six Months ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_22">Condensed Statements of Stockholders' Equity for the Six Months ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_25">Condensed Statements of Cash Flows for the Six Months ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_28">Notes to Unaudited Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_58">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_58">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_73">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_76">32</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_82">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_85">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_88">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_88">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_91">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_94">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_97">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_97">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_100">38</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_103">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i90dcb240c7c649938129ef90b5941787_103">39</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_13"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Financial Statements</span></div><div id="i90dcb240c7c649938129ef90b5941787_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNC00LTEtMS0w_09496911-b41a-45b6-b61d-a9d725e2e622">112,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNC02LTEtMS0w_e37143d1-470c-40a8-8284-f60a2f7e7082">57,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNS00LTEtMS0w_4a0e68cb-0f62-4950-ade3-ba99daf58679">8,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNS02LTEtMS0w_ee00ea5b-c9aa-4bcf-b770-591194adf7af">8,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNi00LTEtMS0w_13a5c91a-6b65-40fb-9fc5-62555941504e">3,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNi02LTEtMS0w_72962d66-1cdc-4ee9-a0f8-444102ba236a">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNy00LTEtMS0w_5f759b85-8bac-4c4e-8519-961693b5f0fd">124,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNy02LTEtMS0w_01f9c46b-051d-4f23-b781-864554020ad2">70,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfOC00LTEtMS0w_92c825b4-e7ca-4e27-8f55-aa7d6870b28e">3,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfOC02LTEtMS0w_7953e4e0-5d31-4975-9be8-6fe9c4770b7c">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfOS00LTEtMS0w_72b5a034-96a8-47ed-bc52-8c6949e52688">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfOS02LTEtMS0w_6b5d15bc-2ebb-4e11-b120-635561f23dd7">5,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTAtNC0xLTEtMA_eaf953a6-68b3-4303-b3ca-6ebdce25a776">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTAtNi0xLTEtMA_8e1d63c3-9165-46c9-8e9f-f389f25ef738">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTEtNC0xLTEtMA_6a3c2cdc-ffca-4e5d-afd0-0df2008927e9">133,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTEtNi0xLTEtMA_e324c2af-c649-40ef-8283-552ffac3b5f5">78,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTQtNC0xLTEtMA_26a309bd-1ff4-45fc-9cc7-673aea4add44">2,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTQtNi0xLTEtMA_71073642-a0b9-4761-83bc-6ca0f52ca3d4">3,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTUtNC0xLTEtMA_23d1fa16-ffb0-47ab-904a-7ec7c2454f25">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTUtNi0xLTEtMA_ce1e8d7c-056b-4e05-8315-d1a5a7b13456">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTctNC0xLTEtMA_baa0bfa0-6ced-4555-9ee9-c62aa2f9848f">8,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTctNi0xLTEtMA_e09941c7-ed8f-4f1b-8b81-64895538e901">8,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings-non-current portion, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTgtNC0xLTEtMA_ed0728e7-4f51-4e10-b257-63d655a0e2a6">27,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTgtNi0xLTEtMA_8ea8b286-9aba-4cb6-bfb6-04bb8c329136">26,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjAtNC0xLTEtMA_1183eb49-18e7-4a97-8a4d-ceb7649bf715">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjAtNi0xLTEtMA_42bb17d2-2173-4d28-9416-d75cf1d5d590">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjEtNC0xLTEtMA_b3c8c95a-7ef5-4097-b8c8-73e7110dcba7">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjEtNi0xLTEtMA_677b75c5-78c8-4916-94d9-868a96c74a0c">948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjItNC0xLTEtMA_80d074ca-b7d8-4014-9242-4718aaaf1a55">36,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjItNi0xLTEtMA_5fb646a8-20a9-42d4-b378-bb3dad20d1cc">36,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjMtNC0xLTEtMA_50849432-71f4-4c96-931c-96efde3fd1fe"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjMtNi0xLTEtMA_3aacecdd-90e1-4a5c-9d85-3d464abeff45"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzIx_4cf5f5ea-4ee9-42f6-93c0-ebe22faef277"><ix:nonFraction unitRef="usdPerShare" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzIx_a659140b-fe64-4254-a7af-9fed426be6bb">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzM1_696de39e-be8c-48d1-b0cd-22ba209c32ad"><ix:nonFraction unitRef="shares" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzM1_d771205d-c48f-4ebf-97cf-b0441ec49f5c">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzU3_4342cc3e-6a64-45f2-b748-2722a009fe18"><ix:nonFraction unitRef="shares" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzU3_459bedb2-f69b-4cfa-822f-ded28cfcbdb1"><ix:nonFraction unitRef="shares" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzU3_b012cd70-c92e-4b26-b172-46e90ce29bf2"><ix:nonFraction unitRef="shares" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzU3_bd17e22f-47b8-4753-b9f5-b501f140b8f0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at June&#160;30, 2021 and December 31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtNC0xLTEtMA_ea494a7b-fe4e-4da6-b1c7-d685d3f358a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtNi0xLTEtMA_3b4148d2-d5b1-42b7-90c7-7285ced27957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzE4_0ca40f39-c631-42eb-b262-3ff01c5ffcc8"><ix:nonFraction unitRef="usdPerShare" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzE4_f14e7645-7ab8-4f98-9cba-8ed7d8a33879">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzMy_9a5bbc06-6893-4210-bf98-9a1fa21a3ca9"><ix:nonFraction unitRef="shares" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzMy_fe0b3001-6a67-49fb-bd09-6cb47ff0466b">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzgy_545527c9-6edd-4f89-b249-acb1f7949f1a"><ix:nonFraction unitRef="shares" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzgy_9115d025-8172-41a1-9c81-8a6b97fe5be1">16,126,784</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzg5_1a26f749-8303-4f9f-b791-a927f72d7b32"><ix:nonFraction unitRef="shares" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzg5_c063c884-4098-48b1-8ae3-d1b192aa72dc">12,652,308</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctNC0xLTEtMA_235fc01d-234e-41d2-904f-daa8eda7fb9d">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctNi0xLTEtMA_bac86b65-bac7-4fda-996b-2a4cfdf67994">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjgtNC0xLTEtMA_465c1916-4ddf-40d5-988e-776ae7e1a5f3">290,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjgtNi0xLTEtMA_397c9024-439a-4069-8496-c271af9485ae">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjktNC0xLTEtMA_e9ecb3cf-ca02-479f-a521-397a5ac02acc">193,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjktNi0xLTEtMA_b64c0d10-4d04-461a-8549-f54d898f5e2c">181,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMzAtNC0xLTEtMA_d84817a9-4937-4436-85b5-576d5518afae">96,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMzAtNi0xLTEtMA_c2692d42-141c-4f2a-87e6-87110e04215b">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMzEtNC0xLTEtMA_c79d028e-3949-49f0-a941-ec87cef69f54">133,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMzEtNi0xLTEtMA_ca4dfc1c-ffe4-4e1e-a939-976bff1e39a0">78,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Condensed Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMy0yLTEtMS0w_fb9f1c97-5dc9-4791-af0a-95bd075f3499">12,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMy00LTEtMS0w_3ba3dc4f-674a-49eb-a1ad-5c0e65a2e35c">8,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMy02LTEtMS0w_4959e1da-4018-42d5-9694-8294a73053c1">23,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMy04LTEtMS0w_20c7ea56-1cab-415a-b6c2-97fb10dfd42a">18,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNS0yLTEtMS0w_8b23ce0d-bed4-4201-830f-4ba27c4821db">5,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNS00LTEtMS0w_741e3a64-9b37-4865-bbdf-2ff604250089">3,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNS02LTEtMS0w_1420dc12-f942-400d-ae1f-cc2478a22202">10,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNS04LTEtMS0w_7b871346-d511-4b97-ac1a-07490631619b">7,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNi0yLTEtMS0w_47b1812a-295e-40c1-8d3f-b8d9cf0556c2">11,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNi00LTEtMS0w_b211b694-d7ef-4f93-bb65-563499f8cd3f">8,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNi02LTEtMS0w_1854d33e-925c-427d-bfab-c7af12ebd25b">21,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNi04LTEtMS0w_9527b1b2-4cb2-44f7-82f2-6d26226a0a1e">17,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNy0yLTEtMS0w_e23da0e6-f744-411b-8604-bb9356e922d2">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNy00LTEtMS0w_ff972a15-0503-432e-94a6-15b3a2b5810d">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNy02LTEtMS0w_aabb5b50-6a0c-4f30-a251-a39b9f0316e4">3,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNy04LTEtMS0w_30d600c3-7682-4dc8-ad61-aa6f711b0171">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTAtMi0xLTEtMA_ffeeb630-de3b-4221-adfa-7d7cfa10a71d">18,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTAtNC0xLTEtMA_420aed2e-3c0d-4eab-88d2-474d5c087c16">12,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTAtNi0xLTEtMA_28695c77-68b8-4ad3-9be9-a8f7823eb943">34,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTAtOC0xLTEtMA_be2265b5-9cab-40d7-a12f-d7089e6f31b0">27,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTEtMi0xLTEtMA_689031a1-8a9c-477d-80ac-29e8e6959877">5,742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTEtNC0xLTEtMA_b4cde856-11a2-49be-b34d-ab958dd39b72">3,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTEtNi0xLTEtMA_d8ad3e1e-86bd-4f26-924a-89e3b1335a25">11,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTEtOC0xLTEtMA_77c2ab7b-4e31-41dc-b51d-9383b01f419b">8,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTItMi0xLTEtMA_41d31680-2685-484f-bf98-a9d59381c533">663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTItNC0xLTEtMA_f3f450b1-562e-46a9-8c43-d72b8231df77">635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTItNi0xLTEtMA_489d585f-199e-47dd-ba8c-e385320b8c45">1,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTItOC0xLTEtMA_d083f80f-b339-4a2a-8c27-6936971a3649">1,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTQtMi0xLTEtMA_0229b835-db6a-45e5-9134-21f013ded9ac">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTQtNC0xLTEtMA_14ef4cf0-1203-4dd9-8d46-9363c573e6da">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTQtNi0xLTEtMA_241b8245-57bd-40fe-b52e-6dc2a9902ae0">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTQtOC0xLTEtMA_63cc8af6-d893-4c7a-a22e-fb659d569666">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTUtMi0xLTEtMA_efbf7b02-c27b-413e-a100-f29c8c1311bb">6,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTUtNC0xLTEtMA_1798c102-567e-45be-8d76-4758bd94666c">3,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTUtNi0xLTEtMA_4ee13c0c-7daf-44d7-8a7e-3fd26af64623">12,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTUtOC0xLTEtMA_a271b464-0492-4dd5-ba87-dc23aa5dce9c">9,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTYtMi0xLTEtMA_c5f5863b-d21f-46da-a8dc-b6adfa3abdc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTYtNC0xLTEtMA_f1f4f1e4-b22f-4fab-86d5-a5fbff618aa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTYtNi0xLTEtMA_d77551c6-3ab2-45c5-9aa0-f53c846971ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTYtOC0xLTEtMA_5693ccd5-c34b-408b-8607-73da4b0ed5dc">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTctMi0xLTEtMA_448102c3-dacd-4c82-a7bb-4240d1ad4d01">6,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTctNC0xLTEtMA_19d732d8-41cb-4c52-874c-85aa4b8808c1">3,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTctNi0xLTEtMA_a3b67acd-1d37-4842-9991-5f120d4a8b4b">12,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTctOC0xLTEtMA_983d78a7-678d-4afc-a02c-9a64aee9bdf5">8,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtMi0xLTEtMA_986273c9-241d-4816-b699-af183f856827"><ix:nonFraction unitRef="usdPerShare" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtMi0xLTEtMA_b176bd89-2aad-4a54-a93f-7b7d30acf7b2">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtNC0xLTEtMA_2ce9de5b-a5a7-4d5a-a3b6-2c1a2e009bf7"><ix:nonFraction unitRef="usdPerShare" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtNC0xLTEtMA_f6bf6809-1597-4c33-b0fb-b95311926a98">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtNi0xLTEtMA_08eda9e7-2470-40cb-9ac7-a5ebaddf1d5a"><ix:nonFraction unitRef="usdPerShare" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtNi0xLTEtMA_616c6ae0-4e58-43d8-98ae-2670308fd3de">0.84</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtOC0xLTEtMA_dad3c26b-76fb-468c-902b-2e79128468c0"><ix:nonFraction unitRef="usdPerShare" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtOC0xLTEtMA_efa4e2b3-4535-4a49-86fb-a1482bc92f9b">0.71</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of shares used to compute net loss per share, basic and diluted (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItMi0xLTEtMA_8b362ebd-b4c6-4566-b7ce-74920d778851"><ix:nonFraction unitRef="shares" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItMi0xLTEtMA_d1df3de3-ae06-4d58-bc67-db04b5a22edd">16,928,613</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItNC0xLTEtMA_4c3bd1c3-4bf7-4749-924a-b23cd174ac7a"><ix:nonFraction unitRef="shares" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItNC0xLTEtMA_c70134ba-3346-40a1-9a1a-ad200aa06bd5">12,637,642</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItNi0xLTEtMA_9ae4fe9a-054f-4a34-abd8-54529ca0edad"><ix:nonFraction unitRef="shares" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItNi0xLTEtMA_d7b7ed31-cd18-49b1-8319-f4c5cdce57f9">14,946,935</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItOC0xLTEtMA_63d63886-a492-4118-84a7-8d1c5340975d"><ix:nonFraction unitRef="shares" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItOC0xLTEtMA_ef3dbad2-e704-4eba-85c6-c71983711c07">12,616,678</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Condensed Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i366fa7cf9c3940e884aa8c8619173cc2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi0yLTEtMS0w_706c5e1b-2039-465f-a529-434d0b10c3f8">12,652,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i366fa7cf9c3940e884aa8c8619173cc2_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi00LTEtMS0w_dda57d5a-e079-4a3b-84f1-33f5c9611a61">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5150cd684b0d46ccba522709fba131b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi02LTEtMS0w_478e6958-b049-415d-8661-a8574fefeb25">223,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i758a0d891e3e480d95465ccb025f61f9_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi04LTEtMS0w_94f02028-799a-4a21-a89a-60ac78b6e9de">181,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi0xMC0xLTEtMA_4825ce90-6ab0-4bf4-8adf-eb6926e82358">41,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock in public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i0deb0612dda8455fad61349cd2e577de_I20210331" decimals="-3" format="ixt:numdotdecimal" name="exdx:StockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy0wLTEtMS0wL3RleHRyZWdpb246OGQ3MGJlYjI0ODIxNDU3MGFlMDdjNDA4ZmFkMTJmY2RfNjc_4aef2df5-8ea7-4471-ac3f-285f4a59a70d">4,435</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy0yLTEtMS0w_1c64be52-d694-4fc9-814f-19319342028b">4,255,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy00LTEtMS0w_a46a9320-78b0-4a0e-81bd-001f7fdc8bf0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy02LTEtMS0w_23a7933a-79ed-4fac-9135-a0f7394fdbff">64,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy0xMC0xLTEtMA_68a9f10f-1cff-4bd0-8005-234b8489e3f7">64,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNC0yLTEtMS0w_6b007534-3ff2-4b97-9089-03a08fd51a3e">3,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNC02LTEtMS0w_9e864e64-cd06-4b77-8226-78c4413bf94d">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNC0xMC0xLTEtMA_7a70c887-5af7-4f3c-b1f3-b98f60ca4a40">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNS0yLTEtMS0w_005e552d-f3be-4899-9b6a-233d168c51da">14,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNS02LTEtMS0w_e8f4be33-546d-4a5f-a112-07de18ce742d">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNS0xMC0xLTEtMA_c341d1cc-2148-4a82-9f2b-80fa88e34bda">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNi02LTEtMS0w_a1d7c18a-9f5d-4f36-bb31-def8478850a4">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNi0xMC0xLTEtMA_11118592-0f7f-43c5-bfa7-a01f35df42a1">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ac5881792a74f33ac659f8310bbcd0b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNy04LTEtMS0w_e3f77ba4-2181-41a2-a56e-b16cd6c361d0">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNy0xMC0xLTEtMA_f7161566-b4f4-49ea-9f14-38032cf5675e">6,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72ebe96bf2e14fb788d101048eba37f6_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC0yLTEtMS0w_aead311f-2589-4343-9db0-9d501466cd7f">16,925,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72ebe96bf2e14fb788d101048eba37f6_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC00LTEtMS0w_1d18ec3c-27b2-4057-871e-b75b0c7958e7">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8061b34d637b4709a07e120a85126e27_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC02LTEtMS0w_f0666a88-ece2-4852-91be-a2d4c513b7a7">288,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d3c385b85e3496db450da0807647ad7_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC04LTEtMS0w_a6c82f92-06ef-4105-96c6-6536bd2383d3">187,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0deb0612dda8455fad61349cd2e577de_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC0xMC0xLTEtMA_01517a33-7869-4409-a9f9-dc990f815033">101,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock in exchange for common stock warrant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8df4d4a6e90f495da04464f80d6009ec_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOS0yLTEtMS01Ng_4e4fd0e3-10f5-4ecb-b891-27347a0ce52c">804,951</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8df4d4a6e90f495da04464f80d6009ec_D20210401-20210630" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOS00LTEtMS01Ng_603a7386-10ae-482f-9902-5c9483f3352e">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOS02LTEtMS01Ng_8cfdfc69-b4da-4315-a157-176afab2afd7">12,774</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOS0xMC0xLTEtNTY_2858f469-209a-4b94-a04e-d74dc7ab0c27">12,775</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock warrant in exchange for retirement of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTAtNi0xLTEtNTY_c4a5dd8f-72c0-45ae-b0de-a5dd2841b88b">12,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTAtMTAtMS0xLTU2_32b684d7-20b1-464b-a2b0-941ebdd5a26e">12,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8df4d4a6e90f495da04464f80d6009ec_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTEtMi0xLTEtNTY_3c95ff85-9fe6-485b-aa37-0fd6867e7138">6,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTEtNi0xLTEtNTY_e5a8a495-eeaf-44e6-b797-135b1866f893">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTEtMTAtMS0xLTU2_6940972a-8167-49af-a671-0755b47b208f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTItNi0xLTEtNTY_f1e3fa9b-87c6-4c01-8243-188dde60fe19">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTItMTAtMS0xLTU2_c96df12f-9f11-434e-adf6-84cdb6a9be83">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0791f27cac87465e9a64cc86bd068ff1_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTMtOC0xLTEtNTY_357f48ba-b64d-4184-9a10-a22a684fe6c5">6,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTMtMTAtMS0xLTU2_dbdaf5cd-fd8f-435b-abeb-70ca49b855b6">6,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if74f91780daf468f8527681009a493cc_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtMi0xLTEtNTY_8d40be5f-ba96-4f66-9f15-5e82ef1607e8">16,126,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74f91780daf468f8527681009a493cc_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtNC0xLTEtNTY_d322d616-d6f8-4109-a8ec-9c2652bc4724">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27834d9ecc64761948dc8797f616336_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtNi0xLTEtNTY_2cae4f72-0341-477d-a790-328ddd58d013">290,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65e7ef5eaa61480cadeee7d277e565f2_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtOC0xLTEtNTY_65f62704-109f-408d-9795-35957d93e05e">193,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtMTAtMS0xLTU2_bd8aeec8-3a0e-454c-8845-a1fd6f2c3c88">96,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibac674a12b624346ba69c6d4c91a087c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi0yLTEtMS0w_00fa9bff-940f-4163-bd05-a89e6bf0c57b">12,560,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac674a12b624346ba69c6d4c91a087c_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi00LTEtMS0w_38e08e3a-fe8b-44fb-bdae-c27700f8e41d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552bc21453cb4af5b990c1672758ce50_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi02LTEtMS0w_d8c027d8-5cc5-49ae-9a42-95ac02b70ae9">220,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1218833ece7f47b482280689d529b3c0_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi04LTEtMS0w_4920e0a8-8fc1-438f-95ef-34d3c1ede9ff">164,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d1a0041a2247299991bb0eb2225c05_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi0xMC0xLTEtMA_a486ccb8-0c54-4202-9427-e6d707024b22">55,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec65931f2bd14b39bad0fda30bdea3c0_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMy0yLTEtMS0w_528ec194-121a-4f9d-98c8-ece5d40fe9f9">43,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6548eab8e25b4293949c913d7e33574c_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMy02LTEtMS0w_7ed46339-ee0b-48ae-bb8f-348779310c01">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMy0xMC0xLTEtMA_2f5b3e93-c145-4947-a9ef-0f64574ba07f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6548eab8e25b4293949c913d7e33574c_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNC02LTEtMS0w_1312f5b1-fb60-4903-a412-259e966c6158">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNC0xMC0xLTEtMA_6b1ba22a-58ec-4189-adcb-02fb66959454">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net exercise of common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec65931f2bd14b39bad0fda30bdea3c0_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNS0yLTEtMS0w_c4fe23a1-b519-4d7e-9417-01f5d5e51e3e">22,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNS0xMC0xLTEtMA_4714963c-d860-4376-bc90-da74a26adf90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0db198013004fa19cd45a4eae00b98c_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNi04LTEtMS0w_2d494f7b-8d4d-492f-9e57-9a1fb950c280">5,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNi0xMC0xLTEtMA_60cf7c73-5f5b-49fc-b618-2d59e3959e82">5,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March&#160;31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00e69de6aff041908d22b9baeecf3fc3_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy0yLTEtMS0w_2f3646e8-63a8-49fa-84c3-f314e8276cfb">12,627,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e69de6aff041908d22b9baeecf3fc3_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy00LTEtMS0w_9c15972f-d8ea-4669-a30a-ebf18c878a9d">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f77899e7cb54d408a8f6746c4d36b03_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy02LTEtMS0w_50f39a08-20cd-441e-8362-a27a65bbb7de">220,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b56bc7f626845b48cb17da5717ddb00_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy04LTEtMS0w_b5ff60a6-fd46-44ed-a4c5-aad352b45cae">170,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i979494764014402c94c0b5072500a2d6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy0xMC0xLTEtMA_86942a18-cb6a-4661-ab0d-6c421d41859b">50,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i507cf8c3a86c47eeaa37f1c4799aabe0_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOC0yLTEtMS0w_5b095296-7e9d-4b8a-94f5-662eb53a646b">3,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb73f35a6dbe4685b6581455ef8c5cd3_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOC02LTEtMS0w_66312707-da26-4f68-99dd-8068831c0d4c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOC0xMC0xLTEtMA_e5ed4fa0-fc63-405f-8627-9f4ef3ee8217">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb73f35a6dbe4685b6581455ef8c5cd3_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOS02LTEtMS0w_45497649-da84-4ff6-b350-c14b2e2a8435">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOS0xMC0xLTEtMA_491d8362-99d8-45c4-bb75-f34262589912">647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i507cf8c3a86c47eeaa37f1c4799aabe0_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTAtMi0xLTEtMA_8b2784a4-2134-4981-83ab-b5c0e45c1058">9,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb73f35a6dbe4685b6581455ef8c5cd3_D20200401-20200630" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTAtNi0xLTEtMA_24641467-ddec-41a9-919f-a8d4da9fd914">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" name="exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTAtMTAtMS0xLTA_0fb875be-6425-41f6-81ca-647666263e0d">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cd12ee06e3146ee848bb4b240212ea1_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTEtOC0xLTEtMA_34896cc5-d637-4aa6-acf5-77e56105d2a7">3,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTEtMTAtMS0xLTA_00488f44-eeab-497c-b906-e5c09c2c3b86">3,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34270509c6ec4547a8c0584c3edda583_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItMi0xLTEtMA_ecd85f5a-697d-4c42-9e72-7962836b32b9">12,640,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34270509c6ec4547a8c0584c3edda583_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItNC0xLTEtMA_a9b42fef-ff8d-4a95-bd9c-dea074e7c35e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id102a5b2a4f048f8b4f9ce799a943014_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItNi0xLTEtMA_8bb9e094-8980-4872-b53f-3665c264f08d">221,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b86b21740cf4825b079ffee255e0a30_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItOC0xLTEtMA_df2b8f26-9d6a-41fd-9557-bac82061e223">173,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717e3a6bdd9d4ede925668cdc7aa8187_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItMTAtMS0xLTA_263ed7ae-c44c-4abe-876f-8fa0bb9f062b">47,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Unaudited Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNC02LTEtMS0w_e2ccc656-3404-4390-b0b6-a53781b1d2d8">12,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNC04LTEtMS0w_84df9465-27d0-4d73-b3ba-b034465658e7">8,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNi02LTEtMS0w_7e5fbcfa-b09c-4cdc-872b-8fd7a03495b4">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNi04LTEtMS0w_527ed6e1-a69d-41dc-b517-cb39171b4d14">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNy02LTEtMS0w_ac57bfcf-6f11-4c0b-9c2b-2556f4974934">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNy04LTEtMS0w_43a9b747-d34c-4ebb-953a-42c7959b2e12">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfOC02LTEtMS0w_d2c285a8-3754-413e-bb41-3fa628506a3c">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfOC04LTEtMS0w_54abd264-3e76-433f-8727-3bc6933ff45b">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTAtNi0xLTEtMA_9b21862d-5571-4dc7-8cac-1c2b20a01f91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTAtOC0xLTEtMA_4288f50b-c555-4095-be87-ee1b0bcee383">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTItNi0xLTEtMA_eebc3ed7-1ba0-4c2c-ad4a-d5eeded29111">2,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTItOC0xLTEtMA_22a416db-3116-478e-8d9d-76e11b55eb58">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTQtNi0xLTEtMA_cb1b76d9-e60b-4df0-90ea-cf273fc92ba2">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTQtOC0xLTEtMA_542624d4-8bcb-491f-bf02-b9a4d649ab50">1,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTUtNi0xLTEtMA_79ae113d-04f3-4a5e-bb4c-796bd1de187c">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" name="exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTUtOC0xLTEtMA_abd032dd-3620-41c2-bb0f-7339bae71a0f">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTYtNi0xLTEtMA_fb64dc8c-c2e6-43a7-9e73-06e9d7b3f3d8">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTYtOC0xLTEtMA_ed7aced8-5c71-452e-abde-b620ceee5118">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTctNi0xLTEtMA_5cbf5a82-ca2c-4b0b-9386-3884eaf76bce">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTctOC0xLTEtMA_c79d5a07-5777-498d-8672-01a80f9ac120">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTgtNi0xLTEtMA_73d118e7-69e6-4884-b8e0-5d2002c63b38">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTgtOC0xLTEtMA_a2727384-16ba-4826-9673-fb5ed5d22dcf">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjAtNi0xLTEtMA_dc6c4925-85f4-411a-8e9a-ba99e7ed14dc">8,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjAtOC0xLTEtMA_c4146e3b-6545-4d65-b76f-dc69f50845db">8,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjItNi0xLTEtMA_3e38ebc7-f4ad-432d-88de-95104f260958">881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjItOC0xLTEtMA_c8bba42d-8830-43d4-b34c-77d71fdc0cf0">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjYtNi0xLTEtMA_3551ebbc-405e-4823-813e-ceffafa6a31d">881</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjYtOC0xLTEtMA_88ab47a4-0d2b-4210-83ed-5ed1c6aae524">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjgtNi0xLTEtMA_6f3a8c74-dbc8-4df2-a515-dbcd71ab1df7">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjgtOC0xLTEtMA_eac0f51f-07e9-4d45-8648-b992bbfdfe4d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from common stock issued under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjktNi0xLTEtMA_7b2e8607-c205-4e05-9b60-4b735d0e7e19">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjktOC0xLTEtMA_04838fb9-007b-4c75-896b-40424d3c262c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzAtNi0xLTEtMA_84d2c8b1-7c57-4462-b0c3-cecee53415a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzAtOC0xLTEtMA_f5d99ea6-5848-4ff0-bc95-ee0052079ef8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payment on capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzEtNi0xLTEtMA_094b8075-06a4-412a-b077-0d4ad33687f2">220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzEtOC0xLTEtMA_3ec2fcb2-5c05-41ca-9280-ca5704bf64ce">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from Paycheck Protection Program loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromBankDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzItNi0xLTEtMA_da18ff4e-77c7-449e-abc1-d333b94908e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromBankDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzItOC0xLTEtMA_3cdac240-8193-42d9-8968-a03493dbe703">2,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of Paycheck Protection Program loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfBankDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzMtNi0xLTEtMA_c680e0ff-eb7e-4c9b-9321-2d912dcf7c9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfBankDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzMtOC0xLTEtMA_f7551a35-3729-4168-a12a-5d3b3d638f9f">2,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the issuance of common stock in public offering, gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzUtNi0xLTEtMA_5a12c6f0-59b3-430d-909f-ed56047edebe">69,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzUtOC0xLTEtMA_64d13884-fc52-4d3e-b059-9fb29334d512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of issuance costs related to public offering</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzYtNi0xLTEtMA_f64578c2-a663-4b14-8fce-713e1eb18a73">4,407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzYtOC0xLTEtMA_6107df4b-277f-459b-8c9a-031c5add9b07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDItNi0xLTEtMA_8da8ab2b-3b8c-4ea1-ad13-70665d2e6301">64,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDItOC0xLTEtMA_9a9a0730-644f-412f-9197-c6661303797a">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDMtNi0xLTEtMA_5c7a3daf-3f81-4a0c-8a9c-c7fb98f49737">55,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDMtOC0xLTEtMA_5b4b33b7-b8ab-4d7e-879c-ec0875a4d1af">8,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDQtNi0xLTEtMA_cf023d72-a68f-4210-8d64-0d51baaa5498">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d1a0041a2247299991bb0eb2225c05_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDQtOC0xLTEtMA_4ea7ad88-d5cf-4bd0-ad7f-c457f785eb3a">72,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDUtNi0xLTEtMA_9b4038f5-c30d-4410-9237-6a08a1083a54">112,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717e3a6bdd9d4ede925668cdc7aa8187_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDUtOC0xLTEtMA_16d86062-110b-4ed6-812d-305b45f9496b">63,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDctNi0xLTEtMA_02877c29-2e18-4687-851e-95ca77b56d88">892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDctOC0xLTEtMA_1f5fce85-c5c7-491f-bdbc-0d3c3f2d99ec">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment purchased under capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTAtNi0xLTEtMA_85e4fbc0-8ef4-4640-a474-d291e4f63bca">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="exdx:EquipmentPurchasedUnderCapitalLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTAtOC0xLTEtMA_54d832d3-6be2-4c40-b1f8-f330510f57d1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs incurred, but not paid, in connection with capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTItNi0xLTEtMA_21270f13-881c-46e8-a4d5-4635a86843f9">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTItOC0xLTEtMA_9eb01ff4-95a0-4e13-8b53-ae8a775d39c5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred offering costs reclassified to equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" name="exdx:DeferredOfferingCostsReclassifiedToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTYtNi0xLTEtMA_01aa60fb-d8f7-421d-adcd-1dca633aeab7">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="exdx:DeferredOfferingCostsReclassifiedToEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTYtOC0xLTEtMA_238f67b0-8017-445c-82ed-da23507c4d32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_31"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exagen Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Condensed Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zMS9mcmFnOmZjOGZmMDVlOGEyMDQ1MWM5Yjg1MjRmNDJkYzhkZmNkL3RleHRyZWdpb246ZmM4ZmYwNWU4YTIwNDUxYzliODUyNGY0MmRjOGRmY2RfMjIwNQ_5f9010e7-2a68-498c-87c3-9d6c29007bbf" continuedAt="i5e03053869a848b4a186cbaa7257ba74" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i5e03053869a848b4a186cbaa7257ba74"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At June&#160;30, 2021, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zMS9mcmFnOmZjOGZmMDVlOGEyMDQ1MWM5Yjg1MjRmNDJkYzhkZmNkL3RleHRyZWdpb246ZmM4ZmYwNWU4YTIwNDUxYzliODUyNGY0MmRjOGRmY2RfNjE4_73175605-2930-433c-99b1-e029b559f0e1">112.6</ix:nonFraction> million and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zMS9mcmFnOmZjOGZmMDVlOGEyMDQ1MWM5Yjg1MjRmNDJkYzhkZmNkL3RleHRyZWdpb246ZmM4ZmYwNWU4YTIwNDUxYzliODUyNGY0MmRjOGRmY2RfNjU1_204b5be6-6c8b-4215-97c7-44ef406cae3e">193.9</ix:nonFraction> million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div></ix:continuation><div id="i90dcb240c7c649938129ef90b5941787_34"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDg_daf85d4d-df52-4819-bcfe-b5e4c6435f57" continuedAt="if7f4934797ad4a538a0a87df6229b614" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if7f4934797ad4a538a0a87df6229b614" continuedAt="iceb7b1e1095d4cc99016fda95cc36913"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of June&#160;30, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three and six months ended June&#160;30, 2021 and 2020 and cash flows for the six months ended June&#160;30, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of June&#160;30, 2021 and its results of operations for the three and six month periods presented. The results for the six months ended June&#160;30, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iceb7b1e1095d4cc99016fda95cc36913" continuedAt="i97a17c4a6d4b45bca96c8662fcce78dd"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDI_716b392c-2e28-4d97-bc69-3b5670cc4a37" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTU_4aaf75c7-a720-457c-b6a0-7fd6b196518d" continuedAt="i6b7a2fd75d00440cbb9b9fbafcf6f99a" escape="true">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</ix:nonNumeric></span></div><ix:continuation id="i6b7a2fd75d00440cbb9b9fbafcf6f99a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4abda3c45354b949166899b405e3a62_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfMy0yLTEtMS0w_11e2a58c-0065-4dce-99bf-d882aef05fc0">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dced9e9019345d899c2982db367d60d_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfMy00LTEtMS0w_43c9833c-9423-4b7a-8e06-88c82528d5c8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37a9723325ae40058c158c22778b76a5_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfMy02LTEtMS0w_62e031e7-7bc8-4ffe-b1f4-2cfe8e510612">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic10ddfd5136e4061b9973d178e27ba18_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfMy04LTEtMS0w_4820aed8-d466-47db-8115-38d1e8409fd3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaea277eb7cbf4254adf6026f29375664_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC0yLTEtMS0xNjM3_4390c0d2-81f2-4731-b541-3a5e369fa15f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d8f685d9b944f60b9103e1913818ac9_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC02LTEtMS0xNjM3_d28e220a-72ec-408d-81fc-9a4a1ddbfb17">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6abedb7e04b40e8aeec6aa02680f33b_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC04LTEtMS0xNjM3_df644eec-51d8-45dc-8767-15e67dff555d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7128036de6754666b5f3a81736dcc5fa_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNS0yLTEtMS0xNjQy_8a4fda36-2728-4c9a-b7f3-98ce72a77430">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2586bfebd6614d1488d082744fec8ef5_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNS00LTEtMS0xNjQy_3708ef87-be67-4c09-8aec-5752d8684ef8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ee787030d814685ab554a163cf5e574_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNS02LTEtMS0xNjQy_53f538e9-4084-43ce-b42b-695248fc18ce">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fb609bc49d8411aacdd2e672d62eb26_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNS04LTEtMS0xNjQy_77acdd3c-dca0-4dfe-abdd-4a2455d0038f">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i453f98cffb604fd48828fd1e8ee2d430_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC00LTEtMS0w_f3c60e28-8d2c-457f-af14-3c56302e3e71">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibac162d49bd04ab38540f0d788ab7b01_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC04LTEtMS0w_032a1c6d-6c1b-412e-8934-e64302e1b7e5">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i835d56825d0a476da36bc88326650f02_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjgzMDdlMjQyOTExODQ0MWU4M2ExNWIyMWU3MDIxZTQ5L3RhYmxlcmFuZ2U6ODMwN2UyNDI5MTE4NDQxZTgzYTE1YjIxZTcwMjFlNDlfMy00LTEtMS0xNjEz_f668454e-12c2-40dc-bb97-a436eaedfe73">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3751d07906149e5b585fd8950ac1b5f_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjgzMDdlMjQyOTExODQ0MWU4M2ExNWIyMWU3MDIxZTQ5L3RhYmxlcmFuZ2U6ODMwN2UyNDI5MTE4NDQxZTgzYTE1YjIxZTcwMjFlNDlfMy02LTEtMS0xNjE2_afabd0cb-193e-4f39-bb1c-4867b8112f76">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifde0bcda7e7545ae9ff38a215ba73eca_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjgzMDdlMjQyOTExODQ0MWU4M2ExNWIyMWU3MDIxZTQ5L3RhYmxlcmFuZ2U6ODMwN2UyNDI5MTE4NDQxZTgzYTE1YjIxZTcwMjFlNDlfNC00LTEtMS0xNjIx_f4e9d524-6c2d-4127-92cf-e946e377f460">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40dd1efb9e15401da3f592bff24d5574_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjgzMDdlMjQyOTExODQ0MWU4M2ExNWIyMWU3MDIxZTQ5L3RhYmxlcmFuZ2U6ODMwN2UyNDI5MTE4NDQxZTgzYTE1YjIxZTcwMjFlNDlfMy02LTEtMS0w_057dca2a-36bd-4742-bf96-fbe5c539a9d2">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.129%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="i68cb5038c4e341a8bb7e0d23eae19b25_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzQyOA_464e3689-a180-4dc9-9870-1e798ab1dd14">81</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i998b7cab204741c28fcd51dd94bad45f_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzQzNg_9829b94c-3d2f-4386-8d66-76b9f674f276">60</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. For the six months ended June&#160;30, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="i6a803537d6434bee8f5afde8a4ef80c5_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTE5Ng_29c91d7a-595b-47ba-873b-dbb8b76b9091">81</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic48e64747d464d9bbd1afc1bf9d6cc47_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTIwNA_32f5d818-cefb-4fbf-b62e-6777932c0f0a">72</ix:nonFraction>%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For each of the three and six months ended June&#160;30, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="i51f9aedf4a1c437d845bc8e10b3515a0_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzY0NQ_006c88f6-b4b2-45b7-a526-b516e89c65e6"><ix:nonFraction unitRef="number" contextRef="i39ca528d80c5424f812a294764c8b9e7_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzY0NQ_17dca416-71fe-4592-a469-560935ac60a1"><ix:nonFraction unitRef="number" contextRef="i0e927f12ecfb4ca884308d22fe725b51_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzY0NQ_dcf5c07e-f827-44ee-994f-a170e1f07794"><ix:nonFraction unitRef="number" contextRef="i5cf77992ac8849b0b8f3496176757612_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzY0NQ_df55ce3d-fa88-42b5-8fa2-2d3c0592e792">97</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTY_64e92288-4547-4d6d-89ca-5bbea754c78b" continuedAt="ibd7a72809e764bad9eecdf0d3e0d64ed" escape="true">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i97a17c4a6d4b45bca96c8662fcce78dd" continuedAt="ic70e5a7f4df34aac823b5dd56c0fc663"><ix:continuation id="ibd7a72809e764bad9eecdf0d3e0d64ed"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7885defdea48b79ac4c92e06b53809_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfMy0yLTEtMS0w_4a439db2-9117-4832-a4dc-9051cd50e6a5">7,381</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie91517e9ab974cbd90efe111ae240752_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfMy00LTEtMS0w_d8471268-d257-4c0f-94cc-2656f565f3ab">4,138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e0cc5e4bba4bedb4ecef0c7823eed5_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfMy02LTEtMS0w_2cc9f8e7-068c-457f-8f1f-39cf50dbd754">13,408</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568a53683fbf488c94e44430a6963b63_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfMy04LTEtMS0w_04f3cfb5-be9d-4d4d-8847-fa74a13c2b9c">10,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a58092b38ba40109a35c69dca20121f_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNC0yLTEtMS0w_d4dddadf-e7c6-40d7-8c77-145f691f3d0a">2,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21a06f4627b43ad9babcc317f3f97d2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNC00LTEtMS0w_d5166685-d3a1-430f-b90f-969ef844c348">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7956a164bef94499b35cc310c4dfa294_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNC02LTEtMS0w_4060056d-276e-45c3-8607-392f5bc63d18">4,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871675045d654924b72a5dff008b67ed_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNC04LTEtMS0w_c389ecb2-839b-43b0-9ecb-74a937f95802">4,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9092bb8a26fc4e91aaa2cd450c799ddd_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNS0yLTEtMS0w_346212ba-54d3-41b7-9111-c4b50aac272c">2,427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3b44a9c5c04e059b0deb00b7ec0856_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNS00LTEtMS0w_91cdc550-9fc3-423a-b962-0c2541c4644b">746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9891076fa8c64cd7a563f92569372319_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNS02LTEtMS0w_f9aac15e-6112-482a-88a1-3455f383ee52">4,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7a7a50804f4d55974db533637b345c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNS04LTEtMS0w_cfd4678e-6299-44b0-afa3-835ff17112a1">1,828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0caa9d180cf9428e911a0e8958c06187_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNi0yLTEtMS0w_a1d82da2-cf34-4945-b1ee-e583325db20d">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92986ea9525425a99124a727802cafa_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNi00LTEtMS0w_1bcaa2cc-0c5b-4d75-85f6-9d7352a0a0ad">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec98ad996148414b982b48ce1fb97499_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNi02LTEtMS0w_19707bbe-4fc2-41b8-b2a3-bf9a5ac46827">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9b2e1719a224e7e80ad848e2e398f17_D20200101-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNi04LTEtMS0w_3c9bbcaf-6dea-48bc-bba7-255f566d1900">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba69b5a6c3564f0f80195f7298100232_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNy0yLTEtMS0w_9ba69ff6-71dc-4986-987e-29286b28dc2a">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcd4bbc200954114b1e61bdcf69d26ef_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNy00LTEtMS0w_d38bc121-65c2-4bb2-b379-e40590dbfc83">2,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32ca735999a14a46b0051553431233d7_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNy02LTEtMS0w_c07646eb-8f98-4c19-a08e-7b8af3daf1b2">600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e011876b544007978e81d4e8a12381_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNy04LTEtMS0w_698b1b62-19fd-4be9-942c-e9b010a33ce5">2,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfOC0yLTEtMS0w_d309cbb5-f583-4bb4-bda1-265116c640f2">12,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfOC00LTEtMS0w_064f4ba5-9d8b-4ee3-ab16-19e54b017035">8,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfOC02LTEtMS0w_80b3e485-0d30-4a1e-94a5-95af8c60e96d">23,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfOC04LTEtMS0w_f861a524-619b-4961-b80e-f12ea557f69b">18,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDM_37090c20-7e3a-4851-aa78-b433f6d0ecf1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTA_c0d677a8-dfd4-483f-a5d9-3f574c6e6318" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $<ix:nonFraction unitRef="usd" contextRef="i06c5a5ab8a2e4bf7895c99d6d53c706e_I20161231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfNjIwOA_232466cb-beb3-415d-8dc6-0941237abf26">0.1</ix:nonFraction> million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMjA_15bf204f-3633-4f62-a7c4-290d1991bcec" continuedAt="ic20789c6c0a14e4b85f734e3e6257beb" escape="true"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMjA_a1460d1c-c82a-4bef-a245-9d9661daaca2" continuedAt="ie2dacc93edf843798266c82e6ca9a7a0" escape="true">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic70e5a7f4df34aac823b5dd56c0fc663" continuedAt="i3bc0bf189fef4df19215f20690d3797f"><div><ix:continuation id="ic20789c6c0a14e4b85f734e3e6257beb"><ix:continuation id="ie2dacc93edf843798266c82e6ca9a7a0"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfMi00LTEtMS0w_fe58c77b-da81-4272-808e-d54ec2a8daa2">112,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfMi02LTEtMS0w_88d20884-088a-47ce-a277-79e8de20eeec">57,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfMy00LTEtMS0w_32c0647c-f328-448f-978f-d6af8213f7fb">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfMy02LTEtMS0w_095be0de-da51-44d9-877e-a9d200722d60">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfNC00LTEtMS0w_0a4a4344-413d-4dd0-aa2f-96262c99e86c">112,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfNC02LTEtMS0w_87790e1f-2792-4038-a0cb-69a67f19ec23">57,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMjE_ba33e32f-5a4f-44a5-a1c1-84c83c8bcd6f" escape="true"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement effective on August 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Janssen Agreement, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the first and second quarters of 2020, the tiered promotion fee ranged from $<ix:nonFraction unitRef="usd" contextRef="i3a0e4213bad142eaa4399139407152d9_I20200331" decimals="0" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfOTg4Mg_c4629882-f8a3-418a-965c-d86ebd619668"><ix:nonFraction unitRef="usd" contextRef="ia28be9a1944346ff97180e2bd48e846e_I20200630" decimals="0" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfOTg4Mg_ed218f4e-0751-4e2c-a6d5-c7fd744d94b7">750</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i2af77a6c91de42baa701376938862bef_I20200331" decimals="0" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfOTg4OA_3158c55b-31ed-4a12-a721-d404a5345668"><ix:nonFraction unitRef="usd" contextRef="iaa0c42e21a78482eb4842f031387a636_I20200630" decimals="0" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfOTg4OA_95bfafdf-f699-4dcf-a469-dd6f3c39ac88">1,250</ix:nonFraction></ix:nonFraction> per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended to adjust the predetermined average baseline for the third and fourth quarters of 2020. The Janssen Agreement was further amended in June 2020 and December 2020 to adjust the predetermined average baseline for prescribed units for the quarters ending December 31, 2020 and March 31, 2021 and was subject to further adjustment under certain circumstances. In June 2021, the Janssen Agreement was again amended to proportionally increase the baseline for prescribed units for the quarter ended June 30, 2021 to reflect the addition of certain geographies to the sales territories covered by the Janssen Agreement. For the first and second quarters of 2021, the Company is entitled to an amended tiered promotion fee ranging from $<ix:nonFraction unitRef="usd" contextRef="i355e8ad01573466884248e15012957d3_I20210331" decimals="-2" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5MTU_8d60c425-3253-444a-b496-bdbc94ce937d"><ix:nonFraction unitRef="usd" contextRef="i997cfa266cc049a8a0eb6ce9d22ce202_I20210630" decimals="-2" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5MTU_a37f8e66-900c-4297-a5b6-889a25cd02a6">500</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="i095b975d91e844528a4ecbc0d02226ab_I20210331" decimals="-3" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5MjE_48fcc296-9330-4e89-9512-40fc4a178d90"><ix:nonFraction unitRef="usd" contextRef="i6b212ea1c94f44ddb43e8958f910b803_I20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFeePerPrescription" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5MjE_54ff4ac7-8b1f-45de-b30d-ce9a5dc57cf5">1,000</ix:nonFraction></ix:nonFraction> per prescription based on the incremental increase in total prescribed units, and the Company is entitled to receive a promotion fee of at least $<ix:nonFraction unitRef="usd" contextRef="i997cfa266cc049a8a0eb6ce9d22ce202_I20210630" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTExNDA_c31a5e61-b5bf-485f-a63d-ef38cc7f6a64"><ix:nonFraction unitRef="usd" contextRef="i355e8ad01573466884248e15012957d3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="exdx:JointVentureQuarterlyPromotionFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTExNDA_ec5d8af5-4558-41b3-9042-133a20ce72bc">0.3</ix:nonFraction></ix:nonFraction>&#160;million, but capped at <ix:nonFraction unitRef="number" contextRef="i0deb0612dda8455fad61349cd2e577de_I20210331" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTExNzM_2034d03a-43be-4caa-bbf3-33a70364b3bd"><ix:nonFraction unitRef="number" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" name="exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTExNzM_fee41727-7c01-4483-9ed8-d53a4587af87">10</ix:nonFraction></ix:nonFraction>% above the adjusted predetermined baseline. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3bc0bf189fef4df19215f20690d3797f" continuedAt="i8267acbd066e4b39b5d09a3ee9eb612a"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Janssen Agreement's termination, the Company is entitled to receive an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iac6d296eb29947729818846e34e334fe_I20210630" decimals="-5" name="exdx:JointVentureTerminationConsiderationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY1NDIyNQ_94eb894d-1899-4280-8358-95610575aa58">0.6</ix:nonFraction> million in consideration. During the remainder of the term of the Janssen Agreement and the 9 month period immediately following its termination on August 31, 2021, the Company will be restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the Amended Janssen Agreement is cancelable. The Company recognized co-promotion revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i7df835bc9321482ea1c21e97a45b2b46_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTMxMzg_fe1e215c-d2bd-44f4-995e-c43ea50a7501">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie5cf118bed6843c49e51e3a063b2f215_D20200401-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTMxNTM_a3defa91-4194-463e-9e07-aa6e896dc323">2.1</ix:nonFraction> million during the three months ended June&#160;30, 2021 and 2020, respectively. The Company recognized co-promotion revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="ifa166a05412145609609afa9045b6c36_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTUzOA_f437282d-f070-4818-8f15-8bfe344ee515">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i28ab5400a6d1441c989c0987429f31c5_D20200101-20200630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTU1Ng_6770b2b7-6947-4977-8594-08bfa93ca2d4">2.1</ix:nonFraction> million during the six months ended June&#160;30, 2021 and 2020, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTc_c1d47b98-9899-4dae-8115-e151442f2554" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTg_7402e965-fa4b-4eec-b3eb-ceb790427e87" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTM5Mjg_7b6feadd-33d3-4ac1-9ce7-cab6ded18c1d">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTM5NDM_afec3b8f-18d0-4707-94db-43d3abc5d2e9">0.3</ix:nonFraction> million for the three months ended June&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTYzNg_5c170de1-0e85-4ee3-ad30-358ae7ed02e8">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTY1Mg_c228435f-e272-41cd-9ea4-6e242e4489e5">0.7</ix:nonFraction> million for the six months ended June&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTY0OTI2NzQ3MDAwNA_a1e4cb5a-cdaa-4c65-ad6d-bc99c3ee5596" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i6d57b7de558142c282a4c8a44d661825_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTQzMTI_b5ff031c-ad10-4eda-ae88-3e2f14e3e2fc">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7b0ebbe6307b48fd8165e0d875dba99a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTQzMTk_abf9c47e-e3c5-4cdd-be19-d8cd7ec52ad2">0.3</ix:nonFraction> million for the three months ended June&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i260acc2d1e664219932adbe50ba9b56c_D20210101-20210630" decimals="-5" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTcyNQ_428e4c6c-193a-4dd7-8b2c-2dc180fa2aa5">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie43b2c29a3af401db0f76f11da748e11_D20200101-20200630" decimals="-5" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTc0MQ_55a67d3f-f29b-49b4-830d-c4525b1df2f2">0.7</ix:nonFraction> million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDU_167c1a1d-f9e3-4404-bf41-3617b110bc53" continuedAt="ie7b8e333ffd94d43840750ef94b9b8e4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was <ix:nonFraction unitRef="number" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTU0Mjg_4bbadb10-f7d2-45d5-9e02-a88c8612cfae">zero</ix:nonFraction>, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8267acbd066e4b39b5d09a3ee9eb612a" continuedAt="i1d14bd11693041cd91bc6f71bb389ac4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie7b8e333ffd94d43840750ef94b9b8e4">The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</ix:continuation></span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDY_a2586088-aa6e-4e0d-bef3-b88028acdaac" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDQ_786aad27-0bb4-46fb-b690-700fdd5873fd" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and six months ended June&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTE_65a7ec33-7fce-4bf4-b36a-26bca8898757" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i727eef9b6d6841bfafb949eedc04adc6_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNC0yLTEtMS0w_7e4cc8f8-1073-4d70-8ee3-6869377da068">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f3bfc019a3043dfa65e9ab76ebb83ba_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNC00LTEtMS0w_56dceb7b-f82c-4a42-874c-4db14765d770">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i748aa018ed14456e8bbd6fefdb2bb343_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNC02LTEtMS0w_22daac04-8e96-478d-a8ee-2ad62d609bc4">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0062233c30074ba2a141cbf88bac2dfc_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNC04LTEtMS0w_bec68c20-1851-49c1-af16-bdc4113c2d56">426,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7f37a50b544479a5a49d2f8a7f1de1_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNS0yLTEtMS0w_5b39cdaf-2c08-47e3-a8e9-6451976a122d">2,123,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cbe68f2531c41b2ac7307191c02d60f_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNS00LTEtMS0w_dcbee6a9-9444-4033-b95b-92b997179fe1">1,677,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1de1f702c3940caa18e3c855c718b6f_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNS02LTEtMS0w_510452de-23f5-4660-bbe8-e0c7fac5f44e">2,123,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i70cd681b7da54b718ba2a94de49fe566_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNS04LTEtMS0w_90415c33-9302-468a-b377-a37b0c278220">1,677,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ee2c605c05b4d7184eee467043f7f7b_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNi0yLTEtMS0w_8f931209-0bd7-4869-8e4a-3d9465d4e1da">375,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i521d00286bef46b8988c748f9b09da38_D20200401-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNi00LTEtMS0w_1a6ff3bb-357f-4ee5-910c-65839c0332b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6c88be424ba4421b0681115a0468ff6_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNi02LTEtMS0yODc_5fc29371-c336-4dbe-9351-e88abc73a6f7">375,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3dc1550c49342788746509b902551e3_D20200101-20200630" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNi04LTEtMS0yODI_1708644d-a4ae-4b04-9589-3f5f4218e335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21b606f430d94e608359e908e5675881_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNy0yLTEtMS0w_fe559141-ad7d-47dd-b1e7-68cb32f55647">12,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40ebe85cfda44056a48e8c86297ff80d_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNy00LTEtMS0w_21dfee8e-72e6-4422-973f-f9519cfec98e">10,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice4ce2fdc8a245879ca524ab3fef616f_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNy02LTEtMS0yODc_8d09cd70-3d19-40f8-bcfb-2182e8cd91ff">12,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50fdc73457e64ff58b4af00e94a3d47a_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNy04LTEtMS0yODI_92c79551-5dbd-4af1-8738-e463d1f52e83">10,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfOC0yLTEtMS0w_267be6a8-9508-4731-9fa1-443c315e23a6">2,938,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfOC00LTEtMS0w_2a5237b8-b4ae-4f2e-9c95-4738e358b937">2,114,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfOC02LTEtMS0w_96195114-b811-476b-bafe-7decae7ae791">2,938,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfOC04LTEtMS0w_4778cc2c-1f1c-4c9e-bd35-e6d6fc2da950">2,114,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Assistance Grant Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and the net amount is included in other income in the accompanying condensed statements of operations.</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDE_01031d58-44c9-49cc-9f09-8ac841a09969" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTgwNTA_7ab211d2-8ca7-4e03-a9ed-518bcdf67471">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTM_ee040fdc-4bd9-409e-bbc4-96c76fef6fd7" continuedAt="ic4f7ec6088ac4ecc890b07d4043bfb5c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1d14bd11693041cd91bc6f71bb389ac4"><ix:continuation id="ic4f7ec6088ac4ecc890b07d4043bfb5c"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div></ix:continuation></ix:continuation><div id="i90dcb240c7c649938129ef90b5941787_37"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNjk3_69a83a78-a2dc-44d9-bf6a-3ac8cce03c22" continuedAt="i1d31c8ef59124149a5b3c92a17401263" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="i1d31c8ef59124149a5b3c92a17401263" continuedAt="i7ae2f92076e4408fbc0febaaae0b9693"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNjk4_42b88859-82e8-4967-a49a-9e9be6a38a14" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMS0yLTEtMS0w_84a0425f-b892-42c3-bbed-2383621b2955">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMS00LTEtMS0w_1d5f00d5-ff80-4e3b-86c8-a5f0f5d97027">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMi0yLTEtMS0w_679c544d-cae1-4030-90d9-7aa53e3229ed">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:PrepaidRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMi00LTEtMS0w_e8b4e00e-c46e-4066-a63b-53435677d07e">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMy0yLTEtMS0w_a76ea266-cc4f-4bf3-a716-a4447ef5fe37">1,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="exdx:PrepaidMaintenanceAndInsuranceContracts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMy00LTEtMS0w_534deb67-fc42-4639-a602-cd1b08b40de0">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfNC0yLTEtMS0w_49f827a3-df3a-4d64-9a17-13689f33fd6d">424</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfNC00LTEtMS0w_a9b1a75a-734e-4cac-8e71-9bc5c3444d49">659</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfNS0yLTEtMS0w_824c44ac-044b-4817-9544-fe73d8ac19d9">3,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfNS00LTEtMS0w_c4991594-ca6f-4321-963c-fb82eecf3981">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNjk0_d9f4bd68-7e94-4c9f-a236-971ae9ca4d98" continuedAt="i5aeeda7cebe34cb98f04537524e40700" escape="true">Property and equipment consist of the following (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7ae2f92076e4408fbc0febaaae0b9693"><div><ix:continuation id="i5aeeda7cebe34cb98f04537524e40700"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i019b55474b03417188ce0a6599b09a06_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMS0yLTEtMS0w_cd612064-2a7e-4110-9a07-c4b3bf3c29e7">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48774ed5d6c94ea395c2ad9d1ab2ce4f_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMS00LTEtMS0w_78d92320-05cc-4be0-8e76-b857fc127f96">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf9a3c919134b408f3367b2f162100b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMi0yLTEtMS0w_f2f9153f-a575-4387-8ef4-9d6e6f5b5222">3,856</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91228be59b0d4bbbb6dd3e4e3b5aa38f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMi00LTEtMS0w_79a08c3c-7765-4b2e-ba50-37b2bdfbd7de">2,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f0253166e9425b97baa1464c6dadd8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMy0yLTEtMS0w_67a7cc57-3161-4270-9683-383903620628">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0936318fe184480caddef482306a6003_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMy00LTEtMS0w_564a93e6-26e1-49ed-b8e6-b1ea0e5722b5">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac65fe1c3e84b0088c92074e306b603_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNC0yLTEtMS0w_090824a0-ab15-41e5-9036-5fbb18d2ce97">1,132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdcf495c5bbc4290af9da6a68df65ef8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNC00LTEtMS0w_2b2f9558-ac3a-4622-9729-ff015a0d8fdd">1,072</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6b0b82d0abe422985b1fc6559a21381_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNS0yLTEtMS0w_39b0025a-b505-4661-b2b2-a51c5984ffd3">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i838a40fa91e847cf8a46ed8a5c4fd73a_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNS00LTEtMS0w_4d9d07af-7c4f-4e58-b86b-ca94a0f7f08b">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNi0yLTEtMS0w_cbef0c95-174e-4ee7-af11-b518aff3748e">6,402</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNi00LTEtMS0w_6ef7c0ed-5a8f-40ee-a218-cc610e983bee">5,043</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNy0yLTEtMS0w_998fb2b8-63df-4897-a236-9a46d8b721bd">3,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNy00LTEtMS0w_2c57f5e1-a379-437b-9506-36bf5c79d951">2,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfOC0yLTEtMS0w_fd800313-d2f2-4102-9353-cec73e90566b">3,054</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfOC00LTEtMS0w_7da0c35e-1dff-43e4-b62e-095567c8d0b3">2,102</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for each of the three months ended June&#160;30, 2021 and 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfMzU3_040b6fbc-1dba-4fba-a52b-b157da8fa1f7"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfMzU3_7a13a82a-f6a4-4a74-ad8c-dd3d490e795a">0.2</ix:nonFraction></ix:nonFraction> million, and for the six months ended June&#160;30, 2021 and 2020, was approximately $<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfMTA5OTUxMTYyODU0Ng_28446d66-e40a-41c5-8ff7-7b463486bc0d">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfMTA5OTUxMTYyODU2Mg_f44110ac-a498-4add-b008-473f35d7ab79">0.3</ix:nonFraction> million, respectively. At June&#160;30, 2021 and December 31, 2020, the gross book value of assets under capital lease was $<ix:nonFraction unitRef="usd" contextRef="i878741a4ebe5465789238ff029c6bb05_I20210630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNDY3_3c69146c-03f8-484e-b879-60581952d2bd">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i78b05cb96f9b4ad39ce807d4c92ff525_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNDgy_515a0ab9-f8b0-4d8b-bc6d-61e5fd27bd31">1.2</ix:nonFraction> million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNjk1_b54bdb21-b5f0-4945-9c0f-b1f664cee641" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfMS0yLTEtMS0w_45981310-9f52-41ea-a3f3-06370a2757ba">3,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfMS00LTEtMS0w_750cba1e-9e69-4fbe-a8e0-febeed542791">3,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfMy0yLTEtMS0w_e6ee5c92-cfec-4bc5-a4f6-672739a94053">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfMy00LTEtMS0w_2be7856e-d166-4054-b07d-0331f9a7563b">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNC0yLTEtMS0w_43225c8e-4831-4cee-b14b-7aefcd94fac8">570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="exdx:AccruedPurchaseGoodsAndServicesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNC00LTEtMS0w_20655ae9-d7c4-4c06-bde7-bfcecf6ce625">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNS0yLTEtMS0w_ac0e64c3-a34e-43ef-8cfe-56c3bd0ff2fe">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNS00LTEtMS0w_2cf8d93f-c55a-46ce-b8ec-911d8b54be3b">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNi0yLTEtMS0w_ddfaa0b9-afef-489a-a648-07fa9166292e">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="exdx:AccruedLiabilitiesClinicalStudyCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNi00LTEtMS0w_838321d4-c32c-4dcd-b447-7732c7fdadfd">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNy0yLTEtMS0w_2c7cfdf4-b4ed-4181-a070-f8349da6b648">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNy00LTEtMS0w_df668a0a-4e91-4ae1-9e95-ec119db8ac3f">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfOC0yLTEtMS0w_505dd2ff-a396-4426-8da6-2a19405f1d5e">601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfOC00LTEtMS0w_c3b8c119-05ae-4de9-a98f-569e246ce1a9">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfOS0yLTEtMS0w_899c2c98-6bd4-4556-b921-b57300273f58">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfOS00LTEtMS0w_4d70960d-d0e3-4ccb-bc08-5f297d3c5fef">5,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_40"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNDg2OQ_9093bce5-df23-4a19-8a62-5479fa813533" continuedAt="i71bf31ca3b08485a8975464387e47276" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="i71bf31ca3b08485a8975464387e47276" continuedAt="i44692cee76c441c097b4788f7f44dbe0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $<ix:nonFraction unitRef="usd" contextRef="if3aeb264ea9c49aaa65800b5d232f669_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTk3_5c62fd22-98ab-4d71-b7ba-a30b310eb80b">20.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i25a352deb17e46e3a01049447545824a_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMjAx_135096b0-066e-4ad2-8e13-6aa79e552b15">17.8</ix:nonFraction> million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $<ix:nonFraction unitRef="usd" contextRef="i5cae1ab4f7684fc9984e25a56c343ce2_D20181207-20181207" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMzg1_004596d4-711a-4641-8797-ec64a9faff46">5.0</ix:nonFraction> million under the 2017 Term Loan. At June&#160;30, 2021, <ix:nonFraction unitRef="usd" contextRef="ieced59f9bfea440b98b881cd100be221_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNDIx_a2092ce9-f4d2-454e-ac75-31920123817f">no</ix:nonFraction> additional amounts remain available to borrow under the 2017 Term Loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is <ix:nonFraction unitRef="number" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNjgx_3c253710-9048-492e-8e1c-3afc65661c1a">8.5</ix:nonFraction>%, of which <ix:nonFraction unitRef="number" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="INF" name="exdx:DebtInstrumentStatedInterestRatePaidInKind" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNjk0_b99ae25c-e2ba-4af2-af4b-90d8dd442dc6">2.0</ix:nonFraction>% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of <ix:nonFraction unitRef="number" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfODM2_3c253710-9048-492e-8e1c-3afc65661c1a">8.5</ix:nonFraction>%. The Company has estimated the effective interest rate of this loan to be approximately <ix:nonFraction unitRef="number" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="2" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfOTI3_6dd84702-35d3-4dd9-b2a6-c189ed1df4ed">10</ix:nonFraction>%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTExOQ_db518ce5-2992-4221-8603-2271ebaa5ba5">twenty-four</span> equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $<ix:nonFraction unitRef="usd" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTI5Ng_d410c6c4-1aaa-4c5f-b15c-c42246df54ae">1.0</ix:nonFraction> million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the three months ended </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i44692cee76c441c097b4788f7f44dbe0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="i051865121b864843a7aa6d0196c1ce5d_D20210401-20210630" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTUxMQ_09ca4fbf-6492-42d1-a2b7-d1fa36ee3d58"><ix:nonFraction unitRef="usd" contextRef="id1bf67b90be54de7a4cb661c84afb134_D20200401-20200630" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTUxMQ_2b982bd9-adf4-495d-9732-e58225657416">0.1</ix:nonFraction></ix:nonFraction> million. For each of the six months ended June&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $<ix:nonFraction unitRef="usd" contextRef="ib5205c3992de49bd94179b9de9cea768_D20200101-20200630" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTA5OTUxMTYzMjc4NA_1b54259a-407d-40df-a8af-47d518cbf316"><ix:nonFraction unitRef="usd" contextRef="id13bd35b84c84c08b97cf25c25447a01_D20210101-20210630" decimals="-5" name="exdx:DebtInstrumentPaidInKindLoansIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTA5OTUxMTYzMjc4NA_c8b6f8fb-f69f-442e-9a94-d2937c6f2999">0.3</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment requires a prepayment premium of <ix:nonFraction unitRef="number" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTU3Ng_2ceb3d87-cd79-4d9e-8303-f999daeffcc6">2</ix:nonFraction>% of the aggregate outstanding principal. The prepayment premium decreases by <ix:nonFraction unitRef="number" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="INF" name="exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTY1NQ_5343e0bb-e8d7-4aac-b42e-b1fb7edf2a68">1</ix:nonFraction>% on November 19, 2021 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="-5" name="exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMjkxNQ_3c8d2f26-e20f-48c5-bbfb-26c82162a45d">2.0</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, the Company was in compliance with all covenants of the Loan Amendment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated, and the applicable interest rate will be increased by <ix:nonFraction unitRef="number" contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130" decimals="INF" name="exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNDI4Ng_3288f6f1-a592-4adf-be66-025dac026acd">4.0</ix:nonFraction>% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNDg3MA_b25f3aac-a9d8-4a9c-8839-9e2f25e1eedf" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfMS0yLTEtMS0w_7c28b379-7b29-4635-9888-f8b18d8498cb">889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfMi0yLTEtMS0w_e02ff648-3a6a-4a1e-adf1-b2f024759fac">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfMy0yLTEtMS0w_a9913c83-dd9a-4b28-b209-53ad71c577c8">15,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfNC0yLTEtMS0w_a85531f2-9954-4e0c-8417-ffb00f658df9">14,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:LongTermDebtIncludingUndiscountedInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfNi0yLTEtMS0w_3c098674-bb7e-41f5-baac-d3fbdaae5361">33,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfOC0yLTEtMS0w_c4a14eb8-2639-4e7d-8ae7-427e96e2e2a0">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:LongTermDebtUndiscountedInterestAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfOS0yLTEtMS0w_3e57ceb4-b3ee-446e-805b-c3456910414e">6,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfMTAtMi0xLTEtMA_bb94b046-a3f8-44b8-945f-5d5c8a1c66a3">27,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_43"></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfNDEwMg_6c5df197-145a-4bb6-bb1b-9b21097d7c26" continuedAt="id833290f14894ff59180f45b9720ab5e" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="id833290f14894ff59180f45b9720ab5e" continuedAt="i4efe0b49aea54a05a24738f365d8065a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional <ix:nonNumeric contextRef="i33be34133ab34424a1d393162ac35351_D20210101-20210630" format="ixt-sec:duryear" name="exdx:OperatingLeasesRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjM5_306185cb-32d8-4f79-9c04-deb4725e5191">5</ix:nonNumeric>-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional <ix:nonNumeric contextRef="i586ccca64fab4ff3922bd68ad5ab7254_D20210101-20210630" format="ixt-sec:duryear" name="exdx:OperatingLeasesRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfNDM0_fb6f505d-26b5-4f68-8678-7c1da64e09fc">5</ix:nonNumeric>-year period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2021 and 2020, rent expense was $<ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfNTk4_920682fe-2b27-477e-bc07-d137e5fd1588">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfNjEz_7328c61a-ef88-4d10-8f95-6bf93c77d4fa">0.1</ix:nonFraction> million, respectively. For the six months ended June&#160;30, 2021 and 2020, rent expense was $<ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTA5OTUxMTYzMTk4NQ_e0d04b34-316e-4163-a0f3-fc202fb95d5f">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTA5OTUxMTYzMjAwMg_d13447af-adac-47ab-abd2-07031db82f1d">0.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. As of June&#160;30, 2021 and December 31, 2020, the remaining potential milestone obligation is for an additional $<ix:nonFraction unitRef="usd" contextRef="ic125d46c253c46218b4ff1c223808e5f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="exdx:MilestoneObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTEzMg_9a8b6e6e-cd40-4352-8fbd-2fedb0b324cb"><ix:nonFraction unitRef="usd" contextRef="i64e5fa2583514a499a2c2e814b73a55f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="exdx:MilestoneObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTEzMg_d9749f2c-f08c-4ba2-88f5-4abab0bc180e">2.0</ix:nonFraction></ix:nonFraction> million payment to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be <ix:nonFraction unitRef="usd" contextRef="ic125d46c253c46218b4ff1c223808e5f_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="exdx:MilestoneContingencyFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTIzOQ_1ba56f15-3647-4cf1-a19d-b370a9c580e7"><ix:nonFraction unitRef="usd" contextRef="i64e5fa2583514a499a2c2e814b73a55f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="exdx:MilestoneContingencyFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTIzOQ_c1f4dcfb-07e5-4f6c-90d7-61c28aee21bd">zero</ix:nonFraction></ix:nonFraction> at June&#160;30, 2021 and December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has ongoing royalty payment obligations of <ix:nonFraction unitRef="number" contextRef="ieca6b551f41048dbac2cc2f24a067a81_I20210630" decimals="3" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTM5Nw_b1fc875d-9c69-4489-831a-912f5c567620">2.5</ix:nonFraction>% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ic125d46c253c46218b4ff1c223808e5f_I20210630" decimals="-5" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTQ5Ng_3c433610-738b-4ff2-8c8b-a53a72cdbf35">1.2</ix:nonFraction> million (including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic125d46c253c46218b4ff1c223808e5f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:AdvancePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTU0MA_16dc4c13-83ea-42fb-bf02-745a2a43c772">100,000</ix:nonFraction>) and (ii) the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments ranging from <ix:nonFraction unitRef="number" contextRef="i6ce02fbc4e20421e91f360d2257a0bdf_I20210630" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTk0Mg_1450e53f-b2a5-4439-a140-28e79cadce26">1.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i176ded5488ca41bf8f320b2151888cff_I20210630" decimals="INF" name="exdx:RoyaltyObligationPercentageOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTk0OA_310c7433-1459-49b6-b671-f37b318bb4d0">3.0</ix:nonFraction>% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $<ix:nonFraction unitRef="usd" contextRef="if4f0c91b62b144c98930aada725aeb5f_D20210501-20210531" decimals="-5" name="exdx:LicenseAgreementInitialLicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjQyNA_9c2b7f51-79da-4649-8e2d-b4e6bad726dd">0.4</ix:nonFraction> million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-5" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjYxMQ_2065f9d5-dc55-4afc-ba64-8dc3e71b2158">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="-5" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjYyNg_6733d748-98c3-49f1-a330-b56c536ce453">6.0</ix:nonFraction> million for the years ended December 31, 2021 and 2022, respectively, with a <ix:nonFraction unitRef="number" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="2" name="exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjcwNg_54643166-8cb3-4364-8f1b-b58ce5864b94">15</ix:nonFraction>% annual increase thereafter through the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $<ix:nonFraction unitRef="usd" contextRef="ib81bf8c979f84fd29d5b105929b0d3ce_D20210501-20210531" decimals="-5" name="exdx:CollaborationAgreementAnnualCollaborationFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMzAwNw_49e5f129-93ed-4ee5-b2b0-b3ec536de7b3">0.4</ix:nonFraction> million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $<ix:nonFraction unitRef="usd" contextRef="i9e6063862f0049ad920ccdded39326b3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:CollaborationAgreementCollaborationExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTA5OTUxMTYzMjMwMA_4574f63e-66c3-4553-8e80-dc36a277b6dc"><ix:nonFraction unitRef="usd" contextRef="i17ac12b6a47847b39613a583f3715e22_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="exdx:CollaborationAgreementCollaborationExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTA5OTUxMTYzMjMwMA_b408bda4-dc3f-4f89-8d85-08df3ab2a6fb">67,000</ix:nonFraction></ix:nonFraction> for the three and six months ended June&#160;30, 2021. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4efe0b49aea54a05a24738f365d8065a"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.</span></div></ix:continuation><div id="i90dcb240c7c649938129ef90b5941787_46"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RleHRyZWdpb246MDFkYWE4Yjg4MWY3NDNjYmFlNTIxZTQxZjhlMzFlMTdfMjk4_4cac833c-349d-4c44-bc23-757ebb3d7609" continuedAt="ib0e34f3dd66a4d4b9ded551eea16fd9a" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib0e34f3dd66a4d4b9ded551eea16fd9a" continuedAt="i1ab684e96ea64c829965ddb5b2933af6"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RleHRyZWdpb246MDFkYWE4Yjg4MWY3NDNjYmFlNTIxZTQxZjhlMzFlMTdfMjk5_b7bd71c5-a5d7-42cc-ab30-f4ac2bc61cfa" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie918642c1b394009ad0b69833a6119be_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOjIwY2ViMGIxNGMyODQxMTE4MDY2NDhhNGM3ZjBkMDBlL3RhYmxlcmFuZ2U6MjBjZWIwYjE0YzI4NDExMTgwNjY0OGE0YzdmMGQwMGVfMy0yLTEtMS0w_db2499e8-9f1a-4e38-b913-b37721189d2e">105,719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d194d9380fc4177be4de2c4474844a3_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOjIwY2ViMGIxNGMyODQxMTE4MDY2NDhhNGM3ZjBkMDBlL3RhYmxlcmFuZ2U6MjBjZWIwYjE0YzI4NDExMTgwNjY0OGE0YzdmMGQwMGVfMy00LTEtMS0w_c02e7b1b-34ce-4ebb-9b70-cc3f5358e42b">105,719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i239c9597bcdc4b76b9572e7dc62e7793_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOjIwY2ViMGIxNGMyODQxMTE4MDY2NDhhNGM3ZjBkMDBlL3RhYmxlcmFuZ2U6MjBjZWIwYjE0YzI4NDExMTgwNjY0OGE0YzdmMGQwMGVfMy02LTEtMS0w_a658343e-9085-452d-9d34-acdb1ae2be8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88553bc1fc4946cfacf88eb4b595623d_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOjIwY2ViMGIxNGMyODQxMTE4MDY2NDhhNGM3ZjBkMDBlL3RhYmxlcmFuZ2U6MjBjZWIwYjE0YzI4NDExMTgwNjY0OGE0YzdmMGQwMGVfMy04LTEtMS0w_057725a7-c544-4fe5-bf12-e6bb94ffdb2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21c725659c554256894e6753bca963bb_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOmYyYTgwYjk4MTY0NjQ2N2VhNThlYzMyMjdiMzM0M2U1L3RhYmxlcmFuZ2U6ZjJhODBiOTgxNjQ2NDY3ZWE1OGVjMzIyN2IzMzQzZTVfMy0yLTEtMS0w_e6eb5cbf-78aa-44e1-98b7-7036bc6aa8bf">34,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9801f382d4c346349a3739ac75eb6c29_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOmYyYTgwYjk4MTY0NjQ2N2VhNThlYzMyMjdiMzM0M2U1L3RhYmxlcmFuZ2U6ZjJhODBiOTgxNjQ2NDY3ZWE1OGVjMzIyN2IzMzQzZTVfMy00LTEtMS0w_b1ab74d1-1471-49fd-8f6a-cd7b318e7552">34,507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2a0e15468d14f1d800e862e526e0bd8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOmYyYTgwYjk4MTY0NjQ2N2VhNThlYzMyMjdiMzM0M2U1L3RhYmxlcmFuZ2U6ZjJhODBiOTgxNjQ2NDY3ZWE1OGVjMzIyN2IzMzQzZTVfMy02LTEtMS0w_2bcc54e0-fd00-4b1e-9ee7-749f9ae22a6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad87945e18794ca292bc45b973f89c11_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOmYyYTgwYjk4MTY0NjQ2N2VhNThlYzMyMjdiMzM0M2U1L3RhYmxlcmFuZ2U6ZjJhODBiOTgxNjQ2NDY3ZWE1OGVjMzIyN2IzMzQzZTVfMy04LTEtMS0w_10e909f0-d36a-4db8-ab31-1f13a295f086">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ab684e96ea64c829965ddb5b2933af6">The fair value of the Company's money market funds is based on quoted market prices.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i90dcb240c7c649938129ef90b5941787_49"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfODcz_dd416f80-9208-48a3-88d4-e986731c05c2" continuedAt="ic2cf427c8f2b45ada24b77666840d999" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="ic2cf427c8f2b45ada24b77666840d999" continuedAt="iabf98bee6e89483ca24b4ae2f21bec38"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $<ix:nonFraction unitRef="shares" contextRef="i045a54532883447b9ba4d8e5b2a6eae3_D20201110-20201110" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMjEz_d3d4c9df-a823-4edf-9885-a5fa1b72e366">150.0</ix:nonFraction> million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="ie922f6d9a6124200b1afa6562935970c_D20210325-20210325" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfNDMx_e0051d67-6a4b-4efe-b65c-285ab5b9bad3">4,255,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie15d6bb2bda3454aac07113283b3188f_I20210325" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfNDkx_2917e809-673a-49bd-b860-f51a851fd338">16.25</ix:nonFraction> per share. Net proceeds from the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="ie922f6d9a6124200b1afa6562935970c_D20210325-20210325" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfNTU1_e239e00d-08ef-4fc4-a584-d4d092646c58">64.7</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="ie15d6bb2bda3454aac07113283b3188f_I20210325" decimals="-5" name="exdx:StockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfNjQ3_247c66ce-5e3a-4ef0-bcc3-287783be225a">4.4</ix:nonFraction> million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an Investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9460ad066b9b478eab9cd1f7a6a40ac1_D20210622-20210622" decimals="INF" format="ixt:numdotdecimal" name="exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTA5OTUxMTYyODkyOQ_ffd116a3-a0d8-4d2c-a327-19f7a3366512">804,951</ix:nonFraction> shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1f2162308c734d97b338ad4453278bb5_I20210622" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTY0OTI2NzQ0NDkwNw_d088ade7-4eb4-40ad-9e31-00050bbc5f05">804,951</ix:nonFraction> shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1f2162308c734d97b338ad4453278bb5_I20210622" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTA5OTUxMTYyOTM1OA_28df6ac6-b728-48cc-83a2-c16aa75da169">0.001</ix:nonFraction> per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i9460ad066b9b478eab9cd1f7a6a40ac1_D20210622-20210622" decimals="4" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTA5OTUxMTYyOTYzMA_1a7fa0b7-bc87-4a46-b50c-f2840726bb15">4.99</ix:nonFraction>% of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iabf98bee6e89483ca24b4ae2f21bec38"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTY0OTI2NzQ0NDk0MA_e1f4139e-1754-422e-a54a-9f41ea18c749">none</ix:nonFraction> of the Exchange Warrants have been exercised.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfODc2_61f56acf-e3b9-4ab5-9224-697ac82c7a67" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i492e5c40d7034eaf962d0469c7c795cf_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMS0xLTEtMS0w_5aa94b3a-56df-467e-aef8-0b032a613eef">252,798</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i492e5c40d7034eaf962d0469c7c795cf_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMS0zLTEtMS0w_daf18f9a-c7ce-4314-95a2-4b2b2a1cb664">1.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i071b488b09a1417c91811e6d8f3d29b3_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMi0xLTEtMS0w_777b0c95-90c0-4b0a-9719-0f424298557b">69,176</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i071b488b09a1417c91811e6d8f3d29b3_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMi0zLTEtMS0w_9596d737-d318-40f8-ae69-9f05dad7ddbf">1.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73ee8d512a0840b190f350455a2ed1a9_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMy0xLTEtMS0w_bb146a23-5bef-48d0-8926-833b3758fdff">131</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i73ee8d512a0840b190f350455a2ed1a9_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMy0zLTEtMS0w_dee3c2fa-0af2-43e1-a4ff-895bc98a7349">1.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5761e4153746f5a98d6355c0258668_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNC0xLTEtMS0w_b53629a8-b152-4acc-81dc-c4bf154e491f">83,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e5761e4153746f5a98d6355c0258668_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNC0zLTEtMS0w_1389040a-f450-420c-a27f-65e8b4c3e362">14.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51452bd995b44c0083d3c57b6f6acef2_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNS0xLTEtMS0w_5ecfb672-d599-45f6-ba69-7e1df717fed1">20,944</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51452bd995b44c0083d3c57b6f6acef2_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNS0zLTEtMS0w_8daa1a31-ece8-4e07-acd8-dcf25b7e245a">14.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9815b27e2974facbe3b603ea097a3f5_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNi0xLTEtMS02NDc_ca8a880b-8ead-4496-a428-afba01721b87">804,951</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9815b27e2974facbe3b603ea097a3f5_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNi0zLTEtMS05NTE_aef78a5b-f6cf-48b3-a935-c09506fa2e30">0.001</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNi0xLTEtMS0w_4c1c93f7-6a7e-4b56-83ff-d275b58eaf4f">1,231,778</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_52"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzA0MA_09952ac1-6527-40c5-992f-fecc252cfb1a" continuedAt="i80619932f17d4b129a0bc5c7922d6b47" escape="true">Stock Option Plan</ix:nonNumeric></span></div><ix:continuation id="i80619932f17d4b129a0bc5c7922d6b47" continuedAt="iecac22452df34d318d62b6fb993245e7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire <ix:nonNumeric contextRef="i380b31af79e04aba8a6b53172095dbb6_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfNTM2_c5cdc72c-1aca-4a19-9f4b-ff07c4485407">ten years</ix:nonNumeric> after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally <ix:nonNumeric contextRef="i380b31af79e04aba8a6b53172095dbb6_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfNjcx_d554ceab-eee6-42a0-a105-d64a14e62d21">four years</ix:nonNumeric> from the date of grant. As of June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="ic82819fc6d4c4f04baba439733edc724_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfNzA4_f8910b18-6f5f-44e9-8b21-9e716df346cc">1,112,598</ix:nonFraction> shares of common stock remained available for future awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="i0298f7cc8a044f3ea0148fea59992a10_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMTExMw_b621c197-f7c0-4142-8d32-1bfdeb58c191">20</ix:nonFraction>% of their eligible compensation. As of June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i0298f7cc8a044f3ea0148fea59992a10_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMTE1OA_14f82e93-8f31-4076-923b-f55bb4924b4a">345,493</ix:nonFraction> shares of common stock remained available for issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzA0MQ_f1be83e4-1de2-4414-a921-d83665280b20" continuedAt="i7b9d2f9fb8034bf2a7d752a639f684c0" escape="true">Stock option activity under the Company's 2019 Plan is set forth below:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iecac22452df34d318d62b6fb993245e7" continuedAt="i54148982d2ab4cd3be518dd356741f2b"><div><ix:continuation id="i7b9d2f9fb8034bf2a7d752a639f684c0"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4ffae978ff094b5595bb90b4291d7670_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMS0yLTEtMS0w_174d6893-dcca-402e-9ba0-97f93fe982e8">1,975,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4ffae978ff094b5595bb90b4291d7670_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMS00LTEtMS0w_ce5e41d9-3c2c-419e-a995-4289a80b7bd5">11.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7ac35630d5b74bbdb0694e77844fc22f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMS02LTEtMS0w_00dc2352-10f3-4bfd-b807-2d42f17c1be3">8.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ffae978ff094b5595bb90b4291d7670_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMS04LTEtMS0w_d90115ca-ea77-4ff5-8cd4-6fbfb9c4fc69">6,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMi0yLTEtMS0w_194d4149-a521-4175-b7f1-d934aad5e07a">214,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMi00LTEtMS0w_f93230ef-e92f-4a2f-b155-e3f7611fad9e">17.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMy0yLTEtMS0w_6896a6bf-c306-40de-881e-35440129129c">9,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMy00LTEtMS0w_c2299d0b-4356-45a7-82ce-795b8c8c989a">8.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNC0yLTEtMS0w_e7ad49aa-39b7-4093-899e-7b5e41d6b1bd">54,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNC00LTEtMS0w_68d5a8d5-b783-46d9-9eb1-76a0bc0f2335">12.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNS0yLTEtMS0w_0b827e0c-beee-4e74-9c80-b37afacd4570">2,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNS00LTEtMS0w_77827af1-4dfb-46c5-99db-2d3588124666">26.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNi0yLTEtMS0w_1b034b3e-a9e9-4255-81b9-795b5baa2d51">2,123,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNi00LTEtMS0w_5337c897-1ebf-48e6-96ad-758794a22ea7">12.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNi02LTEtMS0w_3ec6307e-c3d6-495b-9fcc-47400c1cffe4">7.96</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNi04LTEtMS0w_66c68eb7-def5-4a50-b9aa-0c599eb73d7e">8,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNy0yLTEtMS0w_16505a5d-8a53-4a0c-9f93-354952f499fe">2,123,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNy00LTEtMS0w_dc6c28c5-f960-4f3d-8f96-4a1891583063">12.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNy02LTEtMS0w_0d0b66aa-cfc4-43fa-8250-481241342ed0">7.96</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNy04LTEtMS0w_d960ed8c-3833-4106-b3cc-104f4e2fceae">8,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfOC0yLTEtMS0w_01da33d8-bab6-4137-b0e5-ceed9be34001">812,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfOC00LTEtMS0w_f79347eb-6771-4072-80c6-686ce7b741cb">10.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfOC02LTEtMS0w_d09e27ea-23a0-4ba7-884a-c2ab695601bf">7.47</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfOC04LTEtMS0w_c8071346-00a6-441c-b445-9de20b0d6a1e">5,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of June&#160;30, 2021, total unrecognized compensation cost related to option awards was $<ix:nonFraction unitRef="usd" contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMTUzMQ_edb40a79-946a-4621-847d-20cb516bb4fe">9.1</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMTYzMA_19a53e12-a2bb-4d9a-9a74-e8ac9b772e54">2.4</ix:nonNumeric>&#160;years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzA0Mg_908dbbbf-d378-4c9e-8e7b-15d38d90f241" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMS0yLTEtMS0w_ab2364e7-a475-4f61-b6c0-c663d4a7bd03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMS00LTEtMS0w_09e41bac-14e4-4262-b5da-6bd88d938515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMS02LTEtMS0w_19f8c427-dc7a-4c83-aea1-3e8b4a07c6e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMi0yLTEtMS0w_8debe7f9-5eb2-4e0c-9a4c-2520b9d69232">389,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMi00LTEtMS0w_00509269-3dce-4c7d-b3af-71649d8c0dff">17.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMy0yLTEtMS0w_d60ca452-04c0-4a24-a73d-3c8014b23a94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMy00LTEtMS0w_5b78fee5-2ff0-4957-859b-e279ddf03de3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNC0yLTEtMS0w_53c93581-2471-40e1-86a4-71138f03deff">14,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNC00LTEtMS0w_81517000-6389-47d0-8a7a-e7c667694a0e">16.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i809b83fd5e2949e98dfca51a6405bc5e_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNS0yLTEtMS0w_b34385c5-2598-4c77-9ead-34661611009a">375,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i809b83fd5e2949e98dfca51a6405bc5e_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNS00LTEtMS0w_595a79f1-7401-4f67-b32d-c2f30fa13556">17.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809b83fd5e2949e98dfca51a6405bc5e_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNS02LTEtMS0w_102cc114-27ba-436c-9614-253b55962e08">5,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, all of the outstanding restricted stock units are unvested. As of June&#160;30, 2021, total unrecognized compensation cost related to restricted stock units was $<ix:nonFraction unitRef="usd" contextRef="i809b83fd5e2949e98dfca51a6405bc5e_I20210630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMjAyMg_a853e93c-4b01-4bff-a1df-7058249fdbd2">6.0</ix:nonFraction> million, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMjEyMQ_dce47679-25c5-402b-b47c-e64a09851189">3.7</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzAzNg_1437b4cf-551e-48ee-9331-5b3dee64f408" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi0yLTEtMS0wL3RleHRyZWdpb246YTk2NzQ3M2RjOTMwNDcyYmEwMDM0MWU4NzUxZjQyZDNfNA_66a9e82d-0dbb-4bb0-9ade-e09840345bda">83</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b2f240e32a94e0091882c0f86aec9c2_D20200401-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi00LTEtMS0wL3RleHRyZWdpb246NTlhMmU1ZDhiYTJhNDAxNTlmOTE2NWJhMTFlMmY1YmZfNA_749f1948-92d5-4dc3-9878-882560ba0678">51</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi02LTEtMS0wL3RleHRyZWdpb246ZDUwZDdkZDk2NjFhNDI3MGFiNjY0ZTc1NjIyOThhZjVfNA_1a9b8059-5b2e-4d14-9c11-faf627317a5e">83</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi02LTEtMS0wL3RleHRyZWdpb246ZDUwZDdkZDk2NjFhNDI3MGFiNjY0ZTc1NjIyOThhZjVfNw_bc7b6529-a416-42e3-b102-5a11ef75d801">84</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi04LTEtMS0wL3RleHRyZWdpb246NTc3NDU1ODhmNGExNDhhZjhiMzkxNjRlNWY5ZWE1OWFfMTA5OTUxMTYyNzc4NA_696a2692-f09d-4eb1-8f54-e8b6cf4ab1ed">47</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi04LTEtMS0wL3RleHRyZWdpb246NTc3NDU1ODhmNGExNDhhZjhiMzkxNjRlNWY5ZWE1OWFfMTA5OTUxMTYyNzc5MA_84b4d883-09d7-4f58-903c-fa7a2b905ebf">51</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy0yLTEtMS0wL3RleHRyZWdpb246NWE1YzIwOTJkZDcyNDZlN2EyZWJmMjBhYmVhOWZmOWZfNA_47f06e38-3eda-4fee-b988-054d5700df43">1.1</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b2f240e32a94e0091882c0f86aec9c2_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy00LTEtMS0wL3RleHRyZWdpb246N2E2OTc3NGI4YzA0NDZkMGE2MGUzMjE3NTIyNDcyOTZfNA_c71bb8b8-bd9f-4f35-9540-86bfc05168fc">0.4</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy02LTEtMS0wL3RleHRyZWdpb246Y2FkYTkzZGZlNmIzNDViYzk2NjlhNmRiYWRlMDYzNWVfNA_73cbf05e-e74f-45bd-b4a1-31940fdc5ceb">0.8</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy02LTEtMS0wL3RleHRyZWdpb246Y2FkYTkzZGZlNmIzNDViYzk2NjlhNmRiYWRlMDYzNWVfNw_50ce8e5a-6435-491d-bc0b-59b22b27851f">1.1</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy04LTEtMS0wL3RleHRyZWdpb246MDg0OWY1YTQ5ZTI2NGMzNDg0ODBmNjM0ZjhmNTUwNGZfNA_bbc77f61-5175-488c-bd9d-4bdb99e3f1e8">0.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy04LTEtMS0wL3RleHRyZWdpb246MDg0OWY1YTQ5ZTI2NGMzNDg0ODBmNjM0ZjhmNTUwNGZfNw_6cc48dd9-1272-436b-996d-e554d8019679">1.7</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNC0yLTEtMS0w_8180021a-184a-43a8-bbf0-3635aa8e51dc">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b2f240e32a94e0091882c0f86aec9c2_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNC00LTEtMS0w_fa234983-6edc-45bc-a11b-d6b917208b67">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNC02LTEtMS0w_9417591e-ac8d-4a8b-b94c-f81ba410dff6">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNC04LTEtMS0w_c933109d-3fe3-4da6-8b65-31b72aa55977">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i053c7646827546d5980da48ba6995176_D20210401-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS0yLTEtMS0wL3RleHRyZWdpb246ZjhjNjUyZTIyZjM1NDY1MWI4MWU5MDkyYWUyYTQ4YjdfNA_8cf3cfe3-0168-4ffe-ad02-704e79e14d87">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="iddcb859bbff74e819108a02b2f35c671_D20210401-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS0yLTEtMS0wL3RleHRyZWdpb246ZjhjNjUyZTIyZjM1NDY1MWI4MWU5MDkyYWUyYTQ4YjdfMTA5OTUxMTYyNzc4Mw_ec120109-4e93-4b16-b12a-99db8799b244">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22f749fcc65a465494ce02dd6f69461e_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS00LTEtMS0wL3RleHRyZWdpb246MzJiYzNhYTJiNWM2NGY1ODk2MjIzZmMyNGNjODA4YTdfMTA5OTUxMTYyNzc4Mg_254c5904-a828-4473-afb2-94f111a644f2">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="iaddaedafdc194a299eae12d2f0b746f8_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS00LTEtMS0wL3RleHRyZWdpb246MzJiYzNhYTJiNWM2NGY1ODk2MjIzZmMyNGNjODA4YTdfNA_c09df3e0-b2b2-4b97-9c65-0ee0693a89d2">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7c18c0730b4c4c2f89587dfd06467595_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS02LTEtMS0wL3RleHRyZWdpb246NDA4YWQyMThmYmY3NDgwY2IyODcwMDU2ZTY1Y2UyM2VfNA_4c194f85-145b-4b66-869a-de0a7ea21426">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="id749abe27a0440ca809efd67793994ed_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS02LTEtMS0wL3RleHRyZWdpb246NDA4YWQyMThmYmY3NDgwY2IyODcwMDU2ZTY1Y2UyM2VfNw_429bcef5-5d31-434a-8525-016a6e94fd2f">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bd31cf38fcb436d84f561912752611e_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS04LTEtMS0wL3RleHRyZWdpb246M2Y5N2ZhNzlhNmY4NDVhZmIxNzJjY2NiYjQyZGZiNTVfNA_e9327669-2c13-45ed-a320-e5c69b3d5b46">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="i53db86996c4a4b2aa8810e431ba1895c_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS04LTEtMS0wL3RleHRyZWdpb246M2Y5N2ZhNzlhNmY4NDVhZmIxNzJjY2NiYjQyZGZiNTVfNw_52f0a58b-cdfb-47da-b4f5-fa4862c883af">6.08</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzAzNw_dcfd6b4e-c7da-49f4-b7ae-ef878071c16d" continuedAt="i5675200208484fddb2e622709399e1e3" escape="true">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i54148982d2ab4cd3be518dd356741f2b"><div style="margin-top:9pt"><ix:continuation id="i5675200208484fddb2e622709399e1e3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMi0yLTEtMS0w_f24e2c3f-5999-4d60-a151-8bb4ee77c9a3">60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMi00LTEtMS0w_d9412978-9f3a-4c39-a951-3b240d585399">58</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMi02LTEtMS0w_e4d7bd64-d974-41bc-a273-f8c6ba25f3c0">60</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMi04LTEtMS0w_d804c05e-d414-49f3-84f6-cba1fa20e5bf">58</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMy0yLTEtMS0w_54cc142a-3e92-4b36-87ff-8f5fb779273c">0.1</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMy00LTEtMS0w_03e8be33-ee01-4c45-b479-2c5ea832d572">1.1</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMy02LTEtMS0w_52d05454-be41-4e1e-9462-54e18f5fbcaf">0.1</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMy04LTEtMS0w_dee7aca6-bf52-46bd-8417-a612a39ad039">1.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNC0yLTEtMS0w_723573b3-7ad8-419e-9b39-d8e0f558b4aa">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNC00LTEtMS0w_ad3fcf52-3644-4168-86b7-f4fa079c3507">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNC02LTEtMS0w_1956a693-bb38-4598-a3b6-cec8b42afd54">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNC04LTEtMS0w_a15be596-6012-4ecd-9b28-5e336039c88e">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNS0yLTEtMS0w_e175fe74-75ce-4f81-b5f5-3b135e32d8ad">0.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNS00LTEtMS0w_1d68da68-6829-4b24-ae3d-f72c50d06909">0.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNS02LTEtMS0w_9c7cfd4a-2c54-4226-8160-18e222c5124c">0.50</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNS04LTEtMS0w_e016f0e4-89f9-4afd-bd88-40f2d7860721">0.50</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for the ESPP was immaterial for the three and six months ended June&#160;30, 2021 and 2020. As of June&#160;30, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was an immaterial amount, which is expected to be recognized over a remaining weighted-average vesting period of <ix:nonNumeric contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMjc4OA_fef4b128-1d5e-46d7-9e3f-37ec5b6a4e98">0.2</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzAzOA_30c23347-9174-4875-8166-89082d9aa537" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd1752efb344048b8a02fcfe6fb0f95_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMi0yLTEtMS0w_a965a9a5-9236-4988-a214-9eaa25a54ff0">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5ea1131c9af47dd8588756554e13957_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMi00LTEtMS0w_654ddafc-2bbb-4406-8aa7-ec88d62f762a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3f62783fe24bacb1e4a648e4847e70_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMi02LTEtMS0w_b41da2ae-d8ad-4c7c-a87d-61d7be9e7775">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9415ee637f114999b6d5d2f67f7050fa_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMi04LTEtMS0w_9e19fe0a-c3f0-47e1-b370-b1b87d2e11ff">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3f26179ffa4405bc060edb0ba198b2_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMy0yLTEtMS0w_2d77c695-a656-4018-b313-5d4b37a45d1d">1,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia27e8ea51bc64e348a17908196ce969c_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMy00LTEtMS0w_1764f1b1-d55e-4e0b-8162-3df036ec8204">564</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6de0d2e713746bb9c050c4ab98f4f51_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMy02LTEtMS0w_fc8ed307-fdb1-4286-9924-46dc06ffd3c6">1,840</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2835a9642ebd49899501526ee781c908_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMy04LTEtMS0w_30c7677b-d21c-4ebd-9451-b5b41346cbe0">986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2bebf6fe6604b9cac9e5fcd8f81e01b_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNC0yLTEtMS0w_52270eab-a421-4e22-aff5-0999f45bdf96">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0827b20b427b4e6ab8c7d6c7c4a5ba90_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNC00LTEtMS0w_1e1fd058-56a4-47af-9e9c-9fedca430c94">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504e664134704f5a90ec38a184fa703b_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNC02LTEtMS0w_b94757fe-2804-44e2-bedc-18c64a4bae76">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344fc6213f364bd0844d383c9bdfc785_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNC04LTEtMS0w_967224cb-5b0a-4bcf-bd6a-fbad17fb0c05">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNS0yLTEtMS0w_14983b33-735b-41f0-8d95-8a527ac41401">1,285</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNS00LTEtMS0w_53a630e1-e8da-4eb3-b153-e80e7118d738">647</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNS02LTEtMS0w_c6554b87-d3a9-4ade-9202-7f41696df5e0">2,197</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNS04LTEtMS0w_b0a6244a-033e-4b36-952f-88ac71ff52fc">1,078</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_55"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMjIxMg_da6dc2f7-591d-4f58-8bc2-1dd6a323843d" continuedAt="i7d6825b09f314c3d977cdfe3cd0eb804" escape="true">COVID-19</ix:nonNumeric></span></div><ix:continuation id="i7d6825b09f314c3d977cdfe3cd0eb804" continuedAt="i4a203a0c96684116bd450e371f0c7069"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, including, the success of ongoing vaccination efforts, the emergence and prevalence of variant strains of COVID-19, the institution or reinstitution of shutdowns, "stay-at-home-orders" and other public health measures as well as the related economic impact of these matters on local, regional and international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $<ix:nonFraction unitRef="usd" contextRef="i717e3a6bdd9d4ede925668cdc7aa8187_I20200630" decimals="-5" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTc3Mw_a40ec91a-32d4-446e-bf0f-d2be213c1d96">0.1</ix:nonFraction> million. The release of valuation allowance resulted in a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTg1OA_ea14c739-0321-436d-9679-03605e458293">0.1</ix:nonFraction>&#160;million in the first quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i574d92d10a8b47df85aa14649bb3aa66_D20200401-20200430" decimals="-5" name="exdx:ProceedsFromGovernmentAssistance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTY0OTI2NzQ0NTkwNQ_c0105546-103e-470a-867c-f350c8427aad">0.7</ix:nonFraction> million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp; Human Services' standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have been met. During the three and six months ended June&#160;30, 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630" decimals="-5" name="exdx:ProceedsFromGovernmentAssistance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTA5OTUxMTYzMTczNg_78c74158-b876-4419-9b92-de6d6fd08819">0.7</ix:nonFraction> million due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its condensed statements of operations.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i4a203a0c96684116bd450e371f0c7069"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 16, 2020, the Company entered into a promissory note (the Note) with BOKF, NA dba Bank of Oklahoma (BofO), the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $<ix:nonFraction unitRef="usd" contextRef="ib7156ce287e04be6adfdde022fd8dc7f_D20200416-20200416" decimals="-5" name="us-gaap:ProceedsFromBankDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTA5OTUxMTYzMTc1Nw_01d1d796-2e97-49fa-9154-c400d7f6107c">2.9</ix:nonFraction> million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the Note. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the unaudited condensed financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2020 included in our Annual Report on Form 10-K for the year ended December 31, 2020, as amended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Looking Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and other parts of this quarterly report contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this quarterly report, including statements regarding our future results of operations and financial position, business strategy, the impact of the COVID-19 pandemic, current and future product offerings, reimbursement and coverage, our ability to implement an integrated testing and therapeutics strategy, the expected benefits from our partnerships or promotion arrangements with third-parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements are often identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; or &#8220;continue,&#8221; and similar expressions or variations. The forward-looking statements in this quarterly report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, operating results, business strategy, and short-term and long-term business operations and objectives. These forward-looking statements speak only as of the date of this quarterly report and are subject to a number of risks, uncertainties and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors.&#8221; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand, several of which are based on our proprietary CB-CAPs technology. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including systemic lupus erythematosus, or SLE, and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel, targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market 10 testing products under our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brand that allow for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases. Our lead testing product, AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD, enables differential diagnosis for patients presenting with symptoms indicative of a wide variety of CTDs and other related diseases with overlapping symptoms. We commercially launched AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and revenue from this product comprised 81% and 72% of our revenue for the six months ended June&#160;30, 2021 and 2020, respectively. There is an unmet need for rheumatologists to add clarity in their CTD clinical evaluation, and we believe there is a significant opportunity for our tests that enable the differential diagnosis of these diseases, particularly for potentially life-threatening diseases such as SLE. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our portfolio of testing products to establish partnerships with leading pharmaceutical companies, academic research centers and patient advocacy organizations. We also have agreements with GlaxoSmithKline plc., or GSK, Covance Inc. and Parexel, among others, that leverage our testing products and/or the information generated from such tests. We provide GSK, a leader in lupus therapeutics, our test result data to provide market insight into and help increase awareness of the benefits of early and accurate diagnosis of SLE and lupus nephritis, and monitoring disease activity. We partner with academic research centers and patient advocacy organizations, such as Brigham and Women's Hospital, Hospital for Special Surgery, Duke University and Emory University as well </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as the Lupus Foundation of America, to help improve the quality of life for people affected by autoimmune diseases through programs of research, education, support and advocacy. We plan to pursue additional strategic partnerships that are synergistic with our evolving portfolio of testing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform all of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tests in our approximately 10,000 square foot clinical laboratory, which is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, by the Centers for Medicare and Medicaid Services, or CMS, and accredited by the College of American Pathologists, or CAP, and located in Vista, California. Our laboratory is certified for performance of high-complexity testing by CMS in accordance with CLIA and is licensed by all states requiring out-of-state licensure. Our clinical laboratory reports all AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing product results within five business days. In the second half of 2021, we expect to begin the conversion of approximately 8,000 square feet of warehouse space into additional clinical laboratory space and approximately 6,000 square feet of warehouse space into additional research and development facility space, and expect to complete such conversion in the third quarter of 2022. The expansion of our clinical laboratory and research and development facility are expected to allow us to enhance our testing capacity and improve efficiencies as well as allow us to develop molecular and multiomic capabilities and advance our product pipeline, including support of development of tests for fibromyalgia, RA, thrombosis and lupus nephritis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products using our specialized sales force. As of June&#160;30, 2021, we have a sales force of 60 representatives covering a total of 63 territories. Unlike many diagnostic sales forces that are trained only to understand the comparative benefits of their tests, the specialized backgrounds of our sales force coupled with our comprehensive training enables our sales representatives to interpret results from our de-identified patient test reports and provide unique insights in a highly tailored discussion with rheumatologists. Our integrated testing and therapeutics strategy results in a unique opportunity to promote and sell targeted therapies in patient focused sales calls with rheumatologists, including those with whom we have a longstanding relationship and history using our portfolio of testing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement for our testing services comes from several sources, including commercial third-party payors, such as insurance companies and health maintenance organizations, government payors, such as Medicare, and patients. Reimbursement rates vary by product and payor. We continue to focus on expanding coverage among existing contracted rheumatologists and to achieve coverage with commercial payors, laboratory benefit managers and evidence review organizations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception we have devoted substantially all of our efforts developing and marketing products for the diagnosis, prognosis and monitoring of autoimmune diseases. Although our revenue has increased sequentially year over year, we have never been profitable and, as of June&#160;30, 2021 we had an accumulated deficit of $193.9&#160;million. We incurred net losses of $12.6&#160;million and $8.9 million for the six months ended June&#160;30, 2021 and 2020, respectively. We expect to continue to incur operating losses in the near term as our operating expenses will increase to support the growth of our business, as well as additional costs associated with being a public company. We have funded our operations primarily through equity and debt financings and revenue from sales of our products. We completed our initial public offering, or IPO, in September 2019, raising net proceeds from the offering of approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. In March 2021, we completed a public offering of 4,255,000 shares of our common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, net of underwriting discounts and commissions and offering costs of $4.4 million. As of June&#160;30, 2021, we had $112.6&#160;million of cash and cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current COVID-19 worldwide pandemic has presented substantial public health challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of "stay-at-home" orders, restricting business functions outside of one's home, restricting gatherings, restricting travel, and mandating social distancing and face coverings. Certain jurisdictions have begun a phased re-opening, although the potential to return to prior restrictions remains if there are increases (or, in some jurisdictions, continued increases) in new cases of COVID-19 or any of its viral variants in the future. Even in areas where "stay-at-home" restrictions have been lifted and the number of COVID-19 cases have declined, many individuals remain cautious about resuming activities such as preventative-care medical visits. As a result of COVID-19 related limitations and reordering of priorities across the U.S. healthcare system, a reduction in patient flow occurred and our test volumes </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">began to decrease in the second half of March 2020 and we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD volume decrease of approximately 5% in the year ended December 31, 2020 as compared to 2019. In the fourth quarter 2020, our volume of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered substantially recovered to pre-COVID-19 levels. For the three months ended June&#160;30, 2021 as compared to the same period in 2020, we experienced a AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test volume increase of approximately 80%. For the six months ended June&#160;30, 2021 as compared to the same period in 2020, we experienced a AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test volume increase of approximately 37%. However, the continued spread of COVID-19, the extent of which is highly uncertain, may adversely affect testing volumes in future periods. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe there are several other important factors that have impacted, and that we expect will impact our operating performance and results of operations, including shutdowns of our facilities and operations as well as those of our suppliers and courier services, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, as well as our inability to achieve volume-based pricing discounts with our key suppliers and absorb fixed laboratory expenses. For example, we have experienced delays in patient enrollment for ongoing and planned clinical studies involving our tests, which may delay or prevent launch of future test products. We have also experienced delays in procurement of our testing supplies due to suppliers rationing testing supplies and prioritizing COVID-19 testing beginning in the first quarter of 2021, which may continue into the future, and our partners may also experience a disruption in their ability to readily obtain supply. Our sales force has been, and for an extended period of time may continue to be limited, in their in-person interactions with healthcare providers, and therefore, also limited in their ability to engage in various types of healthcare provider education activities. Healthcare providers and patients have canceled or delayed scheduling, and for an extended period of time may continue to cancel or delay scheduling, standard wellness visits and other non-emergency appointments and procedures, contributing to a decline in orders of our testing products. The portion of our workforce which has been working remotely in an effort to reduce the spread of COVID-19, may be infected from the virus or otherwise distracted. We may also face increased competition for laboratory employees due to the increased demand in the industry for such personnel. We may inaccurately estimate the duration or severity of the COVID-19 pandemic, which could cause us to misalign our staffing, spending, activities and precautionary measures with market current or future market conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we initially curtailed non-essential travel and have equipped most of our employees with the ability to work remotely with the exception of our clinical laboratory employees, and implemented measures to protect the health of our employees and to support the functionality of our clinical laboratory, such as providing personal protective equipment (including face masks or shields) and maintaining social distancing. In addition, in the second quarter of 2020, our sales force recommenced certain field-based interactions and scaled marketing spend, although access to healthcare providers remains limited and the use of virtual sales tools has increased. From March 2020 through December 31, 2020, as a result of the COVID-19 pandemic, we terminated our temporary employees and 18 full-time employees, which included three employees at the vice president level. The full extent of which the COVID-19 pandemic will directly or indirectly continue to impact our business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, including, the success of ongoing vaccination efforts, the emergence and prevalence of variant strains of COVID-19, the institution or reinstitution of shutdowns, "stay-at-home-orders" and other public health measures as well as the related economic impact of these matters on local, regional and international markets.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of COVID-19, we believe there are several important factors that have impacted, and that we expect will impact, our operating performance and results of operations, including:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Continued Adoption of Our Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Since the launch of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD in 2012 and through June&#160;30, 2021, we have delivered over 549,000 of these tests. Through the second quarter of 2021, 62,357 AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests were delivered, representing approximately 37% growth over the same period in 2020. The number of ordering healthcare providers in the second quarter of 2021 was a record 1,934, representing an approximate 34% increase over the same period in 2020, and we had a record 703 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adopting healthcare providers (defined as those who previously prescribed at least 11 diagnostic tests in the corresponding period) compared to 428 in the same period in 2020. A high percentage of adopting healthcare providers continue to order tests in subsequent quarters, as approximately 99% of adopting healthcare providers from the first quarter of 2021 ordered at least one diagnostic test in the second quarter of 2021. Revenue growth for our testing products will depend on our ability to continue to expand our base of ordering healthcare providers and increase our penetration with existing healthcare providers.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Reimbursement for Our Testing Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payors, including both commercial and government payors such as Medicare. Payment from third-party payors differs depending on whether we have entered into a contract with the payors as a "participating provider" or do not have a contract and are considered a "non-participating provider." Payors will often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of third-party commercial payors, most of which have not contracted with us to be a participating provider. Historically, we have experienced situations where commercial payors proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payors have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications.&#160;If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payors, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Success of Synergistic Partnerships</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;In August 2021, we mutually agreed to terminate the Janssen Agreement regarding our promotion efforts with SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effective August 31, 2021. Our SIMPONI promotion efforts contributed approximately $0.6 million and $2.1 million in revenue for the six months ended June&#160;30, 2021 and 2020, respectively. We will continue to rely on our existing testing products to drive revenue growth and intend to leverage our integrated testing and therapeutics strategy to establish partnerships with a focus on the development and commercialization of therapeutics that are synergistic with our testing products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Development of Additional Testing Products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We rely on sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test to generate the significant majority of our revenue. We expect to continue to invest in research and development in order to develop additional testing products and expect these costs to increase. Our success in developing new testing products will be important in our efforts to grow our business by expanding the potential market for our testing products and diversifying our sources of revenue.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Maintain Meaningful Margin</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We believe we are well positioned to maintain meaningful margin through a continued focus on increasing operating leverage through the implementation of certain internal initiatives, such as conducting additional validation and reimbursement oriented clinical studies to facilitate payor coverage of our testing products, capitalizing on our growing reagent purchasing to negotiate improved volume-based pricing and automation in our clinical laboratory to reduce material and labor costs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">Timing of Our Research and Development Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;Our spending on experiments and clinical studies may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are obtained in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new testing products, as well as ongoing clinical and outcome studies to further expand the published evidence to support our commercialized AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.46pt">How We Recognize Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payor. Changes to such estimates may increase or decrease revenue recognized in future periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. We discuss many of these risks, uncertainties and other factors in the section entitled "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we entered into the Janssen Agreement, under which we are responsible for the costs associated with our sales force in promoting SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement effective on August 31, 2021. Pursuant to the Janssen Agreement, Janssen was responsible for all other costs associated with our promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for our sales and co-promotional services, we were entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the quarter ended June&#160;30, 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020 we amended the Janssen Agreement, to adjust the predetermined average baseline for the third and fourth quarters of 2020. In December 2020, we further amended the Janssen Agreement, to adjust the average baseline for total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the quarters ending December 31, 2020 and March 31, 2021, subject to further adjustment under certain circumstances. In June 2021, the Janssen Agreement was again amended to proportionally increase the baseline for prescribed units for the quarter ending June 30, 2021 to reflect the addition of certain geographies to the sales territories covered by the Janssen Agreement. For the first and second quarters of 2021, we are entitled to an amended quarterly tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over the predetermined baseline, and we are entitled to receive a minimum promotion fee of $0.3 million and the fee will be capped at 10% above the adjusted predetermined baseline. In connection with the Janssen Agreement's termination, we are entitled to receive an aggregate of $0.6 million in consideration. During the remainder of the term of the Janssen Agreement and the 9 month period immediately following its termination on August 31, 2021, we will be restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $0.6 million and $2.1 million in revenue for the six months ended June&#160;30, 2021 and 2020, respectively, for our promotional efforts under the Janssen Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our experience to date, we expect some seasonal variations in our financial results due to a variety of factors, such as the year-end holiday period and other major holidays, vacation patterns of both patients and healthcare providers, including medical conferences, climate and weather conditions in our markets, seasonal conditions that may affect medical practices and provider activity, including for example influenza outbreaks that may reduce the percentage of patients that can be seen, and other factors relating to the timing of patient benefit changes, as well as patient deductibles and co-insurance limits.</span></div><div id="i90dcb240c7c649938129ef90b5941787_67"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have derived nearly all of our revenue from the sale of our testing products, most of which is attributable to our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. We primarily market our testing products to rheumatologists in the United States. The rheumatologists who order our testing products and to whom results are reported are generally not responsible for payment for these products. The parties that pay for these services, or payors, consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (e.g. hospitals, other laboratories, etc.), and patient self-pay. Our service is completed upon the delivery of test results to the prescribing rheumatologists which triggers billing for the service.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the provisions of ASC Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We record revenue on an accrual basis based on our estimate of the amount that will be ultimately realized for each test upon delivery based on a historical analysis of amounts collected by test and by payor. These assessments require significant judgment by management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase our revenue will depend on our ability to further penetrate the market for our current and future testing products, and increase our reimbursement and collection rates for tests delivered.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, our volume of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered substantially recovered to pre-COVID-19 levels in the fourth quarter 2020. However, the continued spread of COVID-19, including any of its viral variants, may adversely affect testing volumes in future periods, and the extent of any such adverse effects is highly uncertain.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue represents the expenses associated with obtaining and testing patient specimens. The components of our costs of revenue include materials costs, direct labor, equipment and infrastructure expenses associated with testing specimens, shipping charges to transport specimens, blood specimen collections fees, royalties, depreciation and allocated overhead, including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each payor, whether a commercial third-party, government, or individual, reimburses us at different amounts. These differences can be significant. As a result, our costs of revenue as a percentage of revenue may vary significantly from period to period due to the composition of payors for each period's billings.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming future testing volumes are not negatively impacted by the continued spread of COVID-19, we expect that our costs of revenue will increase in absolute dollars as the number of tests we perform increases. However, we expect that the cost per test will decrease over time due to volume discounts on materials and shipping costs and other volume efficiencies we may gain as the number of tests we perform increases. As discussed above, the continued spread of COVID-19 may adversely affect testing volumes which may result in an increase in cost per test due to our inability to realize volume efficiencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist of personnel costs, including stock-based compensation expense, direct marketing expenses, accounting and legal expenses, consulting costs, and allocated overhead including rent, information technology, depreciation and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our selling, general and administrative expenses will increase in absolute dollars in 2021 as compared to 2020, as we continue to evaluate the reach and frequency of our sales and sales support functions, expected additions to headcount and increases for personnel costs, including stock-based compensation. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include costs incurred to develop our technology, testing products and product candidates, collect clinical specimens and conduct clinical studies to develop and support our testing products and product candidates. These costs consist of personnel costs, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities. We expense all research and development costs in the periods in which they are incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will increase in absolute dollars in 2021 as compared to 2020, as we continue to invest in research and development activities related to our existing testing products and product candidates, including the expansion of our clinical research and development facility, expected additions to headcount and increases for personnel costs, including stock-based compensation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of cash and non-cash interest expense associated with our financing arrangements, including the borrowings under our amended loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, or Innovatus. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect interest expense to remain consistent in 2021 as compared to 2020, and remain consistent thereafter until 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, consists primarily of interest income earned on our cash and cash equivalents and amount received under the CARES Act Provider Relief Fund in the second quarter of 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes include federal and state income taxes in the United States.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_70"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,514&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,365&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,149&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,742)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,417)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,325)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,410)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,363)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,047)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $3.8&#160;million, or 42.7%, for the three months ended June&#160;30, 2021 compared to the three months ended June&#160;30, 2020, primarily due to an increase in the number of diagnostic tests delivered resulting in part from volume reductions experienced in late March 2020 as a result of the COVID-19 pandemic. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered, which accounted for 81% and 60% of revenue in the three months ended June&#160;30, 2021 and 2020, respectively, increased to 33,328 tests delivered in the three months ended June&#160;30, 2021 compared to 18,522 tests delivered in the same 2020 period. The adoption of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test by rheumatologists for the three months ended June&#160;30, 2021 increased to 1,934 ordering healthcare providers as compared to 1,442 ordering healthcare providers in the same 2020 period. The increase in revenue was partially offset by a decrease in revenue from the co-promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the three months ended June&#160;30, 2021 to approximately $0.3 million compared to approximately $2.1 million during the three months ended June&#160;30, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue increased $2.1 million, or 63.3%, for the three months ended June&#160;30, 2021 compared to the three months ended June&#160;30, 2020. This increase was primarily due to increased direct costs such as materials and supplies, labor and shipping and handling associated with the increase in test volume in 2021 compared to 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $2.9&#160;million, or 35.0%, for the three months ended June&#160;30, 2021 compared to the three months ended June&#160;30, 2020. This increase was primarily due to an increase of $2.2 million of employee related expenses, including stock-based compensation and recruitment expenses, and increases related to audit and professional services of $0.2 million, insurance expenses of $0.3 million, marketing expenses of $0.1 million and facilities expenses of $0.1 million. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $1.1 million for the three months ended June&#160;30, 2021 compared to the three months ended June&#160;30, 2020. This increase was primarily due to increases related to license fees of $0.4 million, clinical trial expenses of $0.4 million, employee related expenses, including stock-based compensation, of $0.2 million and laboratory supplies expense of $0.1 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense remained substantially consistent for the three months ended June&#160;30, 2021 compared to the three months ended June&#160;30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net, decreased $0.7 million for the three months ended June&#160;30, 2021 compared to the three months ended June&#160;30, 2020. The decrease was primarily driven by the $0.7 million we received under the CARES Act Provider Relief Fund due to lost revenues attributable to COVID-19 in the second quarter of 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2021 and 2020:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.284%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited, in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,170&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,309)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,638)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,671)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,619)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,044)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,575)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,619)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,926)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,693)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $4.8&#160;million, or 26.0%, for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020, primarily due to an increase in the number of diagnostic tests delivered resulting in part from volume reductions experienced in late March 2020 as a result of the COVID-19 pandemic. The number of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD tests delivered, which accounted for 81% and 72% of revenue in the six months ended June&#160;30, 2021 and 2020, respectively, increased to 62,357 tests delivered in the six months ended June&#160;30, 2021 compared to 45,648 tests delivered in the same 2020 period. The adoption of the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test by rheumatologists for the six months ended June&#160;30, 2021 increased to 2,236 ordering healthcare providers as compared to 1,950 ordering healthcare providers in the same 2020 period. The increase in revenue was partially offset by a decrease in revenue from the co-promotion of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the six months ended June&#160;30, 2021 to approximately $0.6 million compared to approximately $2.1 million during the six months ended June&#160;30, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Costs of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs of revenue increased $2.3 million, or 28.9%, for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020. This increase was primarily due to increased direct costs such as materials and supplies, labor and shipping and handling associated with the increase in test volume in 2021 compared to 2020, partially offset by decreased royalty costs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $3.3&#160;million, or 18.5%, for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020. This increase was primarily due to an increase of $2.6 million of employee related expenses, including stock-based compensation and recruitment expenses, and increases related to insurance expenses of $0.3 million, audit and professional services of $0.1 million and facilities expenses of $0.2 million. The first quarter of 2020 included one-time restructuring charges of approximately $0.2 million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $1.9 million for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020. This increase was primarily due to increases related to clinical trial expenses of $0.7 million, employee related expenses, including stock-based compensation and recruitment expenses, of $0.5 million, license fees of $0.4 million and laboratory supplies expense of $0.2 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense remained substantially consistent for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net, decreased $0.9 million for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020. The decrease was primarily driven by the $0.7 million we received under the CARES Act Provider Relief Fund due to lost revenues attributable to COVID-19 in the second quarter of 2020 and lower money market interest rates in 2021 compared to 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit decreased $0.1 million for the six months ended June&#160;30, 2021 compared to the six months ended June&#160;30, 2020 due to a change in tax law under the CARES Act enacted in 2020 that resulted in an income tax benefit during the six months ended June&#160;30, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. For the six months ended June&#160;30, 2021 and 2020, we incurred a net loss of $12.6 million and $8.9&#160;million, respectively, and we expect to incur additional losses and increased operating expenses in future periods. As of June&#160;30, 2021, we had an accumulated deficit of $193.9&#160;million. To date, we have generated only limited revenue, and we may never achieve revenue sufficient to offset our expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of our IPO in September 2019, our operations were financed primarily from sales of our common stock and redeemable convertible preferred stock and borrowings under various debt financings. In September 2019, we completed our IPO and received net proceeds of approximately $50.4 million, net of underwriting discounts, commissions and other offering expenses, for aggregate expenses of approximately $7.5 million. On November 10, 2020, we filed a registration statement on Form S-3, or the Shelf Registration Statement, covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020. In March 2021, we completed a public offering of 4,255,000 shares of our common stock at a public offering price of $16.25 per share, which shares were sold under the Shelf Registration Statement. Net proceeds from the offering were approximately $64.7 million, net of underwriting discounts and commissions and other offering expenses of $4.4 million. As of June&#160;30, 2021, we had $112.6&#160;million of cash and cash equivalents. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in cash and money market funds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, we entered into the loan and security agreement with Innovatus under which we immediately drew down $20.0&#160;million. In December 2018, we borrowed an additional $5.0&#160;million under the loan agreement. In November 2019, we amended the loan and security agreement with Innovatus, which we collectively refer to as the Amended Loan Agreement. Pursuant to the Amended Loan Agreement, the loan term is for five years with a final maturity date of November 2024. The Amended Loan Agreement accrues interest at an annual rate of 8.5%, of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which 2.0%, during the first 36 months, will be treated as paid in-kind interest. Paid in-kind interest is added to the principal balance each period. After the initial 36 months of the loan, the entire 8.5% will be paid in cash at the end of each period. On or after the first anniversary of the Loan Amendment, but before the second anniversary of the Loan Amendment, we may, at our option, prepay the term loan borrowings by paying the lender a prepayment premium. Prepayment before the second anniversary of the Loan Amendment may only occur for specified reasons in the Amended Loan Agreement. The prepayment premium decreases by 1% at each of the second anniversary and the third anniversary of the Loan Amendment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, including our intellectual property. The Amended Loan Agreement contains customary conditions to borrowing, events of default, and covenants, including covenants requiring us to maintain certain levels of minimum liquidity of $2.0&#160;million, performance covenants to achieve certain minimum amounts of revenue, and covenants limiting our ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of our capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The consequences of failing to achieve the performance covenant will be cured if, within sixty days of failing to achieve the performance covenant, we issue additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined in the Amended Loan Agreement. At June&#160;30, 2021, we were in compliance with all covenants of the Amended Loan Agreement. In addition, upon the occurrence of an event of default, Innovatus, among other things, can declare all indebtedness due and payable immediately, which would adversely impact our liquidity and reduce the availability of our cash flows to fund working capital needs, capital expenditures and other general corporate purposes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the loan and security agreement with Innovatus in November 2017, we issued the lender a seven-year warrant to purchase 15,384,615 shares of our Series&#160;F redeemable convertible preferred stock at an exercise price of $0.078&#160;per share, and in December 2018, in connection with the additional $5.0 million borrowed under the loan and security agreement, we issued to the lender a seven-year warrant to purchase 3,846,154 shares of our Series F redeemable convertible preferred stock at an exercise price of $0.078 per share. In connection with the completion of our IPO in September 2019, the warrants were automatically converted into warrants exercisable for an aggregate of 104,722 shares of common stock at an exercise price of $14.32 per share.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to our agreement to comply with the Department of Health &amp; Human Services', or HHS, standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support healthcare-related expenses or lost revenue attributable to COVID-19.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash are to fund our operations as we continue to grow our business. We expect to continue to incur operating losses in the near term as our operating expenses will be increased to support the growth of our business. We expect that our costs of revenue, selling, general and administrative expenses, and research and development expenses will continue to increase as we increase our test volume, expand our marketing efforts and increase our internal sales force to drive increased adoption of and reimbursement for our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing products, prepare to commercialize new testing products, continue our research and development efforts and further develop our product pipeline. We believe we have sufficient laboratory capacity to support increased test volume. We expect to make significant investments for laboratory equipment and capital expenditures in the near term related to our laboratory facilities and expansion of research capabilities, including an investment to convert approximately 8,000 square feet of warehouse space into additional clinical laboratory space and approximately 6,000 square feet of warehouse space into additional research and development facility space. We expect to begin such conversion in the second half of 2021 and complete such conversion in the third quarter of 2022. The expansion of our clinical laboratory and research development facility are expected to allow us to enhance our testing capacity and improve efficiencies as well as allow us to develop molecular and multiomic capabilities and advance our product pipeline, including support of development of tests for fibromyalgia, RA, thrombosis and lupus nephritis. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our near- and longer-term liquidity requirements will continue to consist of working capital and general corporate expenses associated with the growth of our business, including payments we may be required to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">make upon the achievement of previously negotiated milestones associated with intellectual property we have licensed, payments related to non-cancelable purchase obligations with one supplier for reagents, payments related to our principal and interest under our long term borrowing arrangements, payments for operating leases related to our office and laboratory space in Vista, California and payments for capital leases related to our laboratory equipment. Based on our current business plan, we believe that our existing cash and cash equivalents and our anticipated future revenue, will be sufficient to meet our anticipated cash requirements for at least the next 12&#160;months from the date of this filing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimate of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our business, including challenges resulting from social distancing and stay-at home orders through a reduction in testing volumes;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain and grow sales of our AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing products, as well as the costs associated with conducting clinical studies to demonstrate the utility of our products and support reimbursement efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for our testing products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in working capital;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of developing our product pipeline, including the costs associated with conducting our ongoing and future validation, utility and outcome studies as well as the success of our development efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the additional costs we may incur as a result of operating as a public company;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we establish additional partnerships or in-license, acquire or invest in complementary businesses or products as well as the success of our existing partnerships and/or in-licenses; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with our promotion of other therapeutics, including the expansion of our sales capabilities, and the extent and timing of generating revenue from each such promotion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate revenue to support our costs structure, we expect to finance our operations through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. If additional funding is required or desired, there can be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all, or that we will generate sufficient cash from operations to adequately fund our operating needs or achieve or sustain profitability. If we are unable to raise additional capital or generate sufficient cash from operations to adequately fund our operations, we will need to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion plans or commercialization efforts. Doing so will likely have an unfavorable effect on our ability to execute on our business plan and could have a negative impact on our relationships with parties such as our commercial and strategic relationships. If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition, and results of operations could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,762)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,057)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,771&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,384)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June&#160;30, 2021 was $8.8 million and primarily resulted from (i) our net loss of $12.6 million adjusted for non-cash charges of $3.0 million related to stock-based compensation, depreciation, amortization and non-cash interest and (ii) changes in our net operating assets of $0.8&#160;million primarily related to net decreases in prepaid expenses and other current assets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the six months ended June&#160;30, 2020 was $8.1&#160;million and primarily resulted from (i) our net loss of $8.9&#160;million adjusted for non-cash charges of $1.6&#160;million related to depreciation, amortization, stock-based compensation, non-cash interest and deferred income taxes and (ii) changes in our net operating assets of $0.7&#160;million primarily related to net increases in accounts receivables. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the six months ended June&#160;30, 2021 and 2020 was $0.9&#160;million and $0.2&#160;million, respectively, and was due to net purchases of property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided in financing activities for the six months ended June&#160;30, 2021 was $64.8 million primarily resulting from the net proceeds received from our public offering in March 2021 of $64.7 million and proceeds from ESPP purchases, partially offset by principal payments on capital lease obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the six months ended June&#160;30, 2020 was $0.1&#160;million and primarily resulted from principal payments on capital lease obligations, as well as proceeds from our unsecured loan pursuant to the U.S. Small Business Administration Paycheck Protection Program of the CARES Act, which we subsequently repaid in May 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Management Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our critical accounting policies, please see the section entitled "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Significant Management Estimates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" contained in our Annual Report on Form 10-K for the year ended December 31, 2020, as amended. There have been no significant changes in our critical accounting policies and estimates during the three months ended June&#160;30, 2021 as compared to the critical accounting policies and estimates disclosed in the Management&#8217;s Discussion and Analysis of Financial Condition and Operations included in our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, other than as set forth in Note 2 to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Note 2 to the unaudited condensed financial statements included in this Quarterly Report on Form 10-Q for a summary of changes in significant accounting policies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented we did not have, nor do we currently have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission, or the SEC.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, contains provisions that, among other things, reduce certain reporting requirements for an "emerging growth company." The JOBS Act permits an "emerging growth company" such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our audited financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth anniversary will occur in 2024. However, if certain events occur prior to the end of such five-year period, including if we become a "large accelerated filer" as defined in Rule&#160;12b-2 under the Exchange Act, our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we may cease to be an emerging growth company prior to the end of such five-year period.</span></div><div id="i90dcb240c7c649938129ef90b5941787_73"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_76"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file with or submit to the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this quarterly report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of June&#160;30, 2021, our disclosure controls and procedures were effective at the reasonable assurance level. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during the three months ended June&#160;30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_79"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div style="text-align:center"><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_82"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors disclosed in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, other than changes to the risk factors set forth below:</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Strategy </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to risks arising from epidemic diseases, such as the continuing global pandemic of the COVID-19 coronavirus.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current COVID-19 worldwide pandemic has presented substantial public health challenges and is affecting our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of "stay-at-home" orders, restricting business functions outside of one's home, restricting gatherings, restricting travel, and mandating social distancing and face coverings. Certain jurisdictions have begun a phased re-opening, although the potential to return to prior restrictions remains if there are increases (or, in some jurisdictions, continued increases) in new cases of COVID-19 or any of its viral variants in the future. The duration of any restrictions may also vary depending on the ultimate success of ongoing vaccination efforts. Even in areas where "stay-at-home" restrictions, masking and social distancing measures have been lifted and the number of COVID-19 cases have declined, some jurisdictions are considering re-imposing these measures as variant strains emerge. Many individuals remain cautious about resuming activities such as preventative-care medical visits. A pandemic, including COVID-19 or other public health epidemic, poses the risk that we or our employees, contractors, suppliers, third-party shipping carriers, government and third-party payors and other members of our supply chain may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. As a result of COVID-19 related limitations and reordering of priorities across the U.S. healthcare system, a reduction in patient flow occurred and our test volumes began to decrease in the second half of March 2020 and we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD volume decrease of approximately 5% in the year ended December 31, 2020 as compared to 2019. In the fourth quarter 2020, our volume of AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD tests delivered substantially recovered to pre-COVID-19 levels. For the three months ended June&#160;30, 2021 as compared to the same period in 2020, we experienced an AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD volume increase of approximately 80%. For the six months ended June&#160;30, 2021 as compared to the same period in 2020, we experienced a AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> CTD test volume increase of approximately 37%. However, the continued spread of COVID-19 may adversely affect testing volumes in future periods, the extent of which is highly uncertain. Healthcare providers and patients have canceled or delayed scheduling, and for an extended period of time may continue to cancel or delay scheduling, standard wellness visits and other non-emergency appointments and procedures, contributing to a decline in orders of our testing products. The economic downturn may also result in closures of the practices of our primary customers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we believe there are several other important factors that have impacted, and that we expect will impact our operating performance and results of operations, including shutdowns of our facilities and operations as well as those of our suppliers and courier services, disruptions to the supply chain of material needed for our tests, our sales and commercialization activities and our ability to receive specimens and perform or deliver the results from our tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, as well as our inability to achieve or re-negotiate volume-based discounts with our key suppliers and to absorb fixed laboratory expenses. For example, we have experienced delays in patient enrollment for ongoing and planned clinical studies involving our tests, which may delay or prevent launch of future test products. Our sales force has been, and for an extended period of time may continue to be limited to their in-person interactions with healthcare providers, and therefore, also limited their ability to engage in various types of healthcare provider education activities. The portion of our workforce which has been working remotely in an effort to reduce the spread of COVID-19, may be infected from the virus or otherwise impaired. We have also experienced delays in procurement of our testing supplies due to suppliers rationing testing supplies and prioritizing COVID-19 testing beginning in the first quarter of 2021, which may continue into the future, and our partners, may also experience a disruption in their ability to readily obtain supply. We may also face increased competition for laboratory employees due to the increased demand in the industry for such personnel. We may inaccurately estimate the duration or severity of the COVID-19 pandemic, which could cause us to misalign our staffing, spending, activities and precautionary measures with market current or future market conditions.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our laboratory operations, including laboratory employees and medical directors, may be subject to closure or shut down, either due to the spread of the disease within these individuals, or as part of a larger scale government recommendation or mandate. Disruptions in our laboratory operations could have a material adverse effect on our business and could impede our ability to process tests in a timely manner, or at all.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The occurrence of any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations. The COVID-19 pandemic and mitigation measures have had and may continue to have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital on a timely basis or at all. The extent to which the COVID-19 pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. COVID-19 may also have the effect of heightening many of the other risks described in this section and in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Developing new testing products involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other testing products we are developing. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will continue to devote considerable resources to the research and development of our planned future testing products and enhancements to our current testing products. We may not be able to develop testing products with the clinical utility necessary to be useful and commercially successful. There are certain products for which a commercial launch would trigger additional payment obligations to licensors of the technology. In these cases, if the economic projections of the product do not outweigh the additional obligations, we may not launch these products. In order to develop and commercialize testing products, we need to: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">expend significant funds to conduct substantial research and development; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conduct successful validation studies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our laboratory processes to accommodate different tests; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">achieve and maintain required regulatory certifications, including the hiring of appropriately licensed laboratory personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop and scale our infrastructure to be able to analyze increasingly large amounts of data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">build the commercial infrastructure to market and sell new testing products. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing product development process involves a high degree of risk and may take several years. Our testing product development efforts may fail for many reasons, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to identify additional biomarkers to incorporate into our testing products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure or sub-optimal performance of the testing product at the research or development stage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining patient consent inclusive of genetic analysis;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty in accessing archival patient blood specimens, especially specimens with known clinical results; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure of clinical validation, utility and outcome studies to support the effectiveness of the test. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Typically, few research and development projects result in commercial products, and success in early clinical studies often is not replicated in later studies. At any point, we may abandon development of a testing product candidate or we may be required to expend considerable resources repeating clinical studies, which would adversely affect the timing for generating potential revenue from a new testing product and our ability to invest in other products in our pipeline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the second half of 2021, we expect to begin the conversion of approximately 8,000 square feet of warehouse space into additional clinical laboratory space and approximately 6,000 square feet of warehouse space into additional research and development facility space in order to develop molecular and multiomic capabilities. We have not yet developed any molecular or multiomic testing products nor do we have experience developing and integrating molecular biomarkers into new or existing testing products, and we may never be successful doing so in the future. As a result, there is considerable risk that the expansion of our clinical laboratory and research and development facility may not lead to the development of additional testing products that generate meaningful revenue. Further, as we begin to expand our clinical laboratory and research and development facility in order to develop molecular and multiomic capabilities, we expect to need to make significant investments in key personnel and highly trained scientists with relevant experience to handle the increased operations and development of molecular biomarkers.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as we develop testing products, we will have to make significant investments in product development, marketing and selling resources. If a clinical validation study fails to demonstrate the prospectively defined </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">endpoints of the study, we might choose to abandon the development of the testing product or product feature that was the subject of the clinical study, which could harm our business. Additionally, competitors may develop and commercialize competing products or technologies faster than us or at a lower cost. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Developing new testing products and enhancements to our existing technologies is expensive and time consuming, and there is no assurance that such activities will result in significant new marketable testing products, enhancements to our current technologies, design improvements, cost savings, revenue or other expected benefits. If we spend significant resources on research and development and are unable to generate an adequate return on our investment or divert resources away from other, more attractive growth opportunities, our business and results of operations may be materially and adversely affected. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our future growth depends, in part, on our ability to execute on our strategy of integrating the promotion of our existing and future proprietary testing products with the promotion of therapeutics through third party collaborations and strategic partnerships, and we may be unsuccessful in our efforts to establish relationships with these third parties or our promotion efforts after any of these relationships are established, which could adversely affect our ability to implement this strategy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We intend to integrate our historical testing products business with the promotion of therapeutics in an integrated testing and therapeutics strategy. Our integrated testing and therapeutics strategy would leverage our sales and marketing efforts, targeting rheumatologists for the commercialization of our testing products in co-promotion with therapeutics. As a result, our future growth is dependent, in part, on the success of this strategy. The Janssen Agreement will be terminated effective as of August 31, 2021. While we remain committed to the strategy of providing an integrated testing and therapeutics model, we may be unsuccessful in our efforts to establish relationships with collaborators in the future. Even if we successfully establish these relationships, our ability to effectively implement this strategy will include creating demand for the applicable therapeutic through our or our collaborator's commercial and sales activities. Moreover, we may encounter difficulties in maintaining an effective salesforce in furtherance of these co-promotion efforts. We have a limited history partnering with pharmaceutical companies for the promotion of therapeutics. Consequently, any predictions made about our future success or viability with respect to our promotion activities may not be as accurate as they could be if we had a history of successfully co-promoting therapeutics.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to successfully establish and maintain relationships with these collaborators and strategic partners, our ability to implement our integrated testing and therapeutics strategy and generate sufficient revenue to grow and sustain our business, and our business, financial condition and results of operations, will be materially adversely affected.</span></div><div><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_88"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Use of Proceeds</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2019, the SEC declared effective our registration statement on Form S-1 (File No. 333-233446), as amended, filed in connection with our IPO. At the closing of the offering on September 23, 2019, we issued and sold 4,140,000 shares of our common stock at the initial public offering price to the public of $14.00 per share, which included the exercise in full of the underwriters&#8217; option to purchase additional shares. We received gross proceeds from the IPO of $58.0 million, before deducting underwriting discounts, commissions and other offering expenses, which resulted in net proceeds of approximately $50.4 million and offering-related transaction costs of approximately $7.5 million. Cowen and Company, LLC, Cantor Fitzgerald &amp; Co and William Blair &amp; Company, L.L.C. acted as joint book-running managers for the offering. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June&#160;30, 2021, we have used approximately $26.4 million of the proceeds from our IPO primarily related to selling and marketing activities. There has been no material change in the planned use of such proceeds from that described in the final prospectus filed by us with the SEC on September 20, 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, we entered into an exchange agreement, or the Exchange Agreement, with an Investor and its affiliates, or the Exchanging Stockholders, pursuant to which we exchanged an aggregate 804,951 shares of our common stock owned by the Exchanging Stockholders for pre-funded warrants, or the Exchange Warrants, to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase an aggregate of 804,951 shares of Common Stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.001 per share. The Exchange Warrants are exercisable at any time, except that the Exchange Warrants will not be exercised by the Exchanging Stockholders if, upon giving effect thereto, the Exchanging Stockholders would beneficially own more than 4.99% of the total number of issued and outstanding Common Stock, which percentage may change at the Exchanging Stockholders' election to any other number upon 61 days' notice to us. The Exchange Warrants were issued in reliance on Section 3(a)(9) of the Securities Act.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid Per Share</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1 - 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable.</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not applicable.</span></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Exchange Warrants.</span></div><div style="text-align:center"><span><br/></span></div><div id="i90dcb240c7c649938129ef90b5941787_91"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i90dcb240c7c649938129ef90b5941787_94"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i90dcb240c7c649938129ef90b5941787_97"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.109%"><tr><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Filing Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/Furnished Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519252366/d769261dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000127473721000017/ex31-amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">001-39049</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/22/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519240403/d692844dex41.htm">Specimen stock certificate evidencing the shares of common stock.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex42.htm">Amended and Restated Investors' Rights Agreement, dated July 12, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex43.htm">Amended and Restated Stockholders' Agreement, dated July 12, 2019, by and among the Registrant and certain of its stockholders.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1274737/000119312519228011/d692844dex44.htm">Form of Common Stock Purchase Warrant issued to investors by the Registrant in connection with private placement financings.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333-233446</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/9/2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex45-formofprexfundedwarra.htm">Form of Exchange Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-amend4tocoxpromotion.htm">Amendment #4 to Co-Promotion Agreement, dated June 30, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn311-63021.htm">Certificate of Principal Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn312-63021.htm">Certificate of Principal Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="xgn321-63021.htm">Certifications Pursuant to U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, has been formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Confidential portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i90dcb240c7c649938129ef90b5941787_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:52.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EXAGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August&#160;9, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August&#160;9, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kamal Adawi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>ex45-formofprexfundedwarra.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9fab5025b9a14cdbba6ca50190e08463_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.5</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXAGEN INC.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrant Shares&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Initial Exercise Date&#58; ___________, 2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issue Date&#58; ___________, 2021</font></div><div><font><br></font></div></td></tr></table></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) certifies that, for value received, __________ or its assigns (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after __________, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and on or prior to the close of business on the date that this Warrant has been exercised in full (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to subscribe for and purchase from Exagen Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), up to __________ shares (as subject to adjustment hereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrant Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1&#58;  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the United States Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means the common stock of the Company, par value $0.001 per share. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; means any securities of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Exchange Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), dated __________, 2021, among the Company and the Holders signatory thereto.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise of Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Within two (2) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate Exercise Price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cashless Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Warrant may also be exercised, in whole or in part, at any time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing &#91;(A-B) (X)&#93; by (A), where&#58;</font></div><div style="padding-left:99pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (A) &#61; as applicable&#58; (i) the volume weighted average price (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">VWAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the bid price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day&#59;</font></div><div style="padding-left:108pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(B) &#61; the Exercise Price of this Warrant, as adjusted hereunder&#59; and </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:103.5pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(X) &#61; the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that, in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.  The Company agrees not to take any position contrary to this Section 2(c).</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mechanics of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery of Warrant Shares Upon Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Warrant Shares purchased through cashless exercise hereunder shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DWAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) if the Company is then a participant in such system, and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is three (3) Trading Days after the delivery to the Company of the Notice of Exercise (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrant Share Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Upon delivery of the Notice of Exercise the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares&#59; provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within two (2) Trading Days of delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. In addition, without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Delivery of New Warrants Upon Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rescission Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:117pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.  For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a BuyIn with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.  Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and&#47;or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Fractional Shares or Scrip</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Charges, Taxes and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for sameday processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</font></div><div style="padding-left:117pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:6pt;padding-left:117pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vii. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Closing of Books</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></div><div style="margin-top:6pt;padding-left:117pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Holder&#8217;s Exercise Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Attribution Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Ownership Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately before and after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant, provided that the Holder shall be permitted to decrease the Beneficial Ownership Limitation upon providing written notice to the Company or increase the Beneficial Ownership Limitation upon providing the Company with at least 61 days&#8217; prior written notice.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Dividends and Splits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Company, at any time while this Warrant is outstanding&#58; (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the number of Warrant Shares issuable upon exercise of this Warrant shall be multiplied by a fraction of which the denominator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the numerator shall be the number of shares of Common Stock outstanding immediately after such event&#59; the Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subsequent Rights Offerings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Rata Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).  To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger, or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fundamental Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Alternate Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Calculations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1&#47;100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notice to Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:97.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustment to Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</font></div><div style="padding-left:97.2pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:97.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notice to Allow Exercise by Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:97.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party (except in the case of a merger for purposes of changing the Company&#8217;s domicile), any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange&#59; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.  The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></div><div style="padding-left:97.2pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer of Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Rights as Stockholder Until Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Loss, Theft, Destruction or Mutilation of Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Saturdays, Sundays, Holidays, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Exchange Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nonwaiver and Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Exchange Agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">k) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">********************</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Signature Page Follows)</font></div><div style="margin-top:6pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.810%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">EXAGEN INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTICE OF EXERCISE</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TO&#58; EXAGEN INC. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Payment shall take the form of (check applicable box)&#58;<br></font></div><div style="padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;  &#93; in lawful money of the United States&#59; or<br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91; &#93; the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c) of the Warrant, to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c) of the Warrant.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below&#58;</font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Warrant Shares shall be delivered to the following DWAC Account Number&#58;</font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;SIGNATURE OF HOLDER&#93;</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of Investing Entity&#58; _________________________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signature of Authorized Signatory of Investing Entity&#58;  _________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of Authorized Signatory&#58; ____________________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of Authorized Signatory&#58;  _____________________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; __________________________________________________________________</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSIGNMENT FORM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</font></div><div style="text-align:justify;text-indent:10.5pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Please Print)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Address&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(Please Print)</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Phone Number&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Email Address&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dated&#58; _______________ __, ______</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Holder&#8217;s Signature&#58;____________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Holder&#8217;s Address&#58;_____________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:1pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex101-amend4tocoxpromotion.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1be5ad6ebe99429e901630cf6e38603a_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDMENT #4 TO CO-PROMOTION AGREEMENT </font></div><div><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, please find attached the final Baseline TRxU for April through June (3th Quarter) of 2021, which has been agreed upon by the Janssen and Exagen Teams. This Baseline TRxU include CVS&#47;Anthem data for the zip codes covered by Exagen sale representatives as of April 1, 2021, inclusive of the additional zip codes added.</font></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties have agreed that the following sections of the Agreement are hereby amended as follows effective as the date of this notice&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Promotion Fee shall be adjusted for the quarter ending June 30, 2021 as follows&#58;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Promotion Fee shall be based on a unit value for each quarter over Baseline TRxU, allocated as follows&#58;</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Quantities</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotion Fee per unit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tiered Baseline</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A minimum payout of $300,000 for Q1 and Q2 of 2021 will be in effect.</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unit quantities below Baseline TRxU in a quarter will be counted as zero for purposes of calculating Quantities for Promotion Fee per unit.</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Janssen will pay Exagen a Minimum Promotion Fee of $300,000 for each of the quarters ending March 31, 2021 and June 30, 2021</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.4.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Promotion Fee will be capped at an amount reflecting the payment due in the event that Exagen's TRxU exceeds 10% above the Baseline TRxU for the quarter ending June 30, 2021.</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the remaining quarters of the Contract Term Extension (July 1, 2021 &#8211; December 31, 2021) and any additional Third Term, the Promotion Fee payment terms shall revert to the terms set forth in the Co-Promotion Agreement, with no Minimum Promotion Fee and no Cap (Section 2.3.3).</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:3.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.363%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">***</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Confidential Information Omitted</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Amendment #2 dated June 18th, 2020 to the Agreement, please find the Second Term Baseline TRxU for the First Half of 2021&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:7.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.242%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarter ending</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Baseline TRxU</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please indicate your acceptance by signing the space provided below and returning to Janssen.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.421%"><tr><td style="width:1.0%"></td><td style="width:35.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JANSSEN BIOTECH, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Howard Reid</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Howard Reid</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Director of Marketing</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; Jul 27, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accepted and agreed</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date set forth above&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Mark Hazeltine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Mark Hazeltine</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; COO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; Jul 9, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:3.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.363%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">***</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Confidential Information Omitted</font></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>xgn311-63021.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i106ffdf94cfb4b1f8fd30e9f36245829_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Fortunato Ron Rocca, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:168%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:168%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;9, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>xgn312-63021.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib57a4a0873ca4991a393efc4a50e2c5e_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EXAGEN INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:242%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I, Kamal Adawi, certify that&#58;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">I have reviewed this Quarterly Report on Form 10-Q of Exagen Inc.&#59;</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:21pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.648%"><tr><td style="width:1.0%"></td><td style="width:49.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;9, 2021</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:3pt"><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>xgn321-63021.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id3ac24de3aab4f4abba366d57668fd6b_1"></div><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:201%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended June&#160;30, 2021 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; August&#160;9, 2021</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fortunato Ron Rocca</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:20pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:167%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Exagen Inc. (the &#34;Company&#34;) hereby certifies, to such officer's knowledge, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The accompanying quarterly report on Form 10-Q of the Company for the quarterly period ended June&#160;30, 2021 (the &#34;Report&#34;) fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:3pt;font-weight:400;line-height:167%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%"> The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Dated&#58; August&#160;9, 2021</font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:43pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.066%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kamal Adawi</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kamal Adawi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:20pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:167%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:43pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>exdx-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6018f8ea-fa05-452a-adea-254786192c77,g:68b7dde8-2230-495d-984a-015fcac6c60d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exdx="http://www.exagen.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exagen.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exdx-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.exagen.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://www.exagen.com/role/CondensedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofOperations" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations">
        <link:definition>1003004 - Statement - Unaudited Condensed Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofStockholdersEquity" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedStatementsofStockholdersEquityParenthetical" roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedStatementsofCashFlows" roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Unaudited Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.exagen.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.exagen.com/role/OrganizationDetails">
        <link:definition>2402401 - Disclosure - Organization - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSecuritiesDetails" roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.exagen.com/role/OtherFinancialInformation">
        <link:definition>2111103 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.exagen.com/role/OtherFinancialInformationTables">
        <link:definition>2312302 - Disclosure - Other Financial Information - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPrepaidexpensesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails">
        <link:definition>2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationPropertyandequipmentDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails">
        <link:definition>2414408 - Disclosure - Other Financial Information - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationNarrativeDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Other Financial Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails">
        <link:definition>2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.exagen.com/role/Borrowings">
        <link:definition>2117104 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.exagen.com/role/BorrowingsTables">
        <link:definition>2318303 - Disclosure - Borrowings - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails">
        <link:definition>2419411 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsFutureminimumpaymentsDetails" roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails">
        <link:definition>2420412 - Disclosure - Borrowings - Future minimum payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.exagen.com/role/CommitmentandContingencies">
        <link:definition>2121105 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesNarrativeDetails" roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails">
        <link:definition>2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exagen.com/role/FairValueMeasurements">
        <link:definition>2123106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exagen.com/role/FairValueMeasurementsTables">
        <link:definition>2324304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails">
        <link:definition>2425414 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exagen.com/role/StockholdersEquity">
        <link:definition>2126107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exagen.com/role/StockholdersEquityTables">
        <link:definition>2327305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2428415 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.exagen.com/role/StockholdersEquityDetails">
        <link:definition>2429416 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlan" roleURI="http://www.exagen.com/role/StockOptionPlan">
        <link:definition>2130108 - Disclosure - Stock Option Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanTables" roleURI="http://www.exagen.com/role/StockOptionPlanTables">
        <link:definition>2331306 - Disclosure - Stock Option Plan (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanNarrativeDetails" roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails">
        <link:definition>2432417 - Disclosure - Stock Option Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockOptionActivityDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails">
        <link:definition>2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanRestrictedStockUnitsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails">
        <link:definition>2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanFairValueAssumptionsDetails" roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails">
        <link:definition>2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionPlanStockBasedCompensationExpenseDetails" roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails">
        <link:definition>2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Covid19" roleURI="http://www.exagen.com/role/Covid19">
        <link:definition>2137109 - Disclosure - Covid-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Covid19Details" roleURI="http://www.exagen.com/role/Covid19Details">
        <link:definition>2438422 - Disclosure - Covid-19 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exdx_DebtInstrumentPaidInKindLoansIssued" abstract="false" name="DebtInstrumentPaidInKindLoansIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CollaborationAgreementAnnualCollaborationFee" abstract="false" name="CollaborationAgreementAnnualCollaborationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_BlueShieldMember" abstract="true" name="BlueShieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_Term2017Member" abstract="true" name="Term2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ProceedsFromGovernmentAssistance" abstract="false" name="ProceedsFromGovernmentAssistance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_AHNCollaborationMember" abstract="true" name="AHNCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DeferredOfferingCostsReclassifiedToEquity" abstract="false" name="DeferredOfferingCostsReclassifiedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LongTermDebtIncludingUndiscountedInterest" abstract="false" name="LongTermDebtIncludingUndiscountedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ExpirationSep72024Member" abstract="true" name="ExpirationSep72024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_InnovatusLifeSciencesLendingFundMember" abstract="true" name="InnovatusLifeSciencesLendingFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeAxis" abstract="true" name="RentalPropertyByTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="exdx_OperatingLeasesRenewalTerm" abstract="false" name="OperatingLeasesRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="exdx_ExpirationDec72025Member" abstract="true" name="ExpirationDec72025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFee" abstract="false" name="JointVentureQuarterlyPromotionFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationApr12026Member" abstract="true" name="ExpirationApr12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ExpirationMar312026Member" abstract="true" name="ExpirationMar312026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exdx_JanssenSIMPONIMember" abstract="true" name="JanssenSIMPONIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFeePerPrescription" abstract="false" name="JointVentureQuarterlyPromotionFeePerPrescription" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_CapitalRoyaltyPartnersIILPMember" abstract="true" name="CapitalRoyaltyPartnersIILPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" abstract="false" name="JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_AdvancePayment" abstract="false" name="AdvancePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" abstract="false" name="ExchangeAgreementNumberOfSharesExchangedForWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exdx_LicenseAgreementInitialLicenseFee" abstract="false" name="LicenseAgreementInitialLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exdx_AccruedLiabilitiesClinicalStudyCurrent" abstract="false" name="AccruedLiabilitiesClinicalStudyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentage" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_AccruedPurchaseGoodsAndServicesCurrent" abstract="false" name="AccruedPurchaseGoodsAndServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" abstract="false" name="PurchaseObligationAnnualIncreaseInCommitmentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_HealthcareInsurersMember" abstract="true" name="HealthcareInsurersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AVISECTDTestMember" abstract="true" name="AVISECTDTestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_NoExpirationMember" abstract="true" name="NoExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exdx_CollaborationAgreementCollaborationExpenses" abstract="false" name="CollaborationAgreementCollaborationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" abstract="false" name="DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_JointVentureTerminationConsiderationReceivable" abstract="false" name="JointVentureTerminationConsiderationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_OfficeMember" abstract="true" name="OfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ExchangingStockholdersMember" abstract="true" name="ExchangingStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_MilestoneContingencyFairValueDisclosure" abstract="false" name="MilestoneContingencyFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_Government1Member" abstract="true" name="Government1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_ClientMember" abstract="true" name="ClientMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" abstract="false" name="DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" abstract="false" name="CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ReceivableBenchmarkMember" abstract="true" name="ReceivableBenchmarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_RoyaltyObligationPercentageOfSales" abstract="false" name="RoyaltyObligationPercentageOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" abstract="false" name="DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_PrepaidMaintenanceAndInsuranceContracts" abstract="false" name="PrepaidMaintenanceAndInsuranceContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_TwoMajorSuppliersMember" abstract="true" name="TwoMajorSuppliersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_IncentiveAwardPlan2019Member" abstract="true" name="IncentiveAwardPlan2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_UnitedHealthcareMember" abstract="true" name="UnitedHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_RentalPropertyByTypeDomain" abstract="true" name="RentalPropertyByTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AssetsUnderCapitalLeaseMember" abstract="true" name="AssetsUnderCapitalLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_PrometheusLaboratoriesIncMember" abstract="true" name="PrometheusLaboratoriesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_AlleghenyHealthNetworkResearchInstituteMember" abstract="true" name="AlleghenyHealthNetworkResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_LongTermDebtUndiscountedInterestAmount" abstract="false" name="LongTermDebtUndiscountedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_EquipmentPurchasedUnderCapitalLease" abstract="false" name="EquipmentPurchasedUnderCapitalLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercisedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exdx_ExpirationJan192026Member" abstract="true" name="ExpirationJan192026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_DebtInstrumentStatedInterestRatePaidInKind" abstract="false" name="DebtInstrumentStatedInterestRatePaidInKind" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exdx_JanssenPromotionAgreementMember" abstract="true" name="JanssenPromotionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exdx_MilestoneObligation" abstract="false" name="MilestoneObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>exdx-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6018f8ea-fa05-452a-adea-254786192c77,g:68b7dde8-2230-495d-984a-015fcac6c60d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20210630.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_daf82f61-5507-4097-adc8-f074d839f315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c80c24e3-011c-4472-b872-6c9200d7e91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_daf82f61-5507-4097-adc8-f074d839f315" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c80c24e3-011c-4472-b872-6c9200d7e91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1acab5c3-f4bc-4c09-9afa-8396997c8ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_daf82f61-5507-4097-adc8-f074d839f315" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1acab5c3-f4bc-4c09-9afa-8396997c8ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_be48c8eb-a74e-4c37-b5ac-64d2de54bf11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_daf82f61-5507-4097-adc8-f074d839f315" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_be48c8eb-a74e-4c37-b5ac-64d2de54bf11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b2f306b1-612f-4367-98a8-5c52cec5cc81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2d81b697-d66c-43f2-8c63-0074c8342f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b2f306b1-612f-4367-98a8-5c52cec5cc81" xlink:to="loc_us-gaap_AccountsPayableCurrent_2d81b697-d66c-43f2-8c63-0074c8342f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5aa63251-9785-4bb7-9d2d-5a1a1a035fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b2f306b1-612f-4367-98a8-5c52cec5cc81" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5aa63251-9785-4bb7-9d2d-5a1a1a035fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61a52d57-44d9-41b7-8dd7-34e500719b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_264c13e2-7ec7-4e46-b7df-3a3d9fedc5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61a52d57-44d9-41b7-8dd7-34e500719b17" xlink:to="loc_us-gaap_PreferredStockValue_264c13e2-7ec7-4e46-b7df-3a3d9fedc5bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ef1f437d-b944-414e-bcce-6bad1f4a2aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61a52d57-44d9-41b7-8dd7-34e500719b17" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ef1f437d-b944-414e-bcce-6bad1f4a2aa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e01ceb94-513b-4f33-94fb-19757f76f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61a52d57-44d9-41b7-8dd7-34e500719b17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e01ceb94-513b-4f33-94fb-19757f76f8e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f024ffcf-4cf9-4219-85c3-b17178125d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61a52d57-44d9-41b7-8dd7-34e500719b17" xlink:to="loc_us-gaap_CommonStockValue_f024ffcf-4cf9-4219-85c3-b17178125d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f45eb317-495b-4ffe-9f18-f857dee7e4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7aab08aa-3c27-4859-89cb-0fa660a10e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f45eb317-495b-4ffe-9f18-f857dee7e4c9" xlink:to="loc_us-gaap_StockholdersEquity_7aab08aa-3c27-4859-89cb-0fa660a10e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6283df39-d12b-4349-88a7-31e905b1734a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f45eb317-495b-4ffe-9f18-f857dee7e4c9" xlink:to="loc_us-gaap_Liabilities_6283df39-d12b-4349-88a7-31e905b1734a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fd5cc9eb-c438-4ccc-916e-99a794380a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f45eb317-495b-4ffe-9f18-f857dee7e4c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fd5cc9eb-c438-4ccc-916e-99a794380a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e39e08eb-e38a-4dd6-8b57-c7cb0845887d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_beaae450-ede9-4b78-9463-6562047f1a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39e08eb-e38a-4dd6-8b57-c7cb0845887d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_beaae450-ede9-4b78-9463-6562047f1a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8af95d6c-1a8d-4681-999f-85d68d903873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39e08eb-e38a-4dd6-8b57-c7cb0845887d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8af95d6c-1a8d-4681-999f-85d68d903873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9adc7170-c958-444e-9d27-e4123e2561f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39e08eb-e38a-4dd6-8b57-c7cb0845887d" xlink:to="loc_us-gaap_AssetsCurrent_9adc7170-c958-444e-9d27-e4123e2561f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0ff0f767-dbaa-4269-9200-02eb5011bf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39e08eb-e38a-4dd6-8b57-c7cb0845887d" xlink:to="loc_us-gaap_Goodwill_0ff0f767-dbaa-4269-9200-02eb5011bf1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d1cd682b-1763-438c-a72f-764c39b05c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08bb2e8e-b47a-4bbe-9a7f-46ec00007680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1cd682b-1763-438c-a72f-764c39b05c21" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08bb2e8e-b47a-4bbe-9a7f-46ec00007680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e96ccc17-0246-4bf1-8a3d-18951f2310b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1cd682b-1763-438c-a72f-764c39b05c21" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e96ccc17-0246-4bf1-8a3d-18951f2310b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c6501e8b-9952-4fec-adc7-f8d08a0d434d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1cd682b-1763-438c-a72f-764c39b05c21" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c6501e8b-9952-4fec-adc7-f8d08a0d434d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8e618393-c053-45c2-8d58-33a9851f73a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1cd682b-1763-438c-a72f-764c39b05c21" xlink:to="loc_us-gaap_LiabilitiesCurrent_8e618393-c053-45c2-8d58-33a9851f73a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20210630.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_83b3c75f-e71e-48bb-9677-ec1d8bf15536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4c813730-9cb7-4b2b-a529-b2408bbd3bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a58d30a2-d947-4f0e-80f0-7b8f3451df85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4c813730-9cb7-4b2b-a529-b2408bbd3bb1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a58d30a2-d947-4f0e-80f0-7b8f3451df85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_59ce9c05-c70f-4bf6-ba1c-c075cc0d632c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4c813730-9cb7-4b2b-a529-b2408bbd3bb1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_59ce9c05-c70f-4bf6-ba1c-c075cc0d632c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6908cdeb-4c8e-4823-bd1d-ef7fb7e473c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4c813730-9cb7-4b2b-a529-b2408bbd3bb1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6908cdeb-4c8e-4823-bd1d-ef7fb7e473c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_76f5d3d4-7780-47a9-915c-ae657fffeaea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ed286210-2472-4e94-841c-793723878765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_76f5d3d4-7780-47a9-915c-ae657fffeaea" xlink:to="loc_us-gaap_CostsAndExpenses_ed286210-2472-4e94-841c-793723878765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46f85d28-99b3-4139-bc27-4aafa4f15021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_76f5d3d4-7780-47a9-915c-ae657fffeaea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46f85d28-99b3-4139-bc27-4aafa4f15021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_14ea5824-8e8e-4014-ab20-8018c2c09b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a93b7f9a-92ed-4375-aeae-481e9a443df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_14ea5824-8e8e-4014-ab20-8018c2c09b84" xlink:to="loc_us-gaap_InterestExpense_a93b7f9a-92ed-4375-aeae-481e9a443df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_25851593-6429-44e8-843f-77e62b9f71aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_14ea5824-8e8e-4014-ab20-8018c2c09b84" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_25851593-6429-44e8-843f-77e62b9f71aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2778eb5d-df93-4ce6-a063-c6a905231892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_14ea5824-8e8e-4014-ab20-8018c2c09b84" xlink:to="loc_us-gaap_OperatingIncomeLoss_2778eb5d-df93-4ce6-a063-c6a905231892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2ba130f1-30fb-43f3-b5d1-4f87131b360e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_7d147442-7fa5-46f1-9ddb-95cd30a92b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2ba130f1-30fb-43f3-b5d1-4f87131b360e" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_7d147442-7fa5-46f1-9ddb-95cd30a92b7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6e73e718-e340-41db-a665-52d62483677b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2ba130f1-30fb-43f3-b5d1-4f87131b360e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6e73e718-e340-41db-a665-52d62483677b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20210630.xsd#UnauditedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bcbbd7d8-d4b4-42ee-867a-e7f3e0dd6bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb96a292-1add-470a-9854-085d8d0edc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bcbbd7d8-d4b4-42ee-867a-e7f3e0dd6bbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb96a292-1add-470a-9854-085d8d0edc21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d18bb72-8327-452f-9139-6609e2096dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bcbbd7d8-d4b4-42ee-867a-e7f3e0dd6bbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d18bb72-8327-452f-9139-6609e2096dec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b59a03a3-c1ef-471b-974f-2880d3e95fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bcbbd7d8-d4b4-42ee-867a-e7f3e0dd6bbd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b59a03a3-c1ef-471b-974f-2880d3e95fd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e26b5a40-bed4-4ad4-9a02-ae235c0b4135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4dd405d7-7452-4e2f-8586-a5288ce515ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e26b5a40-bed4-4ad4-9a02-ae235c0b4135" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4dd405d7-7452-4e2f-8586-a5288ce515ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6bcb161c-f0fe-4eeb-bc60-604e187f670a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6bcb161c-f0fe-4eeb-bc60-604e187f670a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_fc2a22d1-26ac-49d5-81f4-06511bd7248f" xlink:href="exdx-20210630.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_fc2a22d1-26ac-49d5-81f4-06511bd7248f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_60d57b1c-b082-4b5e-970f-7c9c619f80cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_NetIncomeLoss_60d57b1c-b082-4b5e-970f-7c9c619f80cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_0ecc05da-5923-4b92-92f1-f4ca00427c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_PaidInKindInterest_0ecc05da-5923-4b92-92f1-f4ca00427c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_476425fd-5982-4ea3-9641-fd51a9b054d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_476425fd-5982-4ea3-9641-fd51a9b054d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bf328a36-f8f7-4c8a-b4fc-9e466ae3ee17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_ShareBasedCompensation_bf328a36-f8f7-4c8a-b4fc-9e466ae3ee17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_aabb2e26-b689-4521-9bab-53d482e7c2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_aabb2e26-b689-4521-9bab-53d482e7c2f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6b5f866a-2905-4a9d-a72c-4076524a3087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6b5f866a-2905-4a9d-a72c-4076524a3087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_37a0d6c8-54d2-4214-8fd7-13e9df13cc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_37a0d6c8-54d2-4214-8fd7-13e9df13cc8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d4bd0e32-2358-44ad-b8a7-7efe8e8b2b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d4bd0e32-2358-44ad-b8a7-7efe8e8b2b88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e2df092c-5390-4a6a-a9ad-a215558e3b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77926c3f-3b42-4966-bb9f-c789e6345ae0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e2df092c-5390-4a6a-a9ad-a215558e3b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d9618028-7a48-47a4-9088-0bbfbb5c576e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d9618028-7a48-47a4-9088-0bbfbb5c576e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_a2e08ff7-f890-42a7-8119-6ff52a041900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:to="loc_us-gaap_RepaymentsOfBankDebt_a2e08ff7-f890-42a7-8119-6ff52a041900" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_c074344d-cdf3-4312-b1ce-1cba003f1452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_c074344d-cdf3-4312-b1ce-1cba003f1452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d187b0d6-2a0f-4b4f-926e-3db4b7719d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d187b0d6-2a0f-4b4f-926e-3db4b7719d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5c702af6-8f31-4acc-aad5-e6e9642d6c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5c702af6-8f31-4acc-aad5-e6e9642d6c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_230667c0-332e-45e2-b4bb-d27f05e72213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_230667c0-332e-45e2-b4bb-d27f05e72213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_277fa6f6-61fb-4f10-9c22-a281c6bd5c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:to="loc_us-gaap_ProceedsFromStockPlans_277fa6f6-61fb-4f10-9c22-a281c6bd5c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_e240559b-dd3d-467c-aa3e-fa6239fee4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_984f9981-c9a4-42d4-9c27-72b36f7057c0" xlink:to="loc_us-gaap_ProceedsFromBankDebt_e240559b-dd3d-467c-aa3e-fa6239fee4a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e908533b-0f87-49db-a065-c930b8449708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3c70f0e5-2224-485d-90e8-1128d1b99fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e908533b-0f87-49db-a065-c930b8449708" xlink:to="loc_us-gaap_RestrictedCash_3c70f0e5-2224-485d-90e8-1128d1b99fa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e060c05-ac44-49ff-a63e-fc1f8b25c3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e908533b-0f87-49db-a065-c930b8449708" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e060c05-ac44-49ff-a63e-fc1f8b25c3b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d40f21a-ff26-41f2-9cb3-85cd7e6c2427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_10358f01-0ccf-4e93-a958-ff3ca7db5b33" xlink:href="exdx-20210630.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d40f21a-ff26-41f2-9cb3-85cd7e6c2427" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_10358f01-0ccf-4e93-a958-ff3ca7db5b33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_c29c47d5-7bdb-4eb1-a1b9-fc40442f60d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d40f21a-ff26-41f2-9cb3-85cd7e6c2427" xlink:to="loc_us-gaap_PrepaidRoyalties_c29c47d5-7bdb-4eb1-a1b9-fc40442f60d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_15af8dcf-049a-47a8-8f43-08061d127c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d40f21a-ff26-41f2-9cb3-85cd7e6c2427" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_15af8dcf-049a-47a8-8f43-08061d127c1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_29b5d0d0-f316-4778-87c1-3fc5eedd4ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d40f21a-ff26-41f2-9cb3-85cd7e6c2427" xlink:to="loc_us-gaap_OtherAssetsCurrent_29b5d0d0-f316-4778-87c1-3fc5eedd4ddd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1a788737-f62f-4f6d-8794-9aca8953a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b217ea98-548a-45d6-a540-a4d9ceed61e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1a788737-f62f-4f6d-8794-9aca8953a98f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b217ea98-548a-45d6-a540-a4d9ceed61e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_176aa3fc-63f5-4f84-b1aa-f805e7049dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1a788737-f62f-4f6d-8794-9aca8953a98f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_176aa3fc-63f5-4f84-b1aa-f805e7049dcf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_48593c86-b883-419b-a6a6-8a1124ec5471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_0daea102-04da-4037-9d4d-1f967da94bce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_48593c86-b883-419b-a6a6-8a1124ec5471" xlink:to="loc_us-gaap_AccruedSalariesCurrent_0daea102-04da-4037-9d4d-1f967da94bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_3154f53f-9942-4e7d-a0ae-9ffd4b2e6114" xlink:href="exdx-20210630.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_48593c86-b883-419b-a6a6-8a1124ec5471" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_3154f53f-9942-4e7d-a0ae-9ffd4b2e6114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_625429e8-aac2-4ecf-bd17-b01af253ffc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_48593c86-b883-419b-a6a6-8a1124ec5471" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_625429e8-aac2-4ecf-bd17-b01af253ffc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_6f091dbf-cc2e-4e21-809d-14a747263634" xlink:href="exdx-20210630.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_48593c86-b883-419b-a6a6-8a1124ec5471" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_6f091dbf-cc2e-4e21-809d-14a747263634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_4fb6a8b1-d7fe-4314-9648-1046434d4d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_48593c86-b883-419b-a6a6-8a1124ec5471" xlink:to="loc_us-gaap_InterestPayableCurrent_4fb6a8b1-d7fe-4314-9648-1046434d4d9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_1431dae1-5c35-431e-946e-9e60b1a110df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_48593c86-b883-419b-a6a6-8a1124ec5471" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_1431dae1-5c35-431e-946e-9e60b1a110df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3471072b-6811-4416-a7b1-967a1cb6226d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_48593c86-b883-419b-a6a6-8a1124ec5471" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3471072b-6811-4416-a7b1-967a1cb6226d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_1faf82d0-45d3-4b92-ab7a-b7cfb4264d77" xlink:href="exdx-20210630.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_514edcab-740e-4496-81e5-1b411acb7421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_1faf82d0-45d3-4b92-ab7a-b7cfb4264d77" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_514edcab-740e-4496-81e5-1b411acb7421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_65f184a8-a78c-49ce-9904-5633e79c84a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_1faf82d0-45d3-4b92-ab7a-b7cfb4264d77" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_65f184a8-a78c-49ce-9904-5633e79c84a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cb9c10b9-9b92-40a6-8cc1-7fe50b4c7f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_1faf82d0-45d3-4b92-ab7a-b7cfb4264d77" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cb9c10b9-9b92-40a6-8cc1-7fe50b4c7f3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_98df54e3-3ef4-4a0a-bae4-e5b5d0c2c507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest_1faf82d0-45d3-4b92-ab7a-b7cfb4264d77" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_98df54e3-3ef4-4a0a-bae4-e5b5d0c2c507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f3395110-319c-4dc4-b905-9de7a712820a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ef917605-10a9-47c3-aafe-94fba276dae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f3395110-319c-4dc4-b905-9de7a712820a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ef917605-10a9-47c3-aafe-94fba276dae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_5e7b6011-64f1-498f-b38e-adb263219f9d" xlink:href="exdx-20210630.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f3395110-319c-4dc4-b905-9de7a712820a" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_5e7b6011-64f1-498f-b38e-adb263219f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_6da515e0-9608-4788-b937-2f6071b166c3" xlink:href="exdx-20210630.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f3395110-319c-4dc4-b905-9de7a712820a" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_6da515e0-9608-4788-b937-2f6071b166c3" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>exdx-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6018f8ea-fa05-452a-adea-254786192c77,g:68b7dde8-2230-495d-984a-015fcac6c60d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20210630.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended" id="i49256874f05e44899d0eaf9da6a31c7e_UnauditedCondensedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d0706d02-3749-47f9-b78b-754ec4c2af6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d0706d02-3749-47f9-b78b-754ec4c2af6c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fb798fab-8090-4e5e-9b70-349807c0c884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fb798fab-8090-4e5e-9b70-349807c0c884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7b0e34a-9349-4681-8032-1855686a2b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockholdersEquity_b7b0e34a-9349-4681-8032-1855686a2b79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4c46c5fd-c4d9-4a93-844d-a6a76e366a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4c46c5fd-c4d9-4a93-844d-a6a76e366a23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd99746d-1ae1-4e78-98ce-f10aadcc203b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd99746d-1ae1-4e78-98ce-f10aadcc203b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1181361c-d9c8-459d-ae6a-3f804dd22658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1181361c-d9c8-459d-ae6a-3f804dd22658" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3826f426-9cb3-475c-9e64-1c5549699269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3826f426-9cb3-475c-9e64-1c5549699269" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_369913f9-27f2-47c4-87b2-08860d0339c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_369913f9-27f2-47c4-87b2-08860d0339c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0bacb19-bc7a-4da9-887a-b670ab5c7533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0bacb19-bc7a-4da9-887a-b670ab5c7533" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8e7b47dd-97fd-4ba2-8d98-6ccaa67d4066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8e7b47dd-97fd-4ba2-8d98-6ccaa67d4066" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f172c06c-66db-49e2-81ab-919694b64d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f172c06c-66db-49e2-81ab-919694b64d4f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_99606ade-734f-4105-8489-d666eb9381eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_99606ade-734f-4105-8489-d666eb9381eb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50840426-89d2-4871-95ca-a2dc11222d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50840426-89d2-4871-95ca-a2dc11222d65" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_bb508f6a-a658-47be-b8ce-4b750df75813" xlink:href="exdx-20210630.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_bb508f6a-a658-47be-b8ce-4b750df75813" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_5385a557-4238-4e68-88d4-c6b5220c2192" xlink:href="exdx-20210630.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_5385a557-4238-4e68-88d4-c6b5220c2192" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e53d2b7b-ec57-40ee-82c9-37423e6eaab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_NetIncomeLoss_e53d2b7b-ec57-40ee-82c9-37423e6eaab7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d0bf2d0f-56c6-484c-b21c-786a6cdca93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5bdbbf71-5331-408d-87b3-740ab952f171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_570a867c-ba63-429a-9720-b80677fb6456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d0706d02-3749-47f9-b78b-754ec4c2af6c" xlink:to="loc_us-gaap_StatementTable_570a867c-ba63-429a-9720-b80677fb6456" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6ffe7550-2420-4dca-b631-ee343e03752b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_570a867c-ba63-429a-9720-b80677fb6456" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6ffe7550-2420-4dca-b631-ee343e03752b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ffe7550-2420-4dca-b631-ee343e03752b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ffe7550-2420-4dca-b631-ee343e03752b" xlink:to="loc_us-gaap_EquityComponentDomain_6ffe7550-2420-4dca-b631-ee343e03752b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ffe7550-2420-4dca-b631-ee343e03752b" xlink:to="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_956e81f6-407a-42ff-b328-ec118d9a9581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:to="loc_us-gaap_CommonStockMember_956e81f6-407a-42ff-b328-ec118d9a9581" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a47c768a-9aa1-4806-87b1-e02ee5e535b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a47c768a-9aa1-4806-87b1-e02ee5e535b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ff5f4c83-de30-4bbf-86f0-2c2097045ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:to="loc_us-gaap_RetainedEarningsMember_ff5f4c83-de30-4bbf-86f0-2c2097045ec2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended" id="i7d145fb14f9c420e9ad123175dc0ed88_SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_34ea0ffc-b8bd-43da-8d21-1a25830d2953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9d74193e-fa0b-4aa5-8121-7d226effd775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_34ea0ffc-b8bd-43da-8d21-1a25830d2953" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9d74193e-fa0b-4aa5-8121-7d226effd775" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_34ea0ffc-b8bd-43da-8d21-1a25830d2953" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:to="loc_srt_MajorCustomersAxis_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_f7a8d5d8-3bec-4d7c-bd42-cc715a20c4c6" xlink:href="exdx-20210630.xsd#exdx_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_MedicareMember_f7a8d5d8-3bec-4d7c-bd42-cc715a20c4c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_063d5149-4974-4948-b0fd-d49ea9b2b888" xlink:href="exdx-20210630.xsd#exdx_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_MedicareAdvantageMember_063d5149-4974-4948-b0fd-d49ea9b2b888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_df327a89-43cd-4d5e-b5d2-886922ee80de" xlink:href="exdx-20210630.xsd#exdx_BlueShieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_BlueShieldMember_df327a89-43cd-4d5e-b5d2-886922ee80de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_a1191c42-bf5e-4e8e-934e-8abae3afd527" xlink:href="exdx-20210630.xsd#exdx_UnitedHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_UnitedHealthcareMember_a1191c42-bf5e-4e8e-934e-8abae3afd527" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_23845043-4e99-4161-99e7-55838b699215" xlink:href="exdx-20210630.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_JanssenSIMPONIMember_23845043-4e99-4161-99e7-55838b699215" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a88c71d-4f5c-47d2-96ea-059309a90ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a88c71d-4f5c-47d2-96ea-059309a90ef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4a88c71d-4f5c-47d2-96ea-059309a90ef9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a88c71d-4f5c-47d2-96ea-059309a90ef9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4a88c71d-4f5c-47d2-96ea-059309a90ef9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcc8b326-bdde-4e95-8c32-5e4bc81e0aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a88c71d-4f5c-47d2-96ea-059309a90ef9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcc8b326-bdde-4e95-8c32-5e4bc81e0aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_5870f40d-434b-4d4f-b59e-008777053b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcc8b326-bdde-4e95-8c32-5e4bc81e0aca" xlink:to="loc_us-gaap_SalesRevenueNetMember_5870f40d-434b-4d4f-b59e-008777053b72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_df2dc6fe-a6cf-49e7-9df5-1084c2d9666e" xlink:href="exdx-20210630.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcc8b326-bdde-4e95-8c32-5e4bc81e0aca" xlink:to="loc_exdx_ReceivableBenchmarkMember_df2dc6fe-a6cf-49e7-9df5-1084c2d9666e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e894907f-9159-4711-9499-769dd51b1eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e894907f-9159-4711-9499-769dd51b1eba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e894907f-9159-4711-9499-769dd51b1eba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e894907f-9159-4711-9499-769dd51b1eba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e894907f-9159-4711-9499-769dd51b1eba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_38992fea-a4f3-43a7-85a5-093cc003b405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e894907f-9159-4711-9499-769dd51b1eba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_38992fea-a4f3-43a7-85a5-093cc003b405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6019115f-7b80-4f2c-8c5a-236c77bc18c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_38992fea-a4f3-43a7-85a5-093cc003b405" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6019115f-7b80-4f2c-8c5a-236c77bc18c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="if0c62a7d460a48b3893d4baa3d1e12ed_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_cd8a0a92-62f4-46c4-80c8-8aa7f7c79b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_cd8a0a92-62f4-46c4-80c8-8aa7f7c79b62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d527074e-260c-4ec7-9d78-750ed93284b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_RestrictedCash_d527074e-260c-4ec7-9d78-750ed93284b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_b03ccbd0-459c-4ff2-a9c3-c71a370b1d51" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_b03ccbd0-459c-4ff2-a9c3-c71a370b1d51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee_c3ea0b63-d514-4be3-86cb-dbb1d76ee2bd" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFee_c3ea0b63-d514-4be3-86cb-dbb1d76ee2bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_2da47893-c579-45b7-8e5c-5e933b577e6d" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_2da47893-c579-45b7-8e5c-5e933b577e6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureTerminationConsiderationReceivable_3f9caad2-2b57-4b43-8268-b23520cef7ec" xlink:href="exdx-20210630.xsd#exdx_JointVentureTerminationConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_exdx_JointVentureTerminationConsiderationReceivable_3f9caad2-2b57-4b43-8268-b23520cef7ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_760d8c28-7e2f-419d-a325-f9615e471c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_760d8c28-7e2f-419d-a325-f9615e471c2c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_617f3874-ec7d-4f0d-856a-e8d29cded001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_AdvertisingExpense_617f3874-ec7d-4f0d-856a-e8d29cded001" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_63f6efd9-f1e3-4e08-aa52-2b4944cb5b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_CostOfRevenue_63f6efd9-f1e3-4e08-aa52-2b4944cb5b2f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0012a700-1d36-44fc-91c3-1147c014eaee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0012a700-1d36-44fc-91c3-1147c014eaee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c56c17f9-b0df-4a77-b464-feb8f90dd05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c56c17f9-b0df-4a77-b464-feb8f90dd05f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a453f39-f78c-4a47-b73b-12ad2923c57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a453f39-f78c-4a47-b73b-12ad2923c57a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d1cb36f5-7b89-4b73-962d-5624db88aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a453f39-f78c-4a47-b73b-12ad2923c57a" xlink:to="loc_us-gaap_SalesRevenueNetMember_d1cb36f5-7b89-4b73-962d-5624db88aebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_519c3ad7-0307-4680-95d8-da6f586dca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_519c3ad7-0307-4680-95d8-da6f586dca3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_519c3ad7-0307-4680-95d8-da6f586dca3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_519c3ad7-0307-4680-95d8-da6f586dca3f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_519c3ad7-0307-4680-95d8-da6f586dca3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a9a61982-6895-4098-b7b8-e981538c5877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_519c3ad7-0307-4680-95d8-da6f586dca3f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a9a61982-6895-4098-b7b8-e981538c5877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_569f2efd-be4a-412f-830c-300fa528a0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a9a61982-6895-4098-b7b8-e981538c5877" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_569f2efd-be4a-412f-830c-300fa528a0bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_256afea8-a7a4-40ab-bf04-9a8b19db0993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a9a61982-6895-4098-b7b8-e981538c5877" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_256afea8-a7a4-40ab-bf04-9a8b19db0993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_577fb433-9c44-4cd5-8eef-39ed3ba8676c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_srt_ProductOrServiceAxis_577fb433-9c44-4cd5-8eef-39ed3ba8676c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_577fb433-9c44-4cd5-8eef-39ed3ba8676c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_577fb433-9c44-4cd5-8eef-39ed3ba8676c" xlink:to="loc_srt_ProductsAndServicesDomain_577fb433-9c44-4cd5-8eef-39ed3ba8676c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9c077f6-60bb-4851-ad49-0ff61a1c47bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_577fb433-9c44-4cd5-8eef-39ed3ba8676c" xlink:to="loc_srt_ProductsAndServicesDomain_e9c077f6-60bb-4851-ad49-0ff61a1c47bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_ecdcb0ba-6032-43a3-8895-9a8653494422" xlink:href="exdx-20210630.xsd#exdx_AVISECTDTestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9c077f6-60bb-4851-ad49-0ff61a1c47bc" xlink:to="loc_exdx_AVISECTDTestMember_ecdcb0ba-6032-43a3-8895-9a8653494422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_4651565a-5429-44e7-a214-21dbc60a8965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9c077f6-60bb-4851-ad49-0ff61a1c47bc" xlink:to="loc_us-gaap_ShippingAndHandlingMember_4651565a-5429-44e7-a214-21dbc60a8965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f751ee46-4015-49b9-a248-ced0d9bc303d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f751ee46-4015-49b9-a248-ced0d9bc303d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f751ee46-4015-49b9-a248-ced0d9bc303d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f751ee46-4015-49b9-a248-ced0d9bc303d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f751ee46-4015-49b9-a248-ced0d9bc303d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_63bcb768-a5fe-4899-b759-4d5f226a76a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f751ee46-4015-49b9-a248-ced0d9bc303d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_63bcb768-a5fe-4899-b759-4d5f226a76a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_cf199907-c6ca-4777-ab5e-078627538b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_63bcb768-a5fe-4899-b759-4d5f226a76a3" xlink:to="loc_us-gaap_OtherAssetsMember_cf199907-c6ca-4777-ab5e-078627538b6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_071289ae-0173-4141-9f9c-d5240c90db62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_srt_RangeAxis_071289ae-0173-4141-9f9c-d5240c90db62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_071289ae-0173-4141-9f9c-d5240c90db62_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_071289ae-0173-4141-9f9c-d5240c90db62" xlink:to="loc_srt_RangeMember_071289ae-0173-4141-9f9c-d5240c90db62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b209257-9605-4e45-aedf-bd73928f7a97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_071289ae-0173-4141-9f9c-d5240c90db62" xlink:to="loc_srt_RangeMember_0b209257-9605-4e45-aedf-bd73928f7a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_454c6589-2789-4b42-9e05-cd4440c9005f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b209257-9605-4e45-aedf-bd73928f7a97" xlink:to="loc_srt_MinimumMember_454c6589-2789-4b42-9e05-cd4440c9005f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d873ecc-818c-4bb4-ab6d-41ba3b61c852" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b209257-9605-4e45-aedf-bd73928f7a97" xlink:to="loc_srt_MaximumMember_9d873ecc-818c-4bb4-ab6d-41ba3b61c852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_srt_CounterpartyNameAxis_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e4c12ed-4606-4a72-80da-ee02931c8295" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e4c12ed-4606-4a72-80da-ee02931c8295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_01f0d1bf-548f-4a50-87a9-340908ad7951" xlink:href="exdx-20210630.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e4c12ed-4606-4a72-80da-ee02931c8295" xlink:to="loc_exdx_JanssenSIMPONIMember_01f0d1bf-548f-4a50-87a9-340908ad7951" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0332383b-260a-4e9e-8086-4cfac71acc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_AwardTypeAxis_0332383b-260a-4e9e-8086-4cfac71acc6a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0332383b-260a-4e9e-8086-4cfac71acc6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0332383b-260a-4e9e-8086-4cfac71acc6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0332383b-260a-4e9e-8086-4cfac71acc6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df45438d-8335-49d7-b959-20a086bf4365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0332383b-260a-4e9e-8086-4cfac71acc6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df45438d-8335-49d7-b959-20a086bf4365" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_de8cf2fa-9460-4f9e-98c9-8fd87ac990e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df45438d-8335-49d7-b959-20a086bf4365" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_de8cf2fa-9460-4f9e-98c9-8fd87ac990e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1fd71107-fba0-4f8d-ae5c-e074682ffb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1fd71107-fba0-4f8d-ae5c-e074682ffb1a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1fd71107-fba0-4f8d-ae5c-e074682ffb1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1fd71107-fba0-4f8d-ae5c-e074682ffb1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1fd71107-fba0-4f8d-ae5c-e074682ffb1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a51bad19-ff16-4bf3-b252-8650af96a23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1fd71107-fba0-4f8d-ae5c-e074682ffb1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a51bad19-ff16-4bf3-b252-8650af96a23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember_da6549d2-77e3-4bc2-91d1-9dedbefcc11d" xlink:href="exdx-20210630.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a51bad19-ff16-4bf3-b252-8650af96a23d" xlink:to="loc_exdx_JanssenPromotionAgreementMember_da6549d2-77e3-4bc2-91d1-9dedbefcc11d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3a9781f8-1d08-444a-8186-c5a1372c8275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3a9781f8-1d08-444a-8186-c5a1372c8275" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_3a9781f8-1d08-444a-8186-c5a1372c8275_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3a9781f8-1d08-444a-8186-c5a1372c8275" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_3a9781f8-1d08-444a-8186-c5a1372c8275_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d83bc8e8-1be9-4c01-986e-5741aedeb5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3a9781f8-1d08-444a-8186-c5a1372c8275" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d83bc8e8-1be9-4c01-986e-5741aedeb5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember_36991f2d-1d99-4a7b-a434-c0e96cdc97eb" xlink:href="exdx-20210630.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d83bc8e8-1be9-4c01-986e-5741aedeb5a8" xlink:to="loc_exdx_TwoMajorSuppliersMember_36991f2d-1d99-4a7b-a434-c0e96cdc97eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended" id="id04e610c775544f29d8e1abcdb0aefc0_SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_20f6db55-0f4f-4a2e-b7fb-3f07281e4ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c481c287-9f0c-4ea8-ae36-a5cd58d187a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_20f6db55-0f4f-4a2e-b7fb-3f07281e4ae5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c481c287-9f0c-4ea8-ae36-a5cd58d187a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a6ce373a-00c0-4c22-8b62-4a8d2deea5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_20f6db55-0f4f-4a2e-b7fb-3f07281e4ae5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a6ce373a-00c0-4c22-8b62-4a8d2deea5a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dcb022be-b228-4ae5-90bb-494c482379f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6ce373a-00c0-4c22-8b62-4a8d2deea5a8" xlink:to="loc_srt_MajorCustomersAxis_dcb022be-b228-4ae5-90bb-494c482379f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dcb022be-b228-4ae5-90bb-494c482379f5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_dcb022be-b228-4ae5-90bb-494c482379f5" xlink:to="loc_srt_NameOfMajorCustomerDomain_dcb022be-b228-4ae5-90bb-494c482379f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_dcb022be-b228-4ae5-90bb-494c482379f5" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_dfe8c46b-2f7e-4174-9882-5108e6d6bec5" xlink:href="exdx-20210630.xsd#exdx_HealthcareInsurersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_exdx_HealthcareInsurersMember_dfe8c46b-2f7e-4174-9882-5108e6d6bec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_ca2492f1-ef37-4987-88a8-adfc4a3feacb" xlink:href="exdx-20210630.xsd#exdx_Government1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_exdx_Government1Member_ca2492f1-ef37-4987-88a8-adfc4a3feacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_a8f1d915-b144-4f3a-b022-1e0be1d29228" xlink:href="exdx-20210630.xsd#exdx_ClientMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_exdx_ClientMember_a8f1d915-b144-4f3a-b022-1e0be1d29228" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_e4f66c80-e946-4562-9d94-a4b9c1ae3f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_us-gaap_OtherCustomerMember_e4f66c80-e946-4562-9d94-a4b9c1ae3f20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_69728f0b-eed8-454a-acdb-45013f368d2d" xlink:href="exdx-20210630.xsd#exdx_JanssenSIMPONIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_exdx_JanssenSIMPONIMember_69728f0b-eed8-454a-acdb-45013f368d2d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended" id="iaf6fe8ae5a3c4531a0d9c19f08148fd4_SummaryofSignificantAccountingPoliciesSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f2e57746-5ffa-46c2-ab98-660054b29bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21a72279-80a2-45b2-98c9-96cc747345eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2e57746-5ffa-46c2-ab98-660054b29bb6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21a72279-80a2-45b2-98c9-96cc747345eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ac997e3f-1b81-43e5-ae33-fd58e777ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2e57746-5ffa-46c2-ab98-660054b29bb6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ac997e3f-1b81-43e5-ae33-fd58e777ccb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab5a7ea1-4712-4eba-8bb8-383dbf04d287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ac997e3f-1b81-43e5-ae33-fd58e777ccb3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab5a7ea1-4712-4eba-8bb8-383dbf04d287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ab5a7ea1-4712-4eba-8bb8-383dbf04d287_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab5a7ea1-4712-4eba-8bb8-383dbf04d287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ab5a7ea1-4712-4eba-8bb8-383dbf04d287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab5a7ea1-4712-4eba-8bb8-383dbf04d287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_04ff2892-a23d-4790-a3ee-4dcc8fc421ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:to="loc_us-gaap_WarrantMember_04ff2892-a23d-4790-a3ee-4dcc8fc421ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_f63e91f1-bdcc-442f-b0eb-edf185ff96f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:to="loc_us-gaap_StockOptionMember_f63e91f1-bdcc-442f-b0eb-edf185ff96f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_25807057-0ba7-4376-80e0-528fd471daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_25807057-0ba7-4376-80e0-528fd471daa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3e69e156-4ee6-4777-9e08-5fad63e11c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:to="loc_us-gaap_EmployeeStockMember_3e69e156-4ee6-4777-9e08-5fad63e11c63" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended" id="i26d29905ae144449b4434f2f2827d5f8_OtherFinancialInformationPropertyandequipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_66fb5169-1a87-4d82-a2d9-60b690560041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_66fb5169-1a87-4d82-a2d9-60b690560041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ace4bba-253d-4ce5-9cb9-caf5ec2f6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ace4bba-253d-4ce5-9cb9-caf5ec2f6e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7aef9419-9b53-45aa-b4e4-f1345408083a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7aef9419-9b53-45aa-b4e4-f1345408083a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7f94bf24-eccf-453c-8136-d7b6540f46e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7f94bf24-eccf-453c-8136-d7b6540f46e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47e60fcf-763a-41ae-a621-7e94dd8955f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7f94bf24-eccf-453c-8136-d7b6540f46e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47e60fcf-763a-41ae-a621-7e94dd8955f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_47e60fcf-763a-41ae-a621-7e94dd8955f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47e60fcf-763a-41ae-a621-7e94dd8955f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_47e60fcf-763a-41ae-a621-7e94dd8955f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47e60fcf-763a-41ae-a621-7e94dd8955f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_57d1c114-105d-4cac-a988-6b249b316ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_57d1c114-105d-4cac-a988-6b249b316ca5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_fa37f428-cd25-4ff5-a1b4-e9d1ae9a71b2" xlink:href="exdx-20210630.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_exdx_LaboratoryEquipmentMember_fa37f428-cd25-4ff5-a1b4-e9d1ae9a71b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_da136d4c-b581-4980-8d82-9a25a39fa665" xlink:href="exdx-20210630.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_da136d4c-b581-4980-8d82-9a25a39fa665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fd19188d-dac3-4755-a027-27fd384478b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fd19188d-dac3-4755-a027-27fd384478b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_0d460686-a43c-4453-be14-01f79e87745d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_us-gaap_ConstructionInProgressMember_0d460686-a43c-4453-be14-01f79e87745d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended" id="i4886f7d747014fe6a7cc3421206fcd2f_OtherFinancialInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d48e8872-82f6-4168-83ef-ad4fb676e189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a2818a3b-3291-405c-bc4d-4987b7bf664d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d48e8872-82f6-4168-83ef-ad4fb676e189" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a2818a3b-3291-405c-bc4d-4987b7bf664d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c96c3f99-21cd-4f26-9bb8-ffe61cdd3a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d48e8872-82f6-4168-83ef-ad4fb676e189" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c96c3f99-21cd-4f26-9bb8-ffe61cdd3a79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de298ba0-18be-4c86-a376-76dd344f940e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d48e8872-82f6-4168-83ef-ad4fb676e189" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de298ba0-18be-4c86-a376-76dd344f940e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de298ba0-18be-4c86-a376-76dd344f940e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27ec0588-6742-49f5-a8f1-0d5288f1ded4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27ec0588-6742-49f5-a8f1-0d5288f1ded4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_4122f990-c1a2-4bf2-9b06-48d1c4c507e5" xlink:href="exdx-20210630.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27ec0588-6742-49f5-a8f1-0d5288f1ded4" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_4122f990-c1a2-4bf2-9b06-48d1c4c507e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i58e7f638430848b0875d5275f3d4ef48_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f28e3d03-3957-41ca-95d4-826b0d272b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f28e3d03-3957-41ca-95d4-826b0d272b0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f0b88ef0-52ed-4580-a121-e3587cc42a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f0b88ef0-52ed-4580-a121-e3587cc42a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_debee391-e351-4ef7-9f1a-19109380f414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_debee391-e351-4ef7-9f1a-19109380f414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_e40b7978-5e46-4083-975a-a9048f872add" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_e40b7978-5e46-4083-975a-a9048f872add" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78eb1b59-ca8b-4f47-964a-67135f5f21c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78eb1b59-ca8b-4f47-964a-67135f5f21c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_0467e9ff-74c5-430d-94f6-ca1986c741c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentTerm_0467e9ff-74c5-430d-94f6-ca1986c741c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_3b08dd8e-ce39-488d-bfab-bc5be21d4171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_3b08dd8e-ce39-488d-bfab-bc5be21d4171" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_2a961fc1-0897-4f61-85e4-3e50becb95b2" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_2a961fc1-0897-4f61-85e4-3e50becb95b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_f065f639-a5d9-413d-a88d-f20d13e7e417" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_f065f639-a5d9-413d-a88d-f20d13e7e417" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_7ce4eb16-34aa-4313-99f7-51d17dbb959a" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_7ce4eb16-34aa-4313-99f7-51d17dbb959a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_769e1ef1-95fb-4cbd-b690-12790cc5f614" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_769e1ef1-95fb-4cbd-b690-12790cc5f614" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_837c1bf3-7f4e-4408-ad63-1fa69d52e903" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_837c1bf3-7f4e-4408-ad63-1fa69d52e903" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e3c34dec-7f55-4935-a953-dc538a549e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:to="loc_us-gaap_DebtInstrumentAxis_e3c34dec-7f55-4935-a953-dc538a549e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e3c34dec-7f55-4935-a953-dc538a549e62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e3c34dec-7f55-4935-a953-dc538a549e62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e3c34dec-7f55-4935-a953-dc538a549e62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a54637a4-d677-41cb-860c-5cdd56998310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e3c34dec-7f55-4935-a953-dc538a549e62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a54637a4-d677-41cb-860c-5cdd56998310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_a19bfc83-5de3-47e8-98f3-5808e5e3e1ae" xlink:href="exdx-20210630.xsd#exdx_Term2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a54637a4-d677-41cb-860c-5cdd56998310" xlink:to="loc_exdx_Term2017Member_a19bfc83-5de3-47e8-98f3-5808e5e3e1ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f40bd876-2532-4f5a-b505-1a7c3d008f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f40bd876-2532-4f5a-b505-1a7c3d008f18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f40bd876-2532-4f5a-b505-1a7c3d008f18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f40bd876-2532-4f5a-b505-1a7c3d008f18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f40bd876-2532-4f5a-b505-1a7c3d008f18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8683256a-885a-4e93-89f7-289009453508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f40bd876-2532-4f5a-b505-1a7c3d008f18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8683256a-885a-4e93-89f7-289009453508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_3f36f7e8-35f8-4d1f-9ff0-5f5fe2f7498b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8683256a-885a-4e93-89f7-289009453508" xlink:to="loc_us-gaap_LoansPayableMember_3f36f7e8-35f8-4d1f-9ff0-5f5fe2f7498b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_b7c3e689-a5f6-4a3c-ac2e-c87a30eb2355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8683256a-885a-4e93-89f7-289009453508" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_b7c3e689-a5f6-4a3c-ac2e-c87a30eb2355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_621e7790-e9b6-4832-9b45-9962e3b0cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_621e7790-e9b6-4832-9b45-9962e3b0cc55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_621e7790-e9b6-4832-9b45-9962e3b0cc55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_621e7790-e9b6-4832-9b45-9962e3b0cc55" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_621e7790-e9b6-4832-9b45-9962e3b0cc55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea482488-d017-4a1f-81d6-b1ab5dbe9cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_621e7790-e9b6-4832-9b45-9962e3b0cc55" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea482488-d017-4a1f-81d6-b1ab5dbe9cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_205baf15-5748-4305-9b02-bd0541b18979" xlink:href="exdx-20210630.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea482488-d017-4a1f-81d6-b1ab5dbe9cef" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_205baf15-5748-4305-9b02-bd0541b18979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_984dc737-399a-491a-9bfe-0823a804391a" xlink:href="exdx-20210630.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea482488-d017-4a1f-81d6-b1ab5dbe9cef" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_984dc737-399a-491a-9bfe-0823a804391a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended" id="i67396f2c3ddb4cf38e9d92bc240b9476_CommitmentandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm_d63dbe08-7326-4b36-84ad-aa430604ab7f" xlink:href="exdx-20210630.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_OperatingLeasesRenewalTerm_d63dbe08-7326-4b36-84ad-aa430604ab7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_59480360-8d54-4f32-8ad5-b128d792a5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_LeaseAndRentalExpense_59480360-8d54-4f32-8ad5-b128d792a5a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_81462fe6-8555-46ab-bad6-6ea584181461" xlink:href="exdx-20210630.xsd#exdx_MilestoneObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_MilestoneObligation_81462fe6-8555-46ab-bad6-6ea584181461" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure_d266bd3d-1ca2-42d2-afe1-cf0f508b6ac5" xlink:href="exdx-20210630.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_MilestoneContingencyFairValueDisclosure_d266bd3d-1ca2-42d2-afe1-cf0f508b6ac5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_ae0edbbc-3618-4c52-82fc-c5d084173901" xlink:href="exdx-20210630.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_ae0edbbc-3618-4c52-82fc-c5d084173901" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_9c58af9c-210d-4672-aa76-b471cfb72968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_9c58af9c-210d-4672-aa76-b471cfb72968" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_fb3e8f06-f04c-4a48-8f48-921fe4367c66" xlink:href="exdx-20210630.xsd#exdx_AdvancePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_AdvancePayment_fb3e8f06-f04c-4a48-8f48-921fe4367c66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee_96641279-6e9e-4c90-9771-59ac83a378f3" xlink:href="exdx-20210630.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_LicenseAgreementInitialLicenseFee_96641279-6e9e-4c90-9771-59ac83a378f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_1a3d9cec-2cd5-4026-96df-b4a550983196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_1a3d9cec-2cd5-4026-96df-b4a550983196" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4fe59fe1-06bc-440f-ba10-4ace42123195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4fe59fe1-06bc-440f-ba10-4ace42123195" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_e75c2d2b-047d-4837-97cf-a12d0958bed3" xlink:href="exdx-20210630.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_e75c2d2b-047d-4837-97cf-a12d0958bed3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_893829f3-3a63-4b95-bce1-dbad450a45a8" xlink:href="exdx-20210630.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_893829f3-3a63-4b95-bce1-dbad450a45a8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_94c33274-454e-4bfb-b75f-686303098671" xlink:href="exdx-20210630.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_94c33274-454e-4bfb-b75f-686303098671" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_c780696c-a2e3-445d-91a5-b61e6073d754" xlink:href="exdx-20210630.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_exdx_RentalPropertyByTypeAxis_c780696c-a2e3-445d-91a5-b61e6073d754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_c780696c-a2e3-445d-91a5-b61e6073d754_default" xlink:href="exdx-20210630.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exdx_RentalPropertyByTypeAxis_c780696c-a2e3-445d-91a5-b61e6073d754" xlink:to="loc_exdx_RentalPropertyByTypeDomain_c780696c-a2e3-445d-91a5-b61e6073d754_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_4d25487f-0b8f-48c2-9704-9f4e1738b0f5" xlink:href="exdx-20210630.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exdx_RentalPropertyByTypeAxis_c780696c-a2e3-445d-91a5-b61e6073d754" xlink:to="loc_exdx_RentalPropertyByTypeDomain_4d25487f-0b8f-48c2-9704-9f4e1738b0f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_abdf6714-6223-442a-bdae-83f872a888d2" xlink:href="exdx-20210630.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_4d25487f-0b8f-48c2-9704-9f4e1738b0f5" xlink:to="loc_exdx_OfficeAndLaboratoryMember_abdf6714-6223-442a-bdae-83f872a888d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_a99d29ab-0155-436f-bc4b-cc3d3ae3cbe6" xlink:href="exdx-20210630.xsd#exdx_OfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exdx_RentalPropertyByTypeDomain_4d25487f-0b8f-48c2-9704-9f4e1738b0f5" xlink:to="loc_exdx_OfficeMember_a99d29ab-0155-436f-bc4b-cc3d3ae3cbe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8cdedaf6-d4ff-4c25-942a-fdb236855638" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_srt_CounterpartyNameAxis_8cdedaf6-d4ff-4c25-942a-fdb236855638" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cdedaf6-d4ff-4c25-942a-fdb236855638_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8cdedaf6-d4ff-4c25-942a-fdb236855638" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cdedaf6-d4ff-4c25-942a-fdb236855638_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_400892ed-e8af-4109-93bd-a228ca91a24a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8cdedaf6-d4ff-4c25-942a-fdb236855638" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_400892ed-e8af-4109-93bd-a228ca91a24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_2ee21751-5711-49dd-aa08-418c517297e9" xlink:href="exdx-20210630.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_400892ed-e8af-4109-93bd-a228ca91a24a" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_2ee21751-5711-49dd-aa08-418c517297e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_c9684119-da3a-44e0-a84e-0eb395716451" xlink:href="exdx-20210630.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_400892ed-e8af-4109-93bd-a228ca91a24a" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_c9684119-da3a-44e0-a84e-0eb395716451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c398b746-af03-4d68-b99f-50b0a1f4c864" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_srt_RangeAxis_c398b746-af03-4d68-b99f-50b0a1f4c864" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c398b746-af03-4d68-b99f-50b0a1f4c864_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c398b746-af03-4d68-b99f-50b0a1f4c864" xlink:to="loc_srt_RangeMember_c398b746-af03-4d68-b99f-50b0a1f4c864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29f3823d-4aa1-42cc-a806-cc0493c2ad47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c398b746-af03-4d68-b99f-50b0a1f4c864" xlink:to="loc_srt_RangeMember_29f3823d-4aa1-42cc-a806-cc0493c2ad47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bba91061-51e6-40ed-b30d-8814853e0555" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_29f3823d-4aa1-42cc-a806-cc0493c2ad47" xlink:to="loc_srt_MinimumMember_bba91061-51e6-40ed-b30d-8814853e0555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59437dc5-21b9-49b3-92fc-95f1f5540c01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_29f3823d-4aa1-42cc-a806-cc0493c2ad47" xlink:to="loc_srt_MaximumMember_59437dc5-21b9-49b3-92fc-95f1f5540c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a924536-7bcf-4223-8421-eb70bd1785ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a924536-7bcf-4223-8421-eb70bd1785ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4a924536-7bcf-4223-8421-eb70bd1785ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a924536-7bcf-4223-8421-eb70bd1785ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4a924536-7bcf-4223-8421-eb70bd1785ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38f30789-9720-4004-b2da-059b8a0054cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a924536-7bcf-4223-8421-eb70bd1785ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38f30789-9720-4004-b2da-059b8a0054cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_4e98f4e2-7374-4696-bb62-728565e4d657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38f30789-9720-4004-b2da-059b8a0054cb" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_4e98f4e2-7374-4696-bb62-728565e4d657" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d1f7654f-ed66-49b5-9fb3-295ae3021be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d1f7654f-ed66-49b5-9fb3-295ae3021be9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1f7654f-ed66-49b5-9fb3-295ae3021be9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1f7654f-ed66-49b5-9fb3-295ae3021be9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1f7654f-ed66-49b5-9fb3-295ae3021be9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afc6c413-b110-47af-954e-9b482f8e6c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1f7654f-ed66-49b5-9fb3-295ae3021be9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afc6c413-b110-47af-954e-9b482f8e6c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_70bbaea8-c24d-447a-8f36-3be90c92a508" xlink:href="exdx-20210630.xsd#exdx_AHNCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afc6c413-b110-47af-954e-9b482f8e6c4c" xlink:to="loc_exdx_AHNCollaborationMember_70bbaea8-c24d-447a-8f36-3be90c92a508" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i79de1e030a3643f7be5134ec851d3477_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_50b8a878-5da3-48c4-86f9-843303068cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e72cd5b8-b0bb-426d-8e1a-9304741da29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_50b8a878-5da3-48c4-86f9-843303068cee" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e72cd5b8-b0bb-426d-8e1a-9304741da29a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09ea8f15-2484-440c-8fcf-c7f392299e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e72cd5b8-b0bb-426d-8e1a-9304741da29a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09ea8f15-2484-440c-8fcf-c7f392299e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_50b8a878-5da3-48c4-86f9-843303068cee" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c061db4-661a-4bfa-86bf-5bd0c697dd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c061db4-661a-4bfa-86bf-5bd0c697dd59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c061db4-661a-4bfa-86bf-5bd0c697dd59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c061db4-661a-4bfa-86bf-5bd0c697dd59" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9c061db4-661a-4bfa-86bf-5bd0c697dd59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b18d8025-3ada-4162-b184-eb04bd8dd319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c061db4-661a-4bfa-86bf-5bd0c697dd59" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b18d8025-3ada-4162-b184-eb04bd8dd319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e3460755-9330-43aa-93d0-a2310337f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b18d8025-3ada-4162-b184-eb04bd8dd319" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e3460755-9330-43aa-93d0-a2310337f3f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37ef64e0-acf0-4863-a34a-11a36581b373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37ef64e0-acf0-4863-a34a-11a36581b373" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37ef64e0-acf0-4863-a34a-11a36581b373_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37ef64e0-acf0-4863-a34a-11a36581b373" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37ef64e0-acf0-4863-a34a-11a36581b373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37ef64e0-acf0-4863-a34a-11a36581b373" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7d63fec2-f8e7-46c1-943e-06f45842c11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7d63fec2-f8e7-46c1-943e-06f45842c11e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_22a4217b-9ebc-4cf2-a6ee-e708bbbd7e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_22a4217b-9ebc-4cf2-a6ee-e708bbbd7e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3d8804e3-0ee1-40ed-b4e3-f191f4a9c0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3d8804e3-0ee1-40ed-b4e3-f191f4a9c0fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9fa9d400-d1fb-4be1-b9f7-52231e8aea68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9fa9d400-d1fb-4be1-b9f7-52231e8aea68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fa9d400-d1fb-4be1-b9f7-52231e8aea68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9fa9d400-d1fb-4be1-b9f7-52231e8aea68" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fa9d400-d1fb-4be1-b9f7-52231e8aea68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4938202e-1709-49f1-8410-70fc1d59637b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9fa9d400-d1fb-4be1-b9f7-52231e8aea68" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4938202e-1709-49f1-8410-70fc1d59637b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c49eb64f-1139-48b3-91c8-c9e4ea0b5600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4938202e-1709-49f1-8410-70fc1d59637b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c49eb64f-1139-48b3-91c8-c9e4ea0b5600" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i2c45f1d7c9af4035907da30740d20f28_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_783f72f9-54fa-4a67-b16a-5001410d63d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_783f72f9-54fa-4a67-b16a-5001410d63d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_34f52acc-75dd-40dd-a9f8-5c35306204f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_34f52acc-75dd-40dd-a9f8-5c35306204f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a9b96868-c6b8-4cdf-8401-da5be906f2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a9b96868-c6b8-4cdf-8401-da5be906f2c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_728d7202-8299-4b38-b2bb-a3feb4659eca" xlink:href="exdx-20210630.xsd#exdx_StockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_exdx_StockIssuanceCosts_728d7202-8299-4b38-b2bb-a3feb4659eca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_f65b31d8-e825-4ef7-84f6-8f909b234d02" xlink:href="exdx-20210630.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_f65b31d8-e825-4ef7-84f6-8f909b234d02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_417513d1-f72e-4022-bf9e-4095333e8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_417513d1-f72e-4022-bf9e-4095333e8a43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20fa1868-4c7a-4be5-b3ea-23f6a405b5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20fa1868-4c7a-4be5-b3ea-23f6a405b5f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_4b87bf37-e4f9-48cc-86a2-a1f8f050fda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_4b87bf37-e4f9-48cc-86a2-a1f8f050fda6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_b4fdb756-a77f-415e-b467-8cadfd8a4589" xlink:href="exdx-20210630.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_b4fdb756-a77f-415e-b467-8cadfd8a4589" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_13d3070c-d3ba-47f6-b855-69116a4a8dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_13d3070c-d3ba-47f6-b855-69116a4a8dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_13d3070c-d3ba-47f6-b855-69116a4a8dc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_13d3070c-d3ba-47f6-b855-69116a4a8dc1" xlink:to="loc_us-gaap_EquityComponentDomain_13d3070c-d3ba-47f6-b855-69116a4a8dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73d2b74a-7dcf-441c-a952-1297d7d95099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_13d3070c-d3ba-47f6-b855-69116a4a8dc1" xlink:to="loc_us-gaap_EquityComponentDomain_73d2b74a-7dcf-441c-a952-1297d7d95099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_38b24a2b-0362-4067-8604-ca7cc5a8fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_73d2b74a-7dcf-441c-a952-1297d7d95099" xlink:to="loc_us-gaap_CommonStockMember_38b24a2b-0362-4067-8604-ca7cc5a8fd0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7c32642b-ded9-4e90-882d-fc1c5ce841df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7c32642b-ded9-4e90-882d-fc1c5ce841df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c32642b-ded9-4e90-882d-fc1c5ce841df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c32642b-ded9-4e90-882d-fc1c5ce841df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7c32642b-ded9-4e90-882d-fc1c5ce841df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5f95b64-d62c-46fa-aa8b-b1d85bccbf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c32642b-ded9-4e90-882d-fc1c5ce841df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5f95b64-d62c-46fa-aa8b-b1d85bccbf2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_d8e38a1d-63fe-4974-a337-c7d6d38564e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5f95b64-d62c-46fa-aa8b-b1d85bccbf2d" xlink:to="loc_us-gaap_IPOMember_d8e38a1d-63fe-4974-a337-c7d6d38564e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:to="loc_srt_CounterpartyNameAxis_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00f42447-08ca-4c7e-9c93-b1ee468a958b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00f42447-08ca-4c7e-9c93-b1ee468a958b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember_f0294209-8719-4782-9d1c-0ace0bbe579d" xlink:href="exdx-20210630.xsd#exdx_ExchangingStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00f42447-08ca-4c7e-9c93-b1ee468a958b" xlink:to="loc_exdx_ExchangingStockholdersMember_f0294209-8719-4782-9d1c-0ace0bbe579d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended" id="i7b985b930b234cf5a6f6ead2ca3a2c31_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ed75470a-753d-4117-9d41-41ca7c06371b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_50b2c373-4d5f-408a-a36d-dc0ba278b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ed75470a-753d-4117-9d41-41ca7c06371b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_50b2c373-4d5f-408a-a36d-dc0ba278b2fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8c13f1d0-c143-4052-8f20-ee78dc1ed3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ed75470a-753d-4117-9d41-41ca7c06371b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8c13f1d0-c143-4052-8f20-ee78dc1ed3ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fbb1677f-db40-4029-b499-e4113a42d452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ed75470a-753d-4117-9d41-41ca7c06371b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fbb1677f-db40-4029-b499-e4113a42d452" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c3d37f83-3beb-4684-9eb5-98614fb5b000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fbb1677f-db40-4029-b499-e4113a42d452" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c3d37f83-3beb-4684-9eb5-98614fb5b000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c3d37f83-3beb-4684-9eb5-98614fb5b000_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c3d37f83-3beb-4684-9eb5-98614fb5b000" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c3d37f83-3beb-4684-9eb5-98614fb5b000_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c3d37f83-3beb-4684-9eb5-98614fb5b000" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_fa0cdf99-2f2f-4929-be39-eafa8e3142d8" xlink:href="exdx-20210630.xsd#exdx_ExpirationJan192026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationJan192026Member_fa0cdf99-2f2f-4929-be39-eafa8e3142d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_88db5dcc-5c09-4235-a42b-68f1deff9c49" xlink:href="exdx-20210630.xsd#exdx_ExpirationMar312026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationMar312026Member_88db5dcc-5c09-4235-a42b-68f1deff9c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_40669906-6c4f-4ff1-a7f2-01a40eb39917" xlink:href="exdx-20210630.xsd#exdx_ExpirationApr12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationApr12026Member_40669906-6c4f-4ff1-a7f2-01a40eb39917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_b727bb9b-147b-4ece-a06c-2a8d7fa11781" xlink:href="exdx-20210630.xsd#exdx_ExpirationSep72024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationSep72024Member_b727bb9b-147b-4ece-a06c-2a8d7fa11781" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_0d19d05e-bc72-4cb0-827b-d1e23030c865" xlink:href="exdx-20210630.xsd#exdx_ExpirationDec72025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationDec72025Member_0d19d05e-bc72-4cb0-827b-d1e23030c865" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_0b422394-6240-4a5e-a3f9-3c519f17fd3f" xlink:href="exdx-20210630.xsd#exdx_NoExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_NoExpirationMember_0b422394-6240-4a5e-a3f9-3c519f17fd3f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended" id="i3c0349769b6c496c970e9602ddeac9dc_StockOptionPlanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5bdac4a7-f55e-4959-87b6-528d48666b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5bdac4a7-f55e-4959-87b6-528d48666b24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26a1a2f9-5b7a-469c-a954-d858f9ee8e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26a1a2f9-5b7a-469c-a954-d858f9ee8e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2a931fd3-8abc-4c83-a99d-7ed713bf4e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2a931fd3-8abc-4c83-a99d-7ed713bf4e78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_bd31c981-6414-4245-abf1-33d9f83b4e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_bd31c981-6414-4245-abf1-33d9f83b4e36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_32b8a096-8554-4597-b3b8-f6e13a5ac04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_32b8a096-8554-4597-b3b8-f6e13a5ac04f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a90f3843-171c-47e9-8081-b6ddd978c455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a90f3843-171c-47e9-8081-b6ddd978c455" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:to="loc_us-gaap_PlanNameAxis_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30" xlink:to="loc_us-gaap_PlanNameDomain_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_34c6db93-c765-43d8-afb2-e6cd15701d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30" xlink:to="loc_us-gaap_PlanNameDomain_34c6db93-c765-43d8-afb2-e6cd15701d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_3412cd2b-3a79-41c8-bb6b-8ab47df2c856" xlink:href="exdx-20210630.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_34c6db93-c765-43d8-afb2-e6cd15701d08" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_3412cd2b-3a79-41c8-bb6b-8ab47df2c856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3d05e231-8422-43ea-a3b5-8547d8b63a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:to="loc_us-gaap_AwardTypeAxis_3d05e231-8422-43ea-a3b5-8547d8b63a94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d05e231-8422-43ea-a3b5-8547d8b63a94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3d05e231-8422-43ea-a3b5-8547d8b63a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d05e231-8422-43ea-a3b5-8547d8b63a94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3d05e231-8422-43ea-a3b5-8547d8b63a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_15159906-3c7c-4ce0-8f2b-66549f765998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_15159906-3c7c-4ce0-8f2b-66549f765998" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4e5e50d2-a412-45c9-bb2e-ba3746c2834d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:to="loc_us-gaap_EmployeeStockMember_4e5e50d2-a412-45c9-bb2e-ba3746c2834d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_413e02da-7223-4493-8004-66ee44109d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_413e02da-7223-4493-8004-66ee44109d94" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended" id="i26a091c0883d4baea82b7b560218a562_StockOptionPlanStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_084280a9-86ae-4eae-a1c7-78e65f795e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_084280a9-86ae-4eae-a1c7-78e65f795e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4080d0fb-e572-4d75-aea1-3e0dffb481f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4080d0fb-e572-4d75-aea1-3e0dffb481f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ced1ece7-2742-4c87-b2eb-e3f037c3399a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ced1ece7-2742-4c87-b2eb-e3f037c3399a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3771922d-0e08-4d9b-bd96-f561beaf9c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3771922d-0e08-4d9b-bd96-f561beaf9c02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_df7d1576-01f7-4447-8b78-1dbf67eca523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_df7d1576-01f7-4447-8b78-1dbf67eca523" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_924fce82-3b4f-4720-a283-7f31036b5cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_68d85659-783d-4a45-961b-8c748f525611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_68d85659-783d-4a45-961b-8c748f525611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ead7246e-b2a0-4d0d-8b35-b1ffcd09c333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ead7246e-b2a0-4d0d-8b35-b1ffcd09c333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9f40265d-b0a0-457f-b576-5e170fc2a1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9f40265d-b0a0-457f-b576-5e170fc2a1d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57da47a4-552a-4db4-8bd9-960a2728a086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57da47a4-552a-4db4-8bd9-960a2728a086" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ecdbb020-f9dd-4286-ba3c-aa13a90f966f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ecdbb020-f9dd-4286-ba3c-aa13a90f966f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_41ae6fd1-c499-48de-96a7-8f812653737f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a66e642c-3062-4a9b-8a34-7161a10fbe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a66e642c-3062-4a9b-8a34-7161a10fbe5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bcd0445e-00c3-4314-8fcc-e439b39e3b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bcd0445e-00c3-4314-8fcc-e439b39e3b03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_879c52d1-c1d8-4644-bb65-57b5e366f45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_879c52d1-c1d8-4644-bb65-57b5e366f45c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b7c3c035-adf5-4c90-8e65-0a9d3784f42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b7c3c035-adf5-4c90-8e65-0a9d3784f42b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bcc411c8-89f4-4789-845b-206f8f364d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bcc411c8-89f4-4789-845b-206f8f364d38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_924da5d7-5193-4038-80e4-d75719cf43a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_924da5d7-5193-4038-80e4-d75719cf43a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_79440140-9cfc-4ba2-ac44-5d35622bdce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_79440140-9cfc-4ba2-ac44-5d35622bdce0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ef895c7e-e42f-4f10-90ef-1c6a2f547854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ef895c7e-e42f-4f10-90ef-1c6a2f547854" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7661d870-8b24-483d-b7cc-33f07770fe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7661d870-8b24-483d-b7cc-33f07770fe7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4c9cc528-7be2-41aa-8413-fec0386bb097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4c9cc528-7be2-41aa-8413-fec0386bb097" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11dbf955-338f-4ca5-95e5-e82a122d6d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11dbf955-338f-4ca5-95e5-e82a122d6d65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_404cd9e7-e702-480f-ad90-5ed2ed096cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11dbf955-338f-4ca5-95e5-e82a122d6d65" xlink:to="loc_us-gaap_AwardTypeAxis_404cd9e7-e702-480f-ad90-5ed2ed096cd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_404cd9e7-e702-480f-ad90-5ed2ed096cd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_404cd9e7-e702-480f-ad90-5ed2ed096cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_404cd9e7-e702-480f-ad90-5ed2ed096cd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6416c52c-d89d-4acd-a2f7-0ac3d520472f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_404cd9e7-e702-480f-ad90-5ed2ed096cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6416c52c-d89d-4acd-a2f7-0ac3d520472f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e3c086f3-9e8a-4c1a-8853-8fec71f96e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6416c52c-d89d-4acd-a2f7-0ac3d520472f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e3c086f3-9e8a-4c1a-8853-8fec71f96e53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended" id="ife7d485e61c14bfeb854cc1824bd7b41_StockOptionPlanRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f5595a1c-d92d-4ac7-ae69-27d003b5b8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f5595a1c-d92d-4ac7-ae69-27d003b5b8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a221e2f-e43a-4cd7-9ea7-c6fff9239398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a221e2f-e43a-4cd7-9ea7-c6fff9239398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1c06caa-4973-4ca1-b82c-7c2588976571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1c06caa-4973-4ca1-b82c-7c2588976571" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6351fd05-7f80-43f7-b083-edf97b3dbb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6351fd05-7f80-43f7-b083-edf97b3dbb69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_936b9090-d598-442f-bbf6-8de754e5f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b4270e18-4c6a-45da-ac42-b68bfebcb685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b4270e18-4c6a-45da-ac42-b68bfebcb685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30feaae4-6e02-4e3e-b686-375d29787893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30feaae4-6e02-4e3e-b686-375d29787893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7dca05ca-7647-4d79-9f11-80fb22ad1835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7dca05ca-7647-4d79-9f11-80fb22ad1835" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_66bc9dfe-1171-4688-83c8-7238d9e517be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_66bc9dfe-1171-4688-83c8-7238d9e517be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6528e81-a32b-4ef8-83c0-c54a78475365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_7dfe852a-f3e4-46f8-8dd4-0b2e5cf5d272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_7dfe852a-f3e4-46f8-8dd4-0b2e5cf5d272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_da4660fb-02de-4a6a-bdb2-e6ebfb2a6131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_7dfe852a-f3e4-46f8-8dd4-0b2e5cf5d272" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_da4660fb-02de-4a6a-bdb2-e6ebfb2a6131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e53d90c2-5b2e-4b62-9a78-e380e97f8094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e53d90c2-5b2e-4b62-9a78-e380e97f8094" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f90782d8-4dac-4552-86da-b0b0ab74c1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e53d90c2-5b2e-4b62-9a78-e380e97f8094" xlink:to="loc_us-gaap_AwardTypeAxis_f90782d8-4dac-4552-86da-b0b0ab74c1d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f90782d8-4dac-4552-86da-b0b0ab74c1d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f90782d8-4dac-4552-86da-b0b0ab74c1d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f90782d8-4dac-4552-86da-b0b0ab74c1d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75dea5d7-d5d2-447f-83d6-1c8f933a340c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f90782d8-4dac-4552-86da-b0b0ab74c1d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75dea5d7-d5d2-447f-83d6-1c8f933a340c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5409e213-21c8-4aad-8547-c590276eae9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75dea5d7-d5d2-447f-83d6-1c8f933a340c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5409e213-21c8-4aad-8547-c590276eae9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended" id="i6cabc8fec648443e8cd16a639ee798a7_StockOptionPlanFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01e6009d-c318-4bb7-9f0c-40e232352a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01e6009d-c318-4bb7-9f0c-40e232352a22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8e3fb1ea-0221-4c1d-beba-5b839b559a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8e3fb1ea-0221-4c1d-beba-5b839b559a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ed0bf4ab-7687-47d6-a258-be9f4281e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ed0bf4ab-7687-47d6-a258-be9f4281e6fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_31e7c7ee-0716-461d-a258-af6235393075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_31e7c7ee-0716-461d-a258-af6235393075" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_108a4119-bbb2-4f73-bdf7-984241aa9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_108a4119-bbb2-4f73-bdf7-984241aa9ee9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6cb782db-4daf-4b99-9811-2a09d75727c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6cb782db-4daf-4b99-9811-2a09d75727c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f75f937c-3f03-46bd-b01f-c1a1c8057108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f75f937c-3f03-46bd-b01f-c1a1c8057108" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_23661021-0940-4267-8079-84dd23b205ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_23661021-0940-4267-8079-84dd23b205ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9e27368e-8054-47d0-adca-2b03db3f432e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:to="loc_us-gaap_AwardTypeAxis_9e27368e-8054-47d0-adca-2b03db3f432e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e27368e-8054-47d0-adca-2b03db3f432e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9e27368e-8054-47d0-adca-2b03db3f432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e27368e-8054-47d0-adca-2b03db3f432e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d688f5d5-93f5-4a05-bfff-de6e00104391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9e27368e-8054-47d0-adca-2b03db3f432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d688f5d5-93f5-4a05-bfff-de6e00104391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0fcb2a20-36a6-4373-8f52-9ece92b62846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d688f5d5-93f5-4a05-bfff-de6e00104391" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0fcb2a20-36a6-4373-8f52-9ece92b62846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f3205a89-5dfc-4d8b-bfa2-9a72cba81e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d688f5d5-93f5-4a05-bfff-de6e00104391" xlink:to="loc_us-gaap_EmployeeStockMember_f3205a89-5dfc-4d8b-bfa2-9a72cba81e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a92dc5f-aec0-45a6-b42d-107ebec1badd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:to="loc_srt_RangeAxis_0a92dc5f-aec0-45a6-b42d-107ebec1badd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a92dc5f-aec0-45a6-b42d-107ebec1badd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0a92dc5f-aec0-45a6-b42d-107ebec1badd" xlink:to="loc_srt_RangeMember_0a92dc5f-aec0-45a6-b42d-107ebec1badd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8711eeef-367a-4db8-9915-06d262c75155" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0a92dc5f-aec0-45a6-b42d-107ebec1badd" xlink:to="loc_srt_RangeMember_8711eeef-367a-4db8-9915-06d262c75155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_346b258d-7882-420e-ab83-24ee2e376668" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8711eeef-367a-4db8-9915-06d262c75155" xlink:to="loc_srt_MinimumMember_346b258d-7882-420e-ab83-24ee2e376668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d4876bb-b71e-4c58-99e4-0905cd8c6c75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8711eeef-367a-4db8-9915-06d262c75155" xlink:to="loc_srt_MaximumMember_9d4876bb-b71e-4c58-99e4-0905cd8c6c75" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended" id="i9dec7918be9c4b8594b92a3cddb11116_StockOptionPlanStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0193e65e-84de-41b1-9852-9729860c6e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a876ec4-1e2d-471b-9dbd-d3ffc8caf00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0193e65e-84de-41b1-9852-9729860c6e59" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a876ec4-1e2d-471b-9dbd-d3ffc8caf00f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdf4a7d9-923c-4995-8b11-ca8fd4ab0d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0193e65e-84de-41b1-9852-9729860c6e59" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdf4a7d9-923c-4995-8b11-ca8fd4ab0d31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7e397534-f38d-475b-8a7e-8974afa42fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdf4a7d9-923c-4995-8b11-ca8fd4ab0d31" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7e397534-f38d-475b-8a7e-8974afa42fa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7e397534-f38d-475b-8a7e-8974afa42fa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e397534-f38d-475b-8a7e-8974afa42fa6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7e397534-f38d-475b-8a7e-8974afa42fa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e397534-f38d-475b-8a7e-8974afa42fa6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9536e80e-9cd8-4452-bde4-abbfe1c76906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:to="loc_us-gaap_CostOfSalesMember_9536e80e-9cd8-4452-bde4-abbfe1c76906" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ef0f8311-d7c1-4eda-8c10-78b592071ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ef0f8311-d7c1-4eda-8c10-78b592071ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8312db0f-3ff8-45f1-a7f6-0f9b585843fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8312db0f-3ff8-45f1-a7f6-0f9b585843fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20210630.xsd#Covid19Details"/>
  <link:definitionLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended" id="ia4db06fe05c3447da5706d03dd38caa6_Covid19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_da3b315d-1b4b-40dc-b1db-db7f90b013c9" xlink:href="exdx-20210630.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_da3b315d-1b4b-40dc-b1db-db7f90b013c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_85380f95-90f8-4d37-a971-4f93db937f74" xlink:href="exdx-20210630.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_85380f95-90f8-4d37-a971-4f93db937f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromGovernmentAssistance_8e7b0dcb-49ef-4a1f-8620-58080633dd9e" xlink:href="exdx-20210630.xsd#exdx_ProceedsFromGovernmentAssistance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_exdx_ProceedsFromGovernmentAssistance_8e7b0dcb-49ef-4a1f-8620-58080633dd9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_f15162dd-916b-4582-8ceb-6a2a4165d38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_us-gaap_ProceedsFromBankDebt_f15162dd-916b-4582-8ceb-6a2a4165d38f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d10fdee3-0065-4190-b994-badbe2c07959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d10fdee3-0065-4190-b994-badbe2c07959" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bfd08617-8db6-4480-abff-a357d73d9fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d10fdee3-0065-4190-b994-badbe2c07959" xlink:to="loc_us-gaap_DebtInstrumentAxis_bfd08617-8db6-4480-abff-a357d73d9fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bfd08617-8db6-4480-abff-a357d73d9fbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bfd08617-8db6-4480-abff-a357d73d9fbc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bfd08617-8db6-4480-abff-a357d73d9fbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8c427080-5759-4936-87f7-dd9854115ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bfd08617-8db6-4480-abff-a357d73d9fbc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8c427080-5759-4936-87f7-dd9854115ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PaycheckProtectionProgramCARESActMember_e1260bfa-9c99-446a-8d6f-d31a1915dbaa" xlink:href="exdx-20210630.xsd#exdx_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8c427080-5759-4936-87f7-dd9854115ce3" xlink:to="loc_exdx_PaycheckProtectionProgramCARESActMember_e1260bfa-9c99-446a-8d6f-d31a1915dbaa" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>exdx-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6018f8ea-fa05-452a-adea-254786192c77,g:68b7dde8-2230-495d-984a-015fcac6c60d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_c33b3282-06f2-41ef-9e83-efaba130b155_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_11ee0255-ee83-4ac6-b63c-742a70affcfe_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_b4ec10d3-9de7-4536-bdf5-d64096c5e92c_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_947e4863-0e5a-4cae-93b6-2df130df739e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b4ba46bc-0773-4897-be76-512aa571603a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8d153567-8237-4574-be7c-a0298587e0c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_12634e28-da89-43d4-bbf2-e7cc56be5747_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9e99c1d0-d45f-4f72-9f95-42de24c193e1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a92b2a8a-3ae0-4bef-9830-ffb6d21c9a38_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_aaa7538d-3985-431f-aee2-f3fd01782c80_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_5ea2d7b6-0b9b-4d46-bcc2-2fe547c97969_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_e5cadf51-4ad5-40a6-ae92-3b5f4b18d2bc_terseLabel_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_label_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund [Member]</link:label>
    <link:label id="lab_exdx_InnovatusLifeSciencesLendingFundMember_documentation_en-US" xlink:label="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Innovatus Life Sciences Lending Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:href="exdx-20210630.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_InnovatusLifeSciencesLendingFundMember" xlink:to="lab_exdx_InnovatusLifeSciencesLendingFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1d095d96-553f-421d-a441-5024f493f04b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_777db69f-1f39-444b-a51b-f7ab50599859_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_cd195bff-3eec-4884-880a-7e8c578226f5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_4777aaab-1329-44ef-85ac-ac7517c6bfad_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Axis]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeAxis_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis" xlink:href="exdx-20210630.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeAxis" xlink:to="lab_exdx_RentalPropertyByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_0651fb82-b975-45d4-9dca-c6073064214f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1c3eb993-6385-4e2e-b5c1-ef2625d67bcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8c000a80-8139-436d-b73d-bba0d1aaf0c0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c4aeda78-c980-4e73-ba4b-8ee7659573ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_47f7a4c9-5baf-4036-83e9-26494c3263a9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2f30aded-5784-4c72-9dbe-64fc6db2644c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e9ee67c3-486f-44e1-8655-c542956c5d92_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e0adc0e-d548-4fdb-bfc4-a157e64eb8ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_0885e36f-6591-4828-8f03-9f004ddc5f71_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covid-19</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure [Text Block]</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:href="exdx-20210630.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_73e51074-c145-4e21-b0b4-3280303e8fe2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares that remain available for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a2339d01-cf1d-4416-b52f-90d5af68f2e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_98b9050a-fb0f-467c-a00f-f92d88f03f10_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c56a9c55-8445-410a-9480-0ddbcf46e3e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_BlueShieldMember_e218bb22-fd87-4d08-8bf8-ffae845ad2f6_verboseLabel_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:label id="lab_exdx_BlueShieldMember_label_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield [Member]</link:label>
    <link:label id="lab_exdx_BlueShieldMember_documentation_en-US" xlink:label="lab_exdx_BlueShieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blue Shield</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember" xlink:href="exdx-20210630.xsd#exdx_BlueShieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_BlueShieldMember" xlink:to="lab_exdx_BlueShieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_7a0d400d-50b0-4fc7-9ceb-0eb5046f9346_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2a3fa166-b938-45f1-8a6b-4292ee47c23d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a27eb537-e4a6-4dd1-82e4-465d463c29eb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_452a46d2-50a7-4c99-819a-29d8eee2349d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6046beaf-5540-4179-822b-1291f087ae8f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfBankDebt_482603ee-ab0c-4eae-928d-ffc21ae2e653_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfBankDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfBankDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfBankDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Bank Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfBankDebt" xlink:to="lab_us-gaap_RepaymentsOfBankDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_3ee6850e-3ce6-48cb-b94b-37ee299aeed6_terseLabel_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation, percent of net sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_label_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:label id="lab_exdx_RoyaltyObligationPercentageOfSales_documentation_en-US" xlink:label="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation, Percentage of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:href="exdx-20210630.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RoyaltyObligationPercentageOfSales" xlink:to="lab_exdx_RoyaltyObligationPercentageOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a70e58fa-ff26-435b-a742-9b424cde9a35_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_df8c9191-e6f8-47ad-9727-3e8e56df92d2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_af448f15-f2df-4694-8ee9-9b83cfc5f0bc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_ba4ac78c-9022-4156-a5a2-bb386ab7f064_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:href="exdx-20210630.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_00514232-a977-4ab3-a98e-3331f82bff31_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d362adbd-8af5-4e98-8719-64473ddf763e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_36d79557-aa48-426a-ad82-4dedc4cf53c7_terseLabel_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement</link:label>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_label_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement [Member]</link:label>
    <link:label id="lab_exdx_JanssenPromotionAgreementMember_documentation_en-US" xlink:label="lab_exdx_JanssenPromotionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Promotion Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember" xlink:href="exdx-20210630.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenPromotionAgreementMember" xlink:to="lab_exdx_JanssenPromotionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_16ebb2dc-a828-4dd5-aef3-62e59244e24b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59028812-39d6-4979-a61b-1287855e92de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_cd05d18c-0e3d-415f-8ee4-8df065f54ae9_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ee8964c3-fa4f-45ff-9d34-648e4145e23d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ccf9310c-9afd-4ba5-a3ef-fd57722d5616_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bb6d9d72-419b-4805-93d4-b33c63f9f985_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_259a8455-8f61-4c06-b6d7-f9ded48b55a0_terseLabel_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_label_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Renewal Term</link:label>
    <link:label id="lab_exdx_OperatingLeasesRenewalTerm_documentation_en-US" xlink:label="lab_exdx_OperatingLeasesRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm" xlink:href="exdx-20210630.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OperatingLeasesRenewalTerm" xlink:to="lab_exdx_OperatingLeasesRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_963a7965-fd9b-45ee-bb49-a3a192905a81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, June 30, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_323eb72c-3319-4398-bdcf-41e2586e875b_terseLabel_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases of goods and services</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_label_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:label id="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchase, Goods and Services, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:href="exdx-20210630.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:to="lab_exdx_AccruedPurchaseGoodsAndServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5242ac3-b186-4f1b-8b21-d3d7b848d1ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e903ad88-4e9a-4e13-8a59-3a6033fd755f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a1179964-1cc3-462e-ab9e-9e689f08c5c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_256c0754-9aa6-450f-b238-c1a17a30245d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at June&#160;30, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4d5a02e2-e4d6-4aa5-8bcf-831ed6a57b91_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncement, Early Adoption [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1bcee87-1942-4583-9942-031c3ea962bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c9d0731b-8fe5-4857-b7b8-9779c8bb57e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, June 30, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_33c1e8b7-2b91-4448-b4e5-f5b0ead9920d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_48117b5a-9087-4044-b453-cb608797c344_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_1c7ee5a5-68ab-4bf0-84d2-0608b8064c0a_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_57d3e028-e8f0-4725-9f90-5e06aff2278b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_44cd1a5f-265d-414c-8a0a-28650f0cba41_terseLabel_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_label_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type [Domain]</link:label>
    <link:label id="lab_exdx_RentalPropertyByTypeDomain_documentation_en-US" xlink:label="lab_exdx_RentalPropertyByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental Property, by Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain" xlink:href="exdx-20210630.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_RentalPropertyByTypeDomain" xlink:to="lab_exdx_RentalPropertyByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_c749c3d7-90ad-475e-aed4-f936b3191eb7_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising and Marketing Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8478c83d-6c0d-48bf-a459-ae355ce25070_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_a0875b39-8b5a-4430-aa9e-7ab564824aa3_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind loans issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_label_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:label id="lab_exdx_DebtInstrumentPaidInKindLoansIssued_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Paid In Kind Loans Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:to="lab_exdx_DebtInstrumentPaidInKindLoansIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationSep72024Member_19afe3b7-a195-4e5b-a24c-d6d37b5659a2_terseLabel_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration September 7, 2024</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_label_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationSep72024Member_documentation_en-US" xlink:label="lab_exdx_ExpirationSep72024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Sep 7, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member" xlink:href="exdx-20210630.xsd#exdx_ExpirationSep72024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationSep72024Member" xlink:to="lab_exdx_ExpirationSep72024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4415c4bc-7db9-4b8d-b5f8-360099e399e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_6756efe7-95cd-4c14-a953-080e50fe233b_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, quarterly promotion fee</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFee_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFee" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8e2c7a55-b865-44de-84be-4d764b778af6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d1eac5fa-a707-4b94-8a47-c2128271b87a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred, but not paid, in connection with capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_a4e4c468-5f04-4003-b916-e1ff1c5ff9f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum employee payroll deduction percentage</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeMember_dd97aa75-2a6a-45aa-93e8-107f089c4458_terseLabel_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:label id="lab_exdx_OfficeMember_label_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office [Member]</link:label>
    <link:label id="lab_exdx_OfficeMember_documentation_en-US" xlink:label="lab_exdx_OfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember" xlink:href="exdx-20210630.xsd#exdx_OfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeMember" xlink:to="lab_exdx_OfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_718c9feb-9376-45e0-a722-8a526976c4a1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_82d31324-4072-44bc-bfa4-440e7424a001_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationMar312026Member_8346d8d9-9f9f-4959-898b-f7bd64f27d97_terseLabel_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration March 31, 2026</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_label_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationMar312026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationMar312026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Mar 31, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member" xlink:href="exdx-20210630.xsd#exdx_ExpirationMar312026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationMar312026Member" xlink:to="lab_exdx_ExpirationMar312026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_f5f057cd-1972-40d6-b5e4-38ad72230ac0_terseLabel_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial license fee</link:label>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_label_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial License Fee</link:label>
    <link:label id="lab_exdx_LicenseAgreementInitialLicenseFee_documentation_en-US" xlink:label="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Initial License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee" xlink:href="exdx-20210630.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LicenseAgreementInitialLicenseFee" xlink:to="lab_exdx_LicenseAgreementInitialLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_3c9bfbd4-e868-4c6d-bb41-74d1427b1a72_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_d3c2ca1d-9369-411b-b9d3-48e9471add59_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_154af81c-0769-491a-9419-66b500f32bd8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fea027f6-6c76-40f0-ae92-508afb16edfd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_216af144-521b-44a4-8d1e-48d2bca5b70f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, June &#160;30, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_810ea884-13af-4829-b9c6-811ac4385f17_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0fcd1963-d18d-43ca-843d-38efe9f3b562_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_9d9f5a17-d3b1-4f35-b95b-b9d580df088f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareMember_90feaddd-69e5-41f4-8f82-dda1aae72a58_terseLabel_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_exdx_MedicareMember_label_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_exdx_MedicareMember_documentation_en-US" xlink:label="lab_exdx_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember" xlink:href="exdx-20210630.xsd#exdx_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareMember" xlink:to="lab_exdx_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_57c6a81c-a1c3-4058-9902-7ccf2db51807_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d69a4572-6f9f-4646-9960-53349b6c9016_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cf7bb435-19e0-450b-9521-43af87138a23_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_f47657c6-8cf8-43e7-a054-3ca090e4ec6b_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture quarterly promotion fee cap</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_c7387a39-7b91-46e6-b74b-4595834b67dc_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid in-kind note</link:label>
    <link:label id="lab_us-gaap_PaymentInKindPIKNoteMember_label_en-US" xlink:label="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment in Kind (PIK) Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentInKindPIKNoteMember" xlink:to="lab_us-gaap_PaymentInKindPIKNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1cad6257-db10-431b-9edb-977596bf6438_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationDec72025Member_3883f5bf-83fd-407e-9b36-47858839f42e_terseLabel_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration December 7, 2025</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_label_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationDec72025Member_documentation_en-US" xlink:label="lab_exdx_ExpirationDec72025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Dec 7, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member" xlink:href="exdx-20210630.xsd#exdx_ExpirationDec72025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationDec72025Member" xlink:to="lab_exdx_ExpirationDec72025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_e85e0985-bc30-46df-bbf0-98d946bdc5b1_negatedLabel_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_label_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:label id="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_documentation_en-US" xlink:label="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Current Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:href="exdx-20210630.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:to="lab_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_94f183af-62e2-47cd-9fdb-d7e9d66d3852_terseLabel_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_label_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark [Member]</link:label>
    <link:label id="lab_exdx_ReceivableBenchmarkMember_documentation_en-US" xlink:label="lab_exdx_ReceivableBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Benchmark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember" xlink:href="exdx-20210630.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ReceivableBenchmarkMember" xlink:to="lab_exdx_ReceivableBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3df70080-58cd-4a58-994f-3a6c65c1e87f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3af4b080-bb1f-4b89-b891-30d328d59033_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_dca8bcde-a067-4a05-9fdf-391220370f55_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total borrowings, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4ed1be69-bbd8-468f-95e9-75c83d38bbc1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_05bb4218-40b2-4309-8faf-ac67d55419c7_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_UnitedHealthcareMember_5b0c1773-13fc-4455-988c-198a3a11d5ed_terseLabel_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_label_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare [Member]</link:label>
    <link:label id="lab_exdx_UnitedHealthcareMember_documentation_en-US" xlink:label="lab_exdx_UnitedHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember" xlink:href="exdx-20210630.xsd#exdx_UnitedHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_UnitedHealthcareMember" xlink:to="lab_exdx_UnitedHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b176d5b7-101a-4575-8dec-c759543052ec_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_f0ea3674-9635-4a6c-b151-a10faf99324a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_5068ccca-5d7f-4538-9370-7210b1019af3_terseLabel_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment purchased under capital lease obligations</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_label_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:label id="lab_exdx_EquipmentPurchasedUnderCapitalLease_documentation_en-US" xlink:label="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Purchased Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:href="exdx-20210630.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_EquipmentPurchasedUnderCapitalLease" xlink:to="lab_exdx_EquipmentPurchasedUnderCapitalLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a529d08c-e7ed-4bb4-8d36-ec3834079b69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_eb97b2ce-8727-4f9e-bcb7-57e92efa9886_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_13d28198-b269-423f-81eb-7cc4cd95c7b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_639b29f7-2059-4dfa-abd9-7edd20981640_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash items:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0ec2bd27-1e37-44c3-bf76-09333de18eb6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ae148a2a-cc84-44f6-92be-ae8f832203a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureTerminationConsiderationReceivable_15e68efe-68c5-4a5f-be07-bd314e218089_terseLabel_en-US" xlink:label="lab_exdx_JointVentureTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of agreement</link:label>
    <link:label id="lab_exdx_JointVentureTerminationConsiderationReceivable_label_en-US" xlink:label="lab_exdx_JointVentureTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Termination, Consideration Receivable</link:label>
    <link:label id="lab_exdx_JointVentureTerminationConsiderationReceivable_documentation_en-US" xlink:label="lab_exdx_JointVentureTerminationConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Termination, Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureTerminationConsiderationReceivable" xlink:href="exdx-20210630.xsd#exdx_JointVentureTerminationConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureTerminationConsiderationReceivable" xlink:to="lab_exdx_JointVentureTerminationConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_3c49f53b-7a84-4d4f-aa87-11092e3804a7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_f43f4a40-6722-4fa8-a1ad-4e063300c7f2_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_97061fee-3e95-4576-bdf0-3eae08163517_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_97aca62d-295a-47fc-8fbb-5d4f063b5472_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_f936acaa-2672-4afc-bc63-cf00844f2c9e_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum royalty commitment</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_ec817bb6-c10d-43ac-881e-34231d48cb10_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_6decc681-cae4-4e9d-a762-ffe5ccef37cb_terseLabel_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_label_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc. [Member]</link:label>
    <link:label id="lab_exdx_PrometheusLaboratoriesIncMember_documentation_en-US" xlink:label="lab_exdx_PrometheusLaboratoriesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Laboratories, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember" xlink:href="exdx-20210630.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrometheusLaboratoriesIncMember" xlink:to="lab_exdx_PrometheusLaboratoriesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2b87f95e-7675-4005-9fe0-86c8e0d8296e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f0c723fc-e013-46f6-8454-ae570a423a2f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_59038e58-4df0-4e6d-976b-73cdc97e5e42_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_337afb66-042d-4ecd-957a-41f36c37cb55_terseLabel_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Award Plan</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_label_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019 [Member]</link:label>
    <link:label id="lab_exdx_IncentiveAwardPlan2019Member_documentation_en-US" xlink:label="lab_exdx_IncentiveAwardPlan2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Award Plan, 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member" xlink:href="exdx-20210630.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_IncentiveAwardPlan2019Member" xlink:to="lab_exdx_IncentiveAwardPlan2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c64e7a8a-a5a3-4b7e-b27c-76bcc3b237fb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_220d293d-7063-48b6-a26b-a7f102660486_negatedLabel_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_label_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:label id="lab_exdx_LongTermDebtUndiscountedInterestAmount_documentation_en-US" xlink:label="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Undiscounted Interest Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:href="exdx-20210630.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtUndiscountedInterestAmount" xlink:to="lab_exdx_LongTermDebtUndiscountedInterestAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_36e69bda-f03b-416c-97f8-827b92205a01_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_de490660-dd3f-4c85-a36f-12548d242ca1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock in public offering, net of issuance costs of $4,435</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_71662fab-859a-4785-8cf8-d07203c61bd7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2ae71679-8a1f-4326-b8be-af84efcc1d12_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_394c1cf7-1b45-491d-a87a-a67a22bf18db_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRoyalties_225eb93a-0c69-4eb9-9214-c39e4c94ab2d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid product royalties</link:label>
    <link:label id="lab_us-gaap_PrepaidRoyalties_label_en-US" xlink:label="lab_us-gaap_PrepaidRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRoyalties" xlink:to="lab_us-gaap_PrepaidRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_12f25e68-ee36-493a-8e00-5061605aaf04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_3e2264c4-3ff7-48a0-88ff-884f04fbf1c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60b8a8a3-4eb2-4429-8deb-a6db452e443c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_0b28339f-d212-4064-839c-cf888d7dc24e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs related to public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_54445f26-bd65-4646-8b67-614e9d215c0f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_e21d0850-4b86-468f-93ae-efaed96a98dd_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, paid in-kind, interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_label_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:label id="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Stated Interest Rate, Paid In-Kind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:to="lab_exdx_DebtInstrumentStatedInterestRatePaidInKind" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_27389c93-445e-45fe-a19b-30d41598ed09_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized at June&#160;30, 2021 and December 31, 2020; 16,126,784 and 12,652,308 shares issued and outstanding at June&#160;30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_63ebba09-1842-4c88-95d6-801c29690e34_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8c74163a-b9a2-4b0a-bd89-411b68fe5e94_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, cost not yet recognized, remaining weighted average vesting period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_25be1718-c6a3-41b3-9a70-19ec2224144f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December&#160;31, 2020 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_937c8989-e6da-46a2-8f8d-6f01249594ba_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, June 30, 2021 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_770bac64-ad1a-43e7-80e7-8f4c68b45b52_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_811dcb0b-544e-4fd9-8b9f-4afaf3acebe8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PaycheckProtectionProgramCARESActMember_766df4df-436d-40a0-82fa-30755a8db335_terseLabel_en-US" xlink:label="lab_exdx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:label id="lab_exdx_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_exdx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_exdx_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_exdx_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PaycheckProtectionProgramCARESActMember" xlink:href="exdx-20210630.xsd#exdx_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PaycheckProtectionProgramCARESActMember" xlink:to="lab_exdx_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b7d0079e-6a3e-4e89-a138-0713bd71b8b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_6a0a508b-b672-48b7-8a03-3cc4d5e401a0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_3c6d7490-2548-4c03-84c5-0cf3bbe5d2d0_terseLabel_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid maintenance and insurance contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_label_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:label id="lab_exdx_PrepaidMaintenanceAndInsuranceContracts_documentation_en-US" xlink:label="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Maintenance and Insurance Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:href="exdx-20210630.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:to="lab_exdx_PrepaidMaintenanceAndInsuranceContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c7d4f016-0d63-4e26-9392-532af16ac945_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_44dbe6f4-dfac-467b-a5b0-8148390cf765_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_9676963b-c749-4136-9306-a65cc81ab20e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_73183186-d3d7-4aa4-b3c1-41cecd832355_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_dc679246-8da2-4d61-b824-9f725307c96b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c01a5c63-1502-4fbe-90c5-327f95a980b1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3f03d9fc-3e52-4828-958f-eccaec478e62_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued to purchase redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7e1c2b68-59c4-4e92-8018-12c949350417_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_23dc5148-a487-4c50-a3ce-ba7df0144423_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_78b66c53-6a82-4c0b-b1fb-6f465f26c9d9_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, collaboration expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_label_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:label id="lab_exdx_CollaborationAgreementCollaborationExpenses_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Collaboration Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:href="exdx-20210630.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementCollaborationExpenses" xlink:to="lab_exdx_CollaborationAgreementCollaborationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_37ba3a6a-0f57-468a-92d5-08e18b590756_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_06af6508-e45f-436a-8efb-33f8bf6c6359_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2e13e0cd-a804-4a8f-bfb1-5354cdea0c41_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_339caf32-3a16-4f49-9302-acf9a794173c_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8f898216-bbcc-4e7a-b147-ffd8deeff2d5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_HealthcareInsurersMember_cffb7251-95db-46dd-bace-a3ffa1dd51eb_terseLabel_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare insurers</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_label_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers [Member]</link:label>
    <link:label id="lab_exdx_HealthcareInsurersMember_documentation_en-US" xlink:label="lab_exdx_HealthcareInsurersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember" xlink:href="exdx-20210630.xsd#exdx_HealthcareInsurersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_HealthcareInsurersMember" xlink:to="lab_exdx_HealthcareInsurersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ab939162-c6dd-432e-90b1-f7ad7b543d8e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_83ba6ec8-e928-4a3f-a648-b4404c796760_terseLabel_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory [Member]</link:label>
    <link:label id="lab_exdx_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_exdx_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember" xlink:href="exdx-20210630.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OfficeAndLaboratoryMember" xlink:to="lab_exdx_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e321a1b9-5cb1-451c-a35a-864326d30f5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_92c3c43d-a57b-4fab-b7cb-7cce71938ac9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReorganizationsAbstract_label_en-US" xlink:label="lab_us-gaap_ReorganizationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reorganizations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReorganizationsAbstract" xlink:to="lab_us-gaap_ReorganizationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_47936be1-98c0-44e9-abc6-bc74dc72ed91_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4450911e-7ff4-45fd-92bf-c0639f06510a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b617310e-81cb-4401-8848-9a257facf225_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_3c12dd33-d383-4443-8cd3-e2eb1ec4c546_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aaf197f1-2017-4d67-aaf2-2ceb3e4bf17c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_297adcfe-a496-4a54-bdd2-cd75fd53587d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ad9d175b-d788-47f8-9904-83b30e4b5f4c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d6cb3573-54a5-4560-b004-818ca3ed3950_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b2f0260f-1937-4d8d-93b3-6ea0e6623e81_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_1aee075c-b825-48f0-9b24-3e356ddf4176_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:href="exdx-20210630.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_56f28e19-3334-4ec8-b925-f6f49db50e28_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromBankDebt_dab89c25-41cb-45b8-859e-63c67bfd43cb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromBankDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Paycheck Protection Program loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromBankDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromBankDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Bank Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromBankDebt" xlink:to="lab_us-gaap_ProceedsFromBankDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc14d95c-94d5-4592-a88e-732fe35ff5ef_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_50141481-035c-40dd-a64e-fc251b993b36_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c558ca39-3094-450f-95a1-72a4ff5e44ba_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares to be called upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_12092588-1560-4aee-a1fc-fbcc7b92d4bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_426af183-1acc-4de7-bb7d-ad697b8745c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_8d09ab9c-03d2-4bbc-b839-916a70f2a979_terseLabel_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_exdx_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:href="exdx-20210630.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ComputerEquipmentAndSoftwareMember" xlink:to="lab_exdx_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_1cec54f3-3ac8-4214-9570-72f3017cbd55_terseLabel_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture, quarterly promotion fee per prescription</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_label_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee Per Prescription</link:label>
    <link:label id="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription_documentation_en-US" xlink:label="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture, Quarterly Promotion Fee Per Prescription</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:to="lab_exdx_JointVentureQuarterlyPromotionFeePerPrescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_c08f33ba-a10c-4da8-b106-4a9265424b6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1f5d6a74-be9b-4a8d-ab8e-c5114cdbabb6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f7a4450d-bd14-4b07-a5ac-e5589be88824_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a2019bff-acc2-4307-86f5-20fa4b557caf_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_df372100-084a-40f6-ac43-9af2604a713b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4adb226d-3442-4dcc-829d-8d6713332f8d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bbf88200-5c89-42b2-9c8d-e4d1cd2a538c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_f380b3e6-07de-4744-85cd-301c13f7b0be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, June 30, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca5c526e-96ae-44d0-aa44-4ca10a25acb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8518d90c-94fa-4750-a9c3-0d0c82a14f8f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_45690f15-351d-4dcb-aaeb-45007cd344b9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1fe6de1a-179e-439e-bcf6-76f469091d94_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3616cb7b-7596-4d36-9c3a-c0485869a159_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_82df4e73-bab3-4e20-8171-de774798b633_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_251882fe-0b9d-42e4-b552-de44f42c23a7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_9b520f39-6db1-4705-ba88-7f5854f4b672_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_df296d46-d41c-433e-a4a9-4608a5936e34_terseLabel_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_label_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute [Member]</link:label>
    <link:label id="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember_documentation_en-US" xlink:label="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegheny Health Network Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:href="exdx-20210630.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:to="lab_exdx_AlleghenyHealthNetworkResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_18e9358b-9d5d-45a7-94d1-c1cec517a40a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_7424a7b4-ded8-4ca7-8d0c-f1b717ec7067_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_da95f973-06c0-437b-8185-0730c9deb1be_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Other Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d209bf70-fbfe-402d-aef6-f765fd848734_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0f00db49-9e3a-4dd2-acc4-47f310ca344b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6d1721f9-dd51-4398-9ed7-3ad69fa1d3f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Term2017Member_41e06191-bac4-4ac4-811d-a7e5d06b6a2d_terseLabel_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Term loan</link:label>
    <link:label id="lab_exdx_Term2017Member_label_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017 [Member]</link:label>
    <link:label id="lab_exdx_Term2017Member_documentation_en-US" xlink:label="lab_exdx_Term2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member" xlink:href="exdx-20210630.xsd#exdx_Term2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Term2017Member" xlink:to="lab_exdx_Term2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2cfdaa09-75fa-498a-9ed1-c3dc8257b9d7_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a8a09e44-1dd2-44bd-8f7c-a8e1015c65ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2534af0b-f244-4cd0-ace1-8d49e47bbd4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_21eae650-a464-48c0-861a-edd3bb5262d5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0643e469-2b52-4716-8851-944e5d9d16cd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1cecd2e9-fcf5-4e54-9edd-2d1185ff4387_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1ae65324-b5ea-49f8-9ecf-7967c33afa39_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5b036481-f820-4ebc-bf2b-b6ce4942b9be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1cb6c711-b6b9-4318-b1de-4ed93a862415_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_187b9857-41e7-4559-b086-512481b88404_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_746e84a5-491c-4ba6-a835-c5c7231b4e72_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_46770825-9b7c-4644-a55e-b097944336ab_terseLabel_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under capital lease</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_label_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease [Member]</link:label>
    <link:label id="lab_exdx_AssetsUnderCapitalLeaseMember_documentation_en-US" xlink:label="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Under Capital Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:href="exdx-20210630.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AssetsUnderCapitalLeaseMember" xlink:to="lab_exdx_AssetsUnderCapitalLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_46466c31-883a-401c-bb7b-013bd933527a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_bde42839-354c-487d-a0a2-6aa6e729494e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d37ce8c1-c669-4b00-ae59-c927f804bcd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_53bb8609-7fe8-4287-b375-98029f12f262_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_49da8512-edb2-4e7b-9309-542694e20991_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_09233756-dfc3-4615-ac15-620ea66314c9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d6d35c26-47bc-44ee-805c-e7cbd6318d2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b391d49a-c62c-498f-b4df-52e7b9df263e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_eedaa151-cdae-4342-833c-71fe722e919e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f4f1ce2e-705f-4bc5-86e6-e543aae48ac5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cd546413-449a-412f-ac96-51f548312def_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7916f421-6735-4ee9-9876-509b457bb367_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_37a1f4f8-8178-487a-92df-e33018f44473_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c2a53b20-9ee2-48ef-94d5-01502df955f7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_520664f4-47e1-4ee5-933b-273201842ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_8fb9a130-c7cb-45bd-82da-f870502f2001_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_78225a22-31f3-4ec4-acb3-69aada854ff7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_b9c38d43-d98c-4dfc-8a08-60cfb9dca2f7_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, to be paid remainder of fiscal year</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_91660e34-4ad2-4417-b935-090299c7471e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fef3369f-7542-4265-b9bb-a99400f996bd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fee91618-b195-460b-b127-80d69d6036b5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock warrant in exchange for retirement of common stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_78c53c80-acb7-4c97-9ee9-716eb960b4ec_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_13a30874-5e31-4776-9476-7fc855d501cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_59d910fc-b33f-4de3-91a4-2e703c4cdca7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_85bd00b8-a6e4-40d2-892b-c38e41609c4b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d297bae7-b070-4017-b885-767dbc9a2700_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_43852d3e-61aa-4e7a-9b93-efcbd76212dd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8537d3c6-aa33-4fa3-9bc6-b654d1c983c7_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0aa36c8c-e66a-422a-b0d1-f22ddf63a12f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_d9ba3520-8a18-453f-9d82-92e0c2e0b5d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5063dd01-f716-4ab3-9af8-8428091b8014_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ed9cd966-3043-4fb5-9ab0-7ca06cc26980_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AHNCollaborationMember_ec86d681-4a69-4c34-ae34-bb130d428844_terseLabel_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_label_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration [Member]</link:label>
    <link:label id="lab_exdx_AHNCollaborationMember_documentation_en-US" xlink:label="lab_exdx_AHNCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHN Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember" xlink:href="exdx-20210630.xsd#exdx_AHNCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AHNCollaborationMember" xlink:to="lab_exdx_AHNCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_dd33323d-1acb-4d51-a7ef-7d4dd95613c4_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ca79cd97-5495-4dd6-a1d1-a65bb9ed7ffb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1b3fa00b-08bd-4d30-9ade-103f4afcfa2d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_9614d378-af9c-42af-96f8-c4a9adb3d0a6_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d1e6ca3f-d039-4cd3-9925-d3f65a59b58b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_0d470cfd-ecb9-4938-9949-a8648b313e7f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital lease obligations, current portion</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_197a33af-63aa-43f1-9b6a-4d1bba260dc0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_100d9727-c769-4161-87d6-b6a42e63adf7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_37bcee38-f0cd-4c69-bae4-c15d85b45e7a_terseLabel_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_label_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP [Member]</link:label>
    <link:label id="lab_exdx_CapitalRoyaltyPartnersIILPMember_documentation_en-US" xlink:label="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Royalty Partners II LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:href="exdx-20210630.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CapitalRoyaltyPartnersIILPMember" xlink:to="lab_exdx_CapitalRoyaltyPartnersIILPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_af21c32d-3a6a-465e-9117-9359aec9723e_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, minimum unrestricted cash balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:to="lab_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_2969dc9c-3716-4146-b90e-fa286932aa2f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d8ad729a-b509-4916-885f-8407c95bafe0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_699f82df-981d-4a03-8ca7-8fe24eb1cefe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d435f1a9-94f1-45ab-bd79-a478e402acf0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_2452fca7-c2f3-49a8-9d19-b6fc8a6bf9b5_terseLabel_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers</link:label>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_label_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers [Member]</link:label>
    <link:label id="lab_exdx_TwoMajorSuppliersMember_documentation_en-US" xlink:label="lab_exdx_TwoMajorSuppliersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Major Suppliers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember" xlink:href="exdx-20210630.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_TwoMajorSuppliersMember" xlink:to="lab_exdx_TwoMajorSuppliersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_e9c76ceb-bd28-42e3-b81f-17c21d0dedba_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_5e3821f2-8fdf-49a2-999e-ad97ef9e05ed_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_Government1Member_15f1d479-e299-4aa1-94f1-5df9f227848a_terseLabel_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government</link:label>
    <link:label id="lab_exdx_Government1Member_label_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1 [Member]</link:label>
    <link:label id="lab_exdx_Government1Member_documentation_en-US" xlink:label="lab_exdx_Government1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member" xlink:href="exdx-20210630.xsd#exdx_Government1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_Government1Member" xlink:to="lab_exdx_Government1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2c0487d5-f6f0-4350-afb5-e2104115ade2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_84d55733-6571-482c-881d-3df3b7bcc948_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9b8fe33c-4a11-41a0-a5f3-b34ec417b956_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4b5f3ce6-6d07-4c14-a2a5-4f47f9be10fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-cash Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8ba7c031-ae32-4da1-8d5e-bc9f448198a5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuance of common stock in public offering, gross</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d558c5af-7f1e-40b6-90d1-b17cd8c3d1af_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5997d9cc-07fc-4455-98ca-4b50346edc1b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2971a54b-ec09-4ade-9194-078e31a0d31a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_6b456850-ffe5-410f-bd48-054462bcb466_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_3b91d8c1-fdfc-46e4-8fb0-86e445b9fd8b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c5fe2bf2-4506-4b18-9fba-d15810c34101_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a3b39e1e-f73f-4169-9074-6ab5546c4445_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6bca7c2f-a868-451d-9a4c-a2c4da9cb364_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_5658a57a-c4d4-4a53-8c24-f6b111f57ad0_terseLabel_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_label_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]</link:label>
    <link:label id="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:href="exdx-20210630.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:to="lab_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6eaf791d-4191-4318-9cc1-56b7db22c3c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_24dc96e8-b254-4053-89b1-4f45a227f3ba_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f3e4a3df-459f-4beb-a07a-d82aaa1a9a35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7c4b1ba4-8334-45ff-92c4-a8f8960b2709_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_80d6cc5e-32e1-44a2-b6fa-ee888c6992be_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture&#160;and&#160;fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f2f6a5f6-f666-48a1-b3e6-450e26123bd9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6b64a701-6cb1-4656-bf32-08d8cb11c78c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_2515eaa2-9b87-42b9-a445-042d356c44b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, fee incurred upon payment of final installment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0c76ab16-206b-4c58-961d-03f7fa296f68_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e3f389f2-3aa3-4b48-a625-01e8927a72e2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_9cc4ed66-40af-4d3d-9c05-5417f5c29742_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_5383fecc-6430-4384-a71a-d1da7c6e9369_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in public offering, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MedicareAdvantageMember_fc367025-d639-47ae-8cc6-50eeebfae4d7_verboseLabel_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_label_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_exdx_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_exdx_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember" xlink:href="exdx-20210630.xsd#exdx_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MedicareAdvantageMember" xlink:to="lab_exdx_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_eb994d58-3a95-402a-866c-3ae914d00364_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_169e6b55-dd3f-40b0-a4b4-49a0d444855a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_12144435-cbed-4aab-9275-f027ac312332_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_1db2cc7c-b008-448e-ae53-312a15585986_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, prepayment premium percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa39a397-a949-452e-b36f-766ebe124789_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_167b7463-1c07-43f8-968d-462ffd5dbf6a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a0acb48f-ff43-4f73-bc0d-e1d608c4b3e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_4d75b39f-3452-4d2a-8447-a75d2b8b59a0_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ProceedsFromGovernmentAssistance_74a8e1d0-9de7-4305-be23-4575dfea87f7_terseLabel_en-US" xlink:label="lab_exdx_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from government assistance</link:label>
    <link:label id="lab_exdx_ProceedsFromGovernmentAssistance_label_en-US" xlink:label="lab_exdx_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Government Assistance</link:label>
    <link:label id="lab_exdx_ProceedsFromGovernmentAssistance_documentation_en-US" xlink:label="lab_exdx_ProceedsFromGovernmentAssistance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Government Assistance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromGovernmentAssistance" xlink:href="exdx-20210630.xsd#exdx_ProceedsFromGovernmentAssistance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ProceedsFromGovernmentAssistance" xlink:to="lab_exdx_ProceedsFromGovernmentAssistance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9171dbbf-e42d-463c-9802-e07a88ae2c7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_d67cbcdf-f43c-47d9-b90c-979d9b4898a2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_cf1d6a2b-2a0f-4681-86ca-b90a76ef2904_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MilestoneObligation_9a4fc3d4-6408-4769-aa2c-8a6967e1ff89_terseLabel_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestone obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_label_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligation</link:label>
    <link:label id="lab_exdx_MilestoneObligation_documentation_en-US" xlink:label="lab_exdx_MilestoneObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation" xlink:href="exdx-20210630.xsd#exdx_MilestoneObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MilestoneObligation" xlink:to="lab_exdx_MilestoneObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_945dbd0d-3806-4438-8160-5a906732ac14_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e215adae-1c76-4ee8-a9ac-0ee70bba986f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AdvancePayment_7c42cf55-421a-4921-87c0-6c1bbc555c58_terseLabel_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance royalties payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_label_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:label id="lab_exdx_AdvancePayment_documentation_en-US" xlink:label="lab_exdx_AdvancePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment" xlink:href="exdx-20210630.xsd#exdx_AdvancePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AdvancePayment" xlink:to="lab_exdx_AdvancePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_310ed970-8861-4bec-b7b1-3f41621f6235_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_be91b841-e2e4-46a9-967a-6f2ca8a620d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_aaa85f1d-90c5-4245-b28b-41255a951812_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0e04f29b-f8a8-48b9-8f15-b9a645efc85a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_27ca7e3a-e13c-4837-bd8c-84b72f1bcead_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8f1d8153-4852-4442-845e-0479ae2d2ff0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0c612f76-1537-4c4d-bc47-2adb52b638f7_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_fe94508f-153f-4285-ab7e-28078edaf66d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_c7cce5d0-dc8a-4a84-8422-7fcee545507b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, percentage of ownership after transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ec826102-5fb0-4fb9-8dfa-9c9d437a5981_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_JanssenSIMPONIMember_612f7608-29cc-4b89-9a29-4c62335bb0e2_terseLabel_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_label_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI) [Member]</link:label>
    <link:label id="lab_exdx_JanssenSIMPONIMember_documentation_en-US" xlink:label="lab_exdx_JanssenSIMPONIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen (SIMPONI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember" xlink:href="exdx-20210630.xsd#exdx_JanssenSIMPONIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_JanssenSIMPONIMember" xlink:to="lab_exdx_JanssenSIMPONIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ebc85834-c14f-48e8-9401-25e640658b6d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_e81b7103-15e5-4016-8d93-0a78c71393af_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_502afa57-ea14-402a-a616-c3b8cbd798ae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AVISECTDTestMember_a8fc6294-268f-4259-87fb-f9cd9f348756_terseLabel_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_label_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test [Member]</link:label>
    <link:label id="lab_exdx_AVISECTDTestMember_documentation_en-US" xlink:label="lab_exdx_AVISECTDTestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVISE CTD Test</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember" xlink:href="exdx-20210630.xsd#exdx_AVISECTDTestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AVISECTDTestMember" xlink:to="lab_exdx_AVISECTDTestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e9475185-0176-4433-b260-51e609d3cfd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0103fa6a-a7b8-4846-96fa-f145f9699f18_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_9b250286-2dc0-47e5-8adb-612b62245d8a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_7b26227d-7deb-4f37-ae2c-77d177e167db_terseLabel_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exdx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_exdx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember" xlink:href="exdx-20210630.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LaboratoryEquipmentMember" xlink:to="lab_exdx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ea72b9cd-7680-4451-9941-c03c9cfcee2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_60eca3f4-5ace-4cba-8fbc-bb2ea7f6c8d5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationJan192026Member_b94d7592-e06d-48d8-bff9-73cdd492aa02_terseLabel_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration January 19, 2026</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_label_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationJan192026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationJan192026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Jan 19, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member" xlink:href="exdx-20210630.xsd#exdx_ExpirationJan192026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationJan192026Member" xlink:to="lab_exdx_ExpirationJan192026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_54d61906-b713-47df-bd62-0b652241d9ee_terseLabel_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="exdx-20210630.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_c4fcb762-1c67-4cde-914f-83b9b647c28a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_af13f47b-0c01-49ba-a54c-46f50c394b6c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_607bb0cc-7fa3-4de8-8287-fd2c5773536f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_a3a37972-1fad-422e-86a2-569c4501224f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9c85bba5-f43f-40f7-9859-f20b8c5933bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_125b76fa-43f3-4045-9084-9ea35222d2ab_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_1fef25db-03a7-4bb1-804e-9f9dba313523_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_99115115-ed99-4f9d-bc15-2dd6e675828b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a2d2c7a4-a955-47ed-9bac-ba4823d9a72d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d3a51059-c2af-49bc-8e86-4cbbed49d71b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_6c0cfd04-2d3f-4155-8190-3979995f2ffd_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan, annual reduction in prepayment penalty percentage</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_label_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:label id="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Premium Percentage, Annual Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:to="lab_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_d91f13c3-f48b-451f-b3f4-9b4494dc56f3_terseLabel_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares exchanged for warrants (in shares)</link:label>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_label_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, Number Of Shares Exchanged For Warrants</link:label>
    <link:label id="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_documentation_en-US" xlink:label="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, Number Of Shares Exchanged For Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:href="exdx-20210630.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:to="lab_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_519df9aa-fda2-4100-bd3e-9b9a5c3c5ceb_terseLabel_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical study activity</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_label_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:label id="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent_documentation_en-US" xlink:label="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Clinical Study, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:href="exdx-20210630.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:to="lab_exdx_AccruedLiabilitiesClinicalStudyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_75b755e2-ec97-4223-a498-db6ff03b730f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6a659add-cd46-471c-8072-c90402f025c4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_33d79c63-3c23-4f54-8784-7990cb52d124_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, June 30, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_c818ab60-5bc7-4abf-a538-92858c7057cd_terseLabel_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan covenant, increase to interest rate</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_label_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:label id="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_documentation_en-US" xlink:label="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:to="lab_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_630ecae1-93c0-486c-b38e-dc20954d1722_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5393a27-786b-4042-b0bb-539c69634733_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, June 30, 2021, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_00bd3d67-ed9c-4cbf-ab7b-5ac15554ca1d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_903f1309-86c7-4bde-8cdb-5c0b36f7e0e0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ac856d86-e851-4dad-8901-edff0d3ffa56_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a8ce5d13-576e-4847-ba01-392389d07add_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings-non-current portion, net of discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_NoExpirationMember_0c6f778c-41a1-4bb7-809a-f1cb6c3d84a6_terseLabel_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration</link:label>
    <link:label id="lab_exdx_NoExpirationMember_label_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration [Member]</link:label>
    <link:label id="lab_exdx_NoExpirationMember_documentation_en-US" xlink:label="lab_exdx_NoExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember" xlink:href="exdx-20210630.xsd#exdx_NoExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_NoExpirationMember" xlink:to="lab_exdx_NoExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExchangingStockholdersMember_05e76046-1969-4f6d-a76c-18e78b22d7be_terseLabel_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders</link:label>
    <link:label id="lab_exdx_ExchangingStockholdersMember_label_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders [Member]</link:label>
    <link:label id="lab_exdx_ExchangingStockholdersMember_documentation_en-US" xlink:label="lab_exdx_ExchangingStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchanging Stockholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember" xlink:href="exdx-20210630.xsd#exdx_ExchangingStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExchangingStockholdersMember" xlink:to="lab_exdx_ExchangingStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_81442c4f-3e07-4036-824c-76777e6e6d13_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ClientMember_0e4d04fa-a5f8-47c9-b525-9b5173c14e7b_terseLabel_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:label id="lab_exdx_ClientMember_label_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client [Member]</link:label>
    <link:label id="lab_exdx_ClientMember_documentation_en-US" xlink:label="lab_exdx_ClientMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Client</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember" xlink:href="exdx-20210630.xsd#exdx_ClientMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ClientMember" xlink:to="lab_exdx_ClientMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_bbcfb079-a209-451f-b40a-f6c004dba1aa_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_f3327303-8758-4076-bf72-0606c34ed4b4_terseLabel_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_label_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</link:label>
    <link:label id="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_documentation_en-US" xlink:label="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:href="exdx-20210630.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:to="lab_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_01005719-9a3a-41c3-b656-bbc2422c20de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2a6c850d-dc09-4a21-b28d-a6147282d598_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f80f9bde-03a5-4607-9062-2944229633a4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4dcc196a-81bd-4cd2-8681-a50ea60953c1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_32fb7c63-38f5-41b3-b355-fa308bfd58c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_2d56bd15-1e21-4509-8888-42473e5171b3_terseLabel_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in purchase commitments</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_label_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:label id="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_documentation_en-US" xlink:label="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Annual Increase In Commitment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:href="exdx-20210630.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:to="lab_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_584104b8-83c9-485d-b657-c9a12dd9592a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_2cb34bde-26e3-491c-946a-336147e03ca2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_36d30701-7ca4-4720-8b22-428d667f60d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84609192-d5b8-4702-9ef4-48e41cfd4e12_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98369dd7-07fe-4f68-a72e-20dfe1187ffb_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7a897cd0-18e8-4878-b799-4c7d0cd04ea7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dcc249d1-1f4e-4fb4-afec-234ca8a857ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_8738bf47-a83d-4fcd-aa14-7c4a2de09b97_terseLabel_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs reclassified to equity</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_label_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified to Equity</link:label>
    <link:label id="lab_exdx_DeferredOfferingCostsReclassifiedToEquity_documentation_en-US" xlink:label="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Reclassified to Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:href="exdx-20210630.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:to="lab_exdx_DeferredOfferingCostsReclassifiedToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_c02721cb-dcd6-4f04-9c9b-033f999aa9cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_c00cffab-8138-4dd2-b682-4b25b4e7f4ca_totalLabel_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_label_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:label id="lab_exdx_LongTermDebtIncludingUndiscountedInterest_documentation_en-US" xlink:label="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Including Undiscounted Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:href="exdx-20210630.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:to="lab_exdx_LongTermDebtIncludingUndiscountedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c77c2ce2-9717-4f94-bd6a-2c499d4c332e_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1451e3ed-b15d-42c4-8bde-f65eaa48e070_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1cc0aac1-4cfa-403e-bfc2-61985c6ab22a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8ac91a3f-8907-4037-998f-dfb68dbefdf4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_fd40c955-45eb-466c-a741-1ddd0143750f_terseLabel_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_label_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:label id="lab_exdx_CollaborationAgreementAnnualCollaborationFee_documentation_en-US" xlink:label="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Annual Collaboration Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:href="exdx-20210630.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:to="lab_exdx_CollaborationAgreementAnnualCollaborationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_exdx_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_exdx_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract" xlink:href="exdx-20210630.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_OtherFinancialInformationAbstract" xlink:to="lab_exdx_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b1e0df5a-dc05-4dad-974c-d79e6bdf737f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_802e0bc6-fe13-42fb-943b-e76d51e3248d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96c33a3d-9da8-4d4b-80e6-6ed9eb971ca3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_776e5561-5759-4bc8-bdb7-c45ff0f0fb27_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_09b79c4e-0d2d-4169-98c7-c47cac1ebc82_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation, due in year one</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10dd3492-05e3-4caf-8936-f7db48b7b7a5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_ca2c2763-41df-4c86-a2c0-4a8d14b928b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_fd1ef58e-65cf-439a-abe2-cd62f0126289_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_43333dc3-133b-4c20-8a5e-994952a9f6fc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8f75d5c4-d960-4ddb-9a87-99d9a9cb4d37_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b92d3bb8-fe6d-4632-8179-1fff02e56041_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_be80ae32-4518-4ea3-8136-471e9f70d321_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3d6d13f3-7bfb-43b0-9b61-2ca3356e0d70_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4ab6bc46-6d8c-4976-99fc-ea60eae568b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3dd35f89-be3c-4331-8e28-dd4d383d859a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_267b9f2e-5c25-44f7-aebb-e3855a317d93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, June 30, 2021 (in Shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_44cfd07e-7b2c-4d56-9722-a33e192b600e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_77fe21c5-3862-4a54-ae97-a2fa2045100c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0181c4e4-6228-4a00-90cf-ef8a18ee9c99_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b027249e-a60f-4ebe-b004-6fb46cec382a_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ecac403c-fac3-417d-8bfb-33ba705f4a56_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_72be33bb-5656-44cf-a23d-8271d658c72e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses table</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ce6a050c-3e66-4116-859a-d8d1325fa6f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCustomerMember_b0b33db9-8965-4c52-a2ee-d767ef1d8b12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCustomerMember_label_en-US" xlink:label="lab_us-gaap_OtherCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCustomerMember" xlink:to="lab_us-gaap_OtherCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c127782c-856c-4a53-8056-f94ca11d9f41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_30514904-ac0d-4b47-bd32-9d95fdef1acf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_058239b0-3290-46f8-ae68-1026d2497574_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a94770bd-669f-43be-8e82-fb5a8d861555_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds, included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_5d53eea1-db68-4c41-ad3e-032e235b73c4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_eb8d3c13-ed62-47a0-a560-48cfd455c7e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2ee7469f-df2e-45d0-af6f-d3393933ef41_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_658cb597-4718-458e-973c-93b373b31c48_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_ExpirationApr12026Member_85b107e7-4128-4821-ab1c-f294ed91ae0a_terseLabel_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant expiration April 1, 2026</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_label_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026 [Member]</link:label>
    <link:label id="lab_exdx_ExpirationApr12026Member_documentation_en-US" xlink:label="lab_exdx_ExpirationApr12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Apr 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member" xlink:href="exdx-20210630.xsd#exdx_ExpirationApr12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_ExpirationApr12026Member" xlink:to="lab_exdx_ExpirationApr12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_e2b1fe55-4591-47f5-9422-ed27b8cd1128_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_41e2b7bf-1a8c-4896-82e4-371d23287935_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_174d1698-e63e-49da-8edb-c2053a926549_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic&#160;testing&#160;supplies</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_2c394c7e-7b5d-4363-8f33-a5318233aed9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issued under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cc0ca30c-f856-4d31-b99f-4d9285d102b2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_7a38ff7c-77b3-43d8-b7dc-921c36eb6c2a_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_89fb8061-00b4-4ea8-8209-8ed4ea894bea_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ed3028ab-c4d2-43da-a863-ac7f4dbafb01_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5622aef0-baf3-4717-b0f7-c2489c88cd57_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuanceCosts_ffe4d48a-5219-4a5f-9c66-f13ae98b4f15_verboseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_501cb60d-54ca-4ddf-8d9f-c44aebeb843d_terseLabel_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated offering expenses for aggregate expenses</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_label_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_exdx_StockIssuanceCosts_documentation_en-US" xlink:label="lab_exdx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts" xlink:href="exdx-20210630.xsd#exdx_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuanceCosts" xlink:to="lab_exdx_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9cf8c80c-e7c2-43da-a28e-969a8a5d4a7e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_45870249-a482-44b7-8075-a293a97eb334_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_0ea54ec2-f6a9-4419-9735-ccebfdbfca74_terseLabel_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining milestone obligation, fair value</link:label>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_label_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contingency, Fair Value Disclosure</link:label>
    <link:label id="lab_exdx_MilestoneContingencyFairValueDisclosure_documentation_en-US" xlink:label="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Contingency, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure" xlink:href="exdx-20210630.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_MilestoneContingencyFairValueDisclosure" xlink:to="lab_exdx_MilestoneContingencyFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_cbf466a1-9b45-4921-af73-13a07a307fa8_terseLabel_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of common stock warrants</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_label_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:label id="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_documentation_en-US" xlink:label="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:href="exdx-20210630.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:to="lab_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_2627fd1f-07f2-4f44-93f5-1a956065c578_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_31b3063d-3dd3-44a9-b4df-baf083689712_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_27e482e3-3762-43ab-9a19-cb89c80e43f0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_5ae47246-817d-428a-91d1-9ee01235e582_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_d2a02fe9-883e-4461-8840-74ab2584ac91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions, Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0dbee74e-f072-47f9-bd8c-87ed099af6f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_020fa424-afe6-4c8a-bbea-638f34471000_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>exdx-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6018f8ea-fa05-452a-adea-254786192c77,g:68b7dde8-2230-495d-984a-015fcac6c60d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exagen.com/role/Cover" xlink:type="simple" xlink:href="exdx-20210630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3f1d741d-1060-4831-b366-cb9d8de0cd73" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_DocumentType_3f1d741d-1060-4831-b366-cb9d8de0cd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_aeedaf78-555b-41f6-a8b5-bd7e5c0fb060" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_DocumentQuarterlyReport_aeedaf78-555b-41f6-a8b5-bd7e5c0fb060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d2c60737-9fd1-45c7-86a6-2b34d5ece205" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_DocumentPeriodEndDate_d2c60737-9fd1-45c7-86a6-2b34d5ece205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c2b96a0d-db49-47b0-a057-4a464f8674b5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_DocumentTransitionReport_c2b96a0d-db49-47b0-a057-4a464f8674b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_32f5aeae-16e6-4109-93a3-febdb7b17874" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityFileNumber_32f5aeae-16e6-4109-93a3-febdb7b17874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f53eed7d-dba4-4ad4-9b8b-2a63cfc9efa8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityRegistrantName_f53eed7d-dba4-4ad4-9b8b-2a63cfc9efa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_37af69d8-e099-4266-817a-3fb6b29840c1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityIncorporationStateCountryCode_37af69d8-e099-4266-817a-3fb6b29840c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_09fefd84-f788-4d42-bced-493935d130d7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityTaxIdentificationNumber_09fefd84-f788-4d42-bced-493935d130d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_061c5c10-c172-4fe6-923b-2954aca36599" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityAddressAddressLine1_061c5c10-c172-4fe6-923b-2954aca36599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f0ebd3a2-aa14-41a2-92c5-0c45860b0b63" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityAddressCityOrTown_f0ebd3a2-aa14-41a2-92c5-0c45860b0b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1936d609-3708-4518-a131-4e6a055b4551" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityAddressStateOrProvince_1936d609-3708-4518-a131-4e6a055b4551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dd9630c5-86c6-4cf8-87c4-3eae63c26c66" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityAddressPostalZipCode_dd9630c5-86c6-4cf8-87c4-3eae63c26c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8d55ec2f-850a-47aa-a1bc-c6090714a585" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_CityAreaCode_8d55ec2f-850a-47aa-a1bc-c6090714a585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a46677a2-ca50-43e6-aa0a-05d771fa5b13" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_LocalPhoneNumber_a46677a2-ca50-43e6-aa0a-05d771fa5b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b08362c9-fb33-4f8e-82b6-e7b3bc83444b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_Security12bTitle_b08362c9-fb33-4f8e-82b6-e7b3bc83444b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d4488fe1-0f58-45c4-b9db-f5fde4992af8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_TradingSymbol_d4488fe1-0f58-45c4-b9db-f5fde4992af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d4c67a46-c4fe-4d53-ae2b-8d406de33cc6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_SecurityExchangeName_d4c67a46-c4fe-4d53-ae2b-8d406de33cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8b4b9aee-e223-4bb9-b626-049e54fe39f1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityCurrentReportingStatus_8b4b9aee-e223-4bb9-b626-049e54fe39f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_05c61a43-bbe2-4b7e-8b46-726cd9e03429" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityInteractiveDataCurrent_05c61a43-bbe2-4b7e-8b46-726cd9e03429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c3d53bff-0502-45c0-8b58-bc31e7200c04" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityFilerCategory_c3d53bff-0502-45c0-8b58-bc31e7200c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b7f32716-597f-4d33-878f-21881b6fdd22" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntitySmallBusiness_b7f32716-597f-4d33-878f-21881b6fdd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_72e585fd-9572-4a61-b66e-c9eefb81993d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityEmergingGrowthCompany_72e585fd-9572-4a61-b66e-c9eefb81993d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_673d2226-0c0b-446b-a7e9-634dafe8aeb0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityExTransitionPeriod_673d2226-0c0b-446b-a7e9-634dafe8aeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9e07ad06-b0e4-41bb-888d-fcf7b86d7fb0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityShellCompany_9e07ad06-b0e4-41bb-888d-fcf7b86d7fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ef002619-87a1-487b-9b79-3e96973a2906" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ef002619-87a1-487b-9b79-3e96973a2906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9775a5e8-7186-45fb-8754-6a4ddaf62521" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_EntityCentralIndexKey_9775a5e8-7186-45fb-8754-6a4ddaf62521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_935a0a46-5017-417f-83c3-50877c775a66" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_CurrentFiscalYearEndDate_935a0a46-5017-417f-83c3-50877c775a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_62555044-c488-4d44-b89b-1453667b76fd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_DocumentFiscalYearFocus_62555044-c488-4d44-b89b-1453667b76fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1b6c5c29-9529-4a0d-859b-2f06900dd28f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1b6c5c29-9529-4a0d-859b-2f06900dd28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4fbe1df0-073c-42ff-9b4d-0a58b1f269dd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cadb3276-c3d8-4f2e-848f-67cfb7256d38" xlink:to="loc_dei_AmendmentFlag_4fbe1df0-073c-42ff-9b4d-0a58b1f269dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="exdx-20210630.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3ae80618-b3c8-48b4-9a91-262ddeff4bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6bdb0723-0520-484b-840a-ce466ca75c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3ae80618-b3c8-48b4-9a91-262ddeff4bed" xlink:to="loc_us-gaap_AssetsAbstract_6bdb0723-0520-484b-840a-ce466ca75c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8706a1a8-cdd5-456b-93b9-4a3e1578d739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb0723-0520-484b-840a-ce466ca75c73" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8706a1a8-cdd5-456b-93b9-4a3e1578d739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ea78b32-f8df-4a98-90d8-eeed7c6d74c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8706a1a8-cdd5-456b-93b9-4a3e1578d739" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ea78b32-f8df-4a98-90d8-eeed7c6d74c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ca503a3b-5deb-4517-9df4-1c778b339ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8706a1a8-cdd5-456b-93b9-4a3e1578d739" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ca503a3b-5deb-4517-9df4-1c778b339ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1ca205c8-cb91-4433-a087-184b240c75ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8706a1a8-cdd5-456b-93b9-4a3e1578d739" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1ca205c8-cb91-4433-a087-184b240c75ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a82f6047-1ae9-4310-8884-6bf9f4833564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8706a1a8-cdd5-456b-93b9-4a3e1578d739" xlink:to="loc_us-gaap_AssetsCurrent_a82f6047-1ae9-4310-8884-6bf9f4833564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9d85bc09-cc09-4b08-a088-e587fec88a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb0723-0520-484b-840a-ce466ca75c73" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9d85bc09-cc09-4b08-a088-e587fec88a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ecb5fd34-2f7e-4cf3-a7c5-03037f1d1424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb0723-0520-484b-840a-ce466ca75c73" xlink:to="loc_us-gaap_Goodwill_ecb5fd34-2f7e-4cf3-a7c5-03037f1d1424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fd372f1a-3a0b-46b1-937e-4001be1f74bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb0723-0520-484b-840a-ce466ca75c73" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fd372f1a-3a0b-46b1-937e-4001be1f74bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d6b9998d-1176-4247-b289-0190d47999f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb0723-0520-484b-840a-ce466ca75c73" xlink:to="loc_us-gaap_Assets_d6b9998d-1176-4247-b289-0190d47999f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3ae80618-b3c8-48b4-9a91-262ddeff4bed" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3b79cada-24fc-4f27-914c-85cd06ddc4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3b79cada-24fc-4f27-914c-85cd06ddc4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_58211073-6644-4afa-b2cf-dc054faf257d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3b79cada-24fc-4f27-914c-85cd06ddc4cc" xlink:to="loc_us-gaap_AccountsPayableCurrent_58211073-6644-4afa-b2cf-dc054faf257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_32a82ae7-6743-4182-afab-be297577cd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3b79cada-24fc-4f27-914c-85cd06ddc4cc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_32a82ae7-6743-4182-afab-be297577cd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_27e9dc02-8e5b-4a00-bc8f-84ac40a5aed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3b79cada-24fc-4f27-914c-85cd06ddc4cc" xlink:to="loc_us-gaap_LiabilitiesCurrent_27e9dc02-8e5b-4a00-bc8f-84ac40a5aed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f9bde546-b689-4a64-88c6-b069319c41c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f9bde546-b689-4a64-88c6-b069319c41c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d880ff0f-be86-4076-9443-9ff03265ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d880ff0f-be86-4076-9443-9ff03265ce34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dfeebcd9-1f8e-4fae-866b-13af46941587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_dfeebcd9-1f8e-4fae-866b-13af46941587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a5af19a8-85e6-4f73-a4fb-e947ed3cd921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:to="loc_us-gaap_Liabilities_a5af19a8-85e6-4f73-a4fb-e947ed3cd921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3d44e1c9-0bc2-4d35-ac9e-33644ef3f454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3d44e1c9-0bc2-4d35-ac9e-33644ef3f454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_dafb1ecc-0fdf-433f-bc53-c8c34873e381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_dafb1ecc-0fdf-433f-bc53-c8c34873e381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cf461dd6-c703-46bd-9f38-b7a02d211294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dafb1ecc-0fdf-433f-bc53-c8c34873e381" xlink:to="loc_us-gaap_PreferredStockValue_cf461dd6-c703-46bd-9f38-b7a02d211294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2b6429a6-9b03-4d0b-b2b7-ead1d64ccddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dafb1ecc-0fdf-433f-bc53-c8c34873e381" xlink:to="loc_us-gaap_CommonStockValue_2b6429a6-9b03-4d0b-b2b7-ead1d64ccddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c921c6a1-b576-4043-aa3f-41acf7435c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dafb1ecc-0fdf-433f-bc53-c8c34873e381" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c921c6a1-b576-4043-aa3f-41acf7435c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_05f6a846-e4e5-4ba1-ab21-ed3d782e1f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dafb1ecc-0fdf-433f-bc53-c8c34873e381" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_05f6a846-e4e5-4ba1-ab21-ed3d782e1f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb8c5650-8ddb-475c-b4db-cee1bbca908f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dafb1ecc-0fdf-433f-bc53-c8c34873e381" xlink:to="loc_us-gaap_StockholdersEquity_eb8c5650-8ddb-475c-b4db-cee1bbca908f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6afcc97-84eb-4467-909a-84d90b97088b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d45fe3dd-8d72-4612-856e-8fe71492011a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a6afcc97-84eb-4467-909a-84d90b97088b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exdx-20210630.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5d0e503d-3c9e-4966-b80d-ceff1598a8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5265db09-7a1e-470e-a09c-c10ed6fcadbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d0e503d-3c9e-4966-b80d-ceff1598a8c8" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5265db09-7a1e-470e-a09c-c10ed6fcadbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8c87d7f7-e047-4ae9-82b1-a7b144db0333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5265db09-7a1e-470e-a09c-c10ed6fcadbb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8c87d7f7-e047-4ae9-82b1-a7b144db0333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bd40530e-1008-48ed-96ae-e5fe7affb339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5265db09-7a1e-470e-a09c-c10ed6fcadbb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bd40530e-1008-48ed-96ae-e5fe7affb339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_12394fa9-2c9e-4d3c-8a0f-e492db2617c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5265db09-7a1e-470e-a09c-c10ed6fcadbb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_12394fa9-2c9e-4d3c-8a0f-e492db2617c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_aaafa112-0a17-47cc-a424-7bd2242e5bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5265db09-7a1e-470e-a09c-c10ed6fcadbb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_aaafa112-0a17-47cc-a424-7bd2242e5bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_681916bb-3022-43fc-84c6-e0b478ba12be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5d0e503d-3c9e-4966-b80d-ceff1598a8c8" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_681916bb-3022-43fc-84c6-e0b478ba12be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_dc2764bb-c47f-4b30-8294-b28d63870c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_681916bb-3022-43fc-84c6-e0b478ba12be" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_dc2764bb-c47f-4b30-8294-b28d63870c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_acd86660-c7ce-4641-8053-50c13591b85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_681916bb-3022-43fc-84c6-e0b478ba12be" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_acd86660-c7ce-4641-8053-50c13591b85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_51697ce1-ad40-4c93-aa2d-6fa6ed8074e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_681916bb-3022-43fc-84c6-e0b478ba12be" xlink:to="loc_us-gaap_CommonStockSharesIssued_51697ce1-ad40-4c93-aa2d-6fa6ed8074e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a9863d41-d5cf-48e2-a5a1-5041e4fa92b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_681916bb-3022-43fc-84c6-e0b478ba12be" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a9863d41-d5cf-48e2-a5a1-5041e4fa92b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="simple" xlink:href="exdx-20210630.xsd#UnauditedCondensedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5413dcaa-d86a-4b0d-a94d-e3fc1f1f7b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5413dcaa-d86a-4b0d-a94d-e3fc1f1f7b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d0c2c09a-4acf-4bde-93ea-78d6aa043505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d0c2c09a-4acf-4bde-93ea-78d6aa043505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b0ab4259-6b9d-4f3a-90a1-d95ea77a0ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d0c2c09a-4acf-4bde-93ea-78d6aa043505" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b0ab4259-6b9d-4f3a-90a1-d95ea77a0ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_63ca99c0-9c6d-4002-b582-1afe252ba14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d0c2c09a-4acf-4bde-93ea-78d6aa043505" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_63ca99c0-9c6d-4002-b582-1afe252ba14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_45f06d55-77f9-4f61-b1ef-a9cc1ca52625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d0c2c09a-4acf-4bde-93ea-78d6aa043505" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_45f06d55-77f9-4f61-b1ef-a9cc1ca52625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c3b2596a-4890-4551-8ec5-187085f1a027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d0c2c09a-4acf-4bde-93ea-78d6aa043505" xlink:to="loc_us-gaap_CostsAndExpenses_c3b2596a-4890-4551-8ec5-187085f1a027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4f7994d9-78f4-410d-828a-04f8ddc3b586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_OperatingIncomeLoss_4f7994d9-78f4-410d-828a-04f8ddc3b586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dcc0c555-a923-4761-b25a-e53553972cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_InterestExpense_dcc0c555-a923-4761-b25a-e53553972cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_31913c6c-b11b-4328-8385-66135c987e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_31913c6c-b11b-4328-8385-66135c987e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9197d103-ccf4-4845-9bd5-c64a9452bd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_9197d103-ccf4-4845-9bd5-c64a9452bd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0de9c08e-92ab-444f-b32f-b1c2d750ff5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0de9c08e-92ab-444f-b32f-b1c2d750ff5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c90a8b92-0aa5-46ba-9d75-0eb8765c8d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_NetIncomeLoss_c90a8b92-0aa5-46ba-9d75-0eb8765c8d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5ea8bf5c-4541-444e-801d-dd266e5e77fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_EarningsPerShareBasic_5ea8bf5c-4541-444e-801d-dd266e5e77fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_55b5154e-7c12-4c5a-afa6-77f407667433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_EarningsPerShareDiluted_55b5154e-7c12-4c5a-afa6-77f407667433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9876d6a-3ea4-4459-a01c-8c17d3a47a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9876d6a-3ea4-4459-a01c-8c17d3a47a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e410b07a-9a92-4e6c-ac1d-9fe2d693a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4cc5271f-6346-4d49-ad68-db82f0c84420" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e410b07a-9a92-4e6c-ac1d-9fe2d693a0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exdx-20210630.xsd#UnauditedCondensedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1b6677d6-4702-410a-bcf4-233cac6cf920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_570a867c-ba63-429a-9720-b80677fb6456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1b6677d6-4702-410a-bcf4-233cac6cf920" xlink:to="loc_us-gaap_StatementTable_570a867c-ba63-429a-9720-b80677fb6456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6ffe7550-2420-4dca-b631-ee343e03752b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_570a867c-ba63-429a-9720-b80677fb6456" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6ffe7550-2420-4dca-b631-ee343e03752b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ffe7550-2420-4dca-b631-ee343e03752b" xlink:to="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_956e81f6-407a-42ff-b328-ec118d9a9581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:to="loc_us-gaap_CommonStockMember_956e81f6-407a-42ff-b328-ec118d9a9581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a47c768a-9aa1-4806-87b1-e02ee5e535b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a47c768a-9aa1-4806-87b1-e02ee5e535b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ff5f4c83-de30-4bbf-86f0-2c2097045ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c486317a-e00f-4257-a34c-6435a6144d84" xlink:to="loc_us-gaap_RetainedEarningsMember_ff5f4c83-de30-4bbf-86f0-2c2097045ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d0706d02-3749-47f9-b78b-754ec4c2af6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_570a867c-ba63-429a-9720-b80677fb6456" xlink:to="loc_us-gaap_StatementLineItems_d0706d02-3749-47f9-b78b-754ec4c2af6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d0706d02-3749-47f9-b78b-754ec4c2af6c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_fb798fab-8090-4e5e-9b70-349807c0c884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_fb798fab-8090-4e5e-9b70-349807c0c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7b0e34a-9349-4681-8032-1855686a2b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockholdersEquity_b7b0e34a-9349-4681-8032-1855686a2b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4c46c5fd-c4d9-4a93-844d-a6a76e366a23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4c46c5fd-c4d9-4a93-844d-a6a76e366a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd99746d-1ae1-4e78-98ce-f10aadcc203b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd99746d-1ae1-4e78-98ce-f10aadcc203b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1181361c-d9c8-459d-ae6a-3f804dd22658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1181361c-d9c8-459d-ae6a-3f804dd22658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3826f426-9cb3-475c-9e64-1c5549699269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_3826f426-9cb3-475c-9e64-1c5549699269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_369913f9-27f2-47c4-87b2-08860d0339c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_369913f9-27f2-47c4-87b2-08860d0339c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0bacb19-bc7a-4da9-887a-b670ab5c7533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b0bacb19-bc7a-4da9-887a-b670ab5c7533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8e7b47dd-97fd-4ba2-8d98-6ccaa67d4066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8e7b47dd-97fd-4ba2-8d98-6ccaa67d4066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f172c06c-66db-49e2-81ab-919694b64d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f172c06c-66db-49e2-81ab-919694b64d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_99606ade-734f-4105-8489-d666eb9381eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_99606ade-734f-4105-8489-d666eb9381eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50840426-89d2-4871-95ca-a2dc11222d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50840426-89d2-4871-95ca-a2dc11222d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_bb508f6a-a658-47be-b8ce-4b750df75813" xlink:href="exdx-20210630.xsd#exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet_bb508f6a-a658-47be-b8ce-4b750df75813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_5385a557-4238-4e68-88d4-c6b5220c2192" xlink:href="exdx-20210630.xsd#exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet_5385a557-4238-4e68-88d4-c6b5220c2192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e53d2b7b-ec57-40ee-82c9-37423e6eaab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_NetIncomeLoss_e53d2b7b-ec57-40ee-82c9-37423e6eaab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d0bf2d0f-56c6-484c-b21c-786a6cdca93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d0bf2d0f-56c6-484c-b21c-786a6cdca93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5bdbbf71-5331-408d-87b3-740ab952f171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a36fc722-5dda-4e26-b2a9-a5ffbbdfc424" xlink:to="loc_us-gaap_StockholdersEquity_5bdbbf71-5331-408d-87b3-740ab952f171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="exdx-20210630.xsd#UnauditedCondensedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8e168439-6006-47c1-9a2e-aff4386281de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_541aec9b-6ee5-489e-b64f-67c175fb47df" xlink:href="exdx-20210630.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8e168439-6006-47c1-9a2e-aff4386281de" xlink:to="loc_exdx_StockIssuanceCosts_541aec9b-6ee5-489e-b64f-67c175fb47df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="simple" xlink:href="exdx-20210630.xsd#UnauditedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/UnauditedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e3559784-0998-49fd-8601-0f114036263d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e3559784-0998-49fd-8601-0f114036263d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f164e5c-59b1-4e10-8836-6198e7fc706a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e3559784-0998-49fd-8601-0f114036263d" xlink:to="loc_us-gaap_NetIncomeLoss_8f164e5c-59b1-4e10-8836-6198e7fc706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfc68e9c-2c3b-47fc-9514-c479be1fcba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e3559784-0998-49fd-8601-0f114036263d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfc68e9c-2c3b-47fc-9514-c479be1fcba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_e7f3a52d-d316-48a1-ac20-893c07491c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfc68e9c-2c3b-47fc-9514-c479be1fcba1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_e7f3a52d-d316-48a1-ac20-893c07491c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ac264fd0-4f3f-4611-b5c1-857d31fb9371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfc68e9c-2c3b-47fc-9514-c479be1fcba1" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_ac264fd0-4f3f-4611-b5c1-857d31fb9371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_1dc5e9ed-f962-4903-be57-2f6ffdd678c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfc68e9c-2c3b-47fc-9514-c479be1fcba1" xlink:to="loc_us-gaap_PaidInKindInterest_1dc5e9ed-f962-4903-be57-2f6ffdd678c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c54b9db0-4029-40c9-a07e-db519b570369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfc68e9c-2c3b-47fc-9514-c479be1fcba1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c54b9db0-4029-40c9-a07e-db519b570369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5643454b-fd3f-4b64-a761-20c64fd00841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfc68e9c-2c3b-47fc-9514-c479be1fcba1" xlink:to="loc_us-gaap_ShareBasedCompensation_5643454b-fd3f-4b64-a761-20c64fd00841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ddce129-2dea-42c6-8b7a-04827ba1d612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bfc68e9c-2c3b-47fc-9514-c479be1fcba1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ddce129-2dea-42c6-8b7a-04827ba1d612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_86f53815-5aab-4099-8bb4-607625038d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ddce129-2dea-42c6-8b7a-04827ba1d612" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_86f53815-5aab-4099-8bb4-607625038d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_c47309b8-d0ec-4fc9-94b9-fdae69f1c482" xlink:href="exdx-20210630.xsd#exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ddce129-2dea-42c6-8b7a-04827ba1d612" xlink:to="loc_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets_c47309b8-d0ec-4fc9-94b9-fdae69f1c482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_65bca21e-e0ea-49ba-acaf-a16a2f859c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ddce129-2dea-42c6-8b7a-04827ba1d612" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_65bca21e-e0ea-49ba-acaf-a16a2f859c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ffbcaa36-3109-4105-9214-10fd01940337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ddce129-2dea-42c6-8b7a-04827ba1d612" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ffbcaa36-3109-4105-9214-10fd01940337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fc73a17d-7792-48a9-ad1f-fc96b22d0f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ddce129-2dea-42c6-8b7a-04827ba1d612" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_fc73a17d-7792-48a9-ad1f-fc96b22d0f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5561bddd-963d-488b-9b7b-8d69dc555698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e3559784-0998-49fd-8601-0f114036263d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5561bddd-963d-488b-9b7b-8d69dc555698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4c2f2045-7d78-4f80-9c99-ceb0133ab324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4c2f2045-7d78-4f80-9c99-ceb0133ab324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_29ca0101-f0ff-46df-994e-a6a59db283f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4c2f2045-7d78-4f80-9c99-ceb0133ab324" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_29ca0101-f0ff-46df-994e-a6a59db283f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b74f81ed-0ed4-471a-b5b3-6e0b1b6fefc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_4c2f2045-7d78-4f80-9c99-ceb0133ab324" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b74f81ed-0ed4-471a-b5b3-6e0b1b6fefc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_007d40e2-28ef-4621-bec0-b79365f1bb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_007d40e2-28ef-4621-bec0-b79365f1bb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_5261d64d-f230-406b-aed4-267090dde5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_ProceedsFromStockPlans_5261d64d-f230-406b-aed4-267090dde5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_6c54fd7d-309d-45c8-8214-f77aff7cd580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_6c54fd7d-309d-45c8-8214-f77aff7cd580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_001724f1-87ad-473b-a43f-b602dfa1f2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_001724f1-87ad-473b-a43f-b602dfa1f2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_59c43d88-fb66-42ad-9afc-55cc8a34f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_ProceedsFromBankDebt_59c43d88-fb66-42ad-9afc-55cc8a34f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_c4014204-ed43-42e2-b174-b8480c106e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_RepaymentsOfBankDebt_c4014204-ed43-42e2-b174-b8480c106e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c4146f7d-db1b-495a-a5f0-90df54576841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c4146f7d-db1b-495a-a5f0-90df54576841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c30af798-7f91-451c-869e-2d4464298474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c30af798-7f91-451c-869e-2d4464298474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6941b970-f12b-435a-a6ef-478258214106" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_a8397abe-c3f7-4e89-a3d4-d2ecbe42adb3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6941b970-f12b-435a-a6ef-478258214106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c098750-9d09-4419-8e8a-e1cdebf49832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c098750-9d09-4419-8e8a-e1cdebf49832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_983b5fa2-4e9f-4df5-a62e-c5d7f5c82881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_983b5fa2-4e9f-4df5-a62e-c5d7f5c82881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52107599-9224-41dd-9eb1-6c0b7f3dd1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52107599-9224-41dd-9eb1-6c0b7f3dd1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f257855-bf3f-48d0-9d0e-6a887431bc94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f257855-bf3f-48d0-9d0e-6a887431bc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_cc21a0bf-4f7e-4e24-847b-6579e1ee8765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f257855-bf3f-48d0-9d0e-6a887431bc94" xlink:to="loc_us-gaap_InterestPaidNet_cc21a0bf-4f7e-4e24-847b-6579e1ee8765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_c4872bae-b16a-4bc1-b6c1-ef8f283308a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4fee5375-8247-45bc-a5b3-0a156dddac5d" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_c4872bae-b16a-4bc1-b6c1-ef8f283308a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_EquipmentPurchasedUnderCapitalLease_868baac5-8f5e-4e09-bbda-363288fbd521" xlink:href="exdx-20210630.xsd#exdx_EquipmentPurchasedUnderCapitalLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_c4872bae-b16a-4bc1-b6c1-ef8f283308a4" xlink:to="loc_exdx_EquipmentPurchasedUnderCapitalLease_868baac5-8f5e-4e09-bbda-363288fbd521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1543bf21-a642-4cf0-97bd-b51447596426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_c4872bae-b16a-4bc1-b6c1-ef8f283308a4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1543bf21-a642-4cf0-97bd-b51447596426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_6ffc3d36-c282-44e3-8941-0c102088436e" xlink:href="exdx-20210630.xsd#exdx_DeferredOfferingCostsReclassifiedToEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_c4872bae-b16a-4bc1-b6c1-ef8f283308a4" xlink:to="loc_exdx_DeferredOfferingCostsReclassifiedToEquity_6ffc3d36-c282-44e3-8941-0c102088436e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Organization" xlink:type="simple" xlink:href="exdx-20210630.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_effd1af9-344a-4613-bfab-569f6aa87607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_5e45f252-f21a-46f1-87a1-1a6571e2b029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_effd1af9-344a-4613-bfab-569f6aa87607" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_5e45f252-f21a-46f1-87a1-1a6571e2b029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OrganizationDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d0bc084-f9eb-442c-81b8-09834148a4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9899fa50-1ee0-43fe-904d-f754a4a26eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d0bc084-f9eb-442c-81b8-09834148a4ee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9899fa50-1ee0-43fe-904d-f754a4a26eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64d7b904-01bf-4efd-851e-3380a6012979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d0bc084-f9eb-442c-81b8-09834148a4ee" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_64d7b904-01bf-4efd-851e-3380a6012979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e641b0d9-c7ca-4a2f-9072-0de977a3c705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_47f9efa1-2417-455c-9448-b0e7ee1bf352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e641b0d9-c7ca-4a2f-9072-0de977a3c705" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_47f9efa1-2417-455c-9448-b0e7ee1bf352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4a601a0a-9c29-4435-87f9-38be9197b643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4a601a0a-9c29-4435-87f9-38be9197b643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_74910a6b-b672-4c66-9b0a-9c16bda83022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_74910a6b-b672-4c66-9b0a-9c16bda83022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_44d35f48-861d-4b48-804c-d4e9ddbf4339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_44d35f48-861d-4b48-804c-d4e9ddbf4339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0e90f599-be7a-48c0-b719-c4ee956d61ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_0e90f599-be7a-48c0-b719-c4ee956d61ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f584c088-652b-4d36-a456-7e687f0877c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f584c088-652b-4d36-a456-7e687f0877c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_2ee958fb-b80b-4175-9a5b-6fb2333d608c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_2ee958fb-b80b-4175-9a5b-6fb2333d608c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_9ce62c59-7f10-4335-804b-173251cad13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_9ce62c59-7f10-4335-804b-173251cad13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_be9e794e-f5a6-4c83-b138-4ee1634f23d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPolicy_be9e794e-f5a6-4c83-b138-4ee1634f23d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2f6b8ce2-95f8-4c9c-af1a-d6a4fa53c30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2f6b8ce2-95f8-4c9c-af1a-d6a4fa53c30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_4392a495-d82a-4ad7-9b9a-539c9bf0ea7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_4392a495-d82a-4ad7-9b9a-539c9bf0ea7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_905dd709-3983-4f8c-b463-c11683d6d9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_905dd709-3983-4f8c-b463-c11683d6d9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a083f196-8ea7-429a-80cf-33c83fe7bd33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1e41453f-88d7-4572-a394-3f26812582cf" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a083f196-8ea7-429a-80cf-33c83fe7bd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8a826d27-0485-4500-bcb8-5adcf1916955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_00e506bb-2776-47d8-8b1f-ca4e6d0b0bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a826d27-0485-4500-bcb8-5adcf1916955" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_00e506bb-2776-47d8-8b1f-ca4e6d0b0bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_16a79c98-0e25-4062-b3de-19f2bd0f61a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a826d27-0485-4500-bcb8-5adcf1916955" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_16a79c98-0e25-4062-b3de-19f2bd0f61a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_cbac2137-05dc-406b-9ada-62d0afefe1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a826d27-0485-4500-bcb8-5adcf1916955" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_cbac2137-05dc-406b-9ada-62d0afefe1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a8c394a4-c93f-40cf-95f7-7f3073241d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a826d27-0485-4500-bcb8-5adcf1916955" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a8c394a4-c93f-40cf-95f7-7f3073241d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ea96c1d9-e1c9-4f9c-9e70-1c6188a920ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a826d27-0485-4500-bcb8-5adcf1916955" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ea96c1d9-e1c9-4f9c-9e70-1c6188a920ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_246b5b76-f55b-4be3-a090-c4bc156dcd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_246b5b76-f55b-4be3-a090-c4bc156dcd15" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:to="loc_srt_MajorCustomersAxis_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7bac5bd0-12f7-40d9-9bd2-f1f46875e2ee" xlink:to="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareMember_f7a8d5d8-3bec-4d7c-bd42-cc715a20c4c6" xlink:href="exdx-20210630.xsd#exdx_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_MedicareMember_f7a8d5d8-3bec-4d7c-bd42-cc715a20c4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MedicareAdvantageMember_063d5149-4974-4948-b0fd-d49ea9b2b888" xlink:href="exdx-20210630.xsd#exdx_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_MedicareAdvantageMember_063d5149-4974-4948-b0fd-d49ea9b2b888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_BlueShieldMember_df327a89-43cd-4d5e-b5d2-886922ee80de" xlink:href="exdx-20210630.xsd#exdx_BlueShieldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_BlueShieldMember_df327a89-43cd-4d5e-b5d2-886922ee80de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_UnitedHealthcareMember_a1191c42-bf5e-4e8e-934e-8abae3afd527" xlink:href="exdx-20210630.xsd#exdx_UnitedHealthcareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_UnitedHealthcareMember_a1191c42-bf5e-4e8e-934e-8abae3afd527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_23845043-4e99-4161-99e7-55838b699215" xlink:href="exdx-20210630.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a30962d4-b8e7-4242-8860-aa958837b713" xlink:to="loc_exdx_JanssenSIMPONIMember_23845043-4e99-4161-99e7-55838b699215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a88c71d-4f5c-47d2-96ea-059309a90ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a88c71d-4f5c-47d2-96ea-059309a90ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcc8b326-bdde-4e95-8c32-5e4bc81e0aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_4a88c71d-4f5c-47d2-96ea-059309a90ef9" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcc8b326-bdde-4e95-8c32-5e4bc81e0aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_5870f40d-434b-4d4f-b59e-008777053b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcc8b326-bdde-4e95-8c32-5e4bc81e0aca" xlink:to="loc_us-gaap_SalesRevenueNetMember_5870f40d-434b-4d4f-b59e-008777053b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ReceivableBenchmarkMember_df2dc6fe-a6cf-49e7-9df5-1084c2d9666e" xlink:href="exdx-20210630.xsd#exdx_ReceivableBenchmarkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcc8b326-bdde-4e95-8c32-5e4bc81e0aca" xlink:to="loc_exdx_ReceivableBenchmarkMember_df2dc6fe-a6cf-49e7-9df5-1084c2d9666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e894907f-9159-4711-9499-769dd51b1eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e894907f-9159-4711-9499-769dd51b1eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_38992fea-a4f3-43a7-85a5-093cc003b405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e894907f-9159-4711-9499-769dd51b1eba" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_38992fea-a4f3-43a7-85a5-093cc003b405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6019115f-7b80-4f2c-8c5a-236c77bc18c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_38992fea-a4f3-43a7-85a5-093cc003b405" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6019115f-7b80-4f2c-8c5a-236c77bc18c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_34ea0ffc-b8bd-43da-8d21-1a25830d2953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8794acb7-ea29-43d3-8906-687bb1fc8778" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_34ea0ffc-b8bd-43da-8d21-1a25830d2953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9d74193e-fa0b-4aa5-8121-7d226effd775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_34ea0ffc-b8bd-43da-8d21-1a25830d2953" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9d74193e-fa0b-4aa5-8121-7d226effd775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_02261ca7-68dc-4b02-9586-2c86144a17ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02261ca7-68dc-4b02-9586-2c86144a17ef" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a453f39-f78c-4a47-b73b-12ad2923c57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_250e620e-11f4-4a1e-9fc8-0e9adf6c0ac0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a453f39-f78c-4a47-b73b-12ad2923c57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_d1cb36f5-7b89-4b73-962d-5624db88aebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6a453f39-f78c-4a47-b73b-12ad2923c57a" xlink:to="loc_us-gaap_SalesRevenueNetMember_d1cb36f5-7b89-4b73-962d-5624db88aebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_519c3ad7-0307-4680-95d8-da6f586dca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_519c3ad7-0307-4680-95d8-da6f586dca3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a9a61982-6895-4098-b7b8-e981538c5877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_519c3ad7-0307-4680-95d8-da6f586dca3f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a9a61982-6895-4098-b7b8-e981538c5877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_569f2efd-be4a-412f-830c-300fa528a0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a9a61982-6895-4098-b7b8-e981538c5877" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_569f2efd-be4a-412f-830c-300fa528a0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_256afea8-a7a4-40ab-bf04-9a8b19db0993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a9a61982-6895-4098-b7b8-e981538c5877" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_256afea8-a7a4-40ab-bf04-9a8b19db0993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_577fb433-9c44-4cd5-8eef-39ed3ba8676c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_srt_ProductOrServiceAxis_577fb433-9c44-4cd5-8eef-39ed3ba8676c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9c077f6-60bb-4851-ad49-0ff61a1c47bc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_577fb433-9c44-4cd5-8eef-39ed3ba8676c" xlink:to="loc_srt_ProductsAndServicesDomain_e9c077f6-60bb-4851-ad49-0ff61a1c47bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AVISECTDTestMember_ecdcb0ba-6032-43a3-8895-9a8653494422" xlink:href="exdx-20210630.xsd#exdx_AVISECTDTestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9c077f6-60bb-4851-ad49-0ff61a1c47bc" xlink:to="loc_exdx_AVISECTDTestMember_ecdcb0ba-6032-43a3-8895-9a8653494422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_4651565a-5429-44e7-a214-21dbc60a8965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9c077f6-60bb-4851-ad49-0ff61a1c47bc" xlink:to="loc_us-gaap_ShippingAndHandlingMember_4651565a-5429-44e7-a214-21dbc60a8965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f751ee46-4015-49b9-a248-ced0d9bc303d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f751ee46-4015-49b9-a248-ced0d9bc303d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_63bcb768-a5fe-4899-b759-4d5f226a76a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f751ee46-4015-49b9-a248-ced0d9bc303d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_63bcb768-a5fe-4899-b759-4d5f226a76a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_cf199907-c6ca-4777-ab5e-078627538b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_63bcb768-a5fe-4899-b759-4d5f226a76a3" xlink:to="loc_us-gaap_OtherAssetsMember_cf199907-c6ca-4777-ab5e-078627538b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_071289ae-0173-4141-9f9c-d5240c90db62" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_srt_RangeAxis_071289ae-0173-4141-9f9c-d5240c90db62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b209257-9605-4e45-aedf-bd73928f7a97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_071289ae-0173-4141-9f9c-d5240c90db62" xlink:to="loc_srt_RangeMember_0b209257-9605-4e45-aedf-bd73928f7a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_454c6589-2789-4b42-9e05-cd4440c9005f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b209257-9605-4e45-aedf-bd73928f7a97" xlink:to="loc_srt_MinimumMember_454c6589-2789-4b42-9e05-cd4440c9005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d873ecc-818c-4bb4-ab6d-41ba3b61c852" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b209257-9605-4e45-aedf-bd73928f7a97" xlink:to="loc_srt_MaximumMember_9d873ecc-818c-4bb4-ab6d-41ba3b61c852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_srt_CounterpartyNameAxis_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e4c12ed-4606-4a72-80da-ee02931c8295" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ebcbf95d-99c2-4d8b-9b40-c1c987baa25b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e4c12ed-4606-4a72-80da-ee02931c8295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_01f0d1bf-548f-4a50-87a9-340908ad7951" xlink:href="exdx-20210630.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0e4c12ed-4606-4a72-80da-ee02931c8295" xlink:to="loc_exdx_JanssenSIMPONIMember_01f0d1bf-548f-4a50-87a9-340908ad7951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0332383b-260a-4e9e-8086-4cfac71acc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_AwardTypeAxis_0332383b-260a-4e9e-8086-4cfac71acc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df45438d-8335-49d7-b959-20a086bf4365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0332383b-260a-4e9e-8086-4cfac71acc6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df45438d-8335-49d7-b959-20a086bf4365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_de8cf2fa-9460-4f9e-98c9-8fd87ac990e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df45438d-8335-49d7-b959-20a086bf4365" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_de8cf2fa-9460-4f9e-98c9-8fd87ac990e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1fd71107-fba0-4f8d-ae5c-e074682ffb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1fd71107-fba0-4f8d-ae5c-e074682ffb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a51bad19-ff16-4bf3-b252-8650af96a23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1fd71107-fba0-4f8d-ae5c-e074682ffb1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a51bad19-ff16-4bf3-b252-8650af96a23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenPromotionAgreementMember_da6549d2-77e3-4bc2-91d1-9dedbefcc11d" xlink:href="exdx-20210630.xsd#exdx_JanssenPromotionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a51bad19-ff16-4bf3-b252-8650af96a23d" xlink:to="loc_exdx_JanssenPromotionAgreementMember_da6549d2-77e3-4bc2-91d1-9dedbefcc11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3a9781f8-1d08-444a-8186-c5a1372c8275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3a9781f8-1d08-444a-8186-c5a1372c8275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d83bc8e8-1be9-4c01-986e-5741aedeb5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_3a9781f8-1d08-444a-8186-c5a1372c8275" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d83bc8e8-1be9-4c01-986e-5741aedeb5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_TwoMajorSuppliersMember_36991f2d-1d99-4a7b-a434-c0e96cdc97eb" xlink:href="exdx-20210630.xsd#exdx_TwoMajorSuppliersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_d83bc8e8-1be9-4c01-986e-5741aedeb5a8" xlink:to="loc_exdx_TwoMajorSuppliersMember_36991f2d-1d99-4a7b-a434-c0e96cdc97eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b46bbc5e-c4e4-4fda-b044-3e233094fd92" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_cd8a0a92-62f4-46c4-80c8-8aa7f7c79b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_cd8a0a92-62f4-46c4-80c8-8aa7f7c79b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d527074e-260c-4ec7-9d78-750ed93284b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_RestrictedCash_d527074e-260c-4ec7-9d78-750ed93284b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_b03ccbd0-459c-4ff2-a9c3-c71a370b1d51" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFeePerPrescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeePerPrescription_b03ccbd0-459c-4ff2-a9c3-c71a370b1d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFee_c3ea0b63-d514-4be3-86cb-dbb1d76ee2bd" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFee_c3ea0b63-d514-4be3-86cb-dbb1d76ee2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_2da47893-c579-45b7-8e5c-5e933b577e6d" xlink:href="exdx-20210630.xsd#exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline_2da47893-c579-45b7-8e5c-5e933b577e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JointVentureTerminationConsiderationReceivable_3f9caad2-2b57-4b43-8268-b23520cef7ec" xlink:href="exdx-20210630.xsd#exdx_JointVentureTerminationConsiderationReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_exdx_JointVentureTerminationConsiderationReceivable_3f9caad2-2b57-4b43-8268-b23520cef7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_760d8c28-7e2f-419d-a325-f9615e471c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_760d8c28-7e2f-419d-a325-f9615e471c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_617f3874-ec7d-4f0d-856a-e8d29cded001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_AdvertisingExpense_617f3874-ec7d-4f0d-856a-e8d29cded001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_63f6efd9-f1e3-4e08-aa52-2b4944cb5b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_CostOfRevenue_63f6efd9-f1e3-4e08-aa52-2b4944cb5b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0012a700-1d36-44fc-91c3-1147c014eaee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0012a700-1d36-44fc-91c3-1147c014eaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c56c17f9-b0df-4a77-b464-feb8f90dd05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_76c4167e-86b0-4f3c-9f7a-ee84f8094c21" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c56c17f9-b0df-4a77-b464-feb8f90dd05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_60ff43e9-02d1-4da3-815d-b96df45e7ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a6ce373a-00c0-4c22-8b62-4a8d2deea5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_60ff43e9-02d1-4da3-815d-b96df45e7ee6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a6ce373a-00c0-4c22-8b62-4a8d2deea5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dcb022be-b228-4ae5-90bb-494c482379f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6ce373a-00c0-4c22-8b62-4a8d2deea5a8" xlink:to="loc_srt_MajorCustomersAxis_dcb022be-b228-4ae5-90bb-494c482379f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_dcb022be-b228-4ae5-90bb-494c482379f5" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_HealthcareInsurersMember_dfe8c46b-2f7e-4174-9882-5108e6d6bec5" xlink:href="exdx-20210630.xsd#exdx_HealthcareInsurersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_exdx_HealthcareInsurersMember_dfe8c46b-2f7e-4174-9882-5108e6d6bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Government1Member_ca2492f1-ef37-4987-88a8-adfc4a3feacb" xlink:href="exdx-20210630.xsd#exdx_Government1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_exdx_Government1Member_ca2492f1-ef37-4987-88a8-adfc4a3feacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClientMember_a8f1d915-b144-4f3a-b022-1e0be1d29228" xlink:href="exdx-20210630.xsd#exdx_ClientMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_exdx_ClientMember_a8f1d915-b144-4f3a-b022-1e0be1d29228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCustomerMember_e4f66c80-e946-4562-9d94-a4b9c1ae3f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCustomerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_us-gaap_OtherCustomerMember_e4f66c80-e946-4562-9d94-a4b9c1ae3f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_JanssenSIMPONIMember_69728f0b-eed8-454a-acdb-45013f368d2d" xlink:href="exdx-20210630.xsd#exdx_JanssenSIMPONIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b11203d-e48a-47a6-b0da-12e4c0c1d8ad" xlink:to="loc_exdx_JanssenSIMPONIMember_69728f0b-eed8-454a-acdb-45013f368d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_20f6db55-0f4f-4a2e-b7fb-3f07281e4ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a6ce373a-00c0-4c22-8b62-4a8d2deea5a8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_20f6db55-0f4f-4a2e-b7fb-3f07281e4ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c481c287-9f0c-4ea8-ae36-a5cd58d187a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_20f6db55-0f4f-4a2e-b7fb-3f07281e4ae5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c481c287-9f0c-4ea8-ae36-a5cd58d187a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_787ba05b-3de7-47f1-a453-c2ae0bbbfb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f14c62b9-42f4-493c-916d-77730798e86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_787ba05b-3de7-47f1-a453-c2ae0bbbfb97" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f14c62b9-42f4-493c-916d-77730798e86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_5d202147-6530-4c17-b4d7-ef41f51570fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_787ba05b-3de7-47f1-a453-c2ae0bbbfb97" xlink:to="loc_us-gaap_RestrictedCash_5d202147-6530-4c17-b4d7-ef41f51570fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10083cd7-eb40-4de9-8edb-becfd3cbabe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_787ba05b-3de7-47f1-a453-c2ae0bbbfb97" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10083cd7-eb40-4de9-8edb-becfd3cbabe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#SummaryofSignificantAccountingPoliciesSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b5d6df65-5622-4a4a-a501-8eb1de9286b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ac997e3f-1b81-43e5-ae33-fd58e777ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b5d6df65-5622-4a4a-a501-8eb1de9286b8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ac997e3f-1b81-43e5-ae33-fd58e777ccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab5a7ea1-4712-4eba-8bb8-383dbf04d287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ac997e3f-1b81-43e5-ae33-fd58e777ccb3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab5a7ea1-4712-4eba-8bb8-383dbf04d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab5a7ea1-4712-4eba-8bb8-383dbf04d287" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_04ff2892-a23d-4790-a3ee-4dcc8fc421ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:to="loc_us-gaap_WarrantMember_04ff2892-a23d-4790-a3ee-4dcc8fc421ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_f63e91f1-bdcc-442f-b0eb-edf185ff96f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:to="loc_us-gaap_StockOptionMember_f63e91f1-bdcc-442f-b0eb-edf185ff96f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_25807057-0ba7-4376-80e0-528fd471daa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_25807057-0ba7-4376-80e0-528fd471daa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3e69e156-4ee6-4777-9e08-5fad63e11c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ad799a4-e648-42cb-a1c6-fe0431ce5c3c" xlink:to="loc_us-gaap_EmployeeStockMember_3e69e156-4ee6-4777-9e08-5fad63e11c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f2e57746-5ffa-46c2-ab98-660054b29bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ac997e3f-1b81-43e5-ae33-fd58e777ccb3" xlink:to="loc_us-gaap_ClassOfStockLineItems_f2e57746-5ffa-46c2-ab98-660054b29bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21a72279-80a2-45b2-98c9-96cc747345eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f2e57746-5ffa-46c2-ab98-660054b29bb6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21a72279-80a2-45b2-98c9-96cc747345eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_93e855b2-0773-4e69-8274-694b28a7f4d2" xlink:href="exdx-20210630.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_1e588bc2-40bf-4a8f-86da-9baf6a9422ac" xlink:href="exdx-20210630.xsd#exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_93e855b2-0773-4e69-8274-694b28a7f4d2" xlink:to="loc_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock_1e588bc2-40bf-4a8f-86da-9baf6a9422ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_7fbcd583-ce90-4b5d-8b59-01c60a013ac5" xlink:href="exdx-20210630.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_38a7e167-d6b0-4095-a5cd-cd352c99eed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_7fbcd583-ce90-4b5d-8b59-01c60a013ac5" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_38a7e167-d6b0-4095-a5cd-cd352c99eed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9768d1ec-a517-4c44-89ac-b302a9f3ee7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_7fbcd583-ce90-4b5d-8b59-01c60a013ac5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9768d1ec-a517-4c44-89ac-b302a9f3ee7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_923c8fd6-b6f6-417d-b1d6-e1bcc31fcfee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_7fbcd583-ce90-4b5d-8b59-01c60a013ac5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_923c8fd6-b6f6-417d-b1d6-e1bcc31fcfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationPrepaidexpensesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_612e20c7-0003-4671-8883-28896d206e37" xlink:href="exdx-20210630.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6643ad64-5e87-4424-8178-d162de29766c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_612e20c7-0003-4671-8883-28896d206e37" xlink:to="loc_us-gaap_OtherAssetsCurrent_6643ad64-5e87-4424-8178-d162de29766c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRoyalties_b67a4383-3912-47f9-aed7-879f037af602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_612e20c7-0003-4671-8883-28896d206e37" xlink:to="loc_us-gaap_PrepaidRoyalties_b67a4383-3912-47f9-aed7-879f037af602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_caf91fb5-364f-44f8-bfbd-7151d14aeccd" xlink:href="exdx-20210630.xsd#exdx_PrepaidMaintenanceAndInsuranceContracts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_612e20c7-0003-4671-8883-28896d206e37" xlink:to="loc_exdx_PrepaidMaintenanceAndInsuranceContracts_caf91fb5-364f-44f8-bfbd-7151d14aeccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_dbcd5166-2033-4927-8bee-3d95472ed845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_612e20c7-0003-4671-8883-28896d206e37" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_dbcd5166-2033-4927-8bee-3d95472ed845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2194d9da-805f-47bf-8cad-d84647f53fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_612e20c7-0003-4671-8883-28896d206e37" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2194d9da-805f-47bf-8cad-d84647f53fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationPropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_fe43395b-967a-4809-8eea-16ce21e64ac6" xlink:href="exdx-20210630.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7f94bf24-eccf-453c-8136-d7b6540f46e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_fe43395b-967a-4809-8eea-16ce21e64ac6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7f94bf24-eccf-453c-8136-d7b6540f46e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47e60fcf-763a-41ae-a621-7e94dd8955f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7f94bf24-eccf-453c-8136-d7b6540f46e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47e60fcf-763a-41ae-a621-7e94dd8955f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47e60fcf-763a-41ae-a621-7e94dd8955f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_57d1c114-105d-4cac-a988-6b249b316ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_57d1c114-105d-4cac-a988-6b249b316ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LaboratoryEquipmentMember_fa37f428-cd25-4ff5-a1b4-e9d1ae9a71b2" xlink:href="exdx-20210630.xsd#exdx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_exdx_LaboratoryEquipmentMember_fa37f428-cd25-4ff5-a1b4-e9d1ae9a71b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ComputerEquipmentAndSoftwareMember_da136d4c-b581-4980-8d82-9a25a39fa665" xlink:href="exdx-20210630.xsd#exdx_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_exdx_ComputerEquipmentAndSoftwareMember_da136d4c-b581-4980-8d82-9a25a39fa665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_fd19188d-dac3-4755-a027-27fd384478b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_fd19188d-dac3-4755-a027-27fd384478b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_0d460686-a43c-4453-be14-01f79e87745d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c6697796-3c82-49ee-b4cd-3c5a98fa56bb" xlink:to="loc_us-gaap_ConstructionInProgressMember_0d460686-a43c-4453-be14-01f79e87745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7f94bf24-eccf-453c-8136-d7b6540f46e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_66fb5169-1a87-4d82-a2d9-60b690560041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_66fb5169-1a87-4d82-a2d9-60b690560041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ace4bba-253d-4ce5-9cb9-caf5ec2f6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ace4bba-253d-4ce5-9cb9-caf5ec2f6e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7aef9419-9b53-45aa-b4e4-f1345408083a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7d262820-ad4d-43ab-bfa4-40e4ebbb0c50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7aef9419-9b53-45aa-b4e4-f1345408083a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_204a46c6-de75-4c1c-b7b3-d1c70cbce701" xlink:href="exdx-20210630.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de298ba0-18be-4c86-a376-76dd344f940e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_204a46c6-de75-4c1c-b7b3-d1c70cbce701" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de298ba0-18be-4c86-a376-76dd344f940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de298ba0-18be-4c86-a376-76dd344f940e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27ec0588-6742-49f5-a8f1-0d5288f1ded4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b359bd4f-3bc2-44e6-9b4d-8ca37cdfdc86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27ec0588-6742-49f5-a8f1-0d5288f1ded4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AssetsUnderCapitalLeaseMember_4122f990-c1a2-4bf2-9b06-48d1c4c507e5" xlink:href="exdx-20210630.xsd#exdx_AssetsUnderCapitalLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_27ec0588-6742-49f5-a8f1-0d5288f1ded4" xlink:to="loc_exdx_AssetsUnderCapitalLeaseMember_4122f990-c1a2-4bf2-9b06-48d1c4c507e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d48e8872-82f6-4168-83ef-ad4fb676e189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de298ba0-18be-4c86-a376-76dd344f940e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d48e8872-82f6-4168-83ef-ad4fb676e189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a2818a3b-3291-405c-bc4d-4987b7bf664d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d48e8872-82f6-4168-83ef-ad4fb676e189" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a2818a3b-3291-405c-bc4d-4987b7bf664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c96c3f99-21cd-4f26-9bb8-ffe61cdd3a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d48e8872-82f6-4168-83ef-ad4fb676e189" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c96c3f99-21cd-4f26-9bb8-ffe61cdd3a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:href="exdx-20210630.xsd#exdx_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_6c92d94d-8357-4775-83ef-5afcd06a5ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:to="loc_us-gaap_AccruedSalariesCurrent_6c92d94d-8357-4775-83ef-5afcd06a5ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_162391ef-5d06-4247-90b2-f4c187d10a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:to="loc_us-gaap_InterestPayableCurrent_162391ef-5d06-4247-90b2-f4c187d10a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_8fcdd955-4097-455e-8b37-f39d1eb0218e" xlink:href="exdx-20210630.xsd#exdx_AccruedPurchaseGoodsAndServicesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:to="loc_exdx_AccruedPurchaseGoodsAndServicesCurrent_8fcdd955-4097-455e-8b37-f39d1eb0218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_90ffb142-6674-4417-b13a-3edf0e3ada1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_90ffb142-6674-4417-b13a-3edf0e3ada1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_a48158dd-64b0-4f17-abe4-104da7df4647" xlink:href="exdx-20210630.xsd#exdx_AccruedLiabilitiesClinicalStudyCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:to="loc_exdx_AccruedLiabilitiesClinicalStudyCurrent_a48158dd-64b0-4f17-abe4-104da7df4647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_dc7366cd-60fb-40fd-871f-d1fc425e9890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_dc7366cd-60fb-40fd-871f-d1fc425e9890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c424a294-b950-4ff3-b95f-0c7b3c56604f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c424a294-b950-4ff3-b95f-0c7b3c56604f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cf4709de-f943-4794-a224-0a7125da943d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_OtherFinancialInformationAbstract_b3948e04-2c63-465a-a950-b741b7056cc2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cf4709de-f943-4794-a224-0a7125da943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Borrowings" xlink:type="simple" xlink:href="exdx-20210630.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e140d3de-4650-4b98-b11c-46dae14d11ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_0ffe242d-d72c-406d-8430-632910517be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e140d3de-4650-4b98-b11c-46dae14d11ef" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_0ffe242d-d72c-406d-8430-632910517be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsTables" xlink:type="simple" xlink:href="exdx-20210630.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ed1bd9e1-d0b4-4ce1-b79d-982a13962c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3c4ea88e-0e39-47a5-b355-05921f304c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ed1bd9e1-d0b4-4ce1-b79d-982a13962c54" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3c4ea88e-0e39-47a5-b355-05921f304c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_32addda8-1c85-43c5-a1a5-acbf457cba0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_32addda8-1c85-43c5-a1a5-acbf457cba0a" xlink:to="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e3c34dec-7f55-4935-a953-dc538a549e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:to="loc_us-gaap_DebtInstrumentAxis_e3c34dec-7f55-4935-a953-dc538a549e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a54637a4-d677-41cb-860c-5cdd56998310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e3c34dec-7f55-4935-a953-dc538a549e62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a54637a4-d677-41cb-860c-5cdd56998310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_Term2017Member_a19bfc83-5de3-47e8-98f3-5808e5e3e1ae" xlink:href="exdx-20210630.xsd#exdx_Term2017Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a54637a4-d677-41cb-860c-5cdd56998310" xlink:to="loc_exdx_Term2017Member_a19bfc83-5de3-47e8-98f3-5808e5e3e1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f40bd876-2532-4f5a-b505-1a7c3d008f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f40bd876-2532-4f5a-b505-1a7c3d008f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8683256a-885a-4e93-89f7-289009453508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f40bd876-2532-4f5a-b505-1a7c3d008f18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8683256a-885a-4e93-89f7-289009453508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_3f36f7e8-35f8-4d1f-9ff0-5f5fe2f7498b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8683256a-885a-4e93-89f7-289009453508" xlink:to="loc_us-gaap_LoansPayableMember_3f36f7e8-35f8-4d1f-9ff0-5f5fe2f7498b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentInKindPIKNoteMember_b7c3e689-a5f6-4a3c-ac2e-c87a30eb2355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentInKindPIKNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8683256a-885a-4e93-89f7-289009453508" xlink:to="loc_us-gaap_PaymentInKindPIKNoteMember_b7c3e689-a5f6-4a3c-ac2e-c87a30eb2355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_621e7790-e9b6-4832-9b45-9962e3b0cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_621e7790-e9b6-4832-9b45-9962e3b0cc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea482488-d017-4a1f-81d6-b1ab5dbe9cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_621e7790-e9b6-4832-9b45-9962e3b0cc55" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea482488-d017-4a1f-81d6-b1ab5dbe9cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_InnovatusLifeSciencesLendingFundMember_205baf15-5748-4305-9b02-bd0541b18979" xlink:href="exdx-20210630.xsd#exdx_InnovatusLifeSciencesLendingFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea482488-d017-4a1f-81d6-b1ab5dbe9cef" xlink:to="loc_exdx_InnovatusLifeSciencesLendingFundMember_205baf15-5748-4305-9b02-bd0541b18979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CapitalRoyaltyPartnersIILPMember_984dc737-399a-491a-9bfe-0823a804391a" xlink:href="exdx-20210630.xsd#exdx_CapitalRoyaltyPartnersIILPMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_ea482488-d017-4a1f-81d6-b1ab5dbe9cef" xlink:to="loc_exdx_CapitalRoyaltyPartnersIILPMember_984dc737-399a-491a-9bfe-0823a804391a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_acb82ada-b8a1-4421-9c2a-8b027f827666" xlink:to="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f28e3d03-3957-41ca-95d4-826b0d272b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f28e3d03-3957-41ca-95d4-826b0d272b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f0b88ef0-52ed-4580-a121-e3587cc42a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f0b88ef0-52ed-4580-a121-e3587cc42a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_debee391-e351-4ef7-9f1a-19109380f414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_debee391-e351-4ef7-9f1a-19109380f414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_e40b7978-5e46-4083-975a-a9048f872add" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentStatedInterestRatePaidInKind"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentStatedInterestRatePaidInKind_e40b7978-5e46-4083-975a-a9048f872add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78eb1b59-ca8b-4f47-964a-67135f5f21c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_78eb1b59-ca8b-4f47-964a-67135f5f21c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_0467e9ff-74c5-430d-94f6-ca1986c741c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentTerm_0467e9ff-74c5-430d-94f6-ca1986c741c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_3b08dd8e-ce39-488d-bfab-bc5be21d4171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_3b08dd8e-ce39-488d-bfab-bc5be21d4171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPaidInKindLoansIssued_2a961fc1-0897-4f61-85e4-3e50becb95b2" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPaidInKindLoansIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentPaidInKindLoansIssued_2a961fc1-0897-4f61-85e4-3e50becb95b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_f065f639-a5d9-413d-a88d-f20d13e7e417" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentage_f065f639-a5d9-413d-a88d-f20d13e7e417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_7ce4eb16-34aa-4313-99f7-51d17dbb959a" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction_7ce4eb16-34aa-4313-99f7-51d17dbb959a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_769e1ef1-95fb-4cbd-b690-12790cc5f614" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance_769e1ef1-95fb-4cbd-b690-12790cc5f614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_837c1bf3-7f4e-4408-ad63-1fa69d52e903" xlink:href="exdx-20210630.xsd#exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_67e2b15e-0687-4450-b5d8-30f419782d77" xlink:to="loc_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease_837c1bf3-7f4e-4408-ad63-1fa69d52e903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#BorrowingsFutureminimumpaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_dcb1da75-4140-48ac-b949-184d01041ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_dcb1da75-4140-48ac-b949-184d01041ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c1dcadb5-cbbe-4cba-a612-10c6e3615968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c1dcadb5-cbbe-4cba-a612-10c6e3615968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4c3a6bbb-d254-4d46-ad41-2bbf6785aae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4c3a6bbb-d254-4d46-ad41-2bbf6785aae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7fb05aea-5fe8-46a9-9612-1ac57372eef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7fb05aea-5fe8-46a9-9612-1ac57372eef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtIncludingUndiscountedInterest_a553c08f-fb5e-4ddf-8ea0-9580b2001476" xlink:href="exdx-20210630.xsd#exdx_LongTermDebtIncludingUndiscountedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:to="loc_exdx_LongTermDebtIncludingUndiscountedInterest_a553c08f-fb5e-4ddf-8ea0-9580b2001476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c803c56a-5157-4e30-a1ed-7ebe8def7213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c803c56a-5157-4e30-a1ed-7ebe8def7213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LongTermDebtUndiscountedInterestAmount_7403e42b-91b3-4ac5-9bcb-2ee74634f2dc" xlink:href="exdx-20210630.xsd#exdx_LongTermDebtUndiscountedInterestAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:to="loc_exdx_LongTermDebtUndiscountedInterestAmount_7403e42b-91b3-4ac5-9bcb-2ee74634f2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d4bcf9a8-0642-463a-a8fc-cab9b695f051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e0167338-2eb0-4e03-9660-7bc6df77d5d9" xlink:to="loc_us-gaap_LongTermDebt_d4bcf9a8-0642-463a-a8fc-cab9b695f051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="exdx-20210630.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1c21cdd1-0d06-46d5-a3a5-37a4448c7883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d75a292a-e04b-471a-adc5-05122579fdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1c21cdd1-0d06-46d5-a3a5-37a4448c7883" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d75a292a-e04b-471a-adc5-05122579fdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#CommitmentandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6c04689-cef2-4f2a-89f4-60a3826c11ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6c04689-cef2-4f2a-89f4-60a3826c11ce" xlink:to="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeAxis_c780696c-a2e3-445d-91a5-b61e6073d754" xlink:href="exdx-20210630.xsd#exdx_RentalPropertyByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_exdx_RentalPropertyByTypeAxis_c780696c-a2e3-445d-91a5-b61e6073d754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RentalPropertyByTypeDomain_4d25487f-0b8f-48c2-9704-9f4e1738b0f5" xlink:href="exdx-20210630.xsd#exdx_RentalPropertyByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeAxis_c780696c-a2e3-445d-91a5-b61e6073d754" xlink:to="loc_exdx_RentalPropertyByTypeDomain_4d25487f-0b8f-48c2-9704-9f4e1738b0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeAndLaboratoryMember_abdf6714-6223-442a-bdae-83f872a888d2" xlink:href="exdx-20210630.xsd#exdx_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_4d25487f-0b8f-48c2-9704-9f4e1738b0f5" xlink:to="loc_exdx_OfficeAndLaboratoryMember_abdf6714-6223-442a-bdae-83f872a888d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OfficeMember_a99d29ab-0155-436f-bc4b-cc3d3ae3cbe6" xlink:href="exdx-20210630.xsd#exdx_OfficeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exdx_RentalPropertyByTypeDomain_4d25487f-0b8f-48c2-9704-9f4e1738b0f5" xlink:to="loc_exdx_OfficeMember_a99d29ab-0155-436f-bc4b-cc3d3ae3cbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8cdedaf6-d4ff-4c25-942a-fdb236855638" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_srt_CounterpartyNameAxis_8cdedaf6-d4ff-4c25-942a-fdb236855638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_400892ed-e8af-4109-93bd-a228ca91a24a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8cdedaf6-d4ff-4c25-942a-fdb236855638" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_400892ed-e8af-4109-93bd-a228ca91a24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PrometheusLaboratoriesIncMember_2ee21751-5711-49dd-aa08-418c517297e9" xlink:href="exdx-20210630.xsd#exdx_PrometheusLaboratoriesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_400892ed-e8af-4109-93bd-a228ca91a24a" xlink:to="loc_exdx_PrometheusLaboratoriesIncMember_2ee21751-5711-49dd-aa08-418c517297e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_c9684119-da3a-44e0-a84e-0eb395716451" xlink:href="exdx-20210630.xsd#exdx_AlleghenyHealthNetworkResearchInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_400892ed-e8af-4109-93bd-a228ca91a24a" xlink:to="loc_exdx_AlleghenyHealthNetworkResearchInstituteMember_c9684119-da3a-44e0-a84e-0eb395716451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c398b746-af03-4d68-b99f-50b0a1f4c864" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_srt_RangeAxis_c398b746-af03-4d68-b99f-50b0a1f4c864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29f3823d-4aa1-42cc-a806-cc0493c2ad47" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c398b746-af03-4d68-b99f-50b0a1f4c864" xlink:to="loc_srt_RangeMember_29f3823d-4aa1-42cc-a806-cc0493c2ad47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bba91061-51e6-40ed-b30d-8814853e0555" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_29f3823d-4aa1-42cc-a806-cc0493c2ad47" xlink:to="loc_srt_MinimumMember_bba91061-51e6-40ed-b30d-8814853e0555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59437dc5-21b9-49b3-92fc-95f1f5540c01" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_29f3823d-4aa1-42cc-a806-cc0493c2ad47" xlink:to="loc_srt_MaximumMember_59437dc5-21b9-49b3-92fc-95f1f5540c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a924536-7bcf-4223-8421-eb70bd1785ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a924536-7bcf-4223-8421-eb70bd1785ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38f30789-9720-4004-b2da-059b8a0054cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a924536-7bcf-4223-8421-eb70bd1785ce" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38f30789-9720-4004-b2da-059b8a0054cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_4e98f4e2-7374-4696-bb62-728565e4d657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_38f30789-9720-4004-b2da-059b8a0054cb" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_4e98f4e2-7374-4696-bb62-728565e4d657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d1f7654f-ed66-49b5-9fb3-295ae3021be9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d1f7654f-ed66-49b5-9fb3-295ae3021be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afc6c413-b110-47af-954e-9b482f8e6c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d1f7654f-ed66-49b5-9fb3-295ae3021be9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afc6c413-b110-47af-954e-9b482f8e6c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AHNCollaborationMember_70bbaea8-c24d-447a-8f36-3be90c92a508" xlink:href="exdx-20210630.xsd#exdx_AHNCollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afc6c413-b110-47af-954e-9b482f8e6c4c" xlink:to="loc_exdx_AHNCollaborationMember_70bbaea8-c24d-447a-8f36-3be90c92a508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_65e6dce6-e7e4-4070-8da2-3bbe1751e648" xlink:to="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_OperatingLeasesRenewalTerm_d63dbe08-7326-4b36-84ad-aa430604ab7f" xlink:href="exdx-20210630.xsd#exdx_OperatingLeasesRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_OperatingLeasesRenewalTerm_d63dbe08-7326-4b36-84ad-aa430604ab7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_59480360-8d54-4f32-8ad5-b128d792a5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_LeaseAndRentalExpense_59480360-8d54-4f32-8ad5-b128d792a5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneObligation_81462fe6-8555-46ab-bad6-6ea584181461" xlink:href="exdx-20210630.xsd#exdx_MilestoneObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_MilestoneObligation_81462fe6-8555-46ab-bad6-6ea584181461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_MilestoneContingencyFairValueDisclosure_d266bd3d-1ca2-42d2-afe1-cf0f508b6ac5" xlink:href="exdx-20210630.xsd#exdx_MilestoneContingencyFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_MilestoneContingencyFairValueDisclosure_d266bd3d-1ca2-42d2-afe1-cf0f508b6ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_RoyaltyObligationPercentageOfSales_ae0edbbc-3618-4c52-82fc-c5d084173901" xlink:href="exdx-20210630.xsd#exdx_RoyaltyObligationPercentageOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_RoyaltyObligationPercentageOfSales_ae0edbbc-3618-4c52-82fc-c5d084173901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_9c58af9c-210d-4672-aa76-b471cfb72968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_9c58af9c-210d-4672-aa76-b471cfb72968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_AdvancePayment_fb3e8f06-f04c-4a48-8f48-921fe4367c66" xlink:href="exdx-20210630.xsd#exdx_AdvancePayment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_AdvancePayment_fb3e8f06-f04c-4a48-8f48-921fe4367c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_LicenseAgreementInitialLicenseFee_96641279-6e9e-4c90-9771-59ac83a378f3" xlink:href="exdx-20210630.xsd#exdx_LicenseAgreementInitialLicenseFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_LicenseAgreementInitialLicenseFee_96641279-6e9e-4c90-9771-59ac83a378f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_1a3d9cec-2cd5-4026-96df-b4a550983196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_1a3d9cec-2cd5-4026-96df-b4a550983196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4fe59fe1-06bc-440f-ba10-4ace42123195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4fe59fe1-06bc-440f-ba10-4ace42123195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_e75c2d2b-047d-4837-97cf-a12d0958bed3" xlink:href="exdx-20210630.xsd#exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage_e75c2d2b-047d-4837-97cf-a12d0958bed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementAnnualCollaborationFee_893829f3-3a63-4b95-bce1-dbad450a45a8" xlink:href="exdx-20210630.xsd#exdx_CollaborationAgreementAnnualCollaborationFee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_CollaborationAgreementAnnualCollaborationFee_893829f3-3a63-4b95-bce1-dbad450a45a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CollaborationAgreementCollaborationExpenses_94c33274-454e-4bfb-b75f-686303098671" xlink:href="exdx-20210630.xsd#exdx_CollaborationAgreementCollaborationExpenses"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ea68c4a-02f8-4d44-94e3-227850e3d273" xlink:to="loc_exdx_CollaborationAgreementCollaborationExpenses_94c33274-454e-4bfb-b75f-686303098671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exdx-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_41629114-a046-41a4-9990-4b38e37a4bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ec1bbda6-3657-4b9c-b01a-97f673026b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_41629114-a046-41a4-9990-4b38e37a4bf2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ec1bbda6-3657-4b9c-b01a-97f673026b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exdx-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8d92be74-6d33-465b-a9b6-1c062f3ae439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5d2c1d65-af1c-407b-8dba-a9348b9622a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d92be74-6d33-465b-a9b6-1c062f3ae439" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5d2c1d65-af1c-407b-8dba-a9348b9622a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_234a089c-7f44-48b2-b581-4ec3306951e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_234a089c-7f44-48b2-b581-4ec3306951e9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c061db4-661a-4bfa-86bf-5bd0c697dd59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c061db4-661a-4bfa-86bf-5bd0c697dd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b18d8025-3ada-4162-b184-eb04bd8dd319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9c061db4-661a-4bfa-86bf-5bd0c697dd59" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b18d8025-3ada-4162-b184-eb04bd8dd319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e3460755-9330-43aa-93d0-a2310337f3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b18d8025-3ada-4162-b184-eb04bd8dd319" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e3460755-9330-43aa-93d0-a2310337f3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37ef64e0-acf0-4863-a34a-11a36581b373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37ef64e0-acf0-4863-a34a-11a36581b373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37ef64e0-acf0-4863-a34a-11a36581b373" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7d63fec2-f8e7-46c1-943e-06f45842c11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7d63fec2-f8e7-46c1-943e-06f45842c11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_22a4217b-9ebc-4cf2-a6ee-e708bbbd7e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_22a4217b-9ebc-4cf2-a6ee-e708bbbd7e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3d8804e3-0ee1-40ed-b4e3-f191f4a9c0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5279a560-bd5a-4d0b-b8cf-d7dc9032b1cf" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3d8804e3-0ee1-40ed-b4e3-f191f4a9c0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9fa9d400-d1fb-4be1-b9f7-52231e8aea68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9fa9d400-d1fb-4be1-b9f7-52231e8aea68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4938202e-1709-49f1-8410-70fc1d59637b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9fa9d400-d1fb-4be1-b9f7-52231e8aea68" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4938202e-1709-49f1-8410-70fc1d59637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c49eb64f-1139-48b3-91c8-c9e4ea0b5600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4938202e-1709-49f1-8410-70fc1d59637b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c49eb64f-1139-48b3-91c8-c9e4ea0b5600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_50b8a878-5da3-48c4-86f9-843303068cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_6a811b97-e991-477d-9000-a9ab4228b633" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_50b8a878-5da3-48c4-86f9-843303068cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_e72cd5b8-b0bb-426d-8e1a-9304741da29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_50b8a878-5da3-48c4-86f9-843303068cee" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_e72cd5b8-b0bb-426d-8e1a-9304741da29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09ea8f15-2484-440c-8fcf-c7f392299e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_e72cd5b8-b0bb-426d-8e1a-9304741da29a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09ea8f15-2484-440c-8fcf-c7f392299e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f15be603-2f1f-4c47-8615-da67d3283d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_27b8c9f0-5703-4e87-b49d-11117a872200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f15be603-2f1f-4c47-8615-da67d3283d04" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_27b8c9f0-5703-4e87-b49d-11117a872200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_527a6ebe-6183-4576-8616-02d1a06a15f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_311a7290-5ec5-4c39-82d1-75bcb87d2a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_527a6ebe-6183-4576-8616-02d1a06a15f1" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_311a7290-5ec5-4c39-82d1-75bcb87d2a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b5324995-c2d4-4898-bf90-ce29750698d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b5324995-c2d4-4898-bf90-ce29750698d8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_13d3070c-d3ba-47f6-b855-69116a4a8dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_13d3070c-d3ba-47f6-b855-69116a4a8dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73d2b74a-7dcf-441c-a952-1297d7d95099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_13d3070c-d3ba-47f6-b855-69116a4a8dc1" xlink:to="loc_us-gaap_EquityComponentDomain_73d2b74a-7dcf-441c-a952-1297d7d95099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_38b24a2b-0362-4067-8604-ca7cc5a8fd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_73d2b74a-7dcf-441c-a952-1297d7d95099" xlink:to="loc_us-gaap_CommonStockMember_38b24a2b-0362-4067-8604-ca7cc5a8fd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7c32642b-ded9-4e90-882d-fc1c5ce841df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7c32642b-ded9-4e90-882d-fc1c5ce841df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5f95b64-d62c-46fa-aa8b-b1d85bccbf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7c32642b-ded9-4e90-882d-fc1c5ce841df" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5f95b64-d62c-46fa-aa8b-b1d85bccbf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_d8e38a1d-63fe-4974-a337-c7d6d38564e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5f95b64-d62c-46fa-aa8b-b1d85bccbf2d" xlink:to="loc_us-gaap_IPOMember_d8e38a1d-63fe-4974-a337-c7d6d38564e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:to="loc_srt_CounterpartyNameAxis_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00f42447-08ca-4c7e-9c93-b1ee468a958b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8ce5f12e-6b9a-484f-be35-0b9ec7fe6274" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00f42447-08ca-4c7e-9c93-b1ee468a958b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangingStockholdersMember_f0294209-8719-4782-9d1c-0ace0bbe579d" xlink:href="exdx-20210630.xsd#exdx_ExchangingStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00f42447-08ca-4c7e-9c93-b1ee468a958b" xlink:to="loc_exdx_ExchangingStockholdersMember_f0294209-8719-4782-9d1c-0ace0bbe579d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1ca5b97f-c0cf-4e4d-b98c-da18fb1cd7f5" xlink:to="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_783f72f9-54fa-4a67-b16a-5001410d63d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_783f72f9-54fa-4a67-b16a-5001410d63d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_34f52acc-75dd-40dd-a9f8-5c35306204f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_34f52acc-75dd-40dd-a9f8-5c35306204f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a9b96868-c6b8-4cdf-8401-da5be906f2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a9b96868-c6b8-4cdf-8401-da5be906f2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_StockIssuanceCosts_728d7202-8299-4b38-b2bb-a3feb4659eca" xlink:href="exdx-20210630.xsd#exdx_StockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_exdx_StockIssuanceCosts_728d7202-8299-4b38-b2bb-a3feb4659eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_f65b31d8-e825-4ef7-84f6-8f909b234d02" xlink:href="exdx-20210630.xsd#exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants_f65b31d8-e825-4ef7-84f6-8f909b234d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_417513d1-f72e-4022-bf9e-4095333e8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_417513d1-f72e-4022-bf9e-4095333e8a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20fa1868-4c7a-4be5-b3ea-23f6a405b5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20fa1868-4c7a-4be5-b3ea-23f6a405b5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_4b87bf37-e4f9-48cc-86a2-a1f8f050fda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_4b87bf37-e4f9-48cc-86a2-a1f8f050fda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_b4fdb756-a77f-415e-b467-8cadfd8a4589" xlink:href="exdx-20210630.xsd#exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e34e5ed9-dbfb-459a-88cf-2891cd6d6455" xlink:to="loc_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised_b4fdb756-a77f-415e-b467-8cadfd8a4589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a47803e1-b9b9-497d-b290-d09634fbbcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fbb1677f-db40-4029-b499-e4113a42d452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a47803e1-b9b9-497d-b290-d09634fbbcb5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fbb1677f-db40-4029-b499-e4113a42d452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_c3d37f83-3beb-4684-9eb5-98614fb5b000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fbb1677f-db40-4029-b499-e4113a42d452" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_c3d37f83-3beb-4684-9eb5-98614fb5b000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_c3d37f83-3beb-4684-9eb5-98614fb5b000" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationJan192026Member_fa0cdf99-2f2f-4929-be39-eafa8e3142d8" xlink:href="exdx-20210630.xsd#exdx_ExpirationJan192026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationJan192026Member_fa0cdf99-2f2f-4929-be39-eafa8e3142d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationMar312026Member_88db5dcc-5c09-4235-a42b-68f1deff9c49" xlink:href="exdx-20210630.xsd#exdx_ExpirationMar312026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationMar312026Member_88db5dcc-5c09-4235-a42b-68f1deff9c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationApr12026Member_40669906-6c4f-4ff1-a7f2-01a40eb39917" xlink:href="exdx-20210630.xsd#exdx_ExpirationApr12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationApr12026Member_40669906-6c4f-4ff1-a7f2-01a40eb39917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationSep72024Member_b727bb9b-147b-4ece-a06c-2a8d7fa11781" xlink:href="exdx-20210630.xsd#exdx_ExpirationSep72024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationSep72024Member_b727bb9b-147b-4ece-a06c-2a8d7fa11781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ExpirationDec72025Member_0d19d05e-bc72-4cb0-827b-d1e23030c865" xlink:href="exdx-20210630.xsd#exdx_ExpirationDec72025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_ExpirationDec72025Member_0d19d05e-bc72-4cb0-827b-d1e23030c865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_NoExpirationMember_0b422394-6240-4a5e-a3f9-3c519f17fd3f" xlink:href="exdx-20210630.xsd#exdx_NoExpirationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9a7ab9e3-2814-4835-b0eb-1090955a81c8" xlink:to="loc_exdx_NoExpirationMember_0b422394-6240-4a5e-a3f9-3c519f17fd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ed75470a-753d-4117-9d41-41ca7c06371b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fbb1677f-db40-4029-b499-e4113a42d452" xlink:to="loc_us-gaap_ClassOfStockLineItems_ed75470a-753d-4117-9d41-41ca7c06371b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_50b2c373-4d5f-408a-a36d-dc0ba278b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ed75470a-753d-4117-9d41-41ca7c06371b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_50b2c373-4d5f-408a-a36d-dc0ba278b2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8c13f1d0-c143-4052-8f20-ee78dc1ed3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ed75470a-753d-4117-9d41-41ca7c06371b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8c13f1d0-c143-4052-8f20-ee78dc1ed3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlan" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlan"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236aa5e6-afc8-4f54-b9b6-a0a9478179e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b961afc-0129-4d16-93b0-65405caad6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_236aa5e6-afc8-4f54-b9b6-a0a9478179e9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b961afc-0129-4d16-93b0-65405caad6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanTables"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6fac93f-f07c-4538-a174-c647d2c30852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6754bfc2-01bc-4080-b74a-2c05accd406f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6fac93f-f07c-4538-a174-c647d2c30852" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6754bfc2-01bc-4080-b74a-2c05accd406f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_31379d73-9d63-40bf-a1eb-6dc27bf00b85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6fac93f-f07c-4538-a174-c647d2c30852" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_31379d73-9d63-40bf-a1eb-6dc27bf00b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f92cebb2-0127-4516-a8d8-c3a9dc7eb6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6fac93f-f07c-4538-a174-c647d2c30852" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f92cebb2-0127-4516-a8d8-c3a9dc7eb6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_09d745ff-80bb-46db-a15d-c0d3ba1c8018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6fac93f-f07c-4538-a174-c647d2c30852" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_09d745ff-80bb-46db-a15d-c0d3ba1c8018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c0e052b7-9160-43de-835b-d831497badba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a6fac93f-f07c-4538-a174-c647d2c30852" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c0e052b7-9160-43de-835b-d831497badba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0252b45-2081-4060-a1f6-dc965a590bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0252b45-2081-4060-a1f6-dc965a590bcb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:to="loc_us-gaap_PlanNameAxis_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_34c6db93-c765-43d8-afb2-e6cd15701d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f4a78d66-ba6d-44be-9b7e-25b8f5c72a30" xlink:to="loc_us-gaap_PlanNameDomain_34c6db93-c765-43d8-afb2-e6cd15701d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_IncentiveAwardPlan2019Member_3412cd2b-3a79-41c8-bb6b-8ab47df2c856" xlink:href="exdx-20210630.xsd#exdx_IncentiveAwardPlan2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_34c6db93-c765-43d8-afb2-e6cd15701d08" xlink:to="loc_exdx_IncentiveAwardPlan2019Member_3412cd2b-3a79-41c8-bb6b-8ab47df2c856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3d05e231-8422-43ea-a3b5-8547d8b63a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:to="loc_us-gaap_AwardTypeAxis_3d05e231-8422-43ea-a3b5-8547d8b63a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3d05e231-8422-43ea-a3b5-8547d8b63a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_15159906-3c7c-4ce0-8f2b-66549f765998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_15159906-3c7c-4ce0-8f2b-66549f765998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_4e5e50d2-a412-45c9-bb2e-ba3746c2834d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:to="loc_us-gaap_EmployeeStockMember_4e5e50d2-a412-45c9-bb2e-ba3746c2834d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_413e02da-7223-4493-8004-66ee44109d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a9f8731-b09a-4b32-96ae-c6327d8152b8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_413e02da-7223-4493-8004-66ee44109d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd2f414-a760-4e32-8343-ffa217140044" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5bdac4a7-f55e-4959-87b6-528d48666b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5bdac4a7-f55e-4959-87b6-528d48666b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26a1a2f9-5b7a-469c-a954-d858f9ee8e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_26a1a2f9-5b7a-469c-a954-d858f9ee8e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2a931fd3-8abc-4c83-a99d-7ed713bf4e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2a931fd3-8abc-4c83-a99d-7ed713bf4e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_bd31c981-6414-4245-abf1-33d9f83b4e36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_bd31c981-6414-4245-abf1-33d9f83b4e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_32b8a096-8554-4597-b3b8-f6e13a5ac04f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_32b8a096-8554-4597-b3b8-f6e13a5ac04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a90f3843-171c-47e9-8081-b6ddd978c455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b5c2f81-20f3-4b9c-be0e-4114d0220c2e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a90f3843-171c-47e9-8081-b6ddd978c455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dd76a8d-f50b-4d98-b11a-fd28136bb081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11dbf955-338f-4ca5-95e5-e82a122d6d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7dd76a8d-f50b-4d98-b11a-fd28136bb081" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11dbf955-338f-4ca5-95e5-e82a122d6d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_404cd9e7-e702-480f-ad90-5ed2ed096cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11dbf955-338f-4ca5-95e5-e82a122d6d65" xlink:to="loc_us-gaap_AwardTypeAxis_404cd9e7-e702-480f-ad90-5ed2ed096cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6416c52c-d89d-4acd-a2f7-0ac3d520472f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_404cd9e7-e702-480f-ad90-5ed2ed096cd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6416c52c-d89d-4acd-a2f7-0ac3d520472f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e3c086f3-9e8a-4c1a-8853-8fec71f96e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6416c52c-d89d-4acd-a2f7-0ac3d520472f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e3c086f3-9e8a-4c1a-8853-8fec71f96e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_11dbf955-338f-4ca5-95e5-e82a122d6d65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_084280a9-86ae-4eae-a1c7-78e65f795e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_084280a9-86ae-4eae-a1c7-78e65f795e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4080d0fb-e572-4d75-aea1-3e0dffb481f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4080d0fb-e572-4d75-aea1-3e0dffb481f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ced1ece7-2742-4c87-b2eb-e3f037c3399a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ced1ece7-2742-4c87-b2eb-e3f037c3399a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3771922d-0e08-4d9b-bd96-f561beaf9c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3771922d-0e08-4d9b-bd96-f561beaf9c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_df7d1576-01f7-4447-8b78-1dbf67eca523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_df7d1576-01f7-4447-8b78-1dbf67eca523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_924fce82-3b4f-4720-a283-7f31036b5cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_85e7aa5a-5524-4e3a-a37b-8d4408a22f46" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_924fce82-3b4f-4720-a283-7f31036b5cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_68d85659-783d-4a45-961b-8c748f525611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_68d85659-783d-4a45-961b-8c748f525611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ead7246e-b2a0-4d0d-8b35-b1ffcd09c333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ead7246e-b2a0-4d0d-8b35-b1ffcd09c333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9f40265d-b0a0-457f-b576-5e170fc2a1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9f40265d-b0a0-457f-b576-5e170fc2a1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57da47a4-552a-4db4-8bd9-960a2728a086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57da47a4-552a-4db4-8bd9-960a2728a086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ecdbb020-f9dd-4286-ba3c-aa13a90f966f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_ecdbb020-f9dd-4286-ba3c-aa13a90f966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_41ae6fd1-c499-48de-96a7-8f812653737f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e161db32-b837-431a-8cbb-9168d7194a61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_41ae6fd1-c499-48de-96a7-8f812653737f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a66e642c-3062-4a9b-8a34-7161a10fbe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a66e642c-3062-4a9b-8a34-7161a10fbe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bcd0445e-00c3-4314-8fcc-e439b39e3b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bcd0445e-00c3-4314-8fcc-e439b39e3b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_879c52d1-c1d8-4644-bb65-57b5e366f45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_879c52d1-c1d8-4644-bb65-57b5e366f45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b7c3c035-adf5-4c90-8e65-0a9d3784f42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b7c3c035-adf5-4c90-8e65-0a9d3784f42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bcc411c8-89f4-4789-845b-206f8f364d38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bcc411c8-89f4-4789-845b-206f8f364d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_924da5d7-5193-4038-80e4-d75719cf43a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_955d09ea-819b-49f0-88d7-93e3393d2c32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_924da5d7-5193-4038-80e4-d75719cf43a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_79440140-9cfc-4ba2-ac44-5d35622bdce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_79440140-9cfc-4ba2-ac44-5d35622bdce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ef895c7e-e42f-4f10-90ef-1c6a2f547854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_ef895c7e-e42f-4f10-90ef-1c6a2f547854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7661d870-8b24-483d-b7cc-33f07770fe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7661d870-8b24-483d-b7cc-33f07770fe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4c9cc528-7be2-41aa-8413-fec0386bb097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26ceb3cb-d3ac-4357-9960-5c3a167c6ae6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4c9cc528-7be2-41aa-8413-fec0386bb097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e345436d-1451-45bb-9348-7c8a049e03eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e53d90c2-5b2e-4b62-9a78-e380e97f8094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e345436d-1451-45bb-9348-7c8a049e03eb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e53d90c2-5b2e-4b62-9a78-e380e97f8094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f90782d8-4dac-4552-86da-b0b0ab74c1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e53d90c2-5b2e-4b62-9a78-e380e97f8094" xlink:to="loc_us-gaap_AwardTypeAxis_f90782d8-4dac-4552-86da-b0b0ab74c1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75dea5d7-d5d2-447f-83d6-1c8f933a340c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f90782d8-4dac-4552-86da-b0b0ab74c1d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75dea5d7-d5d2-447f-83d6-1c8f933a340c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5409e213-21c8-4aad-8547-c590276eae9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75dea5d7-d5d2-447f-83d6-1c8f933a340c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5409e213-21c8-4aad-8547-c590276eae9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e53d90c2-5b2e-4b62-9a78-e380e97f8094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f5595a1c-d92d-4ac7-ae69-27d003b5b8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f5595a1c-d92d-4ac7-ae69-27d003b5b8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a221e2f-e43a-4cd7-9ea7-c6fff9239398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4a221e2f-e43a-4cd7-9ea7-c6fff9239398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1c06caa-4973-4ca1-b82c-7c2588976571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f1c06caa-4973-4ca1-b82c-7c2588976571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6351fd05-7f80-43f7-b083-edf97b3dbb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6351fd05-7f80-43f7-b083-edf97b3dbb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_936b9090-d598-442f-bbf6-8de754e5f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98821450-4aaf-4ee1-8e32-04d28a7bbf45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_936b9090-d598-442f-bbf6-8de754e5f9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b4270e18-4c6a-45da-ac42-b68bfebcb685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b4270e18-4c6a-45da-ac42-b68bfebcb685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30feaae4-6e02-4e3e-b686-375d29787893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_30feaae4-6e02-4e3e-b686-375d29787893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7dca05ca-7647-4d79-9f11-80fb22ad1835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7dca05ca-7647-4d79-9f11-80fb22ad1835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_66bc9dfe-1171-4688-83c8-7238d9e517be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_66bc9dfe-1171-4688-83c8-7238d9e517be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6528e81-a32b-4ef8-83c0-c54a78475365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24fe2268-f2f4-4dba-b27a-741b75feb817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6528e81-a32b-4ef8-83c0-c54a78475365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_7dfe852a-f3e4-46f8-8dd4-0b2e5cf5d272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0331746d-596b-4865-971c-ead700ce6cc9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_7dfe852a-f3e4-46f8-8dd4-0b2e5cf5d272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_da4660fb-02de-4a6a-bdb2-e6ebfb2a6131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_7dfe852a-f3e4-46f8-8dd4-0b2e5cf5d272" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_da4660fb-02de-4a6a-bdb2-e6ebfb2a6131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5265989f-4025-46c4-a2a0-27dd48c5c030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5265989f-4025-46c4-a2a0-27dd48c5c030" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9e27368e-8054-47d0-adca-2b03db3f432e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:to="loc_us-gaap_AwardTypeAxis_9e27368e-8054-47d0-adca-2b03db3f432e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d688f5d5-93f5-4a05-bfff-de6e00104391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9e27368e-8054-47d0-adca-2b03db3f432e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d688f5d5-93f5-4a05-bfff-de6e00104391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0fcb2a20-36a6-4373-8f52-9ece92b62846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d688f5d5-93f5-4a05-bfff-de6e00104391" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0fcb2a20-36a6-4373-8f52-9ece92b62846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f3205a89-5dfc-4d8b-bfa2-9a72cba81e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d688f5d5-93f5-4a05-bfff-de6e00104391" xlink:to="loc_us-gaap_EmployeeStockMember_f3205a89-5dfc-4d8b-bfa2-9a72cba81e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a92dc5f-aec0-45a6-b42d-107ebec1badd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:to="loc_srt_RangeAxis_0a92dc5f-aec0-45a6-b42d-107ebec1badd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8711eeef-367a-4db8-9915-06d262c75155" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0a92dc5f-aec0-45a6-b42d-107ebec1badd" xlink:to="loc_srt_RangeMember_8711eeef-367a-4db8-9915-06d262c75155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_346b258d-7882-420e-ab83-24ee2e376668" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8711eeef-367a-4db8-9915-06d262c75155" xlink:to="loc_srt_MinimumMember_346b258d-7882-420e-ab83-24ee2e376668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d4876bb-b71e-4c58-99e4-0905cd8c6c75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8711eeef-367a-4db8-9915-06d262c75155" xlink:to="loc_srt_MaximumMember_9d4876bb-b71e-4c58-99e4-0905cd8c6c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1269e1a1-8bbe-4a0a-98ab-14b215cd5d7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01e6009d-c318-4bb7-9f0c-40e232352a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01e6009d-c318-4bb7-9f0c-40e232352a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8e3fb1ea-0221-4c1d-beba-5b839b559a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8e3fb1ea-0221-4c1d-beba-5b839b559a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ed0bf4ab-7687-47d6-a258-be9f4281e6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_ed0bf4ab-7687-47d6-a258-be9f4281e6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_31e7c7ee-0716-461d-a258-af6235393075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_31e7c7ee-0716-461d-a258-af6235393075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_108a4119-bbb2-4f73-bdf7-984241aa9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_108a4119-bbb2-4f73-bdf7-984241aa9ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6cb782db-4daf-4b99-9811-2a09d75727c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6cb782db-4daf-4b99-9811-2a09d75727c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f75f937c-3f03-46bd-b01f-c1a1c8057108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f75f937c-3f03-46bd-b01f-c1a1c8057108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_23661021-0940-4267-8079-84dd23b205ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bbc8905-2a8b-4605-9680-0648a55d9f9f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_23661021-0940-4267-8079-84dd23b205ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exdx-20210630.xsd#StockOptionPlanStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04c5f685-d951-44ad-aaa0-80f4caded19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdf4a7d9-923c-4995-8b11-ca8fd4ab0d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_04c5f685-d951-44ad-aaa0-80f4caded19b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdf4a7d9-923c-4995-8b11-ca8fd4ab0d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7e397534-f38d-475b-8a7e-8974afa42fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdf4a7d9-923c-4995-8b11-ca8fd4ab0d31" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7e397534-f38d-475b-8a7e-8974afa42fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7e397534-f38d-475b-8a7e-8974afa42fa6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_9536e80e-9cd8-4452-bde4-abbfe1c76906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:to="loc_us-gaap_CostOfSalesMember_9536e80e-9cd8-4452-bde4-abbfe1c76906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ef0f8311-d7c1-4eda-8c10-78b592071ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ef0f8311-d7c1-4eda-8c10-78b592071ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8312db0f-3ff8-45f1-a7f6-0f9b585843fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7c53deb1-50c6-491f-8d07-9487dd35cb91" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8312db0f-3ff8-45f1-a7f6-0f9b585843fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0193e65e-84de-41b1-9852-9729860c6e59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cdf4a7d9-923c-4995-8b11-ca8fd4ab0d31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0193e65e-84de-41b1-9852-9729860c6e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a876ec4-1e2d-471b-9dbd-d3ffc8caf00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0193e65e-84de-41b1-9852-9729860c6e59" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5a876ec4-1e2d-471b-9dbd-d3ffc8caf00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19" xlink:type="simple" xlink:href="exdx-20210630.xsd#Covid19"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Covid19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract_c5e7d26a-43fd-4795-a7cb-7b9fd33c53dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_c9bfffdf-ce8b-4b2a-8b9a-cc26d0f5e58c" xlink:href="exdx-20210630.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_c5e7d26a-43fd-4795-a7cb-7b9fd33c53dc" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock_c9bfffdf-ce8b-4b2a-8b9a-cc26d0f5e58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exagen.com/role/Covid19Details" xlink:type="simple" xlink:href="exdx-20210630.xsd#Covid19Details"/>
  <link:presentationLink xlink:role="http://www.exagen.com/role/Covid19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReorganizationsAbstract_64de0e42-636b-49b7-b55a-e0566aeaeb62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReorganizationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d10fdee3-0065-4190-b994-badbe2c07959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReorganizationsAbstract_64de0e42-636b-49b7-b55a-e0566aeaeb62" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d10fdee3-0065-4190-b994-badbe2c07959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bfd08617-8db6-4480-abff-a357d73d9fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d10fdee3-0065-4190-b994-badbe2c07959" xlink:to="loc_us-gaap_DebtInstrumentAxis_bfd08617-8db6-4480-abff-a357d73d9fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8c427080-5759-4936-87f7-dd9854115ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bfd08617-8db6-4480-abff-a357d73d9fbc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8c427080-5759-4936-87f7-dd9854115ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_PaycheckProtectionProgramCARESActMember_e1260bfa-9c99-446a-8d6f-d31a1915dbaa" xlink:href="exdx-20210630.xsd#exdx_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8c427080-5759-4936-87f7-dd9854115ce3" xlink:to="loc_exdx_PaycheckProtectionProgramCARESActMember_e1260bfa-9c99-446a-8d6f-d31a1915dbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d10fdee3-0065-4190-b994-badbe2c07959" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_da3b315d-1b4b-40dc-b1db-db7f90b013c9" xlink:href="exdx-20210630.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance_da3b315d-1b4b-40dc-b1db-db7f90b013c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_85380f95-90f8-4d37-a971-4f93db937f74" xlink:href="exdx-20210630.xsd#exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit_85380f95-90f8-4d37-a971-4f93db937f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exdx_ProceedsFromGovernmentAssistance_8e7b0dcb-49ef-4a1f-8620-58080633dd9e" xlink:href="exdx-20210630.xsd#exdx_ProceedsFromGovernmentAssistance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_exdx_ProceedsFromGovernmentAssistance_8e7b0dcb-49ef-4a1f-8620-58080633dd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromBankDebt_f15162dd-916b-4582-8ceb-6a2a4165d38f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromBankDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_96d34996-10c5-4304-bed5-f0724115febf" xlink:to="loc_us-gaap_ProceedsFromBankDebt_f15162dd-916b-4582-8ceb-6a2a4165d38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>exdx-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:exdx="http://www.exagen.com/20210630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exdx-20210630.xsd" xlink:type="simple"/>
    <context id="i814429626dec4826a699d35e97d00de2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5780fca0aaf34dcfab553f2efb981de5_I20210806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="i8717a2bf86c340c089d364c29e6c135d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaec6a7c2a312487caf8734b58f397e25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i366fa7cf9c3940e884aa8c8619173cc2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5150cd684b0d46ccba522709fba131b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i758a0d891e3e480d95465ccb025f61f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0deb0612dda8455fad61349cd2e577de_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ac5881792a74f33ac659f8310bbcd0b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i72ebe96bf2e14fb788d101048eba37f6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8061b34d637b4709a07e120a85126e27_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0d3c385b85e3496db450da0807647ad7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8df4d4a6e90f495da04464f80d6009ec_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0791f27cac87465e9a64cc86bd068ff1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if74f91780daf468f8527681009a493cc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib27834d9ecc64761948dc8797f616336_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i65e7ef5eaa61480cadeee7d277e565f2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibac674a12b624346ba69c6d4c91a087c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i552bc21453cb4af5b990c1672758ce50_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1218833ece7f47b482280689d529b3c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if7d1a0041a2247299991bb0eb2225c05_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iec65931f2bd14b39bad0fda30bdea3c0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6548eab8e25b4293949c913d7e33574c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic0db198013004fa19cd45a4eae00b98c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i00e69de6aff041908d22b9baeecf3fc3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8f77899e7cb54d408a8f6746c4d36b03_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3b56bc7f626845b48cb17da5717ddb00_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i979494764014402c94c0b5072500a2d6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i507cf8c3a86c47eeaa37f1c4799aabe0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifb73f35a6dbe4685b6581455ef8c5cd3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5cd12ee06e3146ee848bb4b240212ea1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i34270509c6ec4547a8c0584c3edda583_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id102a5b2a4f048f8b4f9ce799a943014_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1b86b21740cf4825b079ffee255e0a30_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i717e3a6bdd9d4ede925668cdc7aa8187_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib4abda3c45354b949166899b405e3a62_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0dced9e9019345d899c2982db367d60d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i37a9723325ae40058c158c22778b76a5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic10ddfd5136e4061b9973d178e27ba18_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaea277eb7cbf4254adf6026f29375664_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7d8f685d9b944f60b9103e1913818ac9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6abedb7e04b40e8aeec6aa02680f33b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7128036de6754666b5f3a81736dcc5fa_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2586bfebd6614d1488d082744fec8ef5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7ee787030d814685ab554a163cf5e574_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9fb609bc49d8411aacdd2e672d62eb26_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i453f98cffb604fd48828fd1e8ee2d430_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibac162d49bd04ab38540f0d788ab7b01_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i835d56825d0a476da36bc88326650f02_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id3751d07906149e5b585fd8950ac1b5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:BlueShieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifde0bcda7e7545ae9ff38a215ba73eca_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:UnitedHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i40dd1efb9e15401da3f592bff24d5574_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">exdx:ReceivableBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68cb5038c4e341a8bb7e0d23eae19b25_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i998b7cab204741c28fcd51dd94bad45f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6a803537d6434bee8f5afde8a4ef80c5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic48e64747d464d9bbd1afc1bf9d6cc47_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exdx:AVISECTDTestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i51f9aedf4a1c437d845bc8e10b3515a0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i39ca528d80c5424f812a294764c8b9e7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e927f12ecfb4ca884308d22fe725b51_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5cf77992ac8849b0b8f3496176757612_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">exdx:TwoMajorSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icc7885defdea48b79ac4c92e06b53809_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie91517e9ab974cbd90efe111ae240752_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i63e0cc5e4bba4bedb4ecef0c7823eed5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i568a53683fbf488c94e44430a6963b63_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:HealthcareInsurersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8a58092b38ba40109a35c69dca20121f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if21a06f4627b43ad9babcc317f3f97d2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7956a164bef94499b35cc310c4dfa294_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i871675045d654924b72a5dff008b67ed_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:Government1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9092bb8a26fc4e91aaa2cd450c799ddd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2a3b44a9c5c04e059b0deb00b7ec0856_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9891076fa8c64cd7a563f92569372319_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5e7a7a50804f4d55974db533637b345c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:ClientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0caa9d180cf9428e911a0e8958c06187_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic92986ea9525425a99124a727802cafa_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iec98ad996148414b982b48ce1fb97499_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if9b2e1719a224e7e80ad848e2e398f17_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">us-gaap:OtherCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iba69b5a6c3564f0f80195f7298100232_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifcd4bbc200954114b1e61bdcf69d26ef_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i32ca735999a14a46b0051553431233d7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if5e011876b544007978e81d4e8a12381_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i06c5a5ab8a2e4bf7895c99d6d53c706e_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i3a0e4213bad142eaa4399139407152d9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia28be9a1944346ff97180e2bd48e846e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2af77a6c91de42baa701376938862bef_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iaa0c42e21a78482eb4842f031387a636_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i355e8ad01573466884248e15012957d3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i997cfa266cc049a8a0eb6ce9d22ce202_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i095b975d91e844528a4ecbc0d02226ab_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b212ea1c94f44ddb43e8958f910b803_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iac6d296eb29947729818846e34e334fe_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:JanssenPromotionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7df835bc9321482ea1c21e97a45b2b46_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie5cf118bed6843c49e51e3a063b2f215_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifa166a05412145609609afa9045b6c36_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i28ab5400a6d1441c989c0987429f31c5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:JanssenSIMPONIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6d57b7de558142c282a4c8a44d661825_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b0ebbe6307b48fd8165e0d875dba99a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i260acc2d1e664219932adbe50ba9b56c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie43b2c29a3af401db0f76f11da748e11_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i727eef9b6d6841bfafb949eedc04adc6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8f3bfc019a3043dfa65e9ab76ebb83ba_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i748aa018ed14456e8bbd6fefdb2bb343_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0062233c30074ba2a141cbf88bac2dfc_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idb7f37a50b544479a5a49d2f8a7f1de1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9cbe68f2531c41b2ac7307191c02d60f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id1de1f702c3940caa18e3c855c718b6f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70cd681b7da54b718ba2a94de49fe566_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3ee2c605c05b4d7184eee467043f7f7b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i521d00286bef46b8988c748f9b09da38_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia6c88be424ba4421b0681115a0468ff6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3dc1550c49342788746509b902551e3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i21b606f430d94e608359e908e5675881_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i40ebe85cfda44056a48e8c86297ff80d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ice4ce2fdc8a245879ca524ab3fef616f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i50fdc73457e64ff58b4af00e94a3d47a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i019b55474b03417188ce0a6599b09a06_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i48774ed5d6c94ea395c2ad9d1ab2ce4f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbf9a3c919134b408f3367b2f162100b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i91228be59b0d4bbbb6dd3e4e3b5aa38f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43f0253166e9425b97baa1464c6dadd8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0936318fe184480caddef482306a6003_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibac65fe1c3e84b0088c92074e306b603_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifdcf495c5bbc4290af9da6a68df65ef8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib6b0b82d0abe422985b1fc6559a21381_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i838a40fa91e847cf8a46ed8a5c4fd73a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i878741a4ebe5465789238ff029c6bb05_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i78b05cb96f9b4ad39ce807d4c92ff525_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exdx:AssetsUnderCapitalLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3aeb264ea9c49aaa65800b5d232f669_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i25a352deb17e46e3a01049447545824a_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:CapitalRoyaltyPartnersIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i5cae1ab4f7684fc9984e25a56c343ce2_D20181207-20181207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-07</startDate>
            <endDate>2018-12-07</endDate>
        </period>
    </context>
    <context id="ieced59f9bfea440b98b881cd100be221_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i363ecec2e07a4f4f9429105336138bb9_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="idd6b73e6480747b0a96c555a0607e176_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i051865121b864843a7aa6d0196c1ce5d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id1bf67b90be54de7a4cb661c84afb134_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib5205c3992de49bd94179b9de9cea768_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id13bd35b84c84c08b97cf25c25447a01_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:Term2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">exdx:InnovatusLifeSciencesLendingFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:PaymentInKindPIKNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i33be34133ab34424a1d393162ac35351_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i586ccca64fab4ff3922bd68ad5ab7254_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="exdx:RentalPropertyByTypeAxis">exdx:OfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic125d46c253c46218b4ff1c223808e5f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i64e5fa2583514a499a2c2e814b73a55f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieca6b551f41048dbac2cc2f24a067a81_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:PrometheusLaboratoriesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6ce02fbc4e20421e91f360d2257a0bdf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i176ded5488ca41bf8f320b2151888cff_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if4f0c91b62b144c98930aada725aeb5f_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="ib81bf8c979f84fd29d5b105929b0d3ce_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:AlleghenyHealthNetworkResearchInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i9e6063862f0049ad920ccdded39326b3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i17ac12b6a47847b39613a583f3715e22_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exdx:AHNCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie918642c1b394009ad0b69833a6119be_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5d194d9380fc4177be4de2c4474844a3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i239c9597bcdc4b76b9572e7dc62e7793_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i88553bc1fc4946cfacf88eb4b595623d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i21c725659c554256894e6753bca963bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9801f382d4c346349a3739ac75eb6c29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2a0e15468d14f1d800e862e526e0bd8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad87945e18794ca292bc45b973f89c11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i045a54532883447b9ba4d8e5b2a6eae3_D20201110-20201110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="ie922f6d9a6124200b1afa6562935970c_D20210325-20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="ie15d6bb2bda3454aac07113283b3188f_I20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="i9460ad066b9b478eab9cd1f7a6a40ac1_D20210622-20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-22</startDate>
            <endDate>2021-06-22</endDate>
        </period>
    </context>
    <context id="i1f2162308c734d97b338ad4453278bb5_I20210622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">exdx:ExchangingStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-22</instant>
        </period>
    </context>
    <context id="i492e5c40d7034eaf962d0469c7c795cf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationJan192026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i071b488b09a1417c91811e6d8f3d29b3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationMar312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i73ee8d512a0840b190f350455a2ed1a9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationApr12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7e5761e4153746f5a98d6355c0258668_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationSep72024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i51452bd995b44c0083d3c57b6f6acef2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:ExpirationDec72025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia9815b27e2974facbe3b603ea097a3f5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">exdx:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i380b31af79e04aba8a6b53172095dbb6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic82819fc6d4c4f04baba439733edc724_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exdx:IncentiveAwardPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0298f7cc8a044f3ea0148fea59992a10_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4ffae978ff094b5595bb90b4291d7670_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ac35630d5b74bbdb0694e77844fc22f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0759ea92cd33439d8ee655337f3ca564_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i809b83fd5e2949e98dfca51a6405bc5e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b2f240e32a94e0091882c0f86aec9c2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i053c7646827546d5980da48ba6995176_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iddcb859bbff74e819108a02b2f35c671_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22f749fcc65a465494ce02dd6f69461e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaddaedafdc194a299eae12d2f0b746f8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7c18c0730b4c4c2f89587dfd06467595_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id749abe27a0440ca809efd67793994ed_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0bd31cf38fcb436d84f561912752611e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i53db86996c4a4b2aa8810e431ba1895c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2fd1752efb344048b8a02fcfe6fb0f95_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id5ea1131c9af47dd8588756554e13957_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ide3f62783fe24bacb1e4a648e4847e70_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9415ee637f114999b6d5d2f67f7050fa_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0e3f26179ffa4405bc060edb0ba198b2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia27e8ea51bc64e348a17908196ce969c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib6de0d2e713746bb9c050c4ab98f4f51_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2835a9642ebd49899501526ee781c908_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if2bebf6fe6604b9cac9e5fcd8f81e01b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0827b20b427b4e6ab8c7d6c7c4a5ba90_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i504e664134704f5a90ec38a184fa703b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i344fc6213f364bd0844d383c9bdfc785_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i574d92d10a8b47df85aa14649bb3aa66_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ib7156ce287e04be6adfdde022fd8dc7f_D20200416-20200416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001274737</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">exdx:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-16</startDate>
            <endDate>2020-04-16</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>exdx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF8zLTEtMS0xLTA_3d1bef73-1b1e-4919-9392-501582bf9a15">0001274737</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF80LTEtMS0xLTA_55190894-0dca-4489-b287-f38736d4a691">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF81LTEtMS0xLTA_9df5b06d-bcf9-4b36-8a27-32bd0f7cddcd">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF82LTEtMS0xLTA_535e728b-6bf1-4c0d-9380-2e2accaa5619">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180L2ZyYWc6OWRkYWE1NTdkNGE5NGY2OWJkMDNmNWM1ODA5ZDhmODcvdGFibGU6OWZjZDNmY2JlMzZjNGZlNTg2NzIxOGVlZmQwOTdjMjQvdGFibGVyYW5nZTo5ZmNkM2ZjYmUzNmM0ZmU1ODY3MjE4ZWVmZDA5N2MyNF83LTEtMS0xLTA_a66bf16f-e2f7-46f3-a4cd-cc0ea3df8d2c">false</dei:AmendmentFlag>
    <us-gaap:DebtInstrumentTerm
      contextRef="idd6b73e6480747b0a96c555a0607e176_D20191101-20191130"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTExOQ_db518ce5-2992-4221-8603-2271ebaa5ba5">P24M</us-gaap:DebtInstrumentTerm>
    <dei:DocumentType
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y184NA_84e7fd69-c362-4489-9768-f9caa1b0ad71">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6YmIyZGQ4MjdiN2I3NDhhYTk3MTVkMzdkYzViZjc3YmEvdGFibGVyYW5nZTpiYjJkZDgyN2I3Yjc0OGFhOTcxNWQzN2RjNWJmNzdiYV8wLTAtMS0xLTA_ded014f4-49e9-4375-bcb5-2c609c6cee09">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6YmIyZGQ4MjdiN2I3NDhhYTk3MTVkMzdkYzViZjc3YmEvdGFibGVyYW5nZTpiYjJkZDgyN2I3Yjc0OGFhOTcxNWQzN2RjNWJmNzdiYV8xLTAtMS0xLTAvdGV4dHJlZ2lvbjpiYmU4ZTk3MmI0NWI0ZGRkODUyODg5MDBhMDYzMTNiMV8zNg_8ad192cc-0fbf-4f22-9a03-4454b5ddefc8">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6YmIyZGQ4MjdiN2I3NDhhYTk3MTVkMzdkYzViZjc3YmEvdGFibGVyYW5nZTpiYjJkZDgyN2I3Yjc0OGFhOTcxNWQzN2RjNWJmNzdiYV8yLTAtMS0xLTA_f587bfde-b6b3-485e-8043-deab17ae0617">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xMjk_4bd25d56-1e21-424d-8717-beecce60d427">001-39049</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xMzM_35ce1c67-2ff7-401a-86fc-b298d1dba204">EXAGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV8wLTAtMS0xLTA_9a70cc21-5afc-46ad-850a-1ce3cc5b3b85">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV8wLTYtMS0xLTA_ce1524e9-48a3-40a7-a559-7345c2ef764e">20-0434866</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV8zLTEtMS0xLTA_949f4aae-4134-4c2e-8ce2-12aafa413d94">1261 Liberty Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV80LTEtMS0xLTA_ba761a3f-4708-4cda-a902-6d89ad77272d">Vista,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV80LTItMS0xLTA_f7df520f-dbe1-4f7c-b3bd-3e3b9fcd2e3f">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDgwZDdjMTc0M2VhNDI3OTkxZWViNDRlM2UwYTU3MTEvdGFibGVyYW5nZTowODBkN2MxNzQzZWE0Mjc5OTFlZWI0NGUzZTBhNTcxMV80LTYtMS0xLTA_329a0939-bf05-49f7-a076-fa7529500291">92081</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDEyZDRkOGRiZjBkNDVlODhmNDc0NzE2MmQwY2FlODEvdGFibGVyYW5nZTowMTJkNGQ4ZGJmMGQ0NWU4OGY0NzQ3MTYyZDBjYWU4MV8wLTAtMS0xLTA_34b18666-46cb-4c60-8a41-7a92d884b370">(760)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6MDEyZDRkOGRiZjBkNDVlODhmNDc0NzE2MmQwY2FlODEvdGFibGVyYW5nZTowMTJkNGQ4ZGJmMGQ0NWU4OGY0NzQ3MTYyZDBjYWU4MV8wLTEtMS0xLTA_ec185350-8425-4b82-bedf-1fb04acbc4c8">560-1501</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6OGNiYTdjMDBhMzM3NDAzY2JiMjUxY2I3ZGVmOTFlYjQvdGFibGVyYW5nZTo4Y2JhN2MwMGEzMzc0MDNjYmIyNTFjYjdkZWY5MWViNF8xLTAtMS0xLTA_705ceb4a-1d45-4a00-a9df-204f4f0e07fc">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6OGNiYTdjMDBhMzM3NDAzY2JiMjUxY2I3ZGVmOTFlYjQvdGFibGVyYW5nZTo4Y2JhN2MwMGEzMzc0MDNjYmIyNTFjYjdkZWY5MWViNF8xLTItMS0xLTA_8f050bdb-f2d8-4d38-ac2b-47f735b91e69">XGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6OGNiYTdjMDBhMzM3NDAzY2JiMjUxY2I3ZGVmOTFlYjQvdGFibGVyYW5nZTo4Y2JhN2MwMGEzMzc0MDNjYmIyNTFjYjdkZWY5MWViNF8xLTQtMS0xLTA_6034e390-4deb-4602-b13b-f9211dc83f09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y181OTk_2ea96a0b-f938-42d4-b0b3-cbfcb2be202c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y185MDE_39d7de99-9290-4fa6-b949-fe62d35ee2d9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6M2ZhMTEyMDVlMGFkNDUwOThiNWM2MDc1ZTExNGJiY2EvdGFibGVyYW5nZTozZmExMTIwNWUwYWQ0NTA5OGI1YzYwNzVlMTE0YmJjYV8yLTAtMS0xLTA_eb895149-6241-4e2f-8cf0-e23ca94b0745">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6M2ZhMTEyMDVlMGFkNDUwOThiNWM2MDc1ZTExNGJiY2EvdGFibGVyYW5nZTozZmExMTIwNWUwYWQ0NTA5OGI1YzYwNzVlMTE0YmJjYV8yLTQtMS0xLTA_5b300d2b-ed94-45b8-946f-9576b929228b">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGFibGU6M2ZhMTEyMDVlMGFkNDUwOThiNWM2MDc1ZTExNGJiY2EvdGFibGVyYW5nZTozZmExMTIwNWUwYWQ0NTA5OGI1YzYwNzVlMTE0YmJjYV80LTQtMS0xLTA_fa2c37ab-db38-451a-9ebf-3037254ca8a3">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xNTM0_40f0dfce-49f1-45c1-b27e-6a7895bce586">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xNjU0_cbd3db40-08d5-42f3-89b2-8a791251e4ec">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5780fca0aaf34dcfab553f2efb981de5_I20210806"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xL2ZyYWc6YWM1NDcyN2M2NmQ1NDUzOWEzNmVhMzk4MjlmODg4OWMvdGV4dHJlZ2lvbjphYzU0NzI3YzY2ZDU0NTM5YTM2ZWEzOTgyOWY4ODg5Y18xNzQx_ce51f91c-ca52-4b2c-a584-e8d7090821a6"
      unitRef="shares">16126784</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNC00LTEtMS0w_09496911-b41a-45b6-b61d-a9d725e2e622"
      unitRef="usd">112576000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNC02LTEtMS0w_e37143d1-470c-40a8-8284-f60a2f7e7082"
      unitRef="usd">57448000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNS00LTEtMS0w_4a0e68cb-0f62-4950-ade3-ba99daf58679"
      unitRef="usd">8780000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNS02LTEtMS0w_ee00ea5b-c9aa-4bcf-b770-591194adf7af"
      unitRef="usd">8910000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNi00LTEtMS0w_13a5c91a-6b65-40fb-9fc5-62555941504e"
      unitRef="usd">3172000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNi02LTEtMS0w_72962d66-1cdc-4ee9-a0f8-444102ba236a"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNy00LTEtMS0w_5f759b85-8bac-4c4e-8519-961693b5f0fd"
      unitRef="usd">124528000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfNy02LTEtMS0w_01f9c46b-051d-4f23-b781-864554020ad2"
      unitRef="usd">70517000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfOC00LTEtMS0w_92c825b4-e7ca-4e27-8f55-aa7d6870b28e"
      unitRef="usd">3054000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfOC02LTEtMS0w_7953e4e0-5d31-4975-9be8-6fe9c4770b7c"
      unitRef="usd">2102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfOS00LTEtMS0w_72b5a034-96a8-47ed-bc52-8c6949e52688"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfOS02LTEtMS0w_6b5d15bc-2ebb-4e11-b120-635561f23dd7"
      unitRef="usd">5506000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTAtNC0xLTEtMA_eaf953a6-68b3-4303-b3ca-6ebdce25a776"
      unitRef="usd">235000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTAtNi0xLTEtMA_8e1d63c3-9165-46c9-8e9f-f389f25ef738"
      unitRef="usd">250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTEtNC0xLTEtMA_6a3c2cdc-ffca-4e5d-afd0-0df2008927e9"
      unitRef="usd">133323000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTEtNi0xLTEtMA_e324c2af-c649-40ef-8283-552ffac3b5f5"
      unitRef="usd">78375000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTQtNC0xLTEtMA_26a309bd-1ff4-45fc-9cc7-673aea4add44"
      unitRef="usd">2450000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTQtNi0xLTEtMA_71073642-a0b9-4761-83bc-6ca0f52ca3d4"
      unitRef="usd">3014000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTUtNC0xLTEtMA_23d1fa16-ffb0-47ab-904a-7ec7c2454f25"
      unitRef="usd">5815000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTUtNi0xLTEtMA_ce1e8d7c-056b-4e05-8315-d1a5a7b13456"
      unitRef="usd">5757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTctNC0xLTEtMA_baa0bfa0-6ced-4555-9ee9-c62aa2f9848f"
      unitRef="usd">8265000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTctNi0xLTEtMA_e09941c7-ed8f-4f1b-8b81-64895538e901"
      unitRef="usd">8771000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTgtNC0xLTEtMA_ed0728e7-4f51-4e10-b257-63d655a0e2a6"
      unitRef="usd">27073000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMTgtNi0xLTEtMA_8ea8b286-9aba-4cb6-bfb6-04bb8c329136"
      unitRef="usd">26659000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjAtNC0xLTEtMA_1183eb49-18e7-4a97-8a4d-ceb7649bf715"
      unitRef="usd">158000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjAtNi0xLTEtMA_42bb17d2-2173-4d28-9416-d75cf1d5d590"
      unitRef="usd">158000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjEtNC0xLTEtMA_b3c8c95a-7ef5-4097-b8c8-73e7110dcba7"
      unitRef="usd">1447000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjEtNi0xLTEtMA_677b75c5-78c8-4916-94d9-868a96c74a0c"
      unitRef="usd">948000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjItNC0xLTEtMA_80d074ca-b7d8-4014-9242-4718aaaf1a55"
      unitRef="usd">36943000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjItNi0xLTEtMA_5fb646a8-20a9-42d4-b378-bb3dad20d1cc"
      unitRef="usd">36536000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjMtNC0xLTEtMA_50849432-71f4-4c96-931c-96efde3fd1fe"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjMtNi0xLTEtMA_3aacecdd-90e1-4a5c-9d85-3d464abeff45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzIx_4cf5f5ea-4ee9-42f6-93c0-ebe22faef277"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzIx_a659140b-fe64-4254-a7af-9fed426be6bb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzM1_696de39e-be8c-48d1-b0cd-22ba209c32ad"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzM1_d771205d-c48f-4ebf-97cf-b0441ec49f5c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzU3_4342cc3e-6a64-45f2-b748-2722a009fe18"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzU3_459bedb2-f69b-4cfa-822f-ded28cfcbdb1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzU3_b012cd70-c92e-4b26-b172-46e90ce29bf2"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjBmNzUzZDI4ODI5YTRkMWFiMTQzMzAzNzExZjQ5NGZkXzU3_bd17e22f-47b8-4753-b9f5-b501f140b8f0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtNC0xLTEtMA_ea494a7b-fe4e-4da6-b1c7-d685d3f358a7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjYtNi0xLTEtMA_3b4148d2-d5b1-42b7-90c7-7285ced27957"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzE4_0ca40f39-c631-42eb-b262-3ff01c5ffcc8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzE4_f14e7645-7ab8-4f98-9cba-8ed7d8a33879"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzMy_9a5bbc06-6893-4210-bf98-9a1fa21a3ca9"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzMy_fe0b3001-6a67-49fb-bd09-6cb47ff0466b"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzgy_545527c9-6edd-4f89-b249-acb1f7949f1a"
      unitRef="shares">16126784</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzgy_9115d025-8172-41a1-9c81-8a6b97fe5be1"
      unitRef="shares">16126784</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzg5_1a26f749-8303-4f9f-b791-a927f72d7b32"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjViMDIwYzIzNWY4YzQwMmRhNzgxMTM1MGVjODg3MWRjXzg5_c063c884-4098-48b1-8ae3-d1b192aa72dc"
      unitRef="shares">12652308</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctNC0xLTEtMA_235fc01d-234e-41d2-904f-daa8eda7fb9d"
      unitRef="usd">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjctNi0xLTEtMA_bac86b65-bac7-4fda-996b-2a4cfdf67994"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjgtNC0xLTEtMA_465c1916-4ddf-40d5-988e-776ae7e1a5f3"
      unitRef="usd">290272000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjgtNi0xLTEtMA_397c9024-439a-4069-8496-c271af9485ae"
      unitRef="usd">223115000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjktNC0xLTEtMA_e9ecb3cf-ca02-479f-a521-397a5ac02acc"
      unitRef="usd">-193908000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMjktNi0xLTEtMA_b64c0d10-4d04-461a-8549-f54d898f5e2c"
      unitRef="usd">-181289000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMzAtNC0xLTEtMA_d84817a9-4937-4436-85b5-576d5518afae"
      unitRef="usd">96380000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMzAtNi0xLTEtMA_c2692d42-141c-4f2a-87e6-87110e04215b"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMzEtNC0xLTEtMA_c79d028e-3949-49f0-a941-ec87cef69f54"
      unitRef="usd">133323000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xNi9mcmFnOmY4YWZhM2JlMDlhYTQwYmM5MDk3M2RmNTliODMyYTNjL3RhYmxlOmYxNzhmMmUyOTdhYTRkMzBiNjQxZjRlMDUxMzAxMTZkL3RhYmxlcmFuZ2U6ZjE3OGYyZTI5N2FhNGQzMGI2NDFmNGUwNTEzMDExNmRfMzEtNi0xLTEtMA_ca4dfc1c-ffe4-4e1e-a939-976bff1e39a0"
      unitRef="usd">78375000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMy0yLTEtMS0w_fb9f1c97-5dc9-4791-af0a-95bd075f3499"
      unitRef="usd">12772000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMy00LTEtMS0w_3ba3dc4f-674a-49eb-a1ad-5c0e65a2e35c"
      unitRef="usd">8948000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMy02LTEtMS0w_4959e1da-4018-42d5-9694-8294a73053c1"
      unitRef="usd">23359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMy04LTEtMS0w_20c7ea56-1cab-415a-b6c2-97fb10dfd42a"
      unitRef="usd">18532000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNS0yLTEtMS0w_8b23ce0d-bed4-4201-830f-4ba27c4821db"
      unitRef="usd">5451000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNS00LTEtMS0w_741e3a64-9b37-4865-bbdf-2ff604250089"
      unitRef="usd">3338000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNS02LTEtMS0w_1420dc12-f942-400d-ae1f-cc2478a22202"
      unitRef="usd">10162000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNS04LTEtMS0w_7b871346-d511-4b97-ac1a-07490631619b"
      unitRef="usd">7883000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNi0yLTEtMS0w_47b1812a-295e-40c1-8d3f-b8d9cf0556c2"
      unitRef="usd">11171000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNi00LTEtMS0w_b211b694-d7ef-4f93-bb65-563499f8cd3f"
      unitRef="usd">8276000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNi02LTEtMS0w_1854d33e-925c-427d-bfab-c7af12ebd25b"
      unitRef="usd">21211000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNi04LTEtMS0w_9527b1b2-4cb2-44f7-82f2-6d26226a0a1e"
      unitRef="usd">17902000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNy0yLTEtMS0w_e23da0e6-f744-411b-8604-bb9356e922d2"
      unitRef="usd">1892000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNy00LTEtMS0w_ff972a15-0503-432e-94a6-15b3a2b5810d"
      unitRef="usd">751000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNy02LTEtMS0w_aabb5b50-6a0c-4f30-a251-a39b9f0316e4"
      unitRef="usd">3295000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfNy04LTEtMS0w_30d600c3-7682-4dc8-ad61-aa6f711b0171"
      unitRef="usd">1385000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTAtMi0xLTEtMA_ffeeb630-de3b-4221-adfa-7d7cfa10a71d"
      unitRef="usd">18514000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTAtNC0xLTEtMA_420aed2e-3c0d-4eab-88d2-474d5c087c16"
      unitRef="usd">12365000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTAtNi0xLTEtMA_28695c77-68b8-4ad3-9be9-a8f7823eb943"
      unitRef="usd">34668000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTAtOC0xLTEtMA_be2265b5-9cab-40d7-a12f-d7089e6f31b0"
      unitRef="usd">27170000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTEtMi0xLTEtMA_689031a1-8a9c-477d-80ac-29e8e6959877"
      unitRef="usd">-5742000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTEtNC0xLTEtMA_b4cde856-11a2-49be-b34d-ab958dd39b72"
      unitRef="usd">-3417000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTEtNi0xLTEtMA_d8ad3e1e-86bd-4f26-924a-89e3b1335a25"
      unitRef="usd">-11309000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTEtOC0xLTEtMA_77c2ab7b-4e31-41dc-b51d-9383b01f419b"
      unitRef="usd">-8638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTItMi0xLTEtMA_41d31680-2685-484f-bf98-a9d59381c533"
      unitRef="usd">663000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTItNC0xLTEtMA_f3f450b1-562e-46a9-8c43-d72b8231df77"
      unitRef="usd">635000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTItNi0xLTEtMA_489d585f-199e-47dd-ba8c-e385320b8c45"
      unitRef="usd">1308000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTItOC0xLTEtMA_d083f80f-b339-4a2a-8c27-6936971a3649"
      unitRef="usd">1266000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTQtMi0xLTEtMA_0229b835-db6a-45e5-9134-21f013ded9ac"
      unitRef="usd">-5000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTQtNC0xLTEtMA_14ef4cf0-1203-4dd9-8d46-9363c573e6da"
      unitRef="usd">689000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTQtNi0xLTEtMA_241b8245-57bd-40fe-b52e-6dc2a9902ae0"
      unitRef="usd">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTQtOC0xLTEtMA_63cc8af6-d893-4c7a-a22e-fb659d569666"
      unitRef="usd">860000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTUtMi0xLTEtMA_efbf7b02-c27b-413e-a100-f29c8c1311bb"
      unitRef="usd">-6410000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTUtNC0xLTEtMA_1798c102-567e-45be-8d76-4758bd94666c"
      unitRef="usd">-3363000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTUtNi0xLTEtMA_4ee13c0c-7daf-44d7-8a7e-3fd26af64623"
      unitRef="usd">-12619000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTUtOC0xLTEtMA_a271b464-0492-4dd5-ba87-dc23aa5dce9c"
      unitRef="usd">-9044000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTYtMi0xLTEtMA_c5f5863b-d21f-46da-a8dc-b6adfa3abdc8"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTYtNC0xLTEtMA_f1f4f1e4-b22f-4fab-86d5-a5fbff618aa2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTYtNi0xLTEtMA_d77551c6-3ab2-45c5-9aa0-f53c846971ce"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTYtOC0xLTEtMA_5693ccd5-c34b-408b-8607-73da4b0ed5dc"
      unitRef="usd">-118000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTctMi0xLTEtMA_448102c3-dacd-4c82-a7bb-4240d1ad4d01"
      unitRef="usd">-6410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTctNC0xLTEtMA_19d732d8-41cb-4c52-874c-85aa4b8808c1"
      unitRef="usd">-3363000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTctNi0xLTEtMA_a3b67acd-1d37-4842-9991-5f120d4a8b4b"
      unitRef="usd">-12619000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMTctOC0xLTEtMA_983d78a7-678d-4afc-a02c-9a64aee9bdf5"
      unitRef="usd">-8926000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtMi0xLTEtMA_986273c9-241d-4816-b699-af183f856827"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtMi0xLTEtMA_b176bd89-2aad-4a54-a93f-7b7d30acf7b2"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtNC0xLTEtMA_2ce9de5b-a5a7-4d5a-a3b6-2c1a2e009bf7"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtNC0xLTEtMA_f6bf6809-1597-4c33-b0fb-b95311926a98"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtNi0xLTEtMA_08eda9e7-2470-40cb-9ac7-a5ebaddf1d5a"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtNi0xLTEtMA_616c6ae0-4e58-43d8-98ae-2670308fd3de"
      unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtOC0xLTEtMA_dad3c26b-76fb-468c-902b-2e79128468c0"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjEtOC0xLTEtMA_efa4e2b3-4535-4a49-86fb-a1482bc92f9b"
      unitRef="usdPerShare">-0.71</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItMi0xLTEtMA_8b362ebd-b4c6-4566-b7ce-74920d778851"
      unitRef="shares">16928613</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItMi0xLTEtMA_d1df3de3-ae06-4d58-bc67-db04b5a22edd"
      unitRef="shares">16928613</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItNC0xLTEtMA_4c3bd1c3-4bf7-4749-924a-b23cd174ac7a"
      unitRef="shares">12637642</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItNC0xLTEtMA_c70134ba-3346-40a1-9a1a-ad200aa06bd5"
      unitRef="shares">12637642</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItNi0xLTEtMA_9ae4fe9a-054f-4a34-abd8-54529ca0edad"
      unitRef="shares">14946935</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItNi0xLTEtMA_d7b7ed31-cd18-49b1-8319-f4c5cdce57f9"
      unitRef="shares">14946935</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItOC0xLTEtMA_63d63886-a492-4118-84a7-8d1c5340975d"
      unitRef="shares">12616678</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18xOS9mcmFnOmQ3MDY0NzM0N2RjMzRmNjc4YmQ1YTE4Y2UxNTg4MWMxL3RhYmxlOjc1MGUxNjA4NTkyMjRjZDQ5NjJjMDJjY2ZmZWFhN2YxL3RhYmxlcmFuZ2U6NzUwZTE2MDg1OTIyNGNkNDk2MmMwMmNjZmZlYWE3ZjFfMjItOC0xLTEtMA_ef3dbad2-e704-4eba-85c6-c71983711c07"
      unitRef="shares">12616678</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i366fa7cf9c3940e884aa8c8619173cc2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi0yLTEtMS0w_706c5e1b-2039-465f-a529-434d0b10c3f8"
      unitRef="shares">12652308</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i366fa7cf9c3940e884aa8c8619173cc2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi00LTEtMS0w_dda57d5a-e079-4a3b-84f1-33f5c9611a61"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5150cd684b0d46ccba522709fba131b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi02LTEtMS0w_478e6958-b049-415d-8661-a8574fefeb25"
      unitRef="usd">223115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i758a0d891e3e480d95465ccb025f61f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi04LTEtMS0w_94f02028-799a-4a21-a89a-60ac78b6e9de"
      unitRef="usd">-181289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMi0xMC0xLTEtMA_4825ce90-6ab0-4bf4-8adf-eb6926e82358"
      unitRef="usd">41839000</us-gaap:StockholdersEquity>
    <exdx:StockIssuanceCosts
      contextRef="i0deb0612dda8455fad61349cd2e577de_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy0wLTEtMS0wL3RleHRyZWdpb246OGQ3MGJlYjI0ODIxNDU3MGFlMDdjNDA4ZmFkMTJmY2RfNjc_4aef2df5-8ea7-4471-ac3f-285f4a59a70d"
      unitRef="usd">4435000</exdx:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy0yLTEtMS0w_1c64be52-d694-4fc9-814f-19319342028b"
      unitRef="shares">4255000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy00LTEtMS0w_a46a9320-78b0-4a0e-81bd-001f7fdc8bf0"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy02LTEtMS0w_23a7933a-79ed-4fac-9135-a0f7394fdbff"
      unitRef="usd">64705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMy0xMC0xLTEtMA_68a9f10f-1cff-4bd0-8005-234b8489e3f7"
      unitRef="usd">64709000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNC0yLTEtMS0w_6b007534-3ff2-4b97-9089-03a08fd51a3e"
      unitRef="shares">3381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNC02LTEtMS0w_9e864e64-cd06-4b77-8226-78c4413bf94d"
      unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNC0xMC0xLTEtMA_7a70c887-5af7-4f3c-b1f3-b98f60ca4a40"
      unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7115d5854338419bac0a31e17cf6942d_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNS0yLTEtMS0w_005e552d-f3be-4899-9b6a-233d168c51da"
      unitRef="shares">14991</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNS02LTEtMS0w_e8f4be33-546d-4a5f-a112-07de18ce742d"
      unitRef="usd">175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNS0xMC0xLTEtMA_c341d1cc-2148-4a82-9f2b-80fa88e34bda"
      unitRef="usd">175000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib9c31920fe0b4667a1a52c9743115db1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNi02LTEtMS0w_a1d7c18a-9f5d-4f36-bb31-def8478850a4"
      unitRef="usd">912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNi0xMC0xLTEtMA_11118592-0f7f-43c5-bfa7-a01f35df42a1"
      unitRef="usd">912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7ac5881792a74f33ac659f8310bbcd0b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNy04LTEtMS0w_e3f77ba4-2181-41a2-a56e-b16cd6c361d0"
      unitRef="usd">-6209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iffe5e69e1e8b4a349ccf539ab4058d26_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfNy0xMC0xLTEtMA_f7161566-b4f4-49ea-9f14-38032cf5675e"
      unitRef="usd">-6209000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i72ebe96bf2e14fb788d101048eba37f6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC0yLTEtMS0w_aead311f-2589-4343-9db0-9d501466cd7f"
      unitRef="shares">16925680</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i72ebe96bf2e14fb788d101048eba37f6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC00LTEtMS0w_1d18ec3c-27b2-4057-871e-b75b0c7958e7"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8061b34d637b4709a07e120a85126e27_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC02LTEtMS0w_f0666a88-ece2-4852-91be-a2d4c513b7a7"
      unitRef="usd">288951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d3c385b85e3496db450da0807647ad7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC04LTEtMS0w_a6c82f92-06ef-4105-96c6-6536bd2383d3"
      unitRef="usd">-187498000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0deb0612dda8455fad61349cd2e577de_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOC0xMC0xLTEtMA_01517a33-7869-4409-a9f9-dc990f815033"
      unitRef="usd">101470000</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i8df4d4a6e90f495da04464f80d6009ec_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOS0yLTEtMS01Ng_4e4fd0e3-10f5-4ecb-b891-27347a0ce52c"
      unitRef="shares">804951</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i8df4d4a6e90f495da04464f80d6009ec_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOS00LTEtMS01Ng_603a7386-10ae-482f-9902-5c9483f3352e"
      unitRef="usd">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOS02LTEtMS01Ng_8cfdfc69-b4da-4315-a157-176afab2afd7"
      unitRef="usd">12774000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfOS0xMC0xLTEtNTY_2858f469-209a-4b94-a04e-d74dc7ab0c27"
      unitRef="usd">12775000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTAtNi0xLTEtNTY_c4a5dd8f-72c0-45ae-b0de-a5dd2841b88b"
      unitRef="usd">12775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTAtMTAtMS0xLTU2_32b684d7-20b1-464b-a2b0-941ebdd5a26e"
      unitRef="usd">12775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8df4d4a6e90f495da04464f80d6009ec_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTEtMi0xLTEtNTY_3c95ff85-9fe6-485b-aa37-0fd6867e7138"
      unitRef="shares">6055</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTEtNi0xLTEtNTY_e5a8a495-eeaf-44e6-b797-135b1866f893"
      unitRef="usd">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTEtMTAtMS0xLTU2_6940972a-8167-49af-a671-0755b47b208f"
      unitRef="usd">35000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0b1a57d218084d09953c7fb0de0b057d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTItNi0xLTEtNTY_f1e3fa9b-87c6-4c01-8243-188dde60fe19"
      unitRef="usd">1285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTItMTAtMS0xLTU2_c96df12f-9f11-434e-adf6-84cdb6a9be83"
      unitRef="usd">1285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i0791f27cac87465e9a64cc86bd068ff1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTMtOC0xLTEtNTY_357f48ba-b64d-4184-9a10-a22a684fe6c5"
      unitRef="usd">-6410000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTMtMTAtMS0xLTU2_dbdaf5cd-fd8f-435b-abeb-70ca49b855b6"
      unitRef="usd">-6410000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if74f91780daf468f8527681009a493cc_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtMi0xLTEtNTY_8d40be5f-ba96-4f66-9f15-5e82ef1607e8"
      unitRef="shares">16126784</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if74f91780daf468f8527681009a493cc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtNC0xLTEtNTY_d322d616-d6f8-4109-a8ec-9c2652bc4724"
      unitRef="usd">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib27834d9ecc64761948dc8797f616336_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtNi0xLTEtNTY_2cae4f72-0341-477d-a790-328ddd58d013"
      unitRef="usd">290272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65e7ef5eaa61480cadeee7d277e565f2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtOC0xLTEtNTY_65f62704-109f-408d-9795-35957d93e05e"
      unitRef="usd">-193908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmU4ODAyN2ZhZDU4ZjRiMDVhM2RhZGFhMThhZjBlYTE2L3RhYmxlcmFuZ2U6ZTg4MDI3ZmFkNThmNGIwNWEzZGFkYWExOGFmMGVhMTZfMTQtMTAtMS0xLTU2_bd8aeec8-3a0e-454c-8845-a1fd6f2c3c88"
      unitRef="usd">96380000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibac674a12b624346ba69c6d4c91a087c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi0yLTEtMS0w_00fa9bff-940f-4163-bd05-a89e6bf0c57b"
      unitRef="shares">12560990</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibac674a12b624346ba69c6d4c91a087c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi00LTEtMS0w_38e08e3a-fe8b-44fb-bdae-c27700f8e41d"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i552bc21453cb4af5b990c1672758ce50_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi02LTEtMS0w_d8c027d8-5cc5-49ae-9a42-95ac02b70ae9"
      unitRef="usd">220248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1218833ece7f47b482280689d529b3c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi04LTEtMS0w_4920e0a8-8fc1-438f-95ef-34d3c1ede9ff"
      unitRef="usd">-164602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if7d1a0041a2247299991bb0eb2225c05_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMi0xMC0xLTEtMA_a486ccb8-0c54-4202-9427-e6d707024b22"
      unitRef="usd">55659000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iec65931f2bd14b39bad0fda30bdea3c0_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMy0yLTEtMS0w_528ec194-121a-4f9d-98c8-ece5d40fe9f9"
      unitRef="shares">43700</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6548eab8e25b4293949c913d7e33574c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMy02LTEtMS0w_7ed46339-ee0b-48ae-bb8f-348779310c01"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMy0xMC0xLTEtMA_2f5b3e93-c145-4947-a9ef-0f64574ba07f"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6548eab8e25b4293949c913d7e33574c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNC02LTEtMS0w_1312f5b1-fb60-4903-a412-259e966c6158"
      unitRef="usd">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNC0xMC0xLTEtMA_6b1ba22a-58ec-4189-adcb-02fb66959454"
      unitRef="usd">431000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="iec65931f2bd14b39bad0fda30bdea3c0_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNS0yLTEtMS0w_c4fe23a1-b519-4d7e-9417-01f5d5e51e3e"
      unitRef="shares">22366</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNS0xMC0xLTEtMA_4714963c-d860-4376-bc90-da74a26adf90"
      unitRef="usd">0</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <us-gaap:NetIncomeLoss
      contextRef="ic0db198013004fa19cd45a4eae00b98c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNi04LTEtMS0w_2d494f7b-8d4d-492f-9e57-9a1fb950c280"
      unitRef="usd">-5563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic7370a0faa5f42e899de4dc6e089be09_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNi0xMC0xLTEtMA_60cf7c73-5f5b-49fc-b618-2d59e3959e82"
      unitRef="usd">-5563000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i00e69de6aff041908d22b9baeecf3fc3_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy0yLTEtMS0w_2f3646e8-63a8-49fa-84c3-f314e8276cfb"
      unitRef="shares">12627056</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i00e69de6aff041908d22b9baeecf3fc3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy00LTEtMS0w_9c15972f-d8ea-4669-a30a-ebf18c878a9d"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f77899e7cb54d408a8f6746c4d36b03_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy02LTEtMS0w_50f39a08-20cd-441e-8362-a27a65bbb7de"
      unitRef="usd">220689000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b56bc7f626845b48cb17da5717ddb00_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy04LTEtMS0w_b5ff60a6-fd46-44ed-a4c5-aad352b45cae"
      unitRef="usd">-170165000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i979494764014402c94c0b5072500a2d6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfNy0xMC0xLTEtMA_86942a18-cb6a-4661-ab0d-6c421d41859b"
      unitRef="usd">50537000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i507cf8c3a86c47eeaa37f1c4799aabe0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOC0yLTEtMS0w_5b095296-7e9d-4b8a-94f5-662eb53a646b"
      unitRef="shares">3599</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifb73f35a6dbe4685b6581455ef8c5cd3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOC02LTEtMS0w_66312707-da26-4f68-99dd-8068831c0d4c"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOC0xMC0xLTEtMA_e5ed4fa0-fc63-405f-8627-9f4ef3ee8217"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb73f35a6dbe4685b6581455ef8c5cd3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOS02LTEtMS0w_45497649-da84-4ff6-b350-c14b2e2a8435"
      unitRef="usd">647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfOS0xMC0xLTEtMA_491d8362-99d8-45c4-bb75-f34262589912"
      unitRef="usd">647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet
      contextRef="i507cf8c3a86c47eeaa37f1c4799aabe0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTAtMi0xLTEtMA_8b2784a4-2134-4981-83ab-b5c0e45c1058"
      unitRef="shares">9754</exdx:StockIssuedDuringPeriodSharesWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="ifb73f35a6dbe4685b6581455ef8c5cd3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTAtNi0xLTEtMA_24641467-ddec-41a9-919f-a8d4da9fd914"
      unitRef="usd">18000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTAtMTAtMS0xLTA_0fb875be-6425-41f6-81ca-647666263e0d"
      unitRef="usd">18000</exdx:StockIssuedDuringPeriodValueWarrantsExercisedNet>
    <us-gaap:NetIncomeLoss
      contextRef="i5cd12ee06e3146ee848bb4b240212ea1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTEtOC0xLTEtMA_34896cc5-d637-4aa6-acf5-77e56105d2a7"
      unitRef="usd">-3363000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTEtMTAtMS0xLTA_00488f44-eeab-497c-b906-e5c09c2c3b86"
      unitRef="usd">-3363000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i34270509c6ec4547a8c0584c3edda583_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItMi0xLTEtMA_ecd85f5a-697d-4c42-9e72-7962836b32b9"
      unitRef="shares">12640409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i34270509c6ec4547a8c0584c3edda583_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItNC0xLTEtMA_a9b42fef-ff8d-4a95-bd9c-dea074e7c35e"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id102a5b2a4f048f8b4f9ce799a943014_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItNi0xLTEtMA_8bb9e094-8980-4872-b53f-3665c264f08d"
      unitRef="usd">221356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b86b21740cf4825b079ffee255e0a30_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItOC0xLTEtMA_df2b8f26-9d6a-41fd-9557-bac82061e223"
      unitRef="usd">-173528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i717e3a6bdd9d4ede925668cdc7aa8187_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yMi9mcmFnOmVkMTI1MWIxODZmYjRlOTY4MGJhZjMzMTk1MWM2OTI0L3RhYmxlOmM3YmVmZmYyYWFiNjQ2OGM4YjBiNTg0ZTA5YWEwOTM2L3RhYmxlcmFuZ2U6YzdiZWZmZjJhYWI2NDY4YzhiMGI1ODRlMDlhYTA5MzZfMTItMTAtMS0xLTA_263ed7ae-c44c-4abe-876f-8fa0bb9f062b"
      unitRef="usd">47841000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNC02LTEtMS0w_e2ccc656-3404-4390-b0b6-a53781b1d2d8"
      unitRef="usd">-12619000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNC04LTEtMS0w_84df9465-27d0-4d73-b3ba-b034465658e7"
      unitRef="usd">-8926000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNi02LTEtMS0w_7e5fbcfa-b09c-4cdc-872b-8fd7a03495b4"
      unitRef="usd">407000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNi04LTEtMS0w_527ed6e1-a69d-41dc-b517-cb39171b4d14"
      unitRef="usd">253000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNy02LTEtMS0w_ac57bfcf-6f11-4c0b-9c2b-2556f4974934"
      unitRef="usd">148000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNy04LTEtMS0w_43a9b747-d34c-4ebb-953a-42c7959b2e12"
      unitRef="usd">132000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfOC02LTEtMS0w_d2c285a8-3754-413e-bb41-3fa628506a3c"
      unitRef="usd">266000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfOC04LTEtMS0w_54abd264-3e76-433f-8727-3bc6933ff45b"
      unitRef="usd">263000</us-gaap:PaidInKindInterest>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTAtNi0xLTEtMA_9b21862d-5571-4dc7-8cac-1c2b20a01f91"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTAtOC0xLTEtMA_4288f50b-c555-4095-be87-ee1b0bcee383"
      unitRef="usd">-117000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTItNi0xLTEtMA_eebc3ed7-1ba0-4c2c-ad4a-d5eeded29111"
      unitRef="usd">2197000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTItOC0xLTEtMA_22a416db-3116-478e-8d9d-76e11b55eb58"
      unitRef="usd">1078000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTQtNi0xLTEtMA_cb1b76d9-e60b-4df0-90ea-cf273fc92ba2"
      unitRef="usd">-130000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTQtOC0xLTEtMA_542624d4-8bcb-491f-bf02-b9a4d649ab50"
      unitRef="usd">1548000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTUtNi0xLTEtMA_79ae113d-04f3-4a5e-bb4c-796bd1de187c"
      unitRef="usd">-987000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTUtOC0xLTEtMA_abd032dd-3620-41c2-bb0f-7339bae71a0f"
      unitRef="usd">-951000</exdx:IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTYtNi0xLTEtMA_fb64dc8c-c2e6-43a7-9e73-06e9d7b3f3d8"
      unitRef="usd">13000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTYtOC0xLTEtMA_ed7aced8-5c71-452e-abde-b620ceee5118"
      unitRef="usd">1000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTctNi0xLTEtMA_5cbf5a82-ca2c-4b0b-9386-3884eaf76bce"
      unitRef="usd">-102000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTctOC0xLTEtMA_c79d5a07-5777-498d-8672-01a80f9ac120"
      unitRef="usd">-42000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTgtNi0xLTEtMA_73d118e7-69e6-4884-b8e0-5d2002c63b38"
      unitRef="usd">-163000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMTgtOC0xLTEtMA_a2727384-16ba-4826-9673-fb5ed5d22dcf"
      unitRef="usd">-100000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjAtNi0xLTEtMA_dc6c4925-85f4-411a-8e9a-ba99e7ed14dc"
      unitRef="usd">-8762000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjAtOC0xLTEtMA_c4146e3b-6545-4d65-b76f-dc69f50845db"
      unitRef="usd">-8057000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjItNi0xLTEtMA_3e38ebc7-f4ad-432d-88de-95104f260958"
      unitRef="usd">881000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjItOC0xLTEtMA_c8bba42d-8830-43d4-b34c-77d71fdc0cf0"
      unitRef="usd">237000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjYtNi0xLTEtMA_3551ebbc-405e-4823-813e-ceffafa6a31d"
      unitRef="usd">-881000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjYtOC0xLTEtMA_88ab47a4-0d2b-4210-83ed-5ed1c6aae524"
      unitRef="usd">-237000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjgtNi0xLTEtMA_6f3a8c74-dbc8-4df2-a515-dbcd71ab1df7"
      unitRef="usd">79000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjgtOC0xLTEtMA_eac0f51f-07e9-4d45-8648-b992bbfdfe4d"
      unitRef="usd">12000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjktNi0xLTEtMA_7b2e8607-c205-4e05-9b60-4b735d0e7e19"
      unitRef="usd">175000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMjktOC0xLTEtMA_04838fb9-007b-4c75-896b-40424d3c262c"
      unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzAtNi0xLTEtMA_84d2c8b1-7c57-4462-b0c3-cecee53415a2"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzAtOC0xLTEtMA_f5d99ea6-5848-4ff0-bc95-ee0052079ef8"
      unitRef="usd">18000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzEtNi0xLTEtMA_094b8075-06a4-412a-b077-0d4ad33687f2"
      unitRef="usd">220000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzEtOC0xLTEtMA_3ec2fcb2-5c05-41ca-9280-ca5704bf64ce"
      unitRef="usd">120000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:ProceedsFromBankDebt
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzItNi0xLTEtMA_da18ff4e-77c7-449e-abc1-d333b94908e1"
      unitRef="usd">0</us-gaap:ProceedsFromBankDebt>
    <us-gaap:ProceedsFromBankDebt
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzItOC0xLTEtMA_3cdac240-8193-42d9-8968-a03493dbe703"
      unitRef="usd">2865000</us-gaap:ProceedsFromBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzMtNi0xLTEtMA_c680e0ff-eb7e-4c9b-9321-2d912dcf7c9b"
      unitRef="usd">0</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzMtOC0xLTEtMA_f7551a35-3729-4168-a12a-5d3b3d638f9f"
      unitRef="usd">2865000</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzUtNi0xLTEtMA_5a12c6f0-59b3-430d-909f-ed56047edebe"
      unitRef="usd">69144000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzUtOC0xLTEtMA_64d13884-fc52-4d3e-b059-9fb29334d512"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzYtNi0xLTEtMA_f64578c2-a663-4b14-8fce-713e1eb18a73"
      unitRef="usd">4407000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfMzYtOC0xLTEtMA_6107df4b-277f-459b-8c9a-031c5add9b07"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDItNi0xLTEtMA_8da8ab2b-3b8c-4ea1-ad13-70665d2e6301"
      unitRef="usd">64771000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDItOC0xLTEtMA_9a9a0730-644f-412f-9197-c6661303797a"
      unitRef="usd">-90000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDMtNi0xLTEtMA_5c7a3daf-3f81-4a0c-8a9c-c7fb98f49737"
      unitRef="usd">55128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDMtOC0xLTEtMA_5b4b33b7-b8ab-4d7e-879c-ec0875a4d1af"
      unitRef="usd">-8384000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDQtNi0xLTEtMA_cf023d72-a68f-4210-8d64-0d51baaa5498"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if7d1a0041a2247299991bb0eb2225c05_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDQtOC0xLTEtMA_4ea7ad88-d5cf-4bd0-ad7f-c457f785eb3a"
      unitRef="usd">72184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDUtNi0xLTEtMA_9b4038f5-c30d-4410-9237-6a08a1083a54"
      unitRef="usd">112676000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i717e3a6bdd9d4ede925668cdc7aa8187_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDUtOC0xLTEtMA_16d86062-110b-4ed6-812d-305b45f9496b"
      unitRef="usd">63800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDctNi0xLTEtMA_02877c29-2e18-4687-851e-95ca77b56d88"
      unitRef="usd">892000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNDctOC0xLTEtMA_1f5fce85-c5c7-491f-bdbc-0d3c3f2d99ec"
      unitRef="usd">875000</us-gaap:InterestPaidNet>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTAtNi0xLTEtMA_85e4fbc0-8ef4-4640-a474-d291e4f63bca"
      unitRef="usd">940000</exdx:EquipmentPurchasedUnderCapitalLease>
    <exdx:EquipmentPurchasedUnderCapitalLease
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTAtOC0xLTEtMA_54d832d3-6be2-4c40-b1f8-f330510f57d1"
      unitRef="usd">2000</exdx:EquipmentPurchasedUnderCapitalLease>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTItNi0xLTEtMA_21270f13-881c-46e8-a4d5-4635a86843f9"
      unitRef="usd">91000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTItOC0xLTEtMA_9eb01ff4-95a0-4e13-8b53-ae8a775d39c5"
      unitRef="usd">4000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <exdx:DeferredOfferingCostsReclassifiedToEquity
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTYtNi0xLTEtMA_01aa60fb-d8f7-421d-adcd-1dca633aeab7"
      unitRef="usd">28000</exdx:DeferredOfferingCostsReclassifiedToEquity>
    <exdx:DeferredOfferingCostsReclassifiedToEquity
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18yNS9mcmFnOjUyZjM2ZTdlMDcyOTRhNDM4MjUyOWZmZjQ1MzkzYjQ3L3RhYmxlOjU1MDBkNTliYjVmYzQ1NGJhYjIzMmUxOGJiNzQwMWM2L3RhYmxlcmFuZ2U6NTUwMGQ1OWJiNWZjNDU0YmFiMjMyZTE4YmI3NDAxYzZfNTYtOC0xLTEtMA_238f67b0-8017-445c-82ed-da23507c4d32"
      unitRef="usd">0</exdx:DeferredOfferingCostsReclassifiedToEquity>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zMS9mcmFnOmZjOGZmMDVlOGEyMDQ1MWM5Yjg1MjRmNDJkYzhkZmNkL3RleHRyZWdpb246ZmM4ZmYwNWU4YTIwNDUxYzliODUyNGY0MmRjOGRmY2RfMjIwNQ_5f9010e7-2a68-498c-87c3-9d6c29007bbf">Organization&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At June&#160;30, 2021, the Company had cash and cash equivalents of $112.6 million and had an accumulated deficit of $193.9 million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zMS9mcmFnOmZjOGZmMDVlOGEyMDQ1MWM5Yjg1MjRmNDJkYzhkZmNkL3RleHRyZWdpb246ZmM4ZmYwNWU4YTIwNDUxYzliODUyNGY0MmRjOGRmY2RfNjE4_73175605-2930-433c-99b1-e029b559f0e1"
      unitRef="usd">112600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zMS9mcmFnOmZjOGZmMDVlOGEyMDQ1MWM5Yjg1MjRmNDJkYzhkZmNkL3RleHRyZWdpb246ZmM4ZmYwNWU4YTIwNDUxYzliODUyNGY0MmRjOGRmY2RfNjU1_204b5be6-6c8b-4215-97c7-44ef406cae3e"
      unitRef="usd">-193900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDg_daf85d4d-df52-4819-bcfe-b5e4c6435f57">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying interim condensed balance sheet as of June&#160;30, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three and six months ended June&#160;30, 2021 and 2020 and cash flows for the six months ended June&#160;30, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of June&#160;30, 2021 and its results of operations for the three and six month periods presented. The results for the six months ended June&#160;30, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. These unaudited condensed financial statements should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2021 and 2020, approximately 81% and 60%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CTD test. For the six months ended June&#160;30, 2021 and 2020, approximately 81% and 72%, respectively, of the Company's revenue was related to the AVISE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; CTD test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on key suppliers for certain laboratory materials. For each of the three and six months ended June&#160;30, 2021 and 2020, approximately 97% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay that is immaterial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janssen Promotion Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement effective on August 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Janssen Agreement, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for that quarter over a predetermined baseline. For the first and second quarters of 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended to adjust the predetermined average baseline for the third and fourth quarters of 2020. The Janssen Agreement was further amended in June 2020 and December 2020 to adjust the predetermined average baseline for prescribed units for the quarters ending December 31, 2020 and March 31, 2021 and was subject to further adjustment under certain circumstances. In June 2021, the Janssen Agreement was again amended to proportionally increase the baseline for prescribed units for the quarter ended June 30, 2021 to reflect the addition of certain geographies to the sales territories covered by the Janssen Agreement. For the first and second quarters of 2021, the Company is entitled to an amended tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units, and the Company is entitled to receive a promotion fee of at least $0.3&#160;million, but capped at 10% above the adjusted predetermined baseline. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Janssen Agreement's termination, the Company is entitled to receive an aggregate of $0.6 million in consideration. During the remainder of the term of the Janssen Agreement and the 9 month period immediately following its termination on August 31, 2021, the Company will be restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's obligations relating to sales and co-promotion services for SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the Amended Janssen Agreement is cancelable. The Company recognized co-promotion revenue of approximately $0.3 million and $2.1 million during the three months ended June&#160;30, 2021 and 2020, respectively. The Company recognized co-promotion revenue of approximately $0.6 million and $2.1 million during the six months ended June&#160;30, 2021 and 2020, respectively. The related expenses for marketing SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are included in selling, general and administrative expenses and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $0.6 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.6 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $1.0 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and six months ended June&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,123,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,677,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,123,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,677,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,938,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,114,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,938,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,114,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Assistance Grant Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and the net amount is included in other income in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDI_716b392c-2e28-4d97-bc69-3b5670cc4a37">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTU_4aaf75c7-a720-457c-b6a0-7fd6b196518d">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Accounts Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Blue Shield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less than 10%.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib4abda3c45354b949166899b405e3a62_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfMy0yLTEtMS0w_11e2a58c-0065-4dce-99bf-d882aef05fc0"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0dced9e9019345d899c2982db367d60d_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfMy00LTEtMS0w_43c9833c-9423-4b7a-8e06-88c82528d5c8"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i37a9723325ae40058c158c22778b76a5_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfMy02LTEtMS0w_62e031e7-7bc8-4ffe-b1f4-2cfe8e510612"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic10ddfd5136e4061b9973d178e27ba18_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfMy04LTEtMS0w_4820aed8-d466-47db-8115-38d1e8409fd3"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaea277eb7cbf4254adf6026f29375664_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC0yLTEtMS0xNjM3_4390c0d2-81f2-4731-b541-3a5e369fa15f"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7d8f685d9b944f60b9103e1913818ac9_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC02LTEtMS0xNjM3_d28e220a-72ec-408d-81fc-9a4a1ddbfb17"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6abedb7e04b40e8aeec6aa02680f33b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC04LTEtMS0xNjM3_df644eec-51d8-45dc-8767-15e67dff555d"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7128036de6754666b5f3a81736dcc5fa_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNS0yLTEtMS0xNjQy_8a4fda36-2728-4c9a-b7f3-98ce72a77430"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2586bfebd6614d1488d082744fec8ef5_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNS00LTEtMS0xNjQy_3708ef87-be67-4c09-8aec-5752d8684ef8"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7ee787030d814685ab554a163cf5e574_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNS02LTEtMS0xNjQy_53f538e9-4084-43ce-b42b-695248fc18ce"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9fb609bc49d8411aacdd2e672d62eb26_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNS04LTEtMS0xNjQy_77acdd3c-dca0-4dfe-abdd-4a2455d0038f"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i453f98cffb604fd48828fd1e8ee2d430_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC00LTEtMS0w_f3c60e28-8d2c-457f-af14-3c56302e3e71"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibac162d49bd04ab38540f0d788ab7b01_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjdhYjE0MDg3MjA1OTRhY2ZiNjVkNmRlYmQxNTFkYTc3L3RhYmxlcmFuZ2U6N2FiMTQwODcyMDU5NGFjZmI2NWQ2ZGViZDE1MWRhNzdfNC04LTEtMS0w_032a1c6d-6c1b-412e-8934-e64302e1b7e5"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i835d56825d0a476da36bc88326650f02_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjgzMDdlMjQyOTExODQ0MWU4M2ExNWIyMWU3MDIxZTQ5L3RhYmxlcmFuZ2U6ODMwN2UyNDI5MTE4NDQxZTgzYTE1YjIxZTcwMjFlNDlfMy00LTEtMS0xNjEz_f668454e-12c2-40dc-bb97-a436eaedfe73"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id3751d07906149e5b585fd8950ac1b5f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjgzMDdlMjQyOTExODQ0MWU4M2ExNWIyMWU3MDIxZTQ5L3RhYmxlcmFuZ2U6ODMwN2UyNDI5MTE4NDQxZTgzYTE1YjIxZTcwMjFlNDlfMy02LTEtMS0xNjE2_afabd0cb-193e-4f39-bb1c-4867b8112f76"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifde0bcda7e7545ae9ff38a215ba73eca_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjgzMDdlMjQyOTExODQ0MWU4M2ExNWIyMWU3MDIxZTQ5L3RhYmxlcmFuZ2U6ODMwN2UyNDI5MTE4NDQxZTgzYTE1YjIxZTcwMjFlNDlfNC00LTEtMS0xNjIx_f4e9d524-6c2d-4127-92cf-e946e377f460"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i40dd1efb9e15401da3f592bff24d5574_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjgzMDdlMjQyOTExODQ0MWU4M2ExNWIyMWU3MDIxZTQ5L3RhYmxlcmFuZ2U6ODMwN2UyNDI5MTE4NDQxZTgzYTE1YjIxZTcwMjFlNDlfMy02LTEtMS0w_057dca2a-36bd-4742-bf96-fbe5c539a9d2"
      unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i68cb5038c4e341a8bb7e0d23eae19b25_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzQyOA_464e3689-a180-4dc9-9870-1e798ab1dd14"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i998b7cab204741c28fcd51dd94bad45f_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzQzNg_9829b94c-3d2f-4386-8d66-76b9f674f276"
      unitRef="number">0.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6a803537d6434bee8f5afde8a4ef80c5_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTE5Ng_29c91d7a-595b-47ba-873b-dbb8b76b9091"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic48e64747d464d9bbd1afc1bf9d6cc47_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTIwNA_32f5d818-cefb-4fbf-b62e-6777932c0f0a"
      unitRef="number">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i51f9aedf4a1c437d845bc8e10b3515a0_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzY0NQ_006c88f6-b4b2-45b7-a526-b516e89c65e6"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i39ca528d80c5424f812a294764c8b9e7_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzY0NQ_17dca416-71fe-4592-a469-560935ac60a1"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e927f12ecfb4ca884308d22fe725b51_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzY0NQ_dcf5c07e-f827-44ee-994f-a170e1f07794"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5cf77992ac8849b0b8f3496176757612_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMzY0NQ_df55ce3d-fa88-42b5-8fa2-2d3c0592e792"
      unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTY_64e92288-4547-4d6d-89ca-5bbea754c78b">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare insurers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Client(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other(2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Janssen (SIMPONI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes hospitals, other laboratories, etc.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt"&gt;Includes patient self-pay that is immaterial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc7885defdea48b79ac4c92e06b53809_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfMy0yLTEtMS0w_4a439db2-9117-4832-a4dc-9051cd50e6a5"
      unitRef="usd">7381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie91517e9ab974cbd90efe111ae240752_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfMy00LTEtMS0w_d8471268-d257-4c0f-94cc-2656f565f3ab"
      unitRef="usd">4138000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63e0cc5e4bba4bedb4ecef0c7823eed5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfMy02LTEtMS0w_2cc9f8e7-068c-457f-8f1f-39cf50dbd754"
      unitRef="usd">13408000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i568a53683fbf488c94e44430a6963b63_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfMy04LTEtMS0w_04f3cfb5-be9d-4d4d-8847-fa74a13c2b9c"
      unitRef="usd">10200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a58092b38ba40109a35c69dca20121f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNC0yLTEtMS0w_d4dddadf-e7c6-40d7-8c77-145f691f3d0a"
      unitRef="usd">2394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if21a06f4627b43ad9babcc317f3f97d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNC00LTEtMS0w_d5166685-d3a1-430f-b90f-969ef844c348"
      unitRef="usd">1807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7956a164bef94499b35cc310c4dfa294_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNC02LTEtMS0w_4060056d-276e-45c3-8607-392f5bc63d18"
      unitRef="usd">4403000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i871675045d654924b72a5dff008b67ed_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNC04LTEtMS0w_c389ecb2-839b-43b0-9ecb-74a937f95802"
      unitRef="usd">4052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9092bb8a26fc4e91aaa2cd450c799ddd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNS0yLTEtMS0w_346212ba-54d3-41b7-9111-c4b50aac272c"
      unitRef="usd">2427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a3b44a9c5c04e059b0deb00b7ec0856_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNS00LTEtMS0w_91cdc550-9fc3-423a-b962-0c2541c4644b"
      unitRef="usd">746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9891076fa8c64cd7a563f92569372319_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNS02LTEtMS0w_f9aac15e-6112-482a-88a1-3455f383ee52"
      unitRef="usd">4392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e7a7a50804f4d55974db533637b345c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNS04LTEtMS0w_cfd4678e-6299-44b0-afa3-835ff17112a1"
      unitRef="usd">1828000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0caa9d180cf9428e911a0e8958c06187_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNi0yLTEtMS0w_a1d82da2-cf34-4945-b1ee-e583325db20d"
      unitRef="usd">270000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic92986ea9525425a99124a727802cafa_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNi00LTEtMS0w_1bcaa2cc-0c5b-4d75-85f6-9d7352a0a0ad"
      unitRef="usd">206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec98ad996148414b982b48ce1fb97499_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNi02LTEtMS0w_19707bbe-4fc2-41b8-b2a3-bf9a5ac46827"
      unitRef="usd">556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9b2e1719a224e7e80ad848e2e398f17_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNi04LTEtMS0w_3c9bbcaf-6dea-48bc-bba7-255f566d1900"
      unitRef="usd">401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba69b5a6c3564f0f80195f7298100232_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNy0yLTEtMS0w_9ba69ff6-71dc-4986-987e-29286b28dc2a"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcd4bbc200954114b1e61bdcf69d26ef_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNy00LTEtMS0w_d38bc121-65c2-4bb2-b379-e40590dbfc83"
      unitRef="usd">2051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32ca735999a14a46b0051553431233d7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNy02LTEtMS0w_c07646eb-8f98-4c19-a08e-7b8af3daf1b2"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5e011876b544007978e81d4e8a12381_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfNy04LTEtMS0w_698b1b62-19fd-4be9-942c-e9b010a33ce5"
      unitRef="usd">2051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfOC0yLTEtMS0w_d309cbb5-f583-4bb4-bda1-265116c640f2"
      unitRef="usd">12772000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfOC00LTEtMS0w_064f4ba5-9d8b-4ee3-ab16-19e54b017035"
      unitRef="usd">8948000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfOC02LTEtMS0w_80b3e485-0d30-4a1e-94a5-95af8c60e96d"
      unitRef="usd">23359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjMzM2RhOTMwNzZiMDQ0NjU5MWYxODAzN2I5ZmIwMjQ0L3RhYmxlcmFuZ2U6MzMzZGE5MzA3NmIwNDQ2NTkxZjE4MDM3YjlmYjAyNDRfOC04LTEtMS0w_f861a524-619b-4961-b80e-f12ea557f69b"
      unitRef="usd">18532000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDM_37090c20-7e3a-4851-aa78-b433f6d0ecf1">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTA_c0d677a8-dfd4-483f-a5d9-3f574c6e6318">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="i06c5a5ab8a2e4bf7895c99d6d53c706e_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfNjIwOA_232466cb-beb3-415d-8dc6-0941237abf26"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMjA_15bf204f-3633-4f62-a7c4-290d1991bcec">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMjA_a1460d1c-c82a-4bef-a245-9d9661daaca2">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfMi00LTEtMS0w_fe58c77b-da81-4272-808e-d54ec2a8daa2"
      unitRef="usd">112576000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfMi02LTEtMS0w_88d20884-088a-47ce-a277-79e8de20eeec"
      unitRef="usd">57448000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfMy00LTEtMS0w_32c0647c-f328-448f-978f-d6af8213f7fb"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfMy02LTEtMS0w_095be0de-da51-44d9-877e-a9d200722d60"
      unitRef="usd">100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfNC00LTEtMS0w_0a4a4344-413d-4dd0-aa2f-96262c99e86c"
      unitRef="usd">112676000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOmE0N2U2MGQzOWQ1YzQ5NzBiM2I4ZTM2ZWI3YjI2Y2NjL3RhYmxlcmFuZ2U6YTQ3ZTYwZDM5ZDVjNDk3MGIzYjhlMzZlYjdiMjZjY2NfNC02LTEtMS0w_87790e1f-2792-4038-a0cb-69a67f19ec23"
      unitRef="usd">57548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMjE_ba33e32f-5a4f-44a5-a1c1-84c83c8bcd6f">&lt;div style="margin-top:16pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i3a0e4213bad142eaa4399139407152d9_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfOTg4Mg_c4629882-f8a3-418a-965c-d86ebd619668"
      unitRef="usd">750</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="ia28be9a1944346ff97180e2bd48e846e_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfOTg4Mg_ed218f4e-0751-4e2c-a6d5-c7fd744d94b7"
      unitRef="usd">750</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i2af77a6c91de42baa701376938862bef_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfOTg4OA_3158c55b-31ed-4a12-a721-d404a5345668"
      unitRef="usd">1250</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="iaa0c42e21a78482eb4842f031387a636_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfOTg4OA_95bfafdf-f699-4dcf-a469-dd6f3c39ac88"
      unitRef="usd">1250</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i355e8ad01573466884248e15012957d3_I20210331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5MTU_8d60c425-3253-444a-b496-bdbc94ce937d"
      unitRef="usd">500</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i997cfa266cc049a8a0eb6ce9d22ce202_I20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5MTU_a37f8e66-900c-4297-a5b6-889a25cd02a6"
      unitRef="usd">500</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i095b975d91e844528a4ecbc0d02226ab_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5MjE_48fcc296-9330-4e89-9512-40fc4a178d90"
      unitRef="usd">1000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFeePerPrescription
      contextRef="i6b212ea1c94f44ddb43e8958f910b803_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5MjE_54ff4ac7-8b1f-45de-b30d-ce9a5dc57cf5"
      unitRef="usd">1000</exdx:JointVentureQuarterlyPromotionFeePerPrescription>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i997cfa266cc049a8a0eb6ce9d22ce202_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTExNDA_c31a5e61-b5bf-485f-a63d-ef38cc7f6a64"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFee
      contextRef="i355e8ad01573466884248e15012957d3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTExNDA_ec5d8af5-4558-41b3-9042-133a20ce72bc"
      unitRef="usd">300000</exdx:JointVentureQuarterlyPromotionFee>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i0deb0612dda8455fad61349cd2e577de_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTExNzM_2034d03a-43be-4caa-bbf3-33a70364b3bd"
      unitRef="number">0.10</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTExNzM_fee41727-7c01-4483-9ed8-d53a4587af87"
      unitRef="number">0.10</exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline>
    <exdx:JointVentureTerminationConsiderationReceivable
      contextRef="iac6d296eb29947729818846e34e334fe_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY1NDIyNQ_94eb894d-1899-4280-8358-95610575aa58"
      unitRef="usd">600000</exdx:JointVentureTerminationConsiderationReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7df835bc9321482ea1c21e97a45b2b46_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTMxMzg_fe1e215c-d2bd-44f4-995e-c43ea50a7501"
      unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5cf118bed6843c49e51e3a063b2f215_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTMxNTM_a3defa91-4194-463e-9e07-aa6e896dc323"
      unitRef="usd">2100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa166a05412145609609afa9045b6c36_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTUzOA_f437282d-f070-4818-8f15-8bfe344ee515"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28ab5400a6d1441c989c0987429f31c5_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTU1Ng_6770b2b7-6947-4977-8594-08bfa93ca2d4"
      unitRef="usd">2100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTc_c1d47b98-9899-4dae-8115-e151442f2554">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTg_7402e965-fa4b-4eec-b3eb-ceb790427e87">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising and Marketing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $0.6 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTM5Mjg_7b6feadd-33d3-4ac1-9ce7-cab6ded18c1d"
      unitRef="usd">400000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTM5NDM_afec3b8f-18d0-4707-94db-43d3abc5d2e9"
      unitRef="usd">300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTYzNg_5c170de1-0e85-4ee3-ad30-358ae7ed02e8"
      unitRef="usd">600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTY1Mg_c228435f-e272-41cd-9ea4-6e242e4489e5"
      unitRef="usd">700000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTY0OTI2NzQ3MDAwNA_a1e4cb5a-cdaa-4c65-ad6d-bc99c3ee5596">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.6 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $1.0 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:CostOfRevenue
      contextRef="i6d57b7de558142c282a4c8a44d661825_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTQzMTI_b5ff031c-ad10-4eda-ae88-3e2f14e3e2fc"
      unitRef="usd">600000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i7b0ebbe6307b48fd8165e0d875dba99a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTQzMTk_abf9c47e-e3c5-4cdd-be19-d8cd7ec52ad2"
      unitRef="usd">300000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i260acc2d1e664219932adbe50ba9b56c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTcyNQ_428e4c6c-193a-4dd7-8b2c-2dc180fa2aa5"
      unitRef="usd">1000000.0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ie43b2c29a3af401db0f76f11da748e11_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTA5OTUxMTY0OTc0MQ_55a67d3f-f29b-49b4-830d-c4525b1df2f2"
      unitRef="usd">700000</us-gaap:CostOfRevenue>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDU_167c1a1d-f9e3-4404-bf41-3617b110bc53">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.&lt;/span&gt;&lt;/div&gt;The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTU0Mjg_4bbadb10-f7d2-45d5-9e02-a88c8612cfae"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDY_a2586088-aa6e-4e0d-bef3-b88028acdaac">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDQ_786aad27-0bb4-46fb-b690-700fdd5873fd">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and six months ended June&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTE_65a7ec33-7fce-4bf4-b36a-26bca8898757">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,123,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,677,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,123,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,677,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,938,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,114,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,938,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,114,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i727eef9b6d6841bfafb949eedc04adc6_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNC0yLTEtMS0w_7e4cc8f8-1073-4d70-8ee3-6869377da068"
      unitRef="shares">426827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8f3bfc019a3043dfa65e9ab76ebb83ba_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNC00LTEtMS0w_56dceb7b-f82c-4a42-874c-4db14765d770"
      unitRef="shares">426827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i748aa018ed14456e8bbd6fefdb2bb343_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNC02LTEtMS0w_22daac04-8e96-478d-a8ee-2ad62d609bc4"
      unitRef="shares">426827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0062233c30074ba2a141cbf88bac2dfc_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNC04LTEtMS0w_bec68c20-1851-49c1-af16-bdc4113c2d56"
      unitRef="shares">426827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idb7f37a50b544479a5a49d2f8a7f1de1_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNS0yLTEtMS0w_5b39cdaf-2c08-47e3-a8e9-6451976a122d"
      unitRef="shares">2123617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9cbe68f2531c41b2ac7307191c02d60f_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNS00LTEtMS0w_dcbee6a9-9444-4033-b95b-92b997179fe1"
      unitRef="shares">1677000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1de1f702c3940caa18e3c855c718b6f_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNS02LTEtMS0w_510452de-23f5-4660-bbe8-e0c7fac5f44e"
      unitRef="shares">2123617</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i70cd681b7da54b718ba2a94de49fe566_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNS04LTEtMS0w_90415c33-9302-468a-b377-a37b0c278220"
      unitRef="shares">1677000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ee2c605c05b4d7184eee467043f7f7b_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNi0yLTEtMS0w_8f931209-0bd7-4869-8e4a-3d9465d4e1da"
      unitRef="shares">375525</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i521d00286bef46b8988c748f9b09da38_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNi00LTEtMS0w_1a6ff3bb-357f-4ee5-910c-65839c0332b3"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia6c88be424ba4421b0681115a0468ff6_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNi02LTEtMS0yODc_5fc29371-c336-4dbe-9351-e88abc73a6f7"
      unitRef="shares">375525</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic3dc1550c49342788746509b902551e3_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNi04LTEtMS0yODI_1708644d-a4ae-4b04-9589-3f5f4218e335"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i21b606f430d94e608359e908e5675881_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNy0yLTEtMS0w_fe559141-ad7d-47dd-b1e7-68cb32f55647"
      unitRef="shares">12525</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i40ebe85cfda44056a48e8c86297ff80d_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNy00LTEtMS0w_21dfee8e-72e6-4422-973f-f9519cfec98e"
      unitRef="shares">10259</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ice4ce2fdc8a245879ca524ab3fef616f_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNy02LTEtMS0yODc_8d09cd70-3d19-40f8-bcfb-2182e8cd91ff"
      unitRef="shares">12525</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i50fdc73457e64ff58b4af00e94a3d47a_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfNy04LTEtMS0yODI_92c79551-5dbd-4af1-8738-e463d1f52e83"
      unitRef="shares">10259</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfOC0yLTEtMS0w_267be6a8-9508-4731-9fa1-443c315e23a6"
      unitRef="shares">2938494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfOC00LTEtMS0w_2a5237b8-b4ae-4f2e-9c95-4738e358b937"
      unitRef="shares">2114086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfOC02LTEtMS0w_96195114-b811-476b-bafe-7decae7ae791"
      unitRef="shares">2938494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RhYmxlOjkwOWVhY2JkMWFhMzQzZDdiZjQzNjc5MjY5OWM0YmJlL3RhYmxlcmFuZ2U6OTA5ZWFjYmQxYWEzNDNkN2JmNDM2NzkyNjk5YzRiYmVfOC04LTEtMS0w_4778cc2c-1f1c-4c9e-bd35-e6d6fc2da950"
      unitRef="shares">2114086</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMDE_01031d58-44c9-49cc-9f09-8ac841a09969">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMTgwNTA_7ab211d2-8ca7-4e03-a9ed-518bcdf67471"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNC9mcmFnOmE0YzJkY2M0MDc2NzQxMDg4YmM3ODc5YjFkMjQzNDUxL3RleHRyZWdpb246YTRjMmRjYzQwNzY3NDEwODhiYzc4NzliMWQyNDM0NTFfMjEzMTM_ee040fdc-4bd9-409e-bbc4-96c76fef6fd7">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Topic 842). The new topic supersedes Topic 840,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Topic 842&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: Targeted Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNjk3_69a83a78-a2dc-44d9-bf6a-3ac8cce03c22">Other Financial Information&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for each of the three months ended June&#160;30, 2021 and 2020 was approximately $0.2 million, and for the six months ended June&#160;30, 2021 and 2020, was approximately $0.4 million and $0.3 million, respectively. At June&#160;30, 2021 and December 31, 2020, the gross book value of assets under capital lease was $2.3 million and $1.2 million, respectively, and is classified in "Laboratory equipment" in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNjk4_42b88859-82e8-4967-a49a-9e9be6a38a14">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostic&#160;testing&#160;supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid product royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid maintenance and insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMS0yLTEtMS0w_84a0425f-b892-42c3-bbed-2383621b2955"
      unitRef="usd">986000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMS00LTEtMS0w_1d5f00d5-ff80-4e3b-86c8-a5f0f5d97027"
      unitRef="usd">1203000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidRoyalties
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMi0yLTEtMS0w_679c544d-cae1-4030-90d9-7aa53e3229ed"
      unitRef="usd">61000</us-gaap:PrepaidRoyalties>
    <us-gaap:PrepaidRoyalties
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMi00LTEtMS0w_e8b4e00e-c46e-4066-a63b-53435677d07e"
      unitRef="usd">68000</us-gaap:PrepaidRoyalties>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMy0yLTEtMS0w_a76ea266-cc4f-4bf3-a716-a4447ef5fe37"
      unitRef="usd">1701000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <exdx:PrepaidMaintenanceAndInsuranceContracts
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfMy00LTEtMS0w_534deb67-fc42-4639-a602-cd1b08b40de0"
      unitRef="usd">2229000</exdx:PrepaidMaintenanceAndInsuranceContracts>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfNC0yLTEtMS0w_49f827a3-df3a-4d64-9a17-13689f33fd6d"
      unitRef="usd">424000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfNC00LTEtMS0w_a9b1a75a-734e-4cac-8e71-9bc5c3444d49"
      unitRef="usd">659000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfNS0yLTEtMS0w_824c44ac-044b-4817-9544-fe73d8ac19d9"
      unitRef="usd">3172000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjk0ODdkMzQ1YjA3YzQxZjM5YzUxOTVlMDg3MDA4ZWFmL3RhYmxlcmFuZ2U6OTQ4N2QzNDViMDdjNDFmMzljNTE5NWUwODcwMDhlYWZfNS00LTEtMS0w_c4991594-ca6f-4321-963c-fb82eecf3981"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNjk0_d9f4bd68-7e94-4c9f-a236-971ae9ca4d98">Property and equipment consist of the following (in thousands):&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture&#160;and&#160;fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i019b55474b03417188ce0a6599b09a06_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMS0yLTEtMS0w_cd612064-2a7e-4110-9a07-c4b3bf3c29e7"
      unitRef="usd">83000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i48774ed5d6c94ea395c2ad9d1ab2ce4f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMS00LTEtMS0w_78d92320-05cc-4be0-8e76-b857fc127f96"
      unitRef="usd">64000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibbf9a3c919134b408f3367b2f162100b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMi0yLTEtMS0w_f2f9153f-a575-4387-8ef4-9d6e6f5b5222"
      unitRef="usd">3856000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i91228be59b0d4bbbb6dd3e4e3b5aa38f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMi00LTEtMS0w_79a08c3c-7765-4b2e-ba50-37b2bdfbd7de"
      unitRef="usd">2679000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i43f0253166e9425b97baa1464c6dadd8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMy0yLTEtMS0w_67a7cc57-3161-4270-9683-383903620628"
      unitRef="usd">1079000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0936318fe184480caddef482306a6003_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfMy00LTEtMS0w_564a93e6-26e1-49ed-b8e6-b1ea0e5722b5"
      unitRef="usd">927000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibac65fe1c3e84b0088c92074e306b603_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNC0yLTEtMS0w_090824a0-ab15-41e5-9036-5fbb18d2ce97"
      unitRef="usd">1132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifdcf495c5bbc4290af9da6a68df65ef8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNC00LTEtMS0w_2b2f9558-ac3a-4622-9729-ff015a0d8fdd"
      unitRef="usd">1072000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib6b0b82d0abe422985b1fc6559a21381_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNS0yLTEtMS0w_39b0025a-b505-4661-b2b2-a51c5984ffd3"
      unitRef="usd">252000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i838a40fa91e847cf8a46ed8a5c4fd73a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNS00LTEtMS0w_4d9d07af-7c4f-4e58-b86b-ca94a0f7f08b"
      unitRef="usd">301000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNi0yLTEtMS0w_cbef0c95-174e-4ee7-af11-b518aff3748e"
      unitRef="usd">6402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNi00LTEtMS0w_6ef7c0ed-5a8f-40ee-a218-cc610e983bee"
      unitRef="usd">5043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNy0yLTEtMS0w_998fb2b8-63df-4897-a236-9a46d8b721bd"
      unitRef="usd">3348000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfNy00LTEtMS0w_2c57f5e1-a379-437b-9506-36bf5c79d951"
      unitRef="usd">2941000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfOC0yLTEtMS0w_fd800313-d2f2-4102-9353-cec73e90566b"
      unitRef="usd">3054000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOmY0M2IwYTllNjQ4OTRlNzViNmEzMjdkZDNkYThiMTlhL3RhYmxlcmFuZ2U6ZjQzYjBhOWU2NDg5NGU3NWI2YTMyN2RkM2RhOGIxOWFfOC00LTEtMS0w_7da0c35e-1dff-43e4-b62e-095567c8d0b3"
      unitRef="usd">2102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfMzU3_040b6fbc-1dba-4fba-a52b-b157da8fa1f7"
      unitRef="usd">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfMzU3_7a13a82a-f6a4-4a74-ad8c-dd3d490e795a"
      unitRef="usd">200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfMTA5OTUxMTYyODU0Ng_28446d66-e40a-41c5-8ff7-7b463486bc0d"
      unitRef="usd">400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfMTA5OTUxMTYyODU2Mg_f44110ac-a498-4add-b008-473f35d7ab79"
      unitRef="usd">300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i878741a4ebe5465789238ff029c6bb05_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNDY3_3c69146c-03f8-484e-b879-60581952d2bd"
      unitRef="usd">2300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i78b05cb96f9b4ad39ce807d4c92ff525_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNDgy_515a0ab9-f8b0-4d8b-bc6d-61e5fd27bd31"
      unitRef="usd">1200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RleHRyZWdpb246ZmQ0ZWRjMzcwOTY2NDk0MmE2OGFhYWJhMjMxYjM5NDVfNjk1_b54bdb21-b5f0-4945-9c0f-b1f664cee641">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued&#160;payroll&#160;and&#160;related&#160;expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued purchases of goods and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued clinical study activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital lease obligations, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfMS0yLTEtMS0w_45981310-9f52-41ea-a3f3-06370a2757ba"
      unitRef="usd">3491000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfMS00LTEtMS0w_750cba1e-9e69-4fbe-a8e0-febeed542791"
      unitRef="usd">3589000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfMy0yLTEtMS0w_e6ee5c92-cfec-4bc5-a4f6-672739a94053"
      unitRef="usd">144000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfMy00LTEtMS0w_2be7856e-d166-4054-b07d-0331f9a7563b"
      unitRef="usd">147000</us-gaap:InterestPayableCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNC0yLTEtMS0w_43225c8e-4831-4cee-b14b-7aefcd94fac8"
      unitRef="usd">570000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <exdx:AccruedPurchaseGoodsAndServicesCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNC00LTEtMS0w_20655ae9-d7c4-4c06-bde7-bfcecf6ce625"
      unitRef="usd">311000</exdx:AccruedPurchaseGoodsAndServicesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNS0yLTEtMS0w_ac0e64c3-a34e-43ef-8cfe-56c3bd0ff2fe"
      unitRef="usd">193000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNS00LTEtMS0w_2cf8d93f-c55a-46ce-b8ec-911d8b54be3b"
      unitRef="usd">221000</us-gaap:AccruedRoyaltiesCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNi0yLTEtMS0w_ddfaa0b9-afef-489a-a648-07fa9166292e"
      unitRef="usd">269000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <exdx:AccruedLiabilitiesClinicalStudyCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNi00LTEtMS0w_838321d4-c32c-4dcd-b447-7732c7fdadfd"
      unitRef="usd">228000</exdx:AccruedLiabilitiesClinicalStudyCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNy0yLTEtMS0w_2c7cfdf4-b4ed-4181-a070-f8349da6b648"
      unitRef="usd">547000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfNy00LTEtMS0w_df668a0a-4e91-4ae1-9e95-ec119db8ac3f"
      unitRef="usd">308000</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfOC0yLTEtMS0w_505dd2ff-a396-4426-8da6-2a19405f1d5e"
      unitRef="usd">601000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfOC00LTEtMS0w_c3b8c119-05ae-4de9-a98f-569e246ce1a9"
      unitRef="usd">953000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfOS0yLTEtMS0w_899c2c98-6bd4-4556-b921-b57300273f58"
      unitRef="usd">5815000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iaec6a7c2a312487caf8734b58f397e25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N18zNy9mcmFnOmZkNGVkYzM3MDk2NjQ5NDJhNjhhYWFiYTIzMWIzOTQ1L3RhYmxlOjJhYTI1ZTFiNGMwYTRjNmE4NDdmNDNhYTcxZGNiZDUzL3RhYmxlcmFuZ2U6MmFhMjVlMWI0YzBhNGM2YTg0N2Y0M2FhNzFkY2JkNTNfOS00LTEtMS0w_4d70960d-d0e3-4ccb-bc08-5f297d3c5fef"
      unitRef="usd">5757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNDg2OQ_9093bce5-df23-4a19-8a62-5479fa813533">Borrowings&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At June&#160;30, 2021, no additional amounts remain available to borrow under the 2017 Term Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is 8.5%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of 8.5%. The Company has estimated the effective interest rate of this loan to be approximately 10%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTExOQ_db518ce5-2992-4221-8603-2271ebaa5ba5"&gt;twenty-four&lt;/span&gt; equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the three months ended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $0.1 million. For each of the six months ended June&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $0.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Amendment requires a prepayment premium of 2% of the aggregate outstanding principal. The prepayment premium decreases by 1% on November 19, 2021 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, the Company was in compliance with all covenants of the Loan Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Future Minimum Payments on the Outstanding Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if3aeb264ea9c49aaa65800b5d232f669_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTk3_5c62fd22-98ab-4d71-b7ba-a30b310eb80b"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i25a352deb17e46e3a01049447545824a_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMjAx_135096b0-066e-4ad2-8e13-6aa79e552b15"
      unitRef="usd">17800000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i5cae1ab4f7684fc9984e25a56c343ce2_D20181207-20181207"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMzg1_004596d4-711a-4641-8797-ec64a9faff46"
      unitRef="usd">5000000.0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ieced59f9bfea440b98b881cd100be221_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNDIx_a2092ce9-f4d2-454e-ac75-31920123817f"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNjgx_3c253710-9048-492e-8e1c-3afc65661c1a"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <exdx:DebtInstrumentStatedInterestRatePaidInKind
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNjk0_b99ae25c-e2ba-4af2-af4b-90d8dd442dc6"
      unitRef="number">0.020</exdx:DebtInstrumentStatedInterestRatePaidInKind>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfODM2_3c253710-9048-492e-8e1c-3afc65661c1a"
      unitRef="number">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfOTI3_6dd84702-35d3-4dd9-b2a6-c189ed1df4ed"
      unitRef="number">0.10</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTI5Ng_d410c6c4-1aaa-4c5f-b15c-c42246df54ae"
      unitRef="usd">1000000.0</us-gaap:DebtInstrumentFeeAmount>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="i051865121b864843a7aa6d0196c1ce5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTUxMQ_09ca4fbf-6492-42d1-a2b7-d1fa36ee3d58"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="id1bf67b90be54de7a4cb661c84afb134_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTUxMQ_2b982bd9-adf4-495d-9732-e58225657416"
      unitRef="usd">100000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="ib5205c3992de49bd94179b9de9cea768_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTA5OTUxMTYzMjc4NA_1b54259a-407d-40df-a8af-47d518cbf316"
      unitRef="usd">300000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPaidInKindLoansIssued
      contextRef="id13bd35b84c84c08b97cf25c25447a01_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTA5OTUxMTYzMjc4NA_c8b6f8fb-f69f-442e-9a94-d2937c6f2999"
      unitRef="usd">300000</exdx:DebtInstrumentPaidInKindLoansIssued>
    <exdx:DebtInstrumentPrepaymentPremiumPercentage
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTU3Ng_2ceb3d87-cd79-4d9e-8303-f999daeffcc6"
      unitRef="number">0.02</exdx:DebtInstrumentPrepaymentPremiumPercentage>
    <exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTY1NQ_5343e0bb-e8d7-4aac-b42e-b1fb7edf2a68"
      unitRef="number">0.01</exdx:DebtInstrumentPrepaymentPremiumPercentageAnnualReduction>
    <exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMjkxNQ_3c8d2f26-e20f-48c5-bbfb-26c82162a45d"
      unitRef="usd">2000000.0</exdx:DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance>
    <exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease
      contextRef="i363ecec2e07a4f4f9429105336138bb9_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNDI4Ng_3288f6f1-a592-4adf-be66-025dac026acd"
      unitRef="number">0.040</exdx:DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfNDg3MA_b25f3aac-a9d8-4a9c-8839-9e2f25e1eedf">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.837%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total borrowings, net of discounts and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfMS0yLTEtMS0w_7c28b379-7b29-4635-9888-f8b18d8498cb"
      unitRef="usd">889000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfMi0yLTEtMS0w_e02ff648-3a6a-4a1e-adf1-b2f024759fac"
      unitRef="usd">2996000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfMy0yLTEtMS0w_a9913c83-dd9a-4b28-b209-53ad71c577c8"
      unitRef="usd">15619000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfNC0yLTEtMS0w_a85531f2-9954-4e0c-8417-ffb00f658df9"
      unitRef="usd">14280000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <exdx:LongTermDebtIncludingUndiscountedInterest
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfNi0yLTEtMS0w_3c098674-bb7e-41f5-baac-d3fbdaae5361"
      unitRef="usd">33784000</exdx:LongTermDebtIncludingUndiscountedInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfOC0yLTEtMS0w_c4a14eb8-2639-4e7d-8ae7-427e96e2e2a0"
      unitRef="usd">249000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <exdx:LongTermDebtUndiscountedInterestAmount
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfOS0yLTEtMS0w_3e57ceb4-b3ee-446e-805b-c3456910414e"
      unitRef="usd">6462000</exdx:LongTermDebtUndiscountedInterestAmount>
    <us-gaap:LongTermDebt
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RhYmxlOjNiYzhlOTc5NWI1YTQ2ZTc4MDljNzAxNzI3M2U0N2E0L3RhYmxlcmFuZ2U6M2JjOGU5Nzk1YjVhNDZlNzgwOWM3MDE3MjczZTQ3YTRfMTAtMi0xLTEtMA_bb94b046-a3f8-44b8-945f-5d5c8a1c66a3"
      unitRef="usd">27073000</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfNDEwMg_6c5df197-145a-4bb6-bb1b-9b21097d7c26">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional 5-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional 5-year period. The Company's lease payments under each of these leases are subject to escalation clauses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2021 and 2020, rent expense was $0.2 million and $0.1 million, respectively. For the six months ended June&#160;30, 2021 and 2020, rent expense was $0.3 million and $0.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. As of June&#160;30, 2021 and December 31, 2020, the remaining potential milestone obligation is for an additional $2.0 million payment to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be zero at June&#160;30, 2021 and December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has ongoing royalty payment obligations of 2.5% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $1.2 million (including an upfront payment of $100,000) and (ii) the total royalties earned through January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 3.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $0.4 million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Supply Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $4.1 million and $6.0 million for the years ended December 31, 2021 and 2022, respectively, with a 15% annual increase thereafter through the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $67,000 for the three and six months ended June&#160;30, 2021. Collaboration expenses under the AHN collaboration are included in research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <exdx:OperatingLeasesRenewalTerm
      contextRef="i33be34133ab34424a1d393162ac35351_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjM5_306185cb-32d8-4f79-9c04-deb4725e5191">P5Y</exdx:OperatingLeasesRenewalTerm>
    <exdx:OperatingLeasesRenewalTerm
      contextRef="i586ccca64fab4ff3922bd68ad5ab7254_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfNDM0_fb6f505d-26b5-4f68-8678-7c1da64e09fc">P5Y</exdx:OperatingLeasesRenewalTerm>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfNTk4_920682fe-2b27-477e-bc07-d137e5fd1588"
      unitRef="usd">200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfNjEz_7328c61a-ef88-4d10-8f95-6bf93c77d4fa"
      unitRef="usd">100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTA5OTUxMTYzMTk4NQ_e0d04b34-316e-4163-a0f3-fc202fb95d5f"
      unitRef="usd">300000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTA5OTUxMTYzMjAwMg_d13447af-adac-47ab-abd2-07031db82f1d"
      unitRef="usd">200000</us-gaap:LeaseAndRentalExpense>
    <exdx:MilestoneObligation
      contextRef="ic125d46c253c46218b4ff1c223808e5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTEzMg_9a8b6e6e-cd40-4352-8fbd-2fedb0b324cb"
      unitRef="usd">2000000.0</exdx:MilestoneObligation>
    <exdx:MilestoneObligation
      contextRef="i64e5fa2583514a499a2c2e814b73a55f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTEzMg_d9749f2c-f08c-4ba2-88f5-4abab0bc180e"
      unitRef="usd">2000000.0</exdx:MilestoneObligation>
    <exdx:MilestoneContingencyFairValueDisclosure
      contextRef="ic125d46c253c46218b4ff1c223808e5f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTIzOQ_1ba56f15-3647-4cf1-a19d-b370a9c580e7"
      unitRef="usd">0</exdx:MilestoneContingencyFairValueDisclosure>
    <exdx:MilestoneContingencyFairValueDisclosure
      contextRef="i64e5fa2583514a499a2c2e814b73a55f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTIzOQ_c1f4dcfb-07e5-4f6c-90d7-61c28aee21bd"
      unitRef="usd">0</exdx:MilestoneContingencyFairValueDisclosure>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="ieca6b551f41048dbac2cc2f24a067a81_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTM5Nw_b1fc875d-9c69-4489-831a-912f5c567620"
      unitRef="number">0.025</exdx:RoyaltyObligationPercentageOfSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="ic125d46c253c46218b4ff1c223808e5f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTQ5Ng_3c433610-738b-4ff2-8c8b-a53a72cdbf35"
      unitRef="usd">1200000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <exdx:AdvancePayment
      contextRef="ic125d46c253c46218b4ff1c223808e5f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTU0MA_16dc4c13-83ea-42fb-bf02-745a2a43c772"
      unitRef="usd">100000</exdx:AdvancePayment>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i6ce02fbc4e20421e91f360d2257a0bdf_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTk0Mg_1450e53f-b2a5-4439-a140-28e79cadce26"
      unitRef="number">0.015</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:RoyaltyObligationPercentageOfSales
      contextRef="i176ded5488ca41bf8f320b2151888cff_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTk0OA_310c7433-1459-49b6-b671-f37b318bb4d0"
      unitRef="number">0.030</exdx:RoyaltyObligationPercentageOfSales>
    <exdx:LicenseAgreementInitialLicenseFee
      contextRef="if4f0c91b62b144c98930aada725aeb5f_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjQyNA_9c2b7f51-79da-4649-8e2d-b4e6bad726dd"
      unitRef="usd">400000</exdx:LicenseAgreementInitialLicenseFee>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjYxMQ_2065f9d5-dc55-4afc-ba64-8dc3e71b2158"
      unitRef="usd">4100000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjYyNg_6733d748-98c3-49f1-a330-b56c536ce453"
      unitRef="usd">6000000.0</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMjcwNg_54643166-8cb3-4364-8f1b-b58ce5864b94"
      unitRef="number">0.15</exdx:PurchaseObligationAnnualIncreaseInCommitmentPercentage>
    <exdx:CollaborationAgreementAnnualCollaborationFee
      contextRef="ib81bf8c979f84fd29d5b105929b0d3ce_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMzAwNw_49e5f129-93ed-4ee5-b2b0-b3ec536de7b3"
      unitRef="usd">400000</exdx:CollaborationAgreementAnnualCollaborationFee>
    <exdx:CollaborationAgreementCollaborationExpenses
      contextRef="i9e6063862f0049ad920ccdded39326b3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTA5OTUxMTYzMjMwMA_4574f63e-66c3-4553-8e80-dc36a277b6dc"
      unitRef="usd">67000</exdx:CollaborationAgreementCollaborationExpenses>
    <exdx:CollaborationAgreementCollaborationExpenses
      contextRef="i17ac12b6a47847b39613a583f3715e22_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180My9mcmFnOjY2NjdkN2UzN2NlMTQ0OGZhNWQ3OWMyOGM5ZjVhZjhmL3RleHRyZWdpb246NjY2N2Q3ZTM3Y2UxNDQ4ZmE1ZDc5YzI4YzlmNWFmOGZfMTA5OTUxMTYzMjMwMA_b408bda4-dc3f-4f89-8d85-08df3ab2a6fb"
      unitRef="usd">67000</exdx:CollaborationAgreementCollaborationExpenses>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RleHRyZWdpb246MDFkYWE4Yjg4MWY3NDNjYmFlNTIxZTQxZjhlMzFlMTdfMjk4_4cac833c-349d-4c44-bc23-757ebb3d7609">Fair Value Measurements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of the Company's money market funds is based on quoted market prices.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RleHRyZWdpb246MDFkYWE4Yjg4MWY3NDNjYmFlNTIxZTQxZjhlMzFlMTdfMjk5_b7bd71c5-a5d7-42cc-ab30-f4ac2bc61cfa">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds, included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie918642c1b394009ad0b69833a6119be_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOjIwY2ViMGIxNGMyODQxMTE4MDY2NDhhNGM3ZjBkMDBlL3RhYmxlcmFuZ2U6MjBjZWIwYjE0YzI4NDExMTgwNjY0OGE0YzdmMGQwMGVfMy0yLTEtMS0w_db2499e8-9f1a-4e38-b913-b37721189d2e"
      unitRef="usd">105719000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5d194d9380fc4177be4de2c4474844a3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOjIwY2ViMGIxNGMyODQxMTE4MDY2NDhhNGM3ZjBkMDBlL3RhYmxlcmFuZ2U6MjBjZWIwYjE0YzI4NDExMTgwNjY0OGE0YzdmMGQwMGVfMy00LTEtMS0w_c02e7b1b-34ce-4ebb-9b70-cc3f5358e42b"
      unitRef="usd">105719000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i239c9597bcdc4b76b9572e7dc62e7793_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOjIwY2ViMGIxNGMyODQxMTE4MDY2NDhhNGM3ZjBkMDBlL3RhYmxlcmFuZ2U6MjBjZWIwYjE0YzI4NDExMTgwNjY0OGE0YzdmMGQwMGVfMy02LTEtMS0w_a658343e-9085-452d-9d34-acdb1ae2be8a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i88553bc1fc4946cfacf88eb4b595623d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOjIwY2ViMGIxNGMyODQxMTE4MDY2NDhhNGM3ZjBkMDBlL3RhYmxlcmFuZ2U6MjBjZWIwYjE0YzI4NDExMTgwNjY0OGE0YzdmMGQwMGVfMy04LTEtMS0w_057725a7-c544-4fe5-bf12-e6bb94ffdb2a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i21c725659c554256894e6753bca963bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOmYyYTgwYjk4MTY0NjQ2N2VhNThlYzMyMjdiMzM0M2U1L3RhYmxlcmFuZ2U6ZjJhODBiOTgxNjQ2NDY3ZWE1OGVjMzIyN2IzMzQzZTVfMy0yLTEtMS0w_e6eb5cbf-78aa-44e1-98b7-7036bc6aa8bf"
      unitRef="usd">34507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9801f382d4c346349a3739ac75eb6c29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOmYyYTgwYjk4MTY0NjQ2N2VhNThlYzMyMjdiMzM0M2U1L3RhYmxlcmFuZ2U6ZjJhODBiOTgxNjQ2NDY3ZWE1OGVjMzIyN2IzMzQzZTVfMy00LTEtMS0w_b1ab74d1-1471-49fd-8f6a-cd7b318e7552"
      unitRef="usd">34507000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib2a0e15468d14f1d800e862e526e0bd8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOmYyYTgwYjk4MTY0NjQ2N2VhNThlYzMyMjdiMzM0M2U1L3RhYmxlcmFuZ2U6ZjJhODBiOTgxNjQ2NDY3ZWE1OGVjMzIyN2IzMzQzZTVfMy02LTEtMS0w_2bcc54e0-fd00-4b1e-9ee7-749f9ae22a6e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iad87945e18794ca292bc45b973f89c11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180Ni9mcmFnOjAxZGFhOGI4ODFmNzQzY2JhZTUyMWU0MWY4ZTMxZTE3L3RhYmxlOmYyYTgwYjk4MTY0NjQ2N2VhNThlYzMyMjdiMzM0M2U1L3RhYmxlcmFuZ2U6ZjJhODBiOTgxNjQ2NDY3ZWE1OGVjMzIyN2IzMzQzZTVfMy04LTEtMS0w_10e909f0-d36a-4db8-ab31-1f13a295f086"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfODcz_dd416f80-9208-48a3-88d4-e986731c05c2">Stockholders' Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2021, the Company completed a public offering of 4,255,000 shares of its common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, after deducting underwriting discounts and commissions and offering expenses of $4.4 million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an Investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of 804,951 shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of 804,951 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.001 per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 4.99% of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of June&#160;30, 2021, none of the Exchange Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Outstanding Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of June&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252,798&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i045a54532883447b9ba4d8e5b2a6eae3_D20201110-20201110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMjEz_d3d4c9df-a823-4edf-9885-a5fa1b72e366"
      unitRef="shares">150000000.0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie922f6d9a6124200b1afa6562935970c_D20210325-20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfNDMx_e0051d67-6a4b-4efe-b65c-285ab5b9bad3"
      unitRef="shares">4255000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ie15d6bb2bda3454aac07113283b3188f_I20210325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfNDkx_2917e809-673a-49bd-b860-f51a851fd338"
      unitRef="usdPerShare">16.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie922f6d9a6124200b1afa6562935970c_D20210325-20210325"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfNTU1_e239e00d-08ef-4fc4-a584-d4d092646c58"
      unitRef="usd">64700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <exdx:StockIssuanceCosts
      contextRef="ie15d6bb2bda3454aac07113283b3188f_I20210325"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfNjQ3_247c66ce-5e3a-4ef0-bcc3-287783be225a"
      unitRef="usd">4400000</exdx:StockIssuanceCosts>
    <exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants
      contextRef="i9460ad066b9b478eab9cd1f7a6a40ac1_D20210622-20210622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTA5OTUxMTYyODkyOQ_ffd116a3-a0d8-4d2c-a327-19f7a3366512"
      unitRef="shares">804951</exdx:ExchangeAgreementNumberOfSharesExchangedForWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i1f2162308c734d97b338ad4453278bb5_I20210622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTY0OTI2NzQ0NDkwNw_d088ade7-4eb4-40ad-9e31-00050bbc5f05"
      unitRef="shares">804951</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1f2162308c734d97b338ad4453278bb5_I20210622"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTA5OTUxMTYyOTM1OA_28df6ac6-b728-48cc-83a2-c16aa75da169"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i9460ad066b9b478eab9cd1f7a6a40ac1_D20210622-20210622"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTA5OTUxMTYyOTYzMA_1a7fa0b7-bc87-4a46-b50c-f2840726bb15"
      unitRef="number">0.0499</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfMTY0OTI2NzQ0NDk0MA_e1f4139e-1754-422e-a54a-9f41ea18c749"
      unitRef="shares">0</exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RleHRyZWdpb246NzE0NDJmMjBiZmY3NDE5NjkxNGQ5NWZiY2JkYzc3N2NfODc2_61f56acf-e3b9-4ab5-9224-697ac82c7a67">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following equity classified warrants to purchase common stock were outstanding as of June&#160;30, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252,798&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 19, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,176&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,944&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock warrants (Exchange Warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;804,951&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 22, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,231,778&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i492e5c40d7034eaf962d0469c7c795cf_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMS0xLTEtMS0w_5aa94b3a-56df-467e-aef8-0b032a613eef"
      unitRef="shares">252798</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i492e5c40d7034eaf962d0469c7c795cf_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMS0zLTEtMS0w_daf18f9a-c7ce-4314-95a2-4b2b2a1cb664"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i071b488b09a1417c91811e6d8f3d29b3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMi0xLTEtMS0w_777b0c95-90c0-4b0a-9719-0f424298557b"
      unitRef="shares">69176</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i071b488b09a1417c91811e6d8f3d29b3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMi0zLTEtMS0w_9596d737-d318-40f8-ae69-9f05dad7ddbf"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i73ee8d512a0840b190f350455a2ed1a9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMy0xLTEtMS0w_bb146a23-5bef-48d0-8926-833b3758fdff"
      unitRef="shares">131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i73ee8d512a0840b190f350455a2ed1a9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfMy0zLTEtMS0w_dee3c2fa-0af2-43e1-a4ff-895bc98a7349"
      unitRef="usdPerShare">1.84</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7e5761e4153746f5a98d6355c0258668_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNC0xLTEtMS0w_b53629a8-b152-4acc-81dc-c4bf154e491f"
      unitRef="shares">83778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7e5761e4153746f5a98d6355c0258668_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNC0zLTEtMS0w_1389040a-f450-420c-a27f-65e8b4c3e362"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i51452bd995b44c0083d3c57b6f6acef2_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNS0xLTEtMS0w_5ecfb672-d599-45f6-ba69-7e1df717fed1"
      unitRef="shares">20944</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i51452bd995b44c0083d3c57b6f6acef2_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNS0zLTEtMS0w_8daa1a31-ece8-4e07-acd8-dcf25b7e245a"
      unitRef="usdPerShare">14.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia9815b27e2974facbe3b603ea097a3f5_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNi0xLTEtMS02NDc_ca8a880b-8ead-4496-a428-afba01721b87"
      unitRef="shares">804951</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia9815b27e2974facbe3b603ea097a3f5_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNi0zLTEtMS05NTE_aef78a5b-f6cf-48b3-a935-c09506fa2e30"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8717a2bf86c340c089d364c29e6c135d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180OS9mcmFnOjcxNDQyZjIwYmZmNzQxOTY5MTRkOTVmYmNiZGM3NzdjL3RhYmxlOjg5NmFkY2MxN2RlYTRlZWM4ZDhiY2U1ZDQyMzY4ZGQzL3RhYmxlcmFuZ2U6ODk2YWRjYzE3ZGVhNGVlYzhkOGJjZTVkNDIzNjhkZDNfNi0xLTEtMS0w_4c1c93f7-6a7e-4b56-83ff-d275b58eaf4f"
      unitRef="shares">1231778</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzA0MA_09952ac1-6527-40c5-992f-fecc252cfb1a">Stock Option Plan&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. As of June&#160;30, 2021, 1,112,598 shares of common stock remained available for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of June&#160;30, 2021, 345,493 shares of common stock remained available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,123,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,123,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of June&#160;30, 2021, total unrecognized compensation cost related to option awards was $9.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.4&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, all of the outstanding restricted stock units are unvested. As of June&#160;30, 2021, total unrecognized compensation cost related to restricted stock units was $6.0 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83%-84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense for the ESPP was immaterial for the three and six months ended June&#160;30, 2021 and 2020. As of June&#160;30, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was an immaterial amount, which is expected to be recognized over a remaining weighted-average vesting period of 0.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i380b31af79e04aba8a6b53172095dbb6_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfNTM2_c5cdc72c-1aca-4a19-9f4b-ff07c4485407">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i380b31af79e04aba8a6b53172095dbb6_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfNjcx_d554ceab-eee6-42a0-a105-d64a14e62d21">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ic82819fc6d4c4f04baba439733edc724_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfNzA4_f8910b18-6f5f-44e9-8b21-9e716df346cc"
      unitRef="shares">1112598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i0298f7cc8a044f3ea0148fea59992a10_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMTExMw_b621c197-f7c0-4142-8d32-1bfdeb58c191"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0298f7cc8a044f3ea0148fea59992a10_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMTE1OA_14f82e93-8f31-4076-923b-f55bb4924b4a"
      unitRef="shares">345493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzA0MQ_f1be83e4-1de2-4414-a921-d83665280b20">Stock option activity under the Company's 2019 Plan is set forth below:&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(54,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,123,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,123,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;812,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4ffae978ff094b5595bb90b4291d7670_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMS0yLTEtMS0w_174d6893-dcca-402e-9ba0-97f93fe982e8"
      unitRef="shares">1975761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4ffae978ff094b5595bb90b4291d7670_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMS00LTEtMS0w_ce5e41d9-3c2c-419e-a995-4289a80b7bd5"
      unitRef="usdPerShare">11.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7ac35630d5b74bbdb0694e77844fc22f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMS02LTEtMS0w_00dc2352-10f3-4bfd-b807-2d42f17c1be3">P8Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4ffae978ff094b5595bb90b4291d7670_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMS04LTEtMS0w_d90115ca-ea77-4ff5-8cd4-6fbfb9c4fc69"
      unitRef="usd">6750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMi0yLTEtMS0w_194d4149-a521-4175-b7f1-d934aad5e07a"
      unitRef="shares">214850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMi00LTEtMS0w_f93230ef-e92f-4a2f-b155-e3f7611fad9e"
      unitRef="usdPerShare">17.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMy0yLTEtMS0w_6896a6bf-c306-40de-881e-35440129129c"
      unitRef="shares">9436</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfMy00LTEtMS0w_c2299d0b-4356-45a7-82ce-795b8c8c989a"
      unitRef="usdPerShare">8.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNC0yLTEtMS0w_e7ad49aa-39b7-4093-899e-7b5e41d6b1bd"
      unitRef="shares">54766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNC00LTEtMS0w_68d5a8d5-b783-46d9-9eb1-76a0bc0f2335"
      unitRef="usdPerShare">12.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNS0yLTEtMS0w_0b827e0c-beee-4e74-9c80-b37afacd4570"
      unitRef="shares">2792</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNS00LTEtMS0w_77827af1-4dfb-46c5-99db-2d3588124666"
      unitRef="usdPerShare">26.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNi0yLTEtMS0w_1b034b3e-a9e9-4255-81b9-795b5baa2d51"
      unitRef="shares">2123617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNi00LTEtMS0w_5337c897-1ebf-48e6-96ad-758794a22ea7"
      unitRef="usdPerShare">12.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNi02LTEtMS0w_3ec6307e-c3d6-495b-9fcc-47400c1cffe4">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNi04LTEtMS0w_66c68eb7-def5-4a50-b9aa-0c599eb73d7e"
      unitRef="usd">8932000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNy0yLTEtMS0w_16505a5d-8a53-4a0c-9f93-354952f499fe"
      unitRef="shares">2123617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNy00LTEtMS0w_dc6c28c5-f960-4f3d-8f96-4a1891583063"
      unitRef="usdPerShare">12.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNy02LTEtMS0w_0d0b66aa-cfc4-43fa-8250-481241342ed0">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfNy04LTEtMS0w_d960ed8c-3833-4106-b3cc-104f4e2fceae"
      unitRef="usd">8932000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfOC0yLTEtMS0w_01da33d8-bab6-4137-b0e5-ceed9be34001"
      unitRef="shares">812611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfOC00LTEtMS0w_f79347eb-6771-4072-80c6-686ce7b741cb"
      unitRef="usdPerShare">10.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfOC02LTEtMS0w_d09e27ea-23a0-4ba7-884a-c2ab695601bf">P7Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmM4ODJkNWQ4NTIyMTQzZDY5OWVkZjJmYWNmNWJiZmVhL3RhYmxlcmFuZ2U6Yzg4MmQ1ZDg1MjIxNDNkNjk5ZWRmMmZhY2Y1YmJmZWFfOC04LTEtMS0w_c8071346-00a6-441c-b445-9de20b0d6a1e"
      unitRef="usd">5125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0759ea92cd33439d8ee655337f3ca564_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMTUzMQ_edb40a79-946a-4621-847d-20cb516bb4fe"
      unitRef="usd">9100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMTYzMA_19a53e12-a2bb-4d9a-9a74-e8ac9b772e54">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzA0Mg_908dbbbf-d378-4c9e-8e7b-15d38d90f241">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company's 2019 Plan is set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;389,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Awards canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMS0yLTEtMS0w_ab2364e7-a475-4f61-b6c0-c663d4a7bd03"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMS00LTEtMS0w_09e41bac-14e4-4262-b5da-6bd88d938515"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMS02LTEtMS0w_19f8c427-dc7a-4c83-aea1-3e8b4a07c6e1"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMi0yLTEtMS0w_8debe7f9-5eb2-4e0c-9a4c-2520b9d69232"
      unitRef="shares">389700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMi00LTEtMS0w_00509269-3dce-4c7d-b3af-71649d8c0dff"
      unitRef="usdPerShare">17.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMy0yLTEtMS0w_d60ca452-04c0-4a24-a73d-3c8014b23a94"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfMy00LTEtMS0w_5b78fee5-2ff0-4957-859b-e279ddf03de3"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNC0yLTEtMS0w_53c93581-2471-40e1-86a4-71138f03deff"
      unitRef="shares">14175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNC00LTEtMS0w_81517000-6389-47d0-8a7a-e7c667694a0e"
      unitRef="usdPerShare">16.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i809b83fd5e2949e98dfca51a6405bc5e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNS0yLTEtMS0w_b34385c5-2598-4c77-9ead-34661611009a"
      unitRef="shares">375525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i809b83fd5e2949e98dfca51a6405bc5e_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNS00LTEtMS0w_595a79f1-7401-4f67-b32d-c2f30fa13556"
      unitRef="usdPerShare">17.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i809b83fd5e2949e98dfca51a6405bc5e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjJjZjNhYjk0N2I4NzQ5ZDliYzc1OTU2NGU3MTJjZjA0L3RhYmxlcmFuZ2U6MmNmM2FiOTQ3Yjg3NDlkOWJjNzU5NTY0ZTcxMmNmMDRfNS02LTEtMS0w_102cc114-27ba-436c-9614-253b55962e08"
      unitRef="usd">5629000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i809b83fd5e2949e98dfca51a6405bc5e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMjAyMg_a853e93c-4b01-4bff-a1df-7058249fdbd2"
      unitRef="usd">6000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i435e601e80ab497ba19f6a89d3985a67_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMjEyMQ_dce47679-25c5-402b-b47c-e64a09851189">P3Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzAzNg_1437b4cf-551e-48ee-9331-5b3dee64f408">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83%-84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47%-51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8%-1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4%-1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.50-6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi0yLTEtMS0wL3RleHRyZWdpb246YTk2NzQ3M2RjOTMwNDcyYmEwMDM0MWU4NzUxZjQyZDNfNA_66a9e82d-0dbb-4bb0-9ade-e09840345bda"
      unitRef="number">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0b2f240e32a94e0091882c0f86aec9c2_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi00LTEtMS0wL3RleHRyZWdpb246NTlhMmU1ZDhiYTJhNDAxNTlmOTE2NWJhMTFlMmY1YmZfNA_749f1948-92d5-4dc3-9878-882560ba0678"
      unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi02LTEtMS0wL3RleHRyZWdpb246ZDUwZDdkZDk2NjFhNDI3MGFiNjY0ZTc1NjIyOThhZjVfNA_1a9b8059-5b2e-4d14-9c11-faf627317a5e"
      unitRef="number">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi02LTEtMS0wL3RleHRyZWdpb246ZDUwZDdkZDk2NjFhNDI3MGFiNjY0ZTc1NjIyOThhZjVfNw_bc7b6529-a416-42e3-b102-5a11ef75d801"
      unitRef="number">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi04LTEtMS0wL3RleHRyZWdpb246NTc3NDU1ODhmNGExNDhhZjhiMzkxNjRlNWY5ZWE1OWFfMTA5OTUxMTYyNzc4NA_696a2692-f09d-4eb1-8f54-e8b6cf4ab1ed"
      unitRef="number">0.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMi04LTEtMS0wL3RleHRyZWdpb246NTc3NDU1ODhmNGExNDhhZjhiMzkxNjRlNWY5ZWE1OWFfMTA5OTUxMTYyNzc5MA_84b4d883-09d7-4f58-903c-fa7a2b905ebf"
      unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy0yLTEtMS0wL3RleHRyZWdpb246NWE1YzIwOTJkZDcyNDZlN2EyZWJmMjBhYmVhOWZmOWZfNA_47f06e38-3eda-4fee-b988-054d5700df43"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0b2f240e32a94e0091882c0f86aec9c2_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy00LTEtMS0wL3RleHRyZWdpb246N2E2OTc3NGI4YzA0NDZkMGE2MGUzMjE3NTIyNDcyOTZfNA_c71bb8b8-bd9f-4f35-9540-86bfc05168fc"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy02LTEtMS0wL3RleHRyZWdpb246Y2FkYTkzZGZlNmIzNDViYzk2NjlhNmRiYWRlMDYzNWVfNA_73cbf05e-e74f-45bd-b4a1-31940fdc5ceb"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy02LTEtMS0wL3RleHRyZWdpb246Y2FkYTkzZGZlNmIzNDViYzk2NjlhNmRiYWRlMDYzNWVfNw_50ce8e5a-6435-491d-bc0b-59b22b27851f"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy04LTEtMS0wL3RleHRyZWdpb246MDg0OWY1YTQ5ZTI2NGMzNDg0ODBmNjM0ZjhmNTUwNGZfNA_bbc77f61-5175-488c-bd9d-4bdb99e3f1e8"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfMy04LTEtMS0wL3RleHRyZWdpb246MDg0OWY1YTQ5ZTI2NGMzNDg0ODBmNjM0ZjhmNTUwNGZfNw_6cc48dd9-1272-436b-996d-e554d8019679"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNC0yLTEtMS0w_8180021a-184a-43a8-bbf0-3635aa8e51dc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0b2f240e32a94e0091882c0f86aec9c2_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNC00LTEtMS0w_fa234983-6edc-45bc-a11b-d6b917208b67"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNC02LTEtMS0w_9417591e-ac8d-4a8b-b94c-f81ba410dff6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5d62d70a95534daeae255cb1227481e1_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNC04LTEtMS0w_c933109d-3fe3-4da6-8b65-31b72aa55977"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i053c7646827546d5980da48ba6995176_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS0yLTEtMS0wL3RleHRyZWdpb246ZjhjNjUyZTIyZjM1NDY1MWI4MWU5MDkyYWUyYTQ4YjdfNA_8cf3cfe3-0168-4ffe-ad02-704e79e14d87">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iddcb859bbff74e819108a02b2f35c671_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS0yLTEtMS0wL3RleHRyZWdpb246ZjhjNjUyZTIyZjM1NDY1MWI4MWU5MDkyYWUyYTQ4YjdfMTA5OTUxMTYyNzc4Mw_ec120109-4e93-4b16-b12a-99db8799b244">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i22f749fcc65a465494ce02dd6f69461e_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS00LTEtMS0wL3RleHRyZWdpb246MzJiYzNhYTJiNWM2NGY1ODk2MjIzZmMyNGNjODA4YTdfMTA5OTUxMTYyNzc4Mg_254c5904-a828-4473-afb2-94f111a644f2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iaddaedafdc194a299eae12d2f0b746f8_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS00LTEtMS0wL3RleHRyZWdpb246MzJiYzNhYTJiNWM2NGY1ODk2MjIzZmMyNGNjODA4YTdfNA_c09df3e0-b2b2-4b97-9c65-0ee0693a89d2">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7c18c0730b4c4c2f89587dfd06467595_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS02LTEtMS0wL3RleHRyZWdpb246NDA4YWQyMThmYmY3NDgwY2IyODcwMDU2ZTY1Y2UyM2VfNA_4c194f85-145b-4b66-869a-de0a7ea21426">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id749abe27a0440ca809efd67793994ed_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS02LTEtMS0wL3RleHRyZWdpb246NDA4YWQyMThmYmY3NDgwY2IyODcwMDU2ZTY1Y2UyM2VfNw_429bcef5-5d31-434a-8525-016a6e94fd2f">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0bd31cf38fcb436d84f561912752611e_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS04LTEtMS0wL3RleHRyZWdpb246M2Y5N2ZhNzlhNmY4NDVhZmIxNzJjY2NiYjQyZGZiNTVfNA_e9327669-2c13-45ed-a320-e5c69b3d5b46">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i53db86996c4a4b2aa8810e431ba1895c_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOjUzNzc3MjM5N2YyNzQwMTc5YTcyNzUyNDVkZmM1ZDE5L3RhYmxlcmFuZ2U6NTM3NzcyMzk3ZjI3NDAxNzlhNzI3NTI0NWRmYzVkMTlfNS04LTEtMS0wL3RleHRyZWdpb246M2Y5N2ZhNzlhNmY4NDVhZmIxNzJjY2NiYjQyZGZiNTVfNw_52f0a58b-cdfb-47da-b4f5-fa4862c883af">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzAzNw_dcfd6b4e-c7da-49f4-b7ae-ef878071c16d">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMi0yLTEtMS0w_f24e2c3f-5999-4d60-a151-8bb4ee77c9a3"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMi00LTEtMS0w_d9412978-9f3a-4c39-a951-3b240d585399"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMi02LTEtMS0w_e4d7bd64-d974-41bc-a273-f8c6ba25f3c0"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMi04LTEtMS0w_d804c05e-d414-49f3-84f6-cba1fa20e5bf"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMy0yLTEtMS0w_54cc142a-3e92-4b36-87ff-8f5fb779273c"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMy00LTEtMS0w_03e8be33-ee01-4c45-b479-2c5ea832d572"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMy02LTEtMS0w_52d05454-be41-4e1e-9462-54e18f5fbcaf"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfMy04LTEtMS0w_dee7aca6-bf52-46bd-8417-a612a39ad039"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNC0yLTEtMS0w_723573b3-7ad8-419e-9b39-d8e0f558b4aa"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNC00LTEtMS0w_ad3fcf52-3644-4168-86b7-f4fa079c3507"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNC02LTEtMS0w_1956a693-bb38-4598-a3b6-cec8b42afd54"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNC04LTEtMS0w_a15be596-6012-4ecd-9b28-5e336039c88e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if75c8dbe70c54994a14d260fcd24c3c5_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNS0yLTEtMS0w_e175fe74-75ce-4f81-b5f5-3b135e32d8ad">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i256e1f16559e40f99b74ba09f3487e1b_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNS00LTEtMS0w_1d68da68-6829-4b24-ae3d-f72c50d06909">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNS02LTEtMS0w_9c7cfd4a-2c54-4226-8160-18e222c5124c">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4cdc921dd79e471e828a64725c7df9ae_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmExMWQwNTY5NTIzNjRmNWI4OTI5YWYwNDBiZTFjYjQ4L3RhYmxlcmFuZ2U6YTExZDA1Njk1MjM2NGY1Yjg5MjlhZjA0MGJlMWNiNDhfNS04LTEtMS0w_e016f0e4-89f9-4afd-bd88-40f2d7860721">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i111593697c5c4ce2a7bc1181d3071e02_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMjc4OA_fef4b128-1d5e-46d7-9e3f-37ec5b6a4e98">P0Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RleHRyZWdpb246OWE3NWRjMjEyODI2NDMyZjg0OWRkMjBiMzRkYThkYjNfMzAzOA_30c23347-9174-4875-8166-89082d9aa537">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2fd1752efb344048b8a02fcfe6fb0f95_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMi0yLTEtMS0w_a965a9a5-9236-4988-a214-9eaa25a54ff0"
      unitRef="usd">61000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id5ea1131c9af47dd8588756554e13957_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMi00LTEtMS0w_654ddafc-2bbb-4406-8aa7-ec88d62f762a"
      unitRef="usd">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide3f62783fe24bacb1e4a648e4847e70_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMi02LTEtMS0w_b41da2ae-d8ad-4c7c-a87d-61d7be9e7775"
      unitRef="usd">72000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9415ee637f114999b6d5d2f67f7050fa_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMi04LTEtMS0w_9e19fe0a-c3f0-47e1-b370-b1b87d2e11ff"
      unitRef="usd">12000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e3f26179ffa4405bc060edb0ba198b2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMy0yLTEtMS0w_2d77c695-a656-4018-b313-5d4b37a45d1d"
      unitRef="usd">1049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia27e8ea51bc64e348a17908196ce969c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMy00LTEtMS0w_1764f1b1-d55e-4e0b-8162-3df036ec8204"
      unitRef="usd">564000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6de0d2e713746bb9c050c4ab98f4f51_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMy02LTEtMS0w_fc8ed307-fdb1-4286-9924-46dc06ffd3c6"
      unitRef="usd">1840000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2835a9642ebd49899501526ee781c908_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfMy04LTEtMS0w_30c7677b-d21c-4ebd-9451-b5b41346cbe0"
      unitRef="usd">986000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2bebf6fe6604b9cac9e5fcd8f81e01b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNC0yLTEtMS0w_52270eab-a421-4e22-aff5-0999f45bdf96"
      unitRef="usd">175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0827b20b427b4e6ab8c7d6c7c4a5ba90_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNC00LTEtMS0w_1e1fd058-56a4-47af-9e9c-9fedca430c94"
      unitRef="usd">77000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i504e664134704f5a90ec38a184fa703b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNC02LTEtMS0w_b94757fe-2804-44e2-bedc-18c64a4bae76"
      unitRef="usd">285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i344fc6213f364bd0844d383c9bdfc785_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNC04LTEtMS0w_967224cb-5b0a-4bcf-bd6a-fbad17fb0c05"
      unitRef="usd">80000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNS0yLTEtMS0w_14983b33-735b-41f0-8d95-8a527ac41401"
      unitRef="usd">1285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNS00LTEtMS0w_53a630e1-e8da-4eb3-b153-e80e7118d738"
      unitRef="usd">647000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNS02LTEtMS0w_c6554b87-d3a9-4ade-9202-7f41696df5e0"
      unitRef="usd">2197000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181Mi9mcmFnOjlhNzVkYzIxMjgyNjQzMmY4NDlkZDIwYjM0ZGE4ZGIzL3RhYmxlOmQwZWY4MzQ2ODUwODQ2YWU4NTE3ZWNjNjNiOWZhNWIzL3RhYmxlcmFuZ2U6ZDBlZjgzNDY4NTA4NDZhZTg1MTdlY2M2M2I5ZmE1YjNfNS04LTEtMS0w_b0a6244a-033e-4b36-952f-88ac71ff52fc"
      unitRef="usd">1078000</us-gaap:AllocatedShareBasedCompensationExpense>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock
      contextRef="i814429626dec4826a699d35e97d00de2_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMjIxMg_da6dc2f7-591d-4f58-8bc2-1dd6a323843d">COVID-19&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, including, the success of ongoing vaccination efforts, the emergence and prevalence of variant strains of COVID-19, the institution or reinstitution of shutdowns, "stay-at-home-orders" and other public health measures as well as the related economic impact of these matters on local, regional and international markets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $0.1 million. The release of valuation allowance resulted in a discrete tax benefit of $0.1&#160;million in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2020, the Company received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp;amp; Human Services' standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have been met. During the three and six months ended June&#160;30, 2020, the Company recognized $0.7 million due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its condensed statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 16, 2020, the Company entered into a promissory note (the Note) with BOKF, NA dba Bank of Oklahoma (BofO), the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $2.9 million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the Note. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.&lt;/span&gt;&lt;/div&gt;</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance
      contextRef="i717e3a6bdd9d4ede925668cdc7aa8187_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTc3Mw_a40ec91a-32d4-446e-bf0f-d2be213c1d96"
      unitRef="usd">100000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance>
    <exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit
      contextRef="i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTg1OA_ea14c739-0321-436d-9679-03605e458293"
      unitRef="usd">100000</exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit>
    <exdx:ProceedsFromGovernmentAssistance
      contextRef="i574d92d10a8b47df85aa14649bb3aa66_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTY0OTI2NzQ0NTkwNQ_c0105546-103e-470a-867c-f350c8427aad"
      unitRef="usd">700000</exdx:ProceedsFromGovernmentAssistance>
    <exdx:ProceedsFromGovernmentAssistance
      contextRef="i8ff9b89ec4ef48a49be6b5f1bde1c79d_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTA5OTUxMTYzMTczNg_78c74158-b876-4419-9b92-de6d6fd08819"
      unitRef="usd">700000</exdx:ProceedsFromGovernmentAssistance>
    <us-gaap:ProceedsFromBankDebt
      contextRef="ib7156ce287e04be6adfdde022fd8dc7f_D20200416-20200416"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N181NS9mcmFnOmViNTQ2MjZkNzI2ODRkNmRiNzI1ZTgyOGNkMzlhOTFhL3RleHRyZWdpb246ZWI1NDYyNmQ3MjY4NGQ2ZGI3MjVlODI4Y2QzOWE5MWFfMTA5OTUxMTYzMTc1Nw_01d1d796-2e97-49fa-9154-c400d7f6107c"
      unitRef="usd">2900000</us-gaap:ProceedsFromBankDebt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693332708536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXAGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-0434866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1261 Liberty Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vista,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">560-1501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,126,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001274737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693253783080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 112,576<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">8,780<span></span>
</td>
<td class="nump">8,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,172<span></span>
</td>
<td class="nump">4,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">124,528<span></span>
</td>
<td class="nump">70,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,054<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,506<span></span>
</td>
<td class="nump">5,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">133,323<span></span>
</td>
<td class="nump">78,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,450<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">5,815<span></span>
</td>
<td class="nump">5,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,265<span></span>
</td>
<td class="nump">8,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Borrowings-non-current portion, net of discounts and debt issuance costs</a></td>
<td class="nump">27,073<span></span>
</td>
<td class="nump">26,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">948<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">36,943<span></span>
</td>
<td class="nump">36,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at June&#160;30, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized at June&#160;30, 2021 and December 31, 2020; 16,126,784 and 12,652,308 shares issued and outstanding at June&#160;30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">290,272<span></span>
</td>
<td class="nump">223,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(193,908)<span></span>
</td>
<td class="num">(181,289)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">96,380<span></span>
</td>
<td class="nump">41,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 133,323<span></span>
</td>
<td class="nump">$ 78,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693254406200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">16,126,784<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">16,126,784<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693332262312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 12,772<span></span>
</td>
<td class="nump">$ 8,948<span></span>
</td>
<td class="nump">$ 23,359<span></span>
</td>
<td class="nump">$ 18,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of revenue</a></td>
<td class="nump">5,451<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
<td class="nump">10,162<span></span>
</td>
<td class="nump">7,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">11,171<span></span>
</td>
<td class="nump">8,276<span></span>
</td>
<td class="nump">21,211<span></span>
</td>
<td class="nump">17,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,514<span></span>
</td>
<td class="nump">12,365<span></span>
</td>
<td class="nump">34,668<span></span>
</td>
<td class="nump">27,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,742)<span></span>
</td>
<td class="num">(3,417)<span></span>
</td>
<td class="num">(11,309)<span></span>
</td>
<td class="num">(8,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(663)<span></span>
</td>
<td class="num">(635)<span></span>
</td>
<td class="num">(1,308)<span></span>
</td>
<td class="num">(1,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(6,410)<span></span>
</td>
<td class="num">(3,363)<span></span>
</td>
<td class="num">(12,619)<span></span>
</td>
<td class="num">(9,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,410)<span></span>
</td>
<td class="num">$ (3,363)<span></span>
</td>
<td class="num">$ (12,619)<span></span>
</td>
<td class="num">$ (8,926)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (0.71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares used to compute net loss per share, basic (in shares)</a></td>
<td class="nump">16,928,613<span></span>
</td>
<td class="nump">12,637,642<span></span>
</td>
<td class="nump">14,946,935<span></span>
</td>
<td class="nump">12,616,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares used to compute net loss per share, diluted (in shares)</a></td>
<td class="nump">16,928,613<span></span>
</td>
<td class="nump">12,637,642<span></span>
</td>
<td class="nump">14,946,935<span></span>
</td>
<td class="nump">12,616,678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693332857416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 55,659<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 220,248<span></span>
</td>
<td class="num">$ (164,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,627,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">50,537<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">220,689<span></span>
</td>
<td class="num">(170,165)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">55,659<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">220,248<span></span>
</td>
<td class="num">(164,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,640,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">47,841<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">221,356<span></span>
</td>
<td class="num">(173,528)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,627,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">50,537<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">220,689<span></span>
</td>
<td class="num">(170,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet', window );">Net exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet', window );">Net exercise of common stock warrants</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,363)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,640,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 47,841<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">221,356<span></span>
</td>
<td class="num">(173,528)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">12,652,308<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 41,839<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">223,115<span></span>
</td>
<td class="num">(181,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock in public offering, net of issuance costs of $4,435</a></td>
<td class="nump">64,709<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">64,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under Employee Stock Purchase Plan</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,209)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,925,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 101,470<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">288,951<span></span>
</td>
<td class="num">(187,498)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">12,652,308<span></span>
</td>
<td class="nump">12,652,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 41,839<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">223,115<span></span>
</td>
<td class="num">(181,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">16,126,784<span></span>
</td>
<td class="nump">16,126,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 96,380<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">290,272<span></span>
</td>
<td class="num">(193,908)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,925,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">101,470<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">288,951<span></span>
</td>
<td class="num">(187,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock in exchange for common stock warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(804,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of common stock in exchange for common stock warrant</a></td>
<td class="num">(12,775)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(12,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrant in exchange for retirement of common stock</a></td>
<td class="nump">12,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,410)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">16,126,784<span></span>
</td>
<td class="nump">16,126,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 96,380<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 290,272<span></span>
</td>
<td class="num">$ (193,908)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693249989416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693250915160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,619)<span></span>
</td>
<td class="num">$ (8,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">130<span></span>
</td>
<td class="num">(1,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">987<span></span>
</td>
<td class="nump">951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,762)<span></span>
</td>
<td class="num">(8,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(881)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(881)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from common stock issued under Employee Stock Purchase Plan</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payment on capital lease obligations</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayment of Paycheck Protection Program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,865)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in public offering, gross</a></td>
<td class="nump">69,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs related to public offering</a></td>
<td class="num">(4,407)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">64,771<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">55,128<span></span>
</td>
<td class="num">(8,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">57,548<span></span>
</td>
<td class="nump">72,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">112,676<span></span>
</td>
<td class="nump">63,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_EquipmentPurchasedUnderCapitalLease', window );">Equipment purchased under capital lease obligations</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Costs incurred, but not paid, in connection with capital expenditures</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DeferredOfferingCostsReclassifiedToEquity', window );">Deferred offering costs reclassified to equity</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DeferredOfferingCostsReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Reclassified to Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DeferredOfferingCostsReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_EquipmentPurchasedUnderCapitalLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment Purchased Under Capital Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_EquipmentPurchasedUnderCapitalLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expense and Current Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693248375976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exagen Inc. (the Company) is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring losses and negative cash flows from operating activities since inception. The Company anticipates that it will continue to incur net losses into the foreseeable future. At June&#160;30, 2021, the Company had cash and cash equivalents of $112.6 million and had an accumulated deficit of $193.9 million. Since inception, the Company has financed its operations primarily through a combination of equity financings of common stock and private placements of preferred securities, debt financing arrangements, and revenue from sales of the Company's products. Based on the Company's current business plan, management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To execute its business plans, the Company may need additional funding to support its continuing operations and pursue its growth strategy. Until such time as the Company can achieve significant cash flows from operations, if ever, it expects to finance its operations through the sale of its stock, debt financings or other strategic transactions. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its programs, product portfolio expansion plans or commercialization efforts, which could have a material adverse effect on the Company's business, operating results and financial condition and the Company's ability to achieve its intended business objectives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693250005832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed balance sheet as of June&#160;30, 2021, the condensed statements of operations and the condensed statements of stockholders' equity for the three and six months ended June&#160;30, 2021 and 2020 and cash flows for the six months ended June&#160;30, 2021 and 2020 and the related footnote disclosure are unaudited and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and with accounting principles generally accepted in the United States (GAAP) applicable to interim financial statements. In management's opinion, the unaudited interim condensed financial statements have been prepared on the same basis as the audited financial statements and include all normal adjustments, necessary for the fair presentation of the Company's financial position as of June&#160;30, 2021 and its results of operations for the three and six month periods presented. The results for the six months ended June&#160;30, 2021 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. These unaudited condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements for the year ended December 31, 2020, included in its Annual Report on Form 10-K filed with the SEC on March 16, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the condensed financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions made in the accompanying condensed financial statements include, but are not limited to revenue recognition, the fair value of financial instruments measured at fair value, the recoverability of its long-lived assets (including goodwill) and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant payors and customers are those which represent more than 10% of the Company's total revenue or accounts receivable balance at each respective balance sheet date. For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2021 and 2020, approximately 81% and 60%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test. For the six months ended June&#160;30, 2021 and 2020, approximately 81% and 72%, respectively, of the Company's revenue was related to the AVISE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CTD test.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on key suppliers for certain laboratory materials. For each of the three and six months ended June&#160;30, 2021 and 2020, approximately 97% of the Company's diagnostic testing supplies were purchased from two suppliers. An interruption in the supply of these materials would impact the Company's ability to perform testing services.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company entered into an arrangement with a financial institution with which it has an existing banking relationship whereby in exchange for the issuance of corporate credit cards, the Company agreed to obtain a $0.1 million certificate of deposit with this financial institution as collateral for the balances borrowed on these credit cards. The Company has classified the value of this certificate of deposit (including all interest earned thereon) within other assets in the accompanying balance sheets. The Company has the right to terminate the credit card program at any time. Upon termination of the credit card program and repayment of all outstanding balances owed, the Company may redeem the certificate of deposit (and all interest earned thereon).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janssen Promotion Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a co-promotion agreement (as amended from time to time, the Janssen Agreement) with Janssen Biotech, Inc. (Janssen) to co-promote SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States. In August 2021, the Company and Janssen mutually agreed to terminate the Janssen Agreement effective on August 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Janssen Agreement, the Company was responsible for the costs associated with its sales force over the course of such co-promotion. Janssen was responsible for all other aspects of the commercialization of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the Janssen Agreement. In exchange for the Company's sales and co-promotional services, the Company was entitled to a quarterly tiered promotion fee based on the incremental increase in total prescribed units of SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for that quarter over a predetermined baseline. For the first and second quarters of 2020, the tiered promotion fee ranged from $750 to $1,250 per prescription over a predetermined baseline. Due in part to COVID-19, in June 2020, the Janssen Agreement was amended to adjust the predetermined average baseline for the third and fourth quarters of 2020. The Janssen Agreement was further amended in June 2020 and December 2020 to adjust the predetermined average baseline for prescribed units for the quarters ending December 31, 2020 and March 31, 2021 and was subject to further adjustment under certain circumstances. In June 2021, the Janssen Agreement was again amended to proportionally increase the baseline for prescribed units for the quarter ended June 30, 2021 to reflect the addition of certain geographies to the sales territories covered by the Janssen Agreement. For the first and second quarters of 2021, the Company is entitled to an amended tiered promotion fee ranging from $500 to $1,000 per prescription based on the incremental increase in total prescribed units, and the Company is entitled to receive a promotion fee of at least $0.3&#160;million, but capped at 10% above the adjusted predetermined baseline. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Janssen Agreement's termination, the Company is entitled to receive an aggregate of $0.6 million in consideration. During the remainder of the term of the Janssen Agreement and the 9 month period immediately following its termination on August 31, 2021, the Company will be restricted from promoting any other biologic or Janus kinase inhibitor used for treatment of indications covered by the Janssen Agreement without first obtaining Janssen's written consent.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relating to sales and co-promotion services for SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was a series of single performance obligations since Janssen simultaneously received and consumed benefits provided by the Company's sales and co-promotional services. The method for measuring progress towards satisfying the performance obligations was based on prescribed units in excess of the contractual baseline at the contractual rate earned per unit since the Amended Janssen Agreement is cancelable. The Company recognized co-promotion revenue of approximately $0.3 million and $2.1 million during the three months ended June&#160;30, 2021 and 2020, respectively. The Company recognized co-promotion revenue of approximately $0.6 million and $2.1 million during the six months ended June&#160;30, 2021 and 2020, respectively. The related expenses for marketing SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are included in selling, general and administrative expenses and are expensed as incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $0.6 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.6 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $1.0 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and six months ended June&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,677,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,677,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,938,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,114,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,938,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,114,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Assistance Grant Income</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance grants which are unconditional when received and intended to compensate for expenses incurred or replace lost revenue are recognized when those expenses are incurred or during the period that lost revenue is experienced, and the net amount is included in other income in the accompanying condensed statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693250253368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,856&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,402&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for each of the three months ended June&#160;30, 2021 and 2020 was approximately $0.2 million, and for the six months ended June&#160;30, 2021 and 2020, was approximately $0.4 million and $0.3 million, respectively. At June&#160;30, 2021 and December 31, 2020, the gross book value of assets under capital lease was $2.3 million and $1.2 million, respectively, and is classified in "Laboratory equipment" in the table above.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Other Current Liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693248312280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Term Loan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company executed a term loan agreement (the 2017 Term Loan) with Innovatus Life Sciences Lending Fund I, LP (Innovatus) and borrowed $20.0 million, $17.8 million of which was immediately used to repay the Company's existing loan with Capital Royalty Partners II L.P. and its affiliates. On December&#160;7, 2018, the Company borrowed an additional $5.0 million under the 2017 Term Loan. At June&#160;30, 2021, no additional amounts remain available to borrow under the 2017 Term Loan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company executed the First Amendment to the Loan and Security Agreement (the 2017 Loan Amendment). The interest rate on all borrowings under the Loan Amendment is 8.5%, of which 2.0% is paid in-kind in the form of additional term loans (PIK Loans) until December of 2022, after which interest accrues at an annual rate of 8.5%. The Company has estimated the effective interest rate of this loan to be approximately 10%. Accrued interest is due and payable monthly, unless the Company elects to pay paid-in-kind interest. The outstanding principal and accrued interest on the Loan Amendment will be repaid in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkwZGNiMjQwYzdjNjQ5OTM4MTI5ZWY5MGI1OTQxNzg3L3NlYzo5MGRjYjI0MGM3YzY0OTkzODEyOWVmOTBiNTk0MTc4N180MC9mcmFnOjcxOTA2NDY3OTJmMzQ1OTM4MmFmNTliY2NmY2Q1OTQ1L3RleHRyZWdpb246NzE5MDY0Njc5MmYzNDU5MzgyYWY1OWJjY2ZjZDU5NDVfMTExOQ_db518ce5-2992-4221-8603-2271ebaa5ba5">twenty-four</span> equal monthly installments commencing in December 2022. Upon repayment of the final installment under the Loan Amendment, the Company is required to pay an additional fee of $1.0 million. This obligation is being accreted into interest expense over the term of Loan Amendment using the effective interest method. For each of the three months ended </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $0.1 million. For each of the six months ended June&#160;30, 2021 and 2020, the Company issued PIK Loans totaling $0.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment requires a prepayment premium of 2% of the aggregate outstanding principal. The prepayment premium decreases by 1% on November 19, 2021 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Amendment is collateralized by a first priority security interest in substantially all of the Company's assets, including intellectual property. The affirmative covenants of the Loan Amendment require that the Company timely file taxes, maintain good standing and government compliance, maintain liability and other insurance, provide prompt notification of significant corporate events, and furnish audited financial statements within 150 days of fiscal year end without qualification as to the scope of the audit or as to going concern and without any other similar qualification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative covenants require that the Company achieve a specified level of revenue, as measured quarterly on a rolling twelve-month basis. The consequences of failing to achieve the performance covenant may be cured if, within sixty days of failing to achieve the performance covenant, the Company issues additional equity securities or subordinated debt with net proceeds sufficient to fund any cash flow deficiency generated from operations, as defined. The Loan Amendment requires that the Company maintain certain levels of minimum liquidity and maintains an unrestricted cash balance of $2.0 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants provide, among other things, that without the prior consent of Innovatus subject to certain exceptions, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company's property, pay dividends on the Company's capital stock or make prohibited investments. The Loan Amendment agreement provides that an event of default will occur if, among other triggers, (i)&#160;the Company defaults in the payment of any amount payable under the agreement when due, (ii)&#160;there occurs any circumstance(s) that could reasonably be expected to result in a material adverse effect on the Company's business, operations or condition, or on the Company's ability to perform its obligations under the agreement, (iii)&#160;the Company becomes insolvent, (iv)&#160;the Company undergoes a change in control or (v)&#160;the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, the Company was in compliance with all covenants of the Loan Amendment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon an event of default in any of the Loan Amendment covenants, the repayment of the Loan Amendment may be accelerated, and the applicable interest rate will be increased by 4.0% until the default is cured. Although repayment of the Loan Amendment can be accelerated under certain circumstances, the Company believes acceleration of this loan is not probable as of the date of these condensed financial statements. Accordingly, the Company has reflected the amounts of the Loan Amendment due beyond twelve months of the balance sheet date as non-current.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Minimum Payments on the Outstanding Borrowings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693249747592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company leases office and laboratory space in Vista, California, under leases that expire in January 2026, with an option to extend a portion of the lease for an additional 5-year period. In addition, the Company also leases additional office space in Vista, California, under a lease that expires in January 2026 with an option to extend the lease for an additional 5-year period. The Company's lease payments under each of these leases are subject to escalation clauses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2021 and 2020, rent expense was $0.2 million and $0.1 million, respectively. For the six months ended June&#160;30, 2021 and 2020, rent expense was $0.3 million and $0.2 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related liabilities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of the medical diagnostics division of Cypress Bioscience, Inc. in 2010, the Company was required to pay certain amounts in the event that certain revenue milestones were achieved and upon the first commercial sale of a product associated with this acquisition. The acquisition also included amounts that may be due under several licensing agreements. As of June&#160;30, 2021 and December 31, 2020, the remaining potential milestone obligation is for an additional $2.0 million payment to Prometheus Laboratories, Inc. (Prometheus) for which the fair value was determined to be zero at June&#160;30, 2021 and December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has ongoing royalty payment obligations of 2.5% on net sales of products which incorporate certain acquired technologies. Future royalties payable under these arrangements are limited to the lesser of (i) an aggregate of $1.2 million (including an upfront payment of $100,000) and (ii) the total royalties earned through January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed technology for use in its diagnostic tests. In addition to the milestone payments required by these agreements as described above, individual license agreements generally provide for ongoing royalty payments ranging from 1.5% to 3.0% on net sales of products which incorporate licensed technology, as defined in such agreements. Royalties are accrued when earned and recorded in costs of revenue in the accompanying condensed statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into an exclusive license agreement with Allegheny Health Network Research Institute, or AHN, to obtain an exclusive license to AHN's patent rights in certain inventions, pursuant to which the Company paid AHN an initial license fee of $0.4 million. In addition, under the terms of the exclusive license agreement, the Company is required to pay the greater of royalties in the low single digits on net sales of diagnostic tests using the assigned patents or a flat annual minimum royalty amount, pending approvals and commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supply Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company entered into an amended supply agreement with one supplier for reagents which includes minimum annual purchase commitments of $4.1 million and $6.0 million for the years ended December 31, 2021 and 2022, respectively, with a 15% annual increase thereafter through the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a master research collaboration agreement with AHN, pursuant to which the Company is required to pay AHN a collaboration fee of $0.4 million for each year during the initial term of the agreement. Collaboration expenses under the master research collaboration agreement were $67,000 for the three and six months ended June&#160;30, 2021. Collaboration expenses under the AHN collaboration are included in research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications; including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payors and managed care organizations reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made or that the Company believes to be immaterial. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various legal proceedings that arise in the ordinary course of business activities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693249995912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The fair value of the Company's money market funds is based on quoted market prices.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693250334520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2020, the Company filed a registration statement on Form S-3 (the Shelf Registration Statement), covering the offering, from time to time, of up to $150.0 million of common stock, preferred stock, debt securities, warrants and units, which Shelf Registration Statement became effective on November 19, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, the Company completed a public offering of 4,255,000 shares of its common stock at a public offering price of $16.25 per share. Net proceeds from the offering were approximately $64.7 million, after deducting underwriting discounts and commissions and offering expenses of $4.4 million. The shares were registered pursuant to the Company's Shelf Registration Statement discussed above. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Agreement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, the Company entered into an exchange agreement (the Exchange Agreement) with an Investor and its affiliates (the Exchanging Stockholders), pursuant to which the Company exchanged an aggregate of 804,951 shares of the Company's common stock owned by the Exchanging Stockholders for pre-funded warrants (the Exchange Warrants) to purchase an aggregate of 804,951 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.001 per share. The Exchange Warrants do not expire and are exercisable at any time except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 4.99% of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's common stock, which percentage may change at the Exchanging Stockholder's election to any other percentage upon 61 days' notice to the Company. The Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity and the fair value of the Exchange Warrants was recorded as an increase to additional paid-in-capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of June&#160;30, 2021, none of the Exchange Warrants have been exercised.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Warrants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693248307992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Option Plan</a></td>
<td class="text">Stock Option Plan<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Incentive Award Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company's Board of Directors adopted, and the Company's stockholders approved, the 2019 Plan. Under the 2019 Plan, which expires in September 2029, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. The options generally expire ten years after the date of grant and are exercisable to the extent vested. Vesting is established by the Board of Directors and is generally four years from the date of grant. As of June&#160;30, 2021, 1,112,598 shares of common stock remained available for future awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Board of Directors adopted, and the Company's stockholders approved, the ESPP. The ESPP became effective on the day the ESPP was adopted by the Company's Board of Directors. The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation. As of June&#160;30, 2021, 345,493 shares of common stock remained available for issuance under the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company's 2019 Plan is set forth below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123,617&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812,611&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the fair value of the Company's common stock and the exercise price of the stock options. As of June&#160;30, 2021, total unrecognized compensation cost related to option awards was $9.1 million, which is expected to be recognized over a remaining weighted-average vesting period of 2.4&#160;years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, all of the outstanding restricted stock units are unvested. As of June&#160;30, 2021, total unrecognized compensation cost related to restricted stock units was $6.0 million, which is expected to be recognized over a remaining weighted-average vesting period of 3.7 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83%-84%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-51%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8%-1.1%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%-1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for the ESPP was immaterial for the three and six months ended June&#160;30, 2021 and 2020. As of June&#160;30, 2021, total unrecognized compensation cost related to stock purchase rights granted under the ESPP was an immaterial amount, which is expected to be recognized over a remaining weighted-average vesting period of 0.2 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693249705464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Covid-19<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReorganizationsAbstract', window );"><strong>Reorganizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock', window );">Covid-19</a></td>
<td class="text">COVID-19<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, due to the worldwide COVID-19 pandemic, the Company experienced a reduction in patient test volumes, delays in patient enrollment in ongoing and planned clinical studies, and delays in the procurement of its testing supplies. In response to the pandemic, the Company has curtailed non-essential employee travel, equipped employees with the ability to work remotely with the exception of clinical laboratory employees, and reduced marketing spend and employee headcount. The full extent to which the COVID-19 pandemic will directly or indirectly continue to impact the Company's business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, including, the success of ongoing vaccination efforts, the emergence and prevalence of variant strains of COVID-19, the institution or reinstitution of shutdowns, "stay-at-home-orders" and other public health measures as well as the related economic impact of these matters on local, regional and international markets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. The CARES Act did not have a material impact on the Company's effective tax rate or income tax provision for the three months ended March 31, 2020. Under the Tax Cuts and Jobs Act (TCJA), NOLs generated post TCJA were allowed to be carried forward indefinitely but were only allowed to offset 80% of taxable income. As a result of the CARES Act and the change to permit NOLs generated in taxable years 2018, 2019 and 2020 to offset 100% of taxable income, the Company released valuation allowance against its deferred tax assets in the amount of $0.1 million. The release of valuation allowance resulted in a discrete tax benefit of $0.1&#160;million in the first quarter of 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, the Company received $0.7 million of funding under the CARES Act Provider Relief Fund, subject to the Company's agreement to comply with the Department of Health &amp; Human Services' standard terms and conditions. The CARES Act Provider Relief Fund is a federal fund allocated for general distributions to Medicare facilities and providers impacted by the COVID-19 pandemic and is intended to support COVID-related expenses or lost revenue attributable to COVID-19. The funding received is considered a government grant which is recognized when there is reasonable assurance that the grant will be received and that conditions attached to the grant have been met. During the three and six months ended June&#160;30, 2020, the Company recognized $0.7 million due to lost revenue attributable to COVID-19, which is reflected in other income, net, on its condensed statements of operations.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 16, 2020, the Company entered into a promissory note (the Note) with BOKF, NA dba Bank of Oklahoma (BofO), the lender, evidencing an unsecured loan pursuant to the U.S. Small Business Administration (SBA) Paycheck Protection Program (PPP) of the CARES Act of approximately $2.9 million (the PPP Loan). The Company applied for and received the PPP Loan pursuant to the then published PPP qualification and certification requirements. On April 23, 2020, the SBA, in consultation with the Department of Treasury, issued new guidance that created uncertainty regarding the qualification requirements for the PPP Loan (the New Guidance). In light of the New Guidance, on May 11, 2020, the Company paid off in full the principal and interest on the PPP Loan, resulting in the termination of the Note. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 27, 2020, the Consolidated Appropriations Act, 2021 was signed into law. It provides additional COVID-19 focused relief and extends certain provisions of the CARES Act. At this time, the Company does not believe that the Consolidated Appropriations Act, 2021 has a material impact on its financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReorganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReorganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693248100584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company's cash and cash equivalents approximate fair value due to the short-term nature of these items. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the Company's long-term borrowings approximates its fair value, which is considered a Level&#160;2 input.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -&#160;&#160;&#160;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -&#160;&#160;&#160;&#160;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span></div><div style="margin-top:12pt;padding-left:94.5pt;text-indent:-72pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -&#160;&#160;&#160;&#160;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments purchased with a remaining maturity date upon acquisition of three months or less to be cash equivalents and are stated at cost, which approximates fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:16pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company's revenue has been derived from sales of its testing products and is primarily comprised of a high volume of relatively low-dollar transactions. The Company primarily markets its testing products to rheumatologists and their physician assistants in the United States. The healthcare professionals who order the Company's testing products and to whom test results are reported are generally not responsible for payment for these products. The parties that pay for these services (each, a payor) consist of healthcare insurers, government payors (primarily Medicare and Medicaid), client payors (i.e., hospitals, other laboratories, etc.), and patient self-pay. The Company's service is a single performance obligation that is completed upon the delivery of test results to the prescribing physician which triggers revenue recognition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors are billed at the Company's list price. Net revenues recognized consist of amounts billed net of allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payors. The process for estimating revenues and the ultimate collection of accounts receivable involves significant judgment and estimation. The Company follows a standard process, which considers historical denial and collection experience, insurance reimbursement policies and other factors, to estimate allowances and implicit price concessions, recording adjustments in the current period as changes in estimates occur. Further adjustments to the allowances, based on actual receipts, is recorded upon settlement. The transaction price is estimated using an expected value method on a portfolio basis. The Company's portfolios are grouped per payor (i.e. each individual third-party insurance, Medicare, client payors, patient self-pay, etc.) and per test basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing. Contracts do not contain significant financing components based on the typical period of time between performance of services and collection of consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with research and development activities are expensed as incurred and include, but are not limited to, personnel-related expenses, including stock-based compensation expense, materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies and allocated overhead including rent and utilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Marketing Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising and marketing activities are expensed as incurred. Total advertising and marketing costs were approximately $0.4 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $0.6 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively, and are included in selling, general and administrative expenses in the accompanying condensed statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling Costs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs incurred for shipping and handling are included in costs of revenue in the accompanying condensed statements of operations and totaled approximately $0.6 million and $0.3 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $1.0 million and $0.7 million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for all stock-based awards to employees and directors based on the grant-date estimated fair values over the requisite service period of the awards (usually the vesting period) on a straight-line basis. The fair value of stock options and purchases under the Company's 2019 Employee Stock Purchase Plan (ESPP) rights is determined using the Black-Scholes-Merton (BSM) option pricing model, which requires management to make certain assumptions regarding a number of complex and subjective variables. Equity award forfeitures are recorded as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BSM option pricing model incorporates various estimates, including the fair value of the Company's common stock, expected volatility, expected term and risk-free interest rates. The weighted-average expected term of options was calculated using the simplified method. The risk-free interest rate for periods within the contractual term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as the Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each restricted stock unit is determined on the grant date using the closing price of the Company's common stock on the grant date and generally vest from the grant date in four equal annual installments subject to the holder's continued service with the Company. The Company issues new shares to satisfy restricted stock units upon vesting.</span></div>The fair value of the Company's common stock is determined by using the closing price of its common stock on the corresponding date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from nonowner sources. There have been no items qualifying as other comprehensive loss and, therefore, for all periods presented, the Company's comprehensive loss was the same as its reported net loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. The weighted-average number of shares in 2021 used to compute basic and diluted shares includes shares issuable upon the exercise of pre-funded warrants at a nominal price. Potentially dilutive common stock equivalents are comprised of warrants for the purchase of common stock, options and restricted stock units outstanding under the Company's 2019 Incentive Award Plan (the 2019 Plan) and shares of the Company's common stock pursuant to the ESPP. For the three and six months ended June&#160;30, 2021 and 2020, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as the inclusion of the potentially dilutive securities would be antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB), or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), the Company meets the definition of an emerging growth company. The Company has elected to use the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Unless otherwise discussed, the impact of </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued Accounting Standards Update (ASU) 2016-02,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842). The new topic supersedes Topic 840,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU 2018-11, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: Targeted Improvements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its condensed financial statements. The effective date of this guidance for public companies is for reporting periods beginning after December&#160;15, 2018. In June 2020, the FASB issued ASU 2020-05, which delays the adoption of ASU 2016-02 for non-public entities to fiscal years beginning after December 15, 2021, and interim periods beginning after December 15, 2022. As an emerging growth company as defined in the JOBS Act, the Company has elected to delay adoption of this ASU until January 1, 2022. Topic 842 mandates a modified retrospective transition method. The Company intends to adopt the new lease standard using a cumulative effect to accumulated deficit and will elect the package of practical expedients, which among other things will allow the Company to carry forward its historical lease classification. The Company is currently evaluating the impact of Topic 842 on its condensed financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The new guidance removes certain exceptions to the general principles of ASC 740 in order to simplify the complexities of its application. These changes include eliminations to the exceptions for intraperiod tax allocation, recognizing deferred tax liabilities related to outside basis differences, and year-to-date losses in interim periods, among others. The effective date of this guidance for public companies is for fiscal years, and interim period within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance on January 1, 2021, and the adoption did not have a material impact on its condensed financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693252630680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk, by Risk Factor and Significant Payer</a></td>
<td class="text">For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Shield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Healthcare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.129%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 10%.</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The following table includes the Company's revenues as disaggregated by payor and customer category (in&#160;thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare insurers</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,408&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Client(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other(2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Janssen (SIMPONI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,532&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes hospitals, other laboratories, etc.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Includes patient self-pay that is immaterial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,677,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,677,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,938,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,114,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,938,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,114,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693249842040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid expenses table</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic&#160;testing&#160;supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid product royalties</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid maintenance and insurance contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other prepaid and other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment</a></td>
<td class="text">Property and equipment consist of the following (in thousands):<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture&#160;and&#160;fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,856&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,402&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,043&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,054&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of the following (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued purchases of goods and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical study activity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital lease obligations, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,757&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693248422712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, future minimum aggregate payments, including interest, for outstanding borrowings under the Loan Amendment are as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.837%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings, net of discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,073&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693248443080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds, included in cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693249655544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following equity classified warrants to purchase common stock were outstanding as of June&#160;30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 19, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,176</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,778</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 7, 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock warrants (Exchange Warrants)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">804,951</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.001</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 22, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,231,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693252622344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text">Stock option activity under the Company's 2019 Plan is set forth below:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123,617&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">812,611&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.47</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company's 2019 Plan is set forth below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Awards canceled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,175)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Stock Options</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions to determine the fair value of stock options granted:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83%-84%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47%-51%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8%-1.1%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4%-1.7%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.50-6.08</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions, Employee Stock Purchase Plan</a></td>
<td class="text">The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the condensed statement of operations is as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693249853000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 112,576<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 193,908<span></span>
</td>
<td class="nump">$ 181,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693251201256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Major Payers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareMember', window );">Medicare | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember', window );">Medicare Advantage | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_BlueShieldMember', window );">Blue Shield | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember', window );">United Healthcare | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI) | Revenue Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI) | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_BlueShieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_BlueShieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=exdx_ReceivableBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_UnitedHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_UnitedHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693254556664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline', window );">Joint venture quarterly promotion fee cap</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 12,772,000<span></span>
</td>
<td class="nump">$ 8,948,000<span></span>
</td>
<td class="nump">$ 23,359,000<span></span>
</td>
<td class="nump">$ 18,532,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember', window );">Janssen Promotion Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureTerminationConsiderationReceivable', window );">Termination of agreement</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFee', window );">Joint venture, quarterly promotion fee</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription', window );">Joint venture, quarterly promotion fee per prescription</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Product Concentration Risk | AVISE CTD Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Supplier Concentration Risk | Two Major Suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncement, Early Adoption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenue</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureQuarterlyPromotionFeePerPrescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Quarterly Promotion Fee Per Prescription</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureQuarterlyPromotionFeePerPrescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_JointVentureTerminationConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture, Termination, Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_JointVentureTerminationConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_JanssenPromotionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exdx_AVISECTDTestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exdx_AVISECTDTestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoMajorSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=exdx_TwoMajorSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693251115928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 12,772<span></span>
</td>
<td class="nump">$ 8,948<span></span>
</td>
<td class="nump">$ 23,359<span></span>
</td>
<td class="nump">$ 18,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember', window );">Healthcare insurers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">7,381<span></span>
</td>
<td class="nump">4,138<span></span>
</td>
<td class="nump">13,408<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_Government1Member', window );">Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,394<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">4,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_ClientMember', window );">Client</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember', window );">Janssen (SIMPONI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 2,051<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 2,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_HealthcareInsurersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_HealthcareInsurersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_Government1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_Government1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_ClientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_ClientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=us-gaap_OtherCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=us-gaap_OtherCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exdx_JanssenSIMPONIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693340529256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 112,576<span></span>
</td>
<td class="nump">$ 57,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">$ 112,676<span></span>
</td>
<td class="nump">$ 57,548<span></span>
</td>
<td class="nump">$ 63,800<span></span>
</td>
<td class="nump">$ 72,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693251064888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,938,494<span></span>
</td>
<td class="nump">2,114,086<span></span>
</td>
<td class="nump">2,938,494<span></span>
</td>
<td class="nump">2,114,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">426,827<span></span>
</td>
<td class="nump">426,827<span></span>
</td>
<td class="nump">426,827<span></span>
</td>
<td class="nump">426,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">2,123,617<span></span>
</td>
<td class="nump">1,677,000<span></span>
</td>
<td class="nump">2,123,617<span></span>
</td>
<td class="nump">1,677,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">375,525<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">375,525<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation (in shares)</a></td>
<td class="nump">12,525<span></span>
</td>
<td class="nump">10,259<span></span>
</td>
<td class="nump">12,525<span></span>
</td>
<td class="nump">10,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693252611208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Prepaid expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Diagnostic&#160;testing&#160;supplies</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="nump">$ 1,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepaid product royalties</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PrepaidMaintenanceAndInsuranceContracts', window );">Prepaid maintenance and insurance contracts</a></td>
<td class="nump">1,701<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid and other current assets</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="nump">$ 4,159<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PrepaidMaintenanceAndInsuranceContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Maintenance and Insurance Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PrepaidMaintenanceAndInsuranceContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693253603464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 6,402<span></span>
</td>
<td class="nump">$ 5,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(3,348)<span></span>
</td>
<td class="num">(2,941)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,054<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture&#160;and&#160;fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,856<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693409658760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember', window );">Assets under capital lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exdx_AssetsUnderCapitalLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693332436920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Accrued and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued&#160;payroll&#160;and&#160;related&#160;expenses</a></td>
<td class="nump">$ 3,491<span></span>
</td>
<td class="nump">$ 3,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedPurchaseGoodsAndServicesCurrent', window );">Accrued purchases of goods and services</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AccruedLiabilitiesClinicalStudyCurrent', window );">Accrued clinical study activity</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capital lease obligations, current portion</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 5,815<span></span>
</td>
<td class="nump">$ 5,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedLiabilitiesClinicalStudyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Clinical Study, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedLiabilitiesClinicalStudyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AccruedPurchaseGoodsAndServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchase, Goods and Services, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AccruedPurchaseGoodsAndServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406127&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693361832744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2018</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loan payable | Capital Royalty Partners II LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Loan repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Loan payable | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Term loan borrowings</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Term loan, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentStatedInterestRatePaidInKind', window );">Term loan, paid in-kind, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Term loan, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Term loan, fee incurred upon payment of final installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentage', window );">Term loan, prepayment premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction', window );">Term loan, annual reduction in prepayment penalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance', window );">Term loan covenant, minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease', window );">Term loan covenant, increase to interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member', window );">2017 Term loan | Paid in-kind note | Innovatus Life Sciences Lending Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_DebtInstrumentPaidInKindLoansIssued', window );">Term loan, paid in-kind loans issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPaidInKindLoansIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Paid In Kind Loans Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPaidInKindLoansIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium Percentage, Annual Reduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_DebtInstrumentStatedInterestRatePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Stated Interest Rate, Paid In-Kind</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_DebtInstrumentStatedInterestRatePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_CapitalRoyaltyPartnersIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_Term2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_Term2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=exdx_InnovatusLifeSciencesLendingFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_PaymentInKindPIKNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693248430360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Future minimum payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021 (remaining)</a></td>
<td class="nump">$ 889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">15,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">14,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtIncludingUndiscountedInterest', window );">Total</a></td>
<td class="nump">33,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LongTermDebtUndiscountedInterestAmount', window );">Interest</a></td>
<td class="num">(6,462)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total borrowings, net of discounts and debt issuance costs</a></td>
<td class="nump">$ 27,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtIncludingUndiscountedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Including Undiscounted Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtIncludingUndiscountedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LongTermDebtUndiscountedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Undiscounted Interest Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LongTermDebtUndiscountedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693332705720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating lease, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">Purchase obligation, to be paid remainder of fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase obligation, due in year one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage', window );">Annual increase in purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember', window );">AHN Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CollaborationAgreementCollaborationExpenses', window );">Collaboration agreement, collaboration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_LicenseAgreementInitialLicenseFee', window );">Initial license fee</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneObligation', window );">Remaining milestone obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_MilestoneContingencyFairValueDisclosure', window );">Remaining milestone obligation, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Future minimum royalty commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_AdvancePayment', window );">Advance royalties payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember', window );">Prometheus Laboratories | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RoyaltyObligationPercentageOfSales', window );">Royalty obligation, percent of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember', window );">Allegheny Health Network Research Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CollaborationAgreementAnnualCollaborationFee', window );">Collaboration fee</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember', window );">Office and Laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeasesRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember', window );">Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_OperatingLeasesRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_AdvancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_AdvancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementAnnualCollaborationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Annual Collaboration Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementAnnualCollaborationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CollaborationAgreementCollaborationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Collaboration Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CollaborationAgreementCollaborationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_LicenseAgreementInitialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Initial License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_LicenseAgreementInitialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneContingencyFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Contingency, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneContingencyFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_MilestoneObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_MilestoneObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_OperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_OperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Annual Increase In Commitment, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RoyaltyObligationPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation, Percentage of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RoyaltyObligationPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exdx_AHNCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_PrometheusLaboratoriesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_AlleghenyHealthNetworkResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_RentalPropertyByTypeAxis=exdx_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_RentalPropertyByTypeAxis=exdx_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693332398808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - Money market funds, included in cash and cash equivalents - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 105,719<span></span>
</td>
<td class="nump">$ 34,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">105,719<span></span>
</td>
<td class="nump">34,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693253808392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 22, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Nov. 10, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember', window );">Exchanging Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants', window );">Number of shares exchanged for warrants (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common shares to be called upon exercise of warrants (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of stock, percentage of ownership after transaction</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in public offering, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from public offering, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_StockIssuanceCosts', window );">Estimated offering expenses for aggregate expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange Agreement, Number Of Shares Exchanged For Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=exdx_ExchangingStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693250947336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">1,231,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member', window );">Warrant expiration January 19, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">252,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member', window );">Warrant expiration March 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">69,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member', window );">Warrant expiration April 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member', window );">Warrant expiration September 7, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">83,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member', window );">Warrant expiration December 7, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">20,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember', window );">No expiration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase redeemable convertible preferred stock (in shares)</a></td>
<td class="nump">804,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationJan192026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationMar312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationApr12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationSep72024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_ExpirationDec72025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=exdx_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693251019864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost | $</a></td>
<td class="nump">$ 9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards (in shares) | shares</a></td>
<td class="nump">345,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee payroll deduction percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Stock options, unrecognized compensation cost | $</a></td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options, cost not yet recognized, remaining weighted average vesting period</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member', window );">2019 Incentive Award Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares that remain available for future awards (in shares) | shares</a></td>
<td class="nump">1,112,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exdx_IncentiveAwardPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693253886568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock Option Activity (Details) - Stock options<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, December 31, 2020 (in shares) | shares</a></td>
<td class="nump">1,975,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">214,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(9,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(54,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(2,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, June 30, 2021 (in shares) | shares</a></td>
<td class="nump">2,123,617<span></span>
</td>
<td class="nump">1,975,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">17.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">8.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">12.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">26.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, June 30, 2021, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.33<span></span>
</td>
<td class="nump">$ 11.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 8,932<span></span>
</td>
<td class="nump">$ 6,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value | $</a></td>
<td class="nump">8,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 5,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, June 30, 2021 (in shares) | shares</a></td>
<td class="nump">2,123,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable, June 30, 2021 (in Shares) | shares</a></td>
<td class="nump">812,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, June 30, 2021, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options exercised, June 30, 2021, Weighted Average Exercise Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693340508344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Restricted Stock Units (Details) - Restricted stock units - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, December 31, 2020 (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">389,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards released (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards canceled (in shares)</a></td>
<td class="num">(14,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, June &#160;30, 2021 (in shares)</a></td>
<td class="nump">375,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, December&#160;31, 2020 (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">17.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">16.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, June 30, 2021 (in dollars per share)</a></td>
<td class="nump">$ 17.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5,629<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693332771800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693250404616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Option Plan - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,285<span></span>
</td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 2,197<span></span>
</td>
<td class="nump">$ 1,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="nump">1,840<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139693253544216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Covid-19 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance', window );">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit', window );">Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exdx_ProceedsFromGovernmentAssistance', window );">Proceeds from government assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=exdx_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from Paycheck Protection Program loan</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exdx_ProceedsFromGovernmentAssistance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Government Assistance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exdx_ProceedsFromGovernmentAssistance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exdx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=exdx_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=exdx_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MU'7-W'P8@;0!YOY&"/W:L4=O^ZF5O !02P,$%     @ !XH)4_!M^#HB!0
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M'%S>W%1BU9S,_2BJ2F3-Y9)'$J&U@?Q^(43U=%,?]MT>'[_X'U!+ P04
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M"S$";>&Q5S*&YA,*(!M(!"\O<_V!/AN_>]$M/0O/R1B>1VH1R'9XH!4<YQ7
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M8$G9W9%U+UH<[#731F@M:ONX9Q2BTPC [UL!E=OQQ2S0WU3>_@]02P,$%
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M'C\WR+,!WK?.Q>F&$\P_8"[_!5!+ P04    "  'B@E3B2^6JW\>  #27
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;+U<ZW/;-K;_5SC9=M>^0SF2
M_.YKQG;2;O9NMIZXZ<Z=._<#14(2&CY4@K2L_O5[?N< ($A13M+MW@]Q)!$$
M#L[[!7RSK>H/9JU4$ST5>6F^?;%NFLU7+U^:=*V*Q)Q4&U72DV55%TE#7^O5
M2[.I59+Q2T7^<CZ=7KPL$EV^^.X;_NV^_NZ;JFUR7:K[.C)M423U[E;EU?;;
M%[,7[H=W>K5N\,/+[[[9)"OUH)KWF_N:OKWTLV2Z4*7151G5:OGMBYO95[=G
M&,\#?M9J:X+/$7:RJ*H/^/(F^_;%% "I7*4-9DCHOT=UI_(<$Q$8O]HY7_@E
M\6+XV<W^/>^=]K)(C+JK\G_JK%E_^^+J192I9=+FS;MJ^U=E]W..^=(J-_PW
MVLK8L],74=J:IBKLRP1!H4OY/WFR> A>N)H>>&%N7Y@SW+(00_DJ:9+OOJFK
M;51C-,V&#[Q5?IN TR6(\M#4]%33>\UW#T*,J%I&#WI5ZJ5.D[*);M*T:LM&
MEZOHOLIUJI7YYF5#Z^&MEZF=^U;FGA^8^R)Z6Y7-VD2ORTQE_?=?$IP>V+D#
M]G;^[(1_:\N3Z'0:1_/I?/;,?*=^\Z<\W^F!^49V&?WOS<(T-3'+_SVSP)E?
MX(P7./N/8/>/FCNZ38PV&'A?*Z/*)A&!*+/HO5'X_;5I-'$X#?UIK4A2TJK8
M).4.D^BR4;4NHK0B(I9&920$>5*F*A*ED?#$1!GE*1-'#<W2O6!H046"W/!0
MTB<U V 8@N>&$O>G']95GJG:_"52O[:ZV46DB/BE9ETKQ5,8_105PFD*G-:'
MAH?0ARE_2!.SCI:DBHR?Z'->Q_A:Y01D1N]735DU*LJT2?/*M#6!0__:,FDS
MC1%X8YT\JFBA5!F1TMS0\XQ0RBBN,T;C5C=KF;?-E>"D5JLVMS@B-.#A@TK;
M6C?:CGC]E*Z3<J6BNZHHM&$5>?3P^NXXYL<\9])QPJ;69:HWF'^E2L)_GN_P
M7&T:@0=+O"\9Z(>&&>'HAYN;^^,HV6R(B9)%3@BO/#,L=4FPZR0/"'82O2E)
M,Y6DRO']+P3Z1I<$F+!#AY5]CAJ;;@QQE0!JDD)!%1-/$_?A%S?UZ$1 "&T_
M;S,:F.=1"6V>1TGV"ZE7'A)'I4J5,1 GQQ7+1-=8N9,72XD[D0W:7[?:IC):
M9&I?&F1]@H/F(E,QE(%GV#FB4;K*C -#92<LGVZB3V5@XDGB4[]'3;379494
MA4%TVW*3JJ<-&4QF;XN(EG"V)!:G?>Y44D?T.^T_JNAA[8DIH I\&#51$+8#
M.B,C2Q5M"5<DV 0"K557Q;-$C*-%2^]5Q)C82DC.3OJ 8M(1X)3%+@+_,CPF
M9+Z/,)U95VU.KP,?"4L&O?!+6XH+X475\L"?_W0UGUU^;9[G/X=(1IX0Z!61
MHE@0^DYG3"0BE=T2KPENN2G+EN9YIS95W8#SX81$L^GDOVF57&4=,"3V>/XV
MJ=-U-+L0J@LE1')Z[-M3[A_!AD6G"<0:6J!(/JA(>9,!GDT,>74;X>AFG9!9
M6"Z)C2QG80M0AP7T$0L C5=6-'.=+'3.JDTT1:!.:22!"!6&I<=?LC+';Q(\
M[O/S6XL#;;X/7:T>5=F*-$(>:!KB5=*_A++N'5:LENUOT@;4<D*4,A<!/;5F
M79MIPD<M?-ZL*Q/@[Z1GO@^CM4B(X:VJ_APB6L82"7*Z(-<%,RQ1TVVV5FE%
M<#1>8[,&?$SREG':S:U+<I!:F;Q0"0A%D#;!^-AB*:T>2<\QH=A/ 5_G5;F:
MY"SUEIY' B&VLJJJ;*OS_)AW7T)5*,(;%FB2)_^"V$BQPEC0^C,YF75HF6-A
M?BNDD9(AA%*L?QC![!+1WU4%4,2^M :?UYH\D5I# X(=:JV@R_"^*,$EN8M5
M;6=DLV*&5-Y;;;LFRX87Y5&JZ[0MB&PT,_&:3D' ?Y.O[BJ:K&PZ^;\C1.HF
M>J?-!U[T1X;>?WU/P^N& CD6J^]'"<["O2&OAP8Q!*9=_.(DW6&<N"J5I6K,
M30Q*N&R<%\*O0;+)%8O%(8.>(2IUDFE]%ZB@5-$C\C](3MH%$&07AN[OVV.>
MRCMYP9S,]FN5,YM69!O[S*R;EC'$>PM4W4+EFH2#^(:UPIH"/+>O7XDJQ-2
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MG6(Z\:G/>T)HQ6-N$""P"%+<XWTJ"H"NG@N :-[)QL^1^#F.$-\4DL27]#K
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MYH2F"5G[J \,\1 >1PJ""@V0[]M>-NF#N./= M=ZM>'W+96FC.7J(NF@1^5
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MTN%@%)WL"[_S^E,_AGN37J%>^7UF(%.-M.W0]]I^9<[;3?'+O=VWETROJ 5
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M8PNV=#C..Q;7GD5RA,6,_:QJNS'LIBY$<7A_#'4&G9)>I^OD589_;^N03:*
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M\1&%K)M5&S"R,JEM<(2CC%IR3,DMB2V $,,GATBPC3%S>;(YR'LR[#%[#W6
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M6<S4SH761@ANEL(.,DL*)X!93NQCL3B32J6%2=#\8*K-'$0F)@ !I\V0G6E
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M%Z.K^2-=*3&>!N#]QKF8O] "_6]U7_\O4$L#!!0    (  >*"5/#2J>WO04
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M:YH.43L">E\J9?<')V"8-^=_ U!+ P04    "  'B@E35UWJX>H"   /!@
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M>#VXX)+)E#,!EY*BU>ZRMQ>?@:M2N,&TUIK+)<R9X>:U!]@;V[7QR%0LQ4E
M?6I0KS"8WA4(N1+4@P[9NL<%@_30U->V $O'9ZJLF-Q\)%W'DG<L#=DP"VO4
M".66,"ERE]W*WZ:GKSOZ"T>?RMD67/H .Z8%1\UT6FS@P!^JVC"9F<,1T&MC
M]]IPIRRQ^(XK%!"W:]*N?9@9E\+(%1QNJ"OT TVQO":@'C%/14T%2 *DS!1
M^(V CS4G%CZG]Q!'P]Y)_.F%].'=:1(GGW>D<TRQ7*"&?NR91?^!67_0&T8G
MN\+?O%XKU7!G&I2HEW[F&4A5+6TS&#IM-U9GS31Y-F]F\A732RH!$)B3:W3D
MIIANYERSL:KRLV6A+$TJ+Q;T:T#M#.@\5\IN-RY ][.9_@%02P,$%     @
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MCL976%;TO4#C VC_H+4[&_Z X0NT_1]02P,$%     @ !XH)4X?U"H>.!0
M6P\  !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULM5?;;N,V$/V5@5NW
M"2#+DJR;TR2 D\WV NRND62W#T4?:&EL"9%%E:3B^.\[I&39V=I"BFX?;/$V
M9X8S9SCDY8:+)YDA*GA9%Z6\&F1*51?CL4PR7#-I\PI+FEERL6:*NF(UEI5
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MH1?0_))SM>MH!=U[^OIO4$L#!!0    (  >*"5-28'2H3 (  #T%   9
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MG''3QQ"H#S(98-ZOA=#[1F*@N!\:_@102P,$%     @ !XH)4_/<QX&I!0
MM!P  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULO5E=;^(X%/TK%MJ5
M9J79$CM H*)(%.B6T=*I2F?V8;4/;F+ .TG,V$[I2/OCUT[2!":.DZE&]('F
MXYYCWP_?XR3C ^-?Q(X0"5ZB,!97G9V4^\MN5_@[$F%QP?8D5G<VC$=8JE.^
M[8H])SA(05'818XSZ$:8QIW).+UVSR=CELB0QN2> Y%$$>;?KDG(#E<=V'F]
M\$"W.ZDO="?C/=Z2-9&?]O=<G74+EH!&)!:4Q8"3S55G"B^7;D\#4HO/E!S$
MT3'0KCPQ]D6?+(.KCJ-G1$+B2TV!U;]G,B-AJ)G4/+[FI)UB3 T\/GYEOTF=
M5\X\84%F+/R+!G)WU1EV0$ V. GE SO<DMRAON;S62C27W#(;#VG _Q$2!;E
M8#6#B,;9?_R2!^((@& - .4 U!;@Y@#W>\"P!M#+ ;VV(_1S0+\M8) #!FT!
M7@[PV@*&.6#8%C#* :.T'++\I<F?8XDG8\X.@&MKQ:8/T@I*T2KG--;%OI9<
MW:4*)R?KK,@!VX UW<9T0WT<2S#U?9;$DL9;<,]"ZE,BP._@#G..=7&"=W,B
M,0W%;^.N5+/07%T_'_$Z&Q'5C.B"%8OE3H!%')# @)_;\0,+OJN\+T* 7D-P
MC:R$'Y+X KC.>X <!#^MY^#=+R:W9NU9G'J6^8_/19"MZB[20+;X*5.ZL;.L
M,%<LL"D\?]A9YL0O6"QSN6T_%PO+LO5<X,#(<E)';K&4W)36K:&]4YW]>-UP
M%JMCG^CDO0<+S,-O8!JP?=KD__Y3H<%2DDC\8QF[5XS=2\?NU8S]0(3DU)<D
M #X6.].JS @&*8&6P.<)=/3?N/M\7)_MS/YH-#MQHU^XT;>Z\8%1U7R>5< 2
M3L#7!'-)=-CVG$4LC=N&$.7AWN2@G1HZ%X[SJVE%OA%W\^.XDY@,BI@,&E*K
MXI$0D\>#:A*0YZ%*MF95P^&H-ZPFOVJ'7+<_JA@N#",/^RZJ+0"O<-:S.CL-
MG@F75.@%1%[4CDX8'<](^D?#]PQ%.JN:N::2]RK.# QFBRJ;9RGY8>'QT.KQ
MG#[3@,0!^$9):)1#.[ZIS$;%/$96GKLD>B)<[P/41EJKO,I KCP"_ ?J16@^
MJL0%FD,"G7)3XMC[ (Z%(+'NH?FZGVXY(=49G/(?;7K@V5LU1.7HR.K=(^%J
M)X=3<A5O;'8MWTNA2G1-Q3G/[2Q%?#K94M2@VRH5[];+U?W'NZ5-*6$I5[!W
M_@24*@/MO=G24G-D4\^8&>R044\-AL;NTH+PU-M2/Z!=0%8TIE$2V2)7MF?H
MG3]O9:N$]EYWLCUX7[L_4/U+72'"YS2=B#'/PTJX^]4D5XV\?B7!+9@6;9AN
M<J.!C>G68'3,=!K9LOE#>_=O%UEC(*OMWRBR+>UNFNU.'_)*34%V35GAEX9E
M@$K]0.?7#U3J![+KQT]<!J@J+[#:[$Q6J+(06G$M6G'=H*J<5;EN35:H;C&@
M4O*07?(^RIT*'5:R)X4M8:7:H?.K'2K5#C6I7=.SX3)G:/LXATKM07;M6>_H
M?J]]QFJ'>ZM^E,'6YE6I1.C\2H1*)4)V)9HQ(?7>C=?O)%"U49N$?V:P,S90
M@UV6H\H*,RB$+9FE2""[2.3;)G!-8G\78?Y%/1>HN >)+\&,J=C'DF>[V@<J
M],WIY^5Z 6:/<_"H:M#VBJ7LXJYS]K2[9=]WH34"]X1K+W7F)9,XM.6_@6H(
M:]XKS!J @]H7&6\=<=$ ]%##,Z9;2I=KERY3":V3_3ZDJN,::^CQP, *_\MX
M86?KR>[1R[KSOZUS2T5P[>_K?JB0[%0CK[:0W@B<OQ6X> ,P"V#WZ M&1/@V
M_?PE0)J>[ UL<;7XQ#9-/RQ]=_T:7LZ@X?H<7BZR#V@E??8];X7YEL8"A&2C
MAG(N/*6%//M$EIU(MD^_GSPQ*5F4'NX(#@C7!NK^AC'Y>J('*#Y43OX'4$L#
M!!0    (  >*"5/S0]Z[J@,  ,<.   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;+5736_C-A#]*X2PAP1H(U+?#FP#B>UVLVBZ1KS;'HH>&)F6B)5(
MEZ3M[;\O12F2+<G:P(4O-DF]-\.91XTXXP,7WV1*B +?\XS)B94JM;VW;1FG
M),?RCF\)TT\V7.18Z:E(;+D5!*\-*<]L!\+ SC%EUG1LUI9B.N8[E5%&E@+(
M79YC\>\CR?AA8B'K;>&%)JDJ%NSI>(L3LB+JZW8I],RNK:QI3IBDG %!-A/K
M =TOT*@@&,0?E!SDT1@4H;QR_JV8/*TG%BQV1#(2J\($UG][,B-95EC2^_BG
M,FK5/@OB\?C-^B\F>!W,*Y9DQK,_Z5JE$RNRP)IL\"Y3+_SPD50!^86]F&?2
M_()#A846B'=2\;PBZQWDE)7_^'N5B"."MM-/<"J"TR9X9PAN17#?Z\&K"-Y[
M/?@5P81NE[&;Q,VQPM.QX <@"K2V5@Q,]@U;YXNRXJ"LE-!/J>:IZ:H\((!O
MP(HFC&YHC)D"#W',=TQ1EH ESVA,B00_@SF5.$D$2; 167->R)ZP'0$W<Z(P
MS>2M1GU=S<'-AUOP 5 &OJ1\)S%;R[&M]'8+IW9<;>VQW)IS9FLN>.9,I1(L
MV)JL>_CS87XPP+=UFNI<.6^Y>G0&#7[:L3O@PI^  QW4LY_9^^FP+YS_YWUQ
ML?>39+CUP7&-/?>,O?-GX:_?-!0\*9++OP<<>;4CSSCRSCBJS/:=GY(8&&)1
M$?=3Y(2A,[;WQZIT4='(BTY!\R[(<5U_=(I:]#B,?+=Q>!*@7P?H#P;XD>!,
MI3$61+\P<B>(D -I"VJKP77U"6M'X:7ZE$3_*%VA&Z&6/%V0A]RV/%T0<CW8
M0BUZ4/JPPWYYHCJ^:#"^7_F>"*:_C6H@6:/:V.BZJB#8%'9XJ2X5TS\Y[2.O
M)4P/"D4P;"G3@_(\Z+:4Z4-!_\R+@XX^7F@PQEE&AW5!3F/*N;(R3>5$[L7*
MN%UE/"=L*]-%A5[0%J8+\MR1TQ:FBT*1$YT1IJG9:+AH?U8I$4/):HHC\J^L
M2U,Q47"Q+D%7EQ"V9>D!P8XL79#O!VU5NB /HC.B-(4:#5?J3YA)21BX63T]
M+S___G0[E+6F/*+HR@(UQ1.-+A9HU/DTN[ C4!?D0!^U%>JB@K:IQ8],E1':
M1Q?SG(C$=$02F+MU>=6J5^NNZ\'T&JWU1W0_0SWK\Z)+,XU 8[YL\9ZQ2/1U
M F1DHUW!NU ?)E%V3>5$\:UI"UZYTDV&&::ZTR2B .CG&\[5VZ1P4/>NT_\
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M<M_6N=&%W"'X)KC.%4CYFJP[\,M^?-*#]XT.K1CH18Q;U$OX5\6O0!C\ 5"
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MXH+(K7N,*."NM?4EJ&UM'SPW[II_TGX+KQ>PHWUI'TCN#KZGKU]7W[#<4JX
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M. CTAAMS 8_>JLB*E%F^AB<&U ,ZIWHF 3C+E+;BG_*@#WN5(.K >A<$X?@
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M'7 ]?F8_\^*MF#NJ82+Y;Y:;8AP<!2B'&:VXN9*K<V@$]1U?)KGVOVC5Y.(
M994VLFS MH*2B?I)'QLCU@"DMP$0-8!H6T#< &(OM*[,RYI20]-$R152+MNR
MN<![X]%6#1/N&*^-LJO,XDQZ1IE"MY17@"Z ZDJ!/2.CT>X4#&5<[Z$#= 59
MI103<QM?2 %/M@!U;_]BLTKD>A\QD?$JA]P&**.Z0%3D=0 /%5M2[AD/T,WU
M%.WN[*$=E_BKD)6VB3H)C=7AJ@FSIN;3NN9H0\T_*G&(8KR/(AR1=^"3;O@4
M,@LG'HY?PT/K7FMAU%H8>;YX ]^)UF#T<0=3W#+%GJFW@>F_S7W/PWJK@=_*
MO<S+E.#^D(R2<+GNU=NTN-?'PS;KE9!>*Z37*>0G+(%__4(&^!OI\*7?TO4_
MZ/"@91I\GL/U5OU_.?PVK</A82MDN*W#48<O1RW=T0<='K5,H\]S>/3&.OR7
MN5T9K^HG^.5&Q-M:&W<80M:N6/)!<\G+74.BS[.WV6O0X6]G2JTA7.L^KO5?
M4#5G0B,.,XO!AT-[.JKNIO7 R(5O2'?2V/;FP\)^@8!R"79])J5Y'K@>UW[3
MI'\ 4$L#!!0    (  >*"5,PISF(!00  &4.   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;+576X^C-A3^*Q;=MC-2&C !DFR32)UD1IVJG8TVG?:A
MZH-#G(#&8-8VDUFI/[['A@"S 395-2^);]\YG\_5S(Y</,F(4H5>$I;*N14I
ME;VW;1E&-"%RR#.:PLZ>BX0HF(J#+3-!R<Z $F:[CA/8"8E3:S$S:VNQF/%<
ML3BE:X%DGB1$?+ZAC!_G%K9."Q_C0Z3T@KV89>1 -U0]9FL!,[N2LHL3FLJ8
MITC0_=SZ";^_PU,-,"?^B.E1-L9(7V7+^9.>W._FEJ,9449#I440^'NF2\J8
ME@0\/I5"K4JG!C;')^EWYO)PF2V1=,G9G_%.17-K8J$=W9.<J8_\^#,M+^1K
M>2%GTORB8WG6L5"82\63$@P,DC@M_LE+:8@& 'L= +<$N)<"1B5@="G *P'>
MI0"_!/B7 H(2$!C;%\8REEX1118SP8](Z-,@30^,NPP:#!RG.K(V2L!N##BU
MV"@>/D6<[:B0WZ/;3WFL/J,?T ,1@FB?HZL5521F\AI6'S<K=/7N&KU#-I(1
M$52B.$6/::SD !9A_'O$<TG2G9S9"MAI'798,KDIF+@=3'[)TR%RW0%R'1>W
MP)?]\-^( +C?"5_UPQ_X\Q!AQ\"=%OCM!>1'3J?VNPO(CW ;W :'5EYU*Z^Z
M1MZH0]Z2$2D1WR/C7O37K["/[A5-Y-\]TD>5])&1[G5(OY4JAIRF.]"PIR).
M#XB^0*F3$ ]0ZQ Y' 0]P(%JN<TBA8[ Z-#U[WGA>2-_9C^W,/,J9EXOLX<\
MV5*A+W[4 9PJ"12H"&,)9*\@/HNHO6YS<"'9;_!QVLGX%1F_WTPO8432@S9/
M,\MZ'!!4DH,W<.^XDCZ^T(AECM/B(F!"[=W*LOWVO!F?V7/B>%,?MQMU4I&;
M7$@NY$G"3PR0XFA+44@8 YIY!ALGQ[^*AJ]PGOPGSM.*\[27<^6ND@8"*PK=
M\08UR4S$X6NJIT,%Z1UGC B),KB\N4 K_X+'N!G#0\?IH(^=ND<XO1?8$&:X
M21UN \TAI*F"AX=>Y,<4HCJ*,T3V"M@IH"^)>3>T-H%^5=YP.OVV)XAQH['A
M?JN;^/CN&QPX/YH\Z9-:%U;\%I45UZ45]]?6+TR=%N%^:K92YE\M9,M20S.*
M/=?W':>CGN&ZNN+^\KIY10-89/F6Q6'5!@9E&%=!>GGH+DO5DP9K' S=CH:
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MC.;(?I*TH#->%%1(5(-H#7B-_D7#]CEF3 LJ'C-I$0?'38E[4^*GTN@3U2%
M/OXIB9)^C60&$F%O2&C>,].H S#FT3+!T?*X[_$H%>.72*0.U7E,PD.BQN2I
M7'JGT1?HYU3"0[[&_AQD&M(J/BNOSDFFX/!$\/&$\X=$C<,72:7P*50:#@9\
MULDPIM(-U#K*6PTMLG0*3H5[R.0XFH-.0WK%9^77.>D4'] I]B?+"SPD;9R\
M2$(EAX0*%CXY;@X9#@ERUB$Q9M05I&-"A:>*U2&E$SP#H<BH&CXKR<Y(J [
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MNRH?,N7$R-P]'IZDP:>(&R;X^&/*'L#]E91F/[$*ZN?DXE]02P,$%     @
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MP<],357O\3/EZG0 NQ4,4QX%%'Z-9T)R)>FF"H+V- V]HX8<Q]$3%JJZ1KB
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M"^/3:488M."!2B724-$(RN,GEBH)%[=4D323E[LDTI 4AJ0%3X^W</'F$MZ
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MT 1X/N=<K1=:0?T0&_T/4$L#!!0    (  >*"5-V33LH/ 0  .,7   9
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MU&UU=0[DS@>1^G!UV.[[2^V>GIZ]^E'= .K5C^H&S,F9/V\ ]:V:S&:EQTJ
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M"  'B@E3HDXQ><P#   R'@  #P   'AL+W=O<FMB;V]K+GAM;,692W/3,!"
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MYHV4Y[[M6GW1O%J_\ER_KCWY U!+ P04    "  'B@E3N#;$W*D!   N&P
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M*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>EMGLX1
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MHP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M
M(:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"
M0M8$A:P)"ED3%+(F*&1-_I.L[UJO_OHW3[O&M2J;HS_K_J7-/P%02P$"% ,4
M    "  'B@E3!T%-8H$   "Q    $               @ $     9&]C4')O
M<',O87!P+GAM;%!+ 0(4 Q0    (  >*"5.@BFN+[P   "L"   1
M      "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  >*"5.9
M7)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N
M>&UL4$L! A0#%     @ !XH)4V0.Z[](!0  \A4  !@              ("!
M#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  >*"5.T
MTY&)8P4  )44   8              " @8P-  !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6Q02P$"% ,4    "  'B@E34KR_FK4"  !V"0  &
M    @($E$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M!XH)4_!M^#HB!0  "A4  !@              ("!$!8  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    (  >*"5-K5(/.W <  $HN   8
M          " @6@;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  'B@E3II62U L"   "!   &               @(%Z(P  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ !XH)4X3X"(X(!P  M1P
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    (  >*"5/5%&V^[P@  /,6   9
M      " @2M@  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ !XH)4T=_N\J\ @  5 8  !D              ("!46D  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  'B@E3-L(J]5(&  !>$
M&0              @(%$;   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    (  >*"5,..5H N0<  (L5   9              " @<UR  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ !XH)4_.AYS3H
M"   910  !D              ("!O7H  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  'B@E3(;7MF#\4  "W.P  &0
M@('<@P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  >*
M"5/#2J>WO04  -H/   9              " @5*8  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ !XH)4R?/CC4O!   >PH  !D
M         ("!1IX  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    "  'B@E35UWJX>H"   /!@  &0              @(&LH@  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  >*"5/^5<*KWP(  '@&
M   9              " @<VE  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ !XH)4VD_WJ?G @  C08  !D              ("!XZ@
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  'B@E3A_4*
MAXX%  !;#P  &0              @($!K   >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    (  >*"5-28'2H3 (  #T%   9
M  " @<:Q  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M!XH)4YE(_'#/ P  *Q(  !D              ("!2;0  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  'B@E3\]S'@:D%  "T'   &0
M            @(%/N   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    (  >*"5/S0]Z[J@,  ,<.   9              " @2^^  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ !XH)4[0!^+&5 @
M-P<  !D              ("!$,(  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  'B@E38>J/Y7P#  !"#@  &0              @('<
MQ   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  >*"5,U
M6S-LJ0(  % '   9              " @8_(  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ !XH)4P"B9J.+ P  5@T  !D
M     ("!;\L  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  >*"5,SC)1V4@4  )89   9              "
M@>/<  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ !XH)
M4Z,*1CV8 @  WP@  !D              ("!;.(  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  'B@E3,*<YB 4$  !E#@  &0
M        @($[Y0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   (  >*"5.J)7^>G ,  +X1   9              " @7?I  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ !XH)4_.7G][. P  6@X
M !D              ("!2NT  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  'B@E3+ UW5?@$  !/%@  &0              @(%/\0
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  >*"5-7L610
MUP,  )0-   9              " @7[V  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ !XH)4W9-.R@\!   XQ<  !D
M ("!C/H  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  '
MB@E3P[MO35@#  "2#   &0              @('__@  >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (  >*"5/RQ3@<^0(  *@)   9
M          " @8X" 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#
M%     @ !XH)4X?3JY$; P  +A(   T              ( !O@4! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  'B@E3EXJ[',     3 @  "P
M    @ $$"0$ 7W)E;',O+G)E;'-02P$"% ,4    "  'B@E3HDXQ><P#   R
M'@  #P              @ 'M"0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ !XH)4[@VQ-RI 0  +AL  !H              ( !Y@T! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ !XH)4U/9*RFR 0  4QL
M !,              ( !QP\! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ #4 -0!J#@  JA$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>213</ContextCount>
  <ElementCount>333</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Unaudited Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofOperations</Role>
      <ShortName>Unaudited Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity</Role>
      <ShortName>Unaudited Condensed Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Unaudited Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/UnauditedStatementsofCashFlows</Role>
      <ShortName>Unaudited Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Stock Option Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlan</Role>
      <ShortName>Stock Option Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137109 - Disclosure - Covid-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Covid19</Role>
      <ShortName>Covid-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Other Financial Information - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/OtherFinancialInformation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - Borrowings - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Borrowings</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Stock Option Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanTables</Role>
      <ShortName>Stock Option Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockOptionPlan</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OrganizationDetails</Role>
      <ShortName>Organization - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Organization</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Major Payers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails</Role>
      <ShortName>Other Financial Information - Prepaid expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Other Financial Information - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails</Role>
      <ShortName>Other Financial Information - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Other Financial Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails</Role>
      <ShortName>Other Financial Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails</Role>
      <ShortName>Other Financial Information - Accrued and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Borrowings - Future minimum payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails</Role>
      <ShortName>Borrowings - Future minimum payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/StockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock Option Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanNarrativeDetails</Role>
      <ShortName>Stock Option Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails</Role>
      <ShortName>Stock Option Plan - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Option Plan - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails</Role>
      <ShortName>Stock Option Plan - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Option Plan - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exdx-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Covid-19 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exagen.com/role/Covid19Details</Role>
      <ShortName>Covid-19 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exagen.com/role/Covid19</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exdx-20210630.htm">exdx-20210630.htm</File>
    <File>ex101-amend4tocoxpromotion.htm</File>
    <File>ex45-formofprexfundedwarra.htm</File>
    <File>exdx-20210630.xsd</File>
    <File>exdx-20210630_cal.xml</File>
    <File>exdx-20210630_def.xml</File>
    <File>exdx-20210630_lab.xml</File>
    <File>exdx-20210630_pre.xml</File>
    <File>xgn311-63021.htm</File>
    <File>xgn312-63021.htm</File>
    <File>xgn321-63021.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exdx-20210630.htm": {
   "axisCustom": 1,
   "axisStandard": 24,
   "contextCount": 213,
   "dts": {
    "calculationLink": {
     "local": [
      "exdx-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exdx-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exdx-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exdx-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exdx-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exdx-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 438,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 37,
   "keyStandard": 296,
   "memberCustom": 32,
   "memberStandard": 32,
   "nsprefix": "exdx",
   "nsuri": "http://www.exagen.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.exagen.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Other Financial Information",
     "role": "http://www.exagen.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Borrowings",
     "role": "http://www.exagen.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Commitment and Contingencies",
     "role": "http://www.exagen.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - Fair Value Measurements",
     "role": "http://www.exagen.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Stockholders' Equity",
     "role": "http://www.exagen.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Stock Option Plan",
     "role": "http://www.exagen.com/role/StockOptionPlan",
     "shortName": "Stock Option Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137109 - Disclosure - Covid-19",
     "role": "http://www.exagen.com/role/Covid19",
     "shortName": "Covid-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies - (Policies)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies - (Tables)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Other Financial Information - (Tables)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Balance Sheets",
     "role": "http://www.exagen.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - Borrowings - (Tables)",
     "role": "http://www.exagen.com/role/BorrowingsTables",
     "shortName": "Borrowings - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.exagen.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Stock Option Plan (Tables)",
     "role": "http://www.exagen.com/role/StockOptionPlanTables",
     "shortName": "Stock Option Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - (Details)",
     "role": "http://www.exagen.com/role/OrganizationDetails",
     "shortName": "Organization - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "ib4abda3c45354b949166899b405e3a62_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Major Payers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "ib4abda3c45354b949166899b405e3a62_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i0deb0612dda8455fad61349cd2e577de_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exdx:JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
     "shortName": "Summary of Significant Accounting Policies - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "icc7885defdea48b79ac4c92e06b53809_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, cash equivalents and restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Securities (Details)",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Other Financial Information - Prepaid expenses (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails",
     "shortName": "Other Financial Information - Prepaid expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Other Financial Information - Property and equipment (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails",
     "shortName": "Other Financial Information - Property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DepreciationDepletionAndAmortization",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Other Financial Information - Narrative (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
     "shortName": "Other Financial Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DepreciationDepletionAndAmortization",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Other Financial Information - Accrued and other current liabilities (Details)",
     "role": "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails",
     "shortName": "Other Financial Information - Accrued and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i25a352deb17e46e3a01049447545824a_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Borrowings - Narrative (Details)",
     "role": "http://www.exagen.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i25a352deb17e46e3a01049447545824a_D20170901-20170930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Borrowings - Future minimum payments (Details)",
     "role": "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails",
     "shortName": "Borrowings - Future minimum payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Commitment and Contingencies - Narrative (Details)",
     "role": "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
     "shortName": "Commitment and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "ie918642c1b394009ad0b69833a6119be_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exagen.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "ie918642c1b394009ad0b69833a6119be_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i0deb0612dda8455fad61349cd2e577de_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exdx:ClassOfWarrantOrRightNumberOfWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.exagen.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i8717a2bf86c340c089d364c29e6c135d_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Unaudited Condensed Statements of Operations",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
     "shortName": "Unaudited Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i0759ea92cd33439d8ee655337f3ca564_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock Option Plan - Narrative (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
     "shortName": "Stock Option Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i0759ea92cd33439d8ee655337f3ca564_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i4ffae978ff094b5595bb90b4291d7670_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock Option Plan - Stock Option Activity (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
     "shortName": "Stock Option Plan - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "iaa9e73e5b9c94fbe8f654dbbf0c9347e_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Stock Option Plan - Restricted Stock Units (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
     "shortName": "Stock Option Plan - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i019bf9bd06d54f99b3edfe3bb93c95a4_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EmployeeStockOwnershipPlanESOPPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Stock Option Plan - Fair Value Assumptions (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
     "shortName": "Stock Option Plan - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i57b6a35ece8e4fcf9972d0aacdade4a1_D20210401-20210630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "role": "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
     "shortName": "Stock Option Plan - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i22e20c4591a94d7a9b75ab8c6a2707eb_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i717e3a6bdd9d4ede925668cdc7aa8187_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Covid-19 (Details)",
     "role": "http://www.exagen.com/role/Covid19Details",
     "shortName": "Covid-19 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i5968250ad2294db0ba69c5aa60aee279_D20200401-20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "exdx:CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "ibac674a12b624346ba69c6d4c91a087c_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Unaudited Condensed Statements of Stockholders' Equity",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity",
     "shortName": "Unaudited Condensed Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "iec65931f2bd14b39bad0fda30bdea3c0_D20200101-20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i0deb0612dda8455fad61349cd2e577de_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "exdx:StockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical",
     "shortName": "Unaudited Condensed Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Unaudited Statements of Cash Flows",
     "role": "http://www.exagen.com/role/UnauditedStatementsofCashFlows",
     "shortName": "Unaudited Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.exagen.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exdx-20210630.htm",
      "contextRef": "i814429626dec4826a699d35e97d00de2_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exagen.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exdx_AHNCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AHN Collaboration",
        "label": "AHN Collaboration [Member]",
        "terseLabel": "AHN Collaboration"
       }
      }
     },
     "localname": "AHNCollaborationMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AVISECTDTestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVISE CTD Test",
        "label": "AVISE CTD Test [Member]",
        "terseLabel": "AVISE CTD Test"
       }
      }
     },
     "localname": "AVISECTDTestMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AccruedLiabilitiesClinicalStudyCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Clinical Study, Current",
        "label": "Accrued Liabilities, Clinical Study, Current",
        "terseLabel": "Accrued clinical study activity"
       }
      }
     },
     "localname": "AccruedLiabilitiesClinicalStudyCurrent",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AccruedPurchaseGoodsAndServicesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchase, Goods and Services, Current",
        "label": "Accrued Purchase, Goods and Services, Current",
        "terseLabel": "Accrued purchases of goods and services"
       }
      }
     },
     "localname": "AccruedPurchaseGoodsAndServicesCurrent",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AdvancePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance Payment",
        "label": "Advance Payment",
        "terseLabel": "Advance royalties payment"
       }
      }
     },
     "localname": "AdvancePayment",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_AlleghenyHealthNetworkResearchInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allegheny Health Network Research Institute",
        "label": "Allegheny Health Network Research Institute [Member]",
        "terseLabel": "Allegheny Health Network Research Institute"
       }
      }
     },
     "localname": "AlleghenyHealthNetworkResearchInstituteMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_AssetsUnderCapitalLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Under Capital Lease",
        "label": "Assets Under Capital Lease [Member]",
        "terseLabel": "Assets under capital lease"
       }
      }
     },
     "localname": "AssetsUnderCapitalLeaseMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_BlueShieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blue Shield",
        "label": "Blue Shield [Member]",
        "verboseLabel": "Blue Shield"
       }
      }
     },
     "localname": "BlueShieldMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CapitalRoyaltyPartnersIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Royalty Partners II LP",
        "label": "Capital Royalty Partners II LP [Member]",
        "terseLabel": "Capital Royalty Partners II LP"
       }
      }
     },
     "localname": "CapitalRoyaltyPartnersIILPMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number Of Warrants Exercised",
        "label": "Class of Warrant or Right, Number Of Warrants Exercised",
        "terseLabel": "Number of warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ClientMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Client",
        "label": "Client [Member]",
        "terseLabel": "Client"
       }
      }
     },
     "localname": "ClientMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CollaborationAgreementAnnualCollaborationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Annual Collaboration Fee",
        "label": "Collaboration Agreement, Annual Collaboration Fee",
        "terseLabel": "Collaboration fee"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualCollaborationFee",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CollaborationAgreementCollaborationExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Collaboration Expenses",
        "label": "Collaboration Agreement, Collaboration Expenses",
        "terseLabel": "Collaboration agreement, collaboration expenses"
       }
      }
     },
     "localname": "CollaborationAgreementCollaborationExpenses",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Income Tax Benefit",
        "terseLabel": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, income tax benefit"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsIncomeTaxBenefit",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act, deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure",
        "label": "Coronavirus, Aid, Relief, And Economic Securities (CARES) Act Disclosure [Text Block]",
        "terseLabel": "Covid-19"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecuritiesCARESActDisclosureTextBlock",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/Covid19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "label": "Debt Instrument, Covenant Compliance, Minimum Unrestricted Cash Balance",
        "terseLabel": "Term loan covenant, minimum unrestricted cash balance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceMinimumUnrestrictedCashBalance",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "label": "Debt Instrument, Covenant Non-Compliance, Interest Rate, Increase (Decrease)",
        "terseLabel": "Term loan covenant, increase to interest rate"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNonComplianceInterestRateIncreaseDecrease",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPaidInKindLoansIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Paid In Kind Loans Issued",
        "label": "Debt Instrument, Paid In Kind Loans Issued",
        "terseLabel": "Term loan, paid in-kind loans issued"
       }
      }
     },
     "localname": "DebtInstrumentPaidInKindLoansIssued",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage",
        "label": "Debt Instrument, Prepayment Premium Percentage",
        "terseLabel": "Term loan, prepayment premium percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentage",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentPrepaymentPremiumPercentageAnnualReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "label": "Debt Instrument, Prepayment Premium Percentage, Annual Reduction",
        "terseLabel": "Term loan, annual reduction in prepayment penalty percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPremiumPercentageAnnualReduction",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DebtInstrumentStatedInterestRatePaidInKind": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "label": "Debt Instrument, Stated Interest Rate, Paid In-Kind",
        "terseLabel": "Term loan, paid in-kind, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentStatedInterestRatePaidInKind",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_DeferredOfferingCostsReclassifiedToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Reclassified to Equity",
        "label": "Deferred Offering Costs Reclassified to Equity",
        "terseLabel": "Deferred offering costs reclassified to equity"
       }
      }
     },
     "localname": "DeferredOfferingCostsReclassifiedToEquity",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_EquipmentPurchasedUnderCapitalLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Purchased Under Capital Lease",
        "label": "Equipment Purchased Under Capital Lease",
        "terseLabel": "Equipment purchased under capital lease obligations"
       }
      }
     },
     "localname": "EquipmentPurchasedUnderCapitalLease",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ExchangeAgreementNumberOfSharesExchangedForWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement, Number Of Shares Exchanged For Warrants",
        "label": "Exchange Agreement, Number Of Shares Exchanged For Warrants",
        "terseLabel": "Number of shares exchanged for warrants (in shares)"
       }
      }
     },
     "localname": "ExchangeAgreementNumberOfSharesExchangedForWarrants",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_ExchangingStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchanging Stockholders",
        "label": "Exchanging Stockholders [Member]",
        "terseLabel": "Exchanging Stockholders"
       }
      }
     },
     "localname": "ExchangingStockholdersMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationApr12026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Apr 1, 2026",
        "label": "Expiration Apr 1, 2026 [Member]",
        "terseLabel": "Warrant expiration April 1, 2026"
       }
      }
     },
     "localname": "ExpirationApr12026Member",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationDec72025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Dec 7, 2025",
        "label": "Expiration Dec 7, 2025 [Member]",
        "terseLabel": "Warrant expiration December 7, 2025"
       }
      }
     },
     "localname": "ExpirationDec72025Member",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationJan192026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Jan 19, 2026",
        "label": "Expiration Jan 19, 2026 [Member]",
        "terseLabel": "Warrant expiration January 19, 2026"
       }
      }
     },
     "localname": "ExpirationJan192026Member",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationMar312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Mar 31, 2026",
        "label": "Expiration Mar 31, 2026 [Member]",
        "terseLabel": "Warrant expiration March 31, 2026"
       }
      }
     },
     "localname": "ExpirationMar312026Member",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_ExpirationSep72024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Sep 7, 2024",
        "label": "Expiration Sep 7, 2024 [Member]",
        "terseLabel": "Warrant expiration September 7, 2024"
       }
      }
     },
     "localname": "ExpirationSep72024Member",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_Government1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government1",
        "label": "Government1 [Member]",
        "terseLabel": "Government"
       }
      }
     },
     "localname": "Government1Member",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_HealthcareInsurersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare Insurers",
        "label": "Healthcare Insurers [Member]",
        "terseLabel": "Healthcare insurers"
       }
      }
     },
     "localname": "HealthcareInsurersMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncentiveAwardPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Award Plan, 2019",
        "label": "Incentive Award Plan, 2019 [Member]",
        "terseLabel": "2019 Incentive Award Plan"
       }
      }
     },
     "localname": "IncentiveAwardPlan2019Member",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Current Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_InnovatusLifeSciencesLendingFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Life Sciences Lending Fund",
        "label": "Innovatus Life Sciences Lending Fund [Member]",
        "terseLabel": "Innovatus Life Sciences Lending Fund"
       }
      }
     },
     "localname": "InnovatusLifeSciencesLendingFundMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JanssenPromotionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Promotion Agreement",
        "label": "Janssen Promotion Agreement [Member]",
        "terseLabel": "Janssen Promotion Agreement"
       }
      }
     },
     "localname": "JanssenPromotionAgreementMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JanssenSIMPONIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen (SIMPONI)",
        "label": "Janssen (SIMPONI) [Member]",
        "terseLabel": "Janssen (SIMPONI)"
       }
      }
     },
     "localname": "JanssenSIMPONIMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee",
        "label": "Joint Venture, Quarterly Promotion Fee",
        "terseLabel": "Joint venture, quarterly promotion fee"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFee",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline",
        "label": "Joint Venture, Quarterly Promotion Fee, Capped Amount, Percentage Above Baseline",
        "terseLabel": "Joint venture quarterly promotion fee cap"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_JointVentureQuarterlyPromotionFeePerPrescription": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Quarterly Promotion Fee Per Prescription",
        "label": "Joint Venture, Quarterly Promotion Fee Per Prescription",
        "terseLabel": "Joint venture, quarterly promotion fee per prescription"
       }
      }
     },
     "localname": "JointVentureQuarterlyPromotionFeePerPrescription",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_JointVentureTerminationConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture, Termination, Consideration Receivable",
        "label": "Joint Venture, Termination, Consideration Receivable",
        "terseLabel": "Termination of agreement"
       }
      }
     },
     "localname": "JointVentureTerminationConsiderationReceivable",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_LicenseAgreementInitialLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Initial License Fee",
        "label": "License Agreement, Initial License Fee",
        "terseLabel": "Initial license fee"
       }
      }
     },
     "localname": "LicenseAgreementInitialLicenseFee",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtIncludingUndiscountedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Including Undiscounted Interest",
        "label": "Long-term Debt, Including Undiscounted Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtIncludingUndiscountedInterest",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_LongTermDebtUndiscountedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Undiscounted Interest Amount",
        "label": "Long-term Debt, Undiscounted Interest Amount",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "LongTermDebtUndiscountedInterestAmount",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "verboseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_MilestoneContingencyFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Contingency, Fair Value Disclosure",
        "label": "Milestone Contingency, Fair Value Disclosure",
        "terseLabel": "Remaining milestone obligation, fair value"
       }
      }
     },
     "localname": "MilestoneContingencyFairValueDisclosure",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_MilestoneObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Obligation",
        "label": "Milestone Obligation",
        "terseLabel": "Remaining milestone obligation"
       }
      }
     },
     "localname": "MilestoneObligation",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_NoExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No expiration",
        "label": "No expiration [Member]",
        "terseLabel": "No expiration"
       }
      }
     },
     "localname": "NoExpirationMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory",
        "label": "Office and Laboratory [Member]",
        "terseLabel": "Office and Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office",
        "label": "Office [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_OperatingLeasesRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases, Renewal Term",
        "label": "Operating Leases, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "OperatingLeasesRenewalTerm",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exdx_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.exagen.com/20210630",
     "xbrltype": "stringItemType"
    },
    "exdx_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities",
        "label": "Prepaid Expenses and Other Current Assets; Property, Plant and Equipment; and Accrued Liabilities [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPropertyPlantAndEquipmentAndAccruedLiabilitiesTextBlock",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exdx_PrepaidMaintenanceAndInsuranceContracts": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Maintenance and Insurance Contracts",
        "label": "Prepaid Maintenance and Insurance Contracts",
        "terseLabel": "Prepaid maintenance and insurance contracts"
       }
      }
     },
     "localname": "PrepaidMaintenanceAndInsuranceContracts",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_ProceedsFromGovernmentAssistance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Government Assistance",
        "label": "Proceeds from Government Assistance",
        "terseLabel": "Proceeds from government assistance"
       }
      }
     },
     "localname": "ProceedsFromGovernmentAssistance",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_PrometheusLaboratoriesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prometheus Laboratories, Inc.",
        "label": "Prometheus Laboratories, Inc. [Member]",
        "terseLabel": "Prometheus Laboratories"
       }
      }
     },
     "localname": "PrometheusLaboratoriesIncMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_PurchaseObligationAnnualIncreaseInCommitmentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "label": "Purchase Obligation, Annual Increase In Commitment, Percentage",
        "terseLabel": "Annual increase in purchase commitments"
       }
      }
     },
     "localname": "PurchaseObligationAnnualIncreaseInCommitmentPercentage",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_ReceivableBenchmarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable Benchmark",
        "label": "Receivable Benchmark [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivableBenchmarkMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RentalPropertyByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Axis]",
        "terseLabel": "Rental Property, by Type [Axis]"
       }
      }
     },
     "localname": "RentalPropertyByTypeAxis",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exdx_RentalPropertyByTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental Property, by Type",
        "label": "Rental Property, by Type [Domain]",
        "terseLabel": "Rental Property, by Type [Domain]"
       }
      }
     },
     "localname": "RentalPropertyByTypeDomain",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_RoyaltyObligationPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation, Percentage of Sales",
        "label": "Royalty Obligation, Percentage of Sales",
        "terseLabel": "Royalty obligation, percent of net sales"
       }
      }
     },
     "localname": "RoyaltyObligationPercentageOfSales",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exdx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs",
        "label": "Stock Issuance Costs",
        "terseLabel": "Estimated offering expenses for aggregate expenses",
        "verboseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_StockIssuedDuringPeriodSharesWarrantsExercisedNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Shares, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "exdx_StockIssuedDuringPeriodValueWarrantsExercisedNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "label": "Stock Issued During Period, Value, Warrants Exercised, Net",
        "terseLabel": "Net exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedNet",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exdx_Term2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term 2017",
        "label": "Term 2017 [Member]",
        "terseLabel": "2017 Term loan"
       }
      }
     },
     "localname": "Term2017Member",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_TwoMajorSuppliersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Major Suppliers",
        "label": "Two Major Suppliers [Member]",
        "terseLabel": "Two Major Suppliers"
       }
      }
     },
     "localname": "TwoMajorSuppliersMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exdx_UnitedHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United Healthcare",
        "label": "United Healthcare [Member]",
        "terseLabel": "United Healthcare"
       }
      }
     },
     "localname": "UnitedHealthcareMember",
     "nsuri": "http://www.exagen.com/20210630",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r50",
      "r52",
      "r97",
      "r98",
      "r241",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r167",
      "r303",
      "r306",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r278",
      "r321",
      "r322",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r476",
      "r510",
      "r515",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r278",
      "r321",
      "r322",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r476",
      "r510",
      "r515",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r167",
      "r303",
      "r306",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r165",
      "r303",
      "r304",
      "r478",
      "r508",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r165",
      "r303",
      "r304",
      "r478",
      "r508",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r278",
      "r312",
      "r321",
      "r322",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r476",
      "r510",
      "r515",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r278",
      "r312",
      "r321",
      "r322",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r476",
      "r510",
      "r515",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r97",
      "r98",
      "r241",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r7",
      "r24",
      "r168",
      "r169"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued\u00a0payroll\u00a0and\u00a0related\u00a0expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r199"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r362",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r359",
      "r360",
      "r361",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r323",
      "r325",
      "r365",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r236",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrant in exchange for retirement of common stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r325",
      "r351",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r78",
      "r260",
      "r270",
      "r271",
      "r437"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r148",
      "r157",
      "r163",
      "r178",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r388",
      "r390",
      "r418",
      "r443",
      "r445",
      "r485",
      "r497"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r12",
      "r49",
      "r94",
      "r178",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r388",
      "r390",
      "r418",
      "r443",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r326",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Costs incurred, but not paid, in connection with capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r19",
      "r440",
      "r441"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.",
        "label": "Capital Lease Obligations, Current",
        "terseLabel": "Capital lease obligations, current portion"
       }
      }
     },
     "localname": "CapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r32",
      "r80"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r80",
      "r86"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r427"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r300",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of warrant or right, exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common shares to be called upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants issued to purchase redeemable convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r212",
      "r489",
      "r503"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r219",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at June\u00a030, 2021 and December 31, 2020; 16,126,784 and 12,652,308 shares issued and outstanding at June\u00a030, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r415",
      "r416",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r415",
      "r416",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r415",
      "r416",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r134",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risk and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r167",
      "r415",
      "r416",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r63",
      "r478"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Costs of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r64",
      "r94",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r136",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r261",
      "r262",
      "r264",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r93",
      "r99",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r438",
      "r486",
      "r487",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Term loan, fee incurred upon payment of final installment"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r41",
      "r267",
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Term loan, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Term loan, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r93",
      "r99",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails",
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r93",
      "r99",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r268",
      "r269",
      "r270",
      "r271",
      "r293",
      "r296",
      "r297",
      "r298",
      "r435",
      "r436",
      "r438",
      "r439",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r250",
      "r265",
      "r268",
      "r269",
      "r437"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid expenses table"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r95",
      "r377",
      "r383",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Option Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r60",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r120",
      "r122",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r406",
      "r407",
      "r491",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r60",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r122",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r406",
      "r407",
      "r491",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock options, unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options, cost not yet recognized, remaining weighted average vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r55",
      "r56",
      "r57",
      "r101",
      "r102",
      "r103",
      "r106",
      "r115",
      "r117",
      "r131",
      "r182",
      "r292",
      "r299",
      "r359",
      "r360",
      "r361",
      "r380",
      "r381",
      "r405",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r519",
      "r520",
      "r521",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r409",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r408",
      "r409",
      "r411",
      "r412",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r252",
      "r313",
      "r314",
      "r319",
      "r320",
      "r409",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r313",
      "r314",
      "r319",
      "r320",
      "r409",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r409",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r252",
      "r268",
      "r269",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r263",
      "r290",
      "r396",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture\u00a0and\u00a0fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r196",
      "r197",
      "r445",
      "r484"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r57",
      "r65"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r201",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r116",
      "r117",
      "r147",
      "r376",
      "r382",
      "r386",
      "r506"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r58",
      "r145",
      "r434",
      "r437",
      "r492"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r73",
      "r75",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest expense"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating lease, rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r94",
      "r158",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r389",
      "r390",
      "r391",
      "r418",
      "r443",
      "r444"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r94",
      "r178",
      "r418",
      "r445",
      "r488",
      "r501"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r94",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r389",
      "r390",
      "r391",
      "r418",
      "r443",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r37",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r37",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r21",
      "r251",
      "r266",
      "r268",
      "r269",
      "r487",
      "r498"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total borrowings, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r99",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 4.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r99",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 3.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r99",
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 2.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails": {
       "order": 1.0,
       "parentTag": "exdx_LongTermDebtIncludingUndiscountedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsFutureminimumpaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Borrowings-non-current portion, net of discounts and debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds, included in cash and cash equivalents"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r53",
      "r54",
      "r57",
      "r59",
      "r79",
      "r94",
      "r105",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r123",
      "r148",
      "r156",
      "r159",
      "r162",
      "r164",
      "r178",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r407",
      "r418",
      "r490",
      "r504"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r118",
      "r129",
      "r171",
      "r172",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r224",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r378",
      "r379",
      "r380",
      "r381",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r442",
      "r479",
      "r480",
      "r481",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncement, Early Adoption [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted, Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r148",
      "r156",
      "r159",
      "r162",
      "r164"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r100",
      "r119",
      "r141",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r39"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationAccruedandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r48",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Diagnostic\u00a0testing\u00a0supplies"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCustomerMember": {
     "auth_ref": [
      "r507",
      "r509",
      "r511",
      "r512",
      "r516",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer classified as other.",
        "label": "Other Customer [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r8",
      "r11",
      "r195"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid and other current assets"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentInKindPIKNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A payment in kind note accrues interest over the term of the note and is repaid at maturity or upon refinancing. A PIK loan is typically unsecured.",
        "label": "Payment in Kind (PIK) Note [Member]",
        "terseLabel": "Paid in-kind note"
       }
      }
     },
     "localname": "PaymentInKindPIKNoteMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of issuance costs related to public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r326",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding at June\u00a030, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRoyalties": {
     "auth_ref": [
      "r9",
      "r11",
      "r194",
      "r195"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Royalties",
        "terseLabel": "Prepaid product royalties"
       }
      }
     },
     "localname": "PrepaidRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationPrepaidexpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromBankDebt": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from bank borrowing during the year.",
        "label": "Proceeds from Bank Debt",
        "terseLabel": "Proceeds from Paycheck Protection Program loan"
       }
      }
     },
     "localname": "ProceedsFromBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details",
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock in public offering, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Term loan borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r354"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from common stock issued under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r198"
     ],
     "calculation": {
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment",
        "verboseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r200",
      "r445",
      "r493",
      "r502"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Purchase obligation, due in year one"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in remainder of current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment.",
        "label": "Purchase Obligation, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Purchase obligation, to be paid remainder of fiscal year"
       }
      }
     },
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReorganizationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reorganizations [Abstract]"
       }
      }
     },
     "localname": "ReorganizationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to settle a bank borrowing during the year.",
        "label": "Repayments of Bank Debt",
        "negatedLabel": "Repayment of Paycheck Protection Program loan"
       }
      }
     },
     "localname": "RepaymentsOfBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedLabel": "Principal payment on capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Loan repayment"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r371",
      "r477",
      "r535"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r86",
      "r483",
      "r499"
     ],
     "calculation": {
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesCashcashequivalentsandrestrictedcashDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r299",
      "r362",
      "r445",
      "r500",
      "r523",
      "r528"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r101",
      "r102",
      "r103",
      "r106",
      "r115",
      "r117",
      "r182",
      "r359",
      "r360",
      "r361",
      "r380",
      "r381",
      "r405",
      "r519",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r143",
      "r144",
      "r155",
      "r160",
      "r161",
      "r165",
      "r166",
      "r167",
      "r302",
      "r303",
      "r478"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesDisaggregationofRevenueDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Future minimum royalty commitment"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Proceeds from public offering, net"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Sale of stock, percentage of ownership after transaction"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares issued in public offering, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r138",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesRevenuebyMajorPayersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r325",
      "r350",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Non-cash Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Financial Instrument Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Aggregate Payments for Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/OtherFinancialInformationNarrativeDetails",
      "http://www.exagen.com/role/OtherFinancialInformationPropertyandequipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r16",
      "r86",
      "r483",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/Covid19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r326",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r330",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions, Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r91",
      "r132",
      "r133",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r285",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityDetails",
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r300",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r135",
      "r138",
      "r139",
      "r140",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Risk, by Risk Factor and Significant Payer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Awards canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards canceled, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards granted, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, June \u00a030, 2021 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, June 30, 2021 (in dollars per share)",
        "periodStartLabel": "Outstanding, December\u00a031, 2020 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Awards released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Awards released, Weighted-Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockBasedCompensationExpenseDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee payroll deduction percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares that remain available for future awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r332",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, June 30, 2021 (in shares)",
        "periodStartLabel": "Outstanding, December 31, 2020 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, June 30, 2021, Weighted Average Exercise Price (in dollars per share)",
        "periodStartLabel": "Outstanding, December 31, 2020, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable, June 30, 2021 (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, June 30, 2021, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, June 30, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, June 30, 2021, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r324",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails",
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails",
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails",
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by supplier.",
        "label": "Supplier [Axis]",
        "terseLabel": "Supplier [Axis]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
        "label": "Supplier [Domain]",
        "terseLabel": "Supplier [Domain]"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r345",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r47",
      "r55",
      "r56",
      "r57",
      "r101",
      "r102",
      "r103",
      "r106",
      "r115",
      "r117",
      "r131",
      "r182",
      "r292",
      "r299",
      "r359",
      "r360",
      "r361",
      "r380",
      "r381",
      "r405",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r519",
      "r520",
      "r521",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r131",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "verboseLabel": "Issuance of stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock in public offering, net of issuance costs of $4,435 (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockOptionPlanStockOptionActivityDetails",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock in public offering, net of issuance costs of $4,435"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r292",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock in exchange for common stock warrant (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r22",
      "r23",
      "r292",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Retirement of common stock in exchange for common stock warrant"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r94",
      "r170",
      "r178",
      "r418",
      "r445"
     ],
     "calculation": {
      "http://www.exagen.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets",
      "http://www.exagen.com/role/UnauditedCondensedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r277",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash items:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Supplier Concentration Risk"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r263",
      "r290",
      "r396",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/CommitmentandContingenciesNarrativeDetails",
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/SummaryofSignificantAccountingPoliciesSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r121",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r120",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares used to compute net loss per share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exagen.com/role/UnauditedCondensedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406127&loc=d3e45023-112735"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124505477&loc=SL117422543-158416"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=d3e14931-158439"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782768-158439"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=SL117422267-158473"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r538": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r539": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r540": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r544": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r545": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r546": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r547": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r548": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r549": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(5)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001274737-21-000094-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001274737-21-000094-xbrl.zip
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M]8!1!RB8/QK:Z,L(RC[HW$9?1YB!+7Q$_D#B<!:-;=JWD8U#D$S((P0%" ]
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M@(/?E].8%#=VEG2CN+%QTB5';C2SV-#@/8D]-\S'/4[%S.\9,+8+#9Q%I@"
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M!3W/_@8_ 3. ,_P?HE(^J_"<EG?367->C0.NT'0L*V!K2!EP(Q+05-L/&N&
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M\1NJ%[W@$=VQ>9U1V\2<U:$,8\&XS9/*X%<5U_!$V-O)5%F0D?@&X9H(I*-
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MX^2^FZH^RT9IT*?/&7=$J 8DX$6XIFBR=HIUQ=Y=;(*<C\@ DAHRBDK6Z3*
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M!Z9'V3'2"%G6&-](%*815E(3/TQ'[9/CAX.XK?*);4C'SM'CIP\?L0]DKJA
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MULNS_RIA+:53W'I<M5S&,))4!Y-%R=AC!P*I$92U.;(SW*;#UWYN9E5&MK:
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MJ<3:WFA4DS81%6K4"*<P3;&D]$5>(>G9<'BVQE9'4]V5TH*08">+=4NNB92
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M,,2-K\J 9,H2B4,7EYH@=(6KY1"-O4=U'G3)C /9? #*($)W;]-%[]=2U%Q
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MP8(@#N?A5)5U3%]3/&,NH5_8A:4T67IDYQHVY"<AHK-0%]8I*[:;E="FZ\I
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M]S>*<(Q*-8T.5=$!\J=73#2_$M"3ZR1Y$%-$5N/C\ 9NGZ.II\,R%$01-LH
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M5.4OZ$#/QYW#&$<O^[ZL8+J!S*RA($</>H(85==W[M[G)&6,S06CW$&@@D4
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MC=9Z8>,_)^WC?(^;#NEX?H*P&N',X(7/VZ?YIP?=R#[%+17":"UBD$'EWO#
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M:T>BS>0@]_GL037,4)N\"L*+1(1#] AN-><QH%T2U5?G7PHP#Q,_,&N2]MX
M$2)E4TZ%21&DM98!)=7'P&U$4A-AB)0@6IW[\UOAI$0*E'L^Y4Z/02M-JK]>
M5A']F-Y"D,[M,1#]03HMG N.*"NBU@:UQ3.6OFA<M)3-K99D[M# YYH@[^'L
M &S$@%PZZZU(+IJDI$!^E/<$<J%CC6A2900Y%]9"M+01+/.!<V0KP<2HI.1<
M)^Y!JAJPEHH8R2F2"&I=LBX0%:1(UCHDD EC0V>YMQ)$;?W6=AR.!FT_BJ$4
MRIM>>S3<WGE3$]\EN(R*T&@(.)$/@42RK\#8P*V1H'3]3=[,Y#-_LV>(=8:G
M(".SPD9K0D)S1T$)(IV7-=A'-V\9/DRV4CL%J&<^FHB,$(V?SH?8@0\0H@!:
MHYVJ5:(5L]^G2ESN)40B9X $GQ!+C6&>)*,@>NM9C5KL5D:0<VDU*X-B01.P
M2 I%@ B12>D=93C1AD9:HU:S51+D[%NN$LF]5D(9IJ5 9FD-"2", V6MO#AN
MH.*F]>';0%4&(O/IBQZ\,])B%)^TB(9:2@P0AJ:<2Z_T+^E]?PJ4#]7(:?X0
M80RA89/W"@-1)845N:E<""HI*Q2--?#KOY 5F0MC@( T(4 *GEH!S%KD#)0%
MEHC+Q2&F!A#YA:S(7""B/36>:$Z<\,*S9*PT.J1 D)]H:64-4BF_D!692X(F
MH)L!%YG.*ZG$@R$VIJ!R\P^+$66H 41^(2LRGZ4+%SCUB9ODG> J&)&D0M**
M 0Y3]#,7J7)H^@M9D;D$O9('9S# 55Z < S &$JBX-0!1:?C:P"17\B*S 4B
M24MO@HN:> QGD+%2$9@BR0<F//=RP8+>A0Q*I8HT426EC8+D%5,M'!";N# Z
M4K=@$<<B1@244FFYLMI+C @B ^T\I88&3C2-A"T8W5M$.B9\\);1$#1J(0K-
M, -*:"8]AG86ZD#'*B3"N?A"E@)%\AQ3/M2*".-R^C?Y%%5R:%?KY LW>[[?
MC9^W:;_L^_'&JB^V9P]'6RFW4YC!_M\YY/-E!$HQ1K*0A [!2&.T1#<I(N56
MZAKYQ8J)<RX^,D2>%-.&I\B0WWA'HT +:Z(P0B-_K9&/K)@XY^(OK: R1L5U
MHA0##^M4D($EI9,FDB2HD;^LF#CGL[Z.VLD4U38E$&45&5$D!D=RH:!Q=6JR
M?RMQ[L1.I]T[>!%[<0"=M5Y8"]UVKST<Y>U^'^/&Z7$^!&4A_2HP'4T$29U7
M(F*0"2AV8JA5/EIE_:+YU6J(>CXG;:L026!1T[RSW3GKT39[ <Z:)%(MSGFM
MH:CGXH^9X1*L$BRZ(*RQ5A*:FX)&;9!!DSH=JEXC4<\GY\M<=$EA7*N(0)T&
M;Z-,/IAD:"07"<,%\M4W'W!V(>%%]-#$,.U8WNNIG8@*G/$Z**_1<DL'EBR:
MAYZG@.=3EDQ0K$I0+C01N>$,B9XC#S,B@2;<+9I?GK,&S]X;\[PC6#'*$U?"
M!6*$"-QP;UU(7ANY:-YXSAH\AZ5Y+8)E@1(P3NB0C 2@0@GK' =0ZDL3+1Y>
MP ]K^<24(A)-)<:9S.B(W 5]6T@!8Q3&4C#!Z\D6>D%5,?FAJHJQ'MWHR[;;
MXY.VX0P'Y#^\&O1'T6=EP9\.!M!]MK:]L;/F1[-P:53=6K"7E]Y6L$_:IT\'
M<=@_&?@X'/]Z&"&4@P_MCZM_XK\NTH0D>,<$0?*"RF&YH<S&9(F35E!M]/N\
M"_CR.\/160<%B4R^.(RY'=-3P1YK>3SZXU,[C Z?4D+^_Y7RTM4_A\?06_W3
M#9[@#<8_C^_SU=WRF OHM ]Z3W,[F#A8&7]Y\KGO=_J#I_]%RG_^2/B218)N
MNW/V]!]K@S9T_O%H"+UA,<3)2../A^WS^)0J'%;YZZ?Q4#5^&V.2.!DZ97FP
M;UJ;NQOKC9W=M=V-G>LCK<P8=S:>O=G>W-W<V&FLM=8;&_]^]J^UUHN-QK.M
M9G-S9V=SJS7S@9-;#?P=# \Q"ASU>X\:ZX^?/6XP(H6]\V!O@M%TWG$7[<:P
MT8J?&MO]+O1N^[;BQK?]G_^BBOPQ&>;LX/%\:[O9^!.5O-?OM=#:#=J^<6$+
MMF/*^Y&I$,PJID+TPC"5=V4%+J/5@9 0;ZQ_:/0@V^P0VT_7^[ZTH7G->N5B
MM8B_/7/K_8\OV?;'/=X\"4<;'_=?V*.MHP^?]E^TVLVCUY_VSL-1Z^BUW-IM
MBN;NIMQ_MR>;+S;IUN[KT];Y 7_)6YV]\S[^;?MH[VB3-%\T^=[Y'MG:_7"^
MM;YQMO7N;7=K]Z]V:_<#:>YZT:+F]"7;/]M[Y]7>NR9MK?NS%FNR5O<U_OSF
M?.O=QGFK^_:P>?Y!-(\ZW:WU ['UKODQO'@KPK_^[NRSSD=W='RX=_Z&M,XW
M\[/8_CK^O-N4>[M-MH_?W]H]P.?N"?RNW$.^WUI[;T34*2A;>*Y8(82QA=7*
M% DC>Z".0-!H)"DI7I>&]E(&=P?L-W ^%2S9'T&)2H32;_DLBL96+_[>^,$P
M;@_B'^E.^>#)TT;@.G'R#-<?H-,J?#YW]W@8GTY^^".TA\<=.'O:[I5W*K_T
M1Q<&!^B87'\TZG>?9J?T,0Y&;0^=B[DNIWW\\86_LN8QL38_?H2^<10F#[[P
M9H]+;_9D%+[^#-V>%M_\E#RFW_SL>W>U\C%AZE:W?5*.>#QJG)<\>_]<X2N3
M+QQ#"&AYG[+CTT:6P%>0^VIR^L=3<@WL5DB;NKU*_4$71OAM?%&DET]=O]]Q
MT.GT1ZY_>I,Y>WV"Q"L..F?;\;@_&-72LCUONQ=OU%YW\VS_Q6O\++1;;).W
MU@\/]W8_\.;NVP_-\_!A[_QM>__(\[WNQL5WWN*S9&]_][B]=_3WA_WU@[/\
MO;TC3[9>/#_<VO6GK7>OSUML^ZCU[N]NZSRT]]Z:3R]WUT;-'7**_WT?8B!4
M)%'D!A>%X%H6SCM9,*^(]1A#1&*S2[1:J#^^:1DO4'XW '=B^EJWIP;?'S*;
M$KZOWZQM[VYLO]QK;&^\VMK>;;QZL[WS9JVUV]C=:B!?VT52UJ"\L;7=H/*W
M\'MCZWEC]U\;C2M4[C.-6WNVFS^FEHMK$W.CBJO[S=##4\/;.9KG_4%C=!@;
M_YDH86,<S#0PQHEA^FSFBG5X&G*N!.]X&.#L+,(@]FXR#Z_*\6R,0ZZE<?B1
M<3B]8AR^I%SMO>X;L9^?V=TDK7>;9/_%]H>M]3=GF68UU_\Z;*[OG3=W<?[>
MFO/6P7L#@5KF?4&22X5(C!46"$?R)863(<3DS<KJWR>].*;<G#QJ9%%_GX M
MW>94W.;N (??SFF3I=^\G6J<7?6;21KM4HB%4PX1;60L#!&\"!$<U1")HOK"
M;XH%])N[VVNMG<W2.SZPXWQ21@4/GV5XN.3$_;UL/B&J/<QYT<;S-L95B",7
M!T\;T\Q1W$[N#YB>V"@3K_G]QJ]72X/TTRF*T^;1A_?"!2:#5 6-C!:"B5 8
M377A8O0^*A($TSG/3@MN24[ /4RBXH$QSW[H(LMTV(-#;3L>E(4LO5'N9_ZK
MP>V\^9Y+'ZE7NF IZ4(0"H51R1>.61-H<,"(6%G=^/?:BXU68[/U[/&] 7=/
MY)A; >>WC5/PHU+<C7YJ##Z+N0'#QO X^KPB%1KM7J,]&C;\81FY_'ZG=YEM
M>LOHQYI^,[WU_2255;?+0]TEO47-8\;Y]&]+'N2VZC%Y@#E@Y$%N*Q_KAYA9
M\2"#I7FT^N?3G)15(&#[H4TA#^*,OHS7AKGRXWC0_YC-UO5,QMA;Y0*1 09J
MX_.E\M7EV8>#LV?]4$_G-0[>FNL'G_;7PQ'>BS39V\/6^B;'9YWNOWO;;JUO
M=YKLS:>]W3<8S'T9O/4_;:W_]0&?A>-^?8Y.CC2//+[7\\[^NTW2>O'F?'_W
MK\,6!G/-+Y*>%C3Q'BF6!'1W0@'R+$F@H#YR[Z7CSLB5U?78@4\PB/>(WD@&
M\\K]+KU5IG QE>1+'=B%T\V+DI)Q>52-(X59HW_O,_J1]$DF<K;? $?:![H
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MKZYA6QEYV\@B@HV/?!)]'P?7CH]M.C'FUDI9N[C$K_OL3$X G"WJH[*J+W(
M]OC%^/"R9T-*,3H0!@J1.<0IA24])(M44#Y9@JTB87H$EO#'[MZVK?MT3PKH
MZSYH4X"^!-!K?:TX!0$%&A'S." >K4-:A]S2G@?AL5:>R*IP&9-+6_ %Z#L
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M]'J+NK*FE37M::QI2V[_%4)[=$*KU775,5@3%7AJ"B..O4/&>@6+7'2@FHG
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MWH]710=R^V;>OYVRVV5W38*/I/G7YE+=.)>OOL K]UNO^_[9?515/AY4[_G
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M5"U1 [=@>U78OMPO3UA*:;5&T4? MA84&>(BLC1P+PASR@*VJ=9M(U95JJ$
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M;77/RC,WI6W=\2:W'L(V]WEI'_OC.'S,U_YV,;CYG/KT</+TY=_=LYOM=V<
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M T^/OO[^Y?#@A'_H';(W!QYLK%_^@F?XFNVF;VVK#\=O/V7[Z</7WS\???W
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M[<QE-N9OFSWH3K^*3N<@X^P%YW>>.@LQ7$[)I)LMYQSX:)U'.ZSL1K XIQ[
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M')#3&8)9)(8P3;3UIK5<'Q$^Z0)\!@K:/^B;2-'H$<<Z9"#UR%AN20@N.:(
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M0(?+CG.P=(;0G-PSR49I$GV&<?J*>J2EX$5L<J1SW:;9A3F-NF2[_Q*M/]P
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MGTSZ3_\)VZ!?9K:5,]TS1Z_EOG[3ZTQCMRDF^JKJ D A=#R=EYW,J_-++AX
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M7?)GW;=E*[/3:]A&?^5=M#7CTU<-:;>;-7@/Y/B)RW-\Q/D\DCL')AK!**E
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MBB=U<]T90,!]-13!]?8@UE]/>PY7O8W.Y3IEO:AW:[&^V7V]H%8"[7U6+4]
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M?61+U%J)2*B#((;C0?DKLU8F1]N"=9TD_;66R'STP<Z,N%N]\&9"VI<3RK;
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M<T:I\#HBKAE!>;\;.<(=4C8F'PQ/UNLW;X7"*T\N5D_/IW4RZNGY:--SRN/
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MON2-O7F]ZSO:)CD9 T 1:QL%?*<WX%M6)^S$"KA*H'@Q5'><NM?9"7PH22/
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M^?7)FZ</3KW7+P>X\^POQ_=2/YYYEH@<4!1>Z%HB3QPK]G+;1JAF+W<^0%$
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MQ+N@-2/FVXA,-BYVQ'P['"BLH\(Y&S'?1LRW$?/M4%"[CN>X/A?FV_&<R$A
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M5MC66UEE;M'OU:?7E>15#L&&</ZKIH<=(:=,/C^K]&2AR9RIFI$<G6H3^LM
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M1D\Z6Z/S='$NN _<@LM<DI80VI2A3GQ=DD E?G*UKCC54Q54#J_6B8^MY(*
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M*P-Z0:<.M%;207>%_ 52B@"">(VKLIS7W=(*,+;(A&RBA#J]O@4>L3_/;)#
M-9:PU+%M]$!$1\#A0NV(<(LM4D8MFE..G$9WY/!+ZZLK)8%324D^JKKCH,WF
M*$SC%PZN=M]1F-VJAW$ YC@ \Z,&8-ZLM3X26LH[-&@I!9,V.34I=K3YGS6A
MA$/5ZEH=&(MLHUCB/7&8VXC 3#\R!//#AT.U[YC.<W8Z3XZ][@J\=H%GOSRS
MYC)?_> &/2@VZ[-B.@]3]?_\GSCPG$\35]UK*=VSLKT3+\##N6\BJ*=9:2P_
MY+R7RK-ZUJ^6_GS,Q<2P^5\N745>:X(N8[#]0R!(M#EW4R=(DR&CLEK?BZFP
MSR@[!9CPL@5.-F@0PR,#9^KZX7A7>^8HJ;+17,.TZ3PA>Z^?(S%EN#J:/)"M
M8DNXJ;TQ92R#;L1-;@[/R1#DVU1@M$\)&KN[PF5[D1/7^[:5Y+EAD09"AHJP
M]1O"F3M6P'0J8)PCJ( 9U-:?%P&"]-LV$O^.YGFCBZSS2E?GE/>_Q$ MHSEK
MQ%]"FQ'U:F+;[98VTV;/F<F*HSTZ+@%T_7TGC^PYD6&L(08])2\/?XW4);BC
M_>9-M%U2XNAF35C<P&T2FG\YD].5'G'\[?O?8H*<@[D"?G'[E,JE[!_3S1(%
M6X2X.E])LGX3E&DPZ?G,O91;^SBX6X@]=)5<OEGFL9^FI12F->12ZMEH%"\S
M?49#W]_)FPONQH1]C\UUV ;K9GO<D+'Z^=7UR39C]6FK;XE)E>("G"FE'%Q5
MBE;ZEKVU;3V AOTVF_F:$! HLTX7&Y6+]QOU-OKT3G#8'[]P^!4*@:U6VZ#4
MZ-) <)M,;'?0H6[":V+,.N^,5L,]AFK#H0"*L8E][E&6B5'#5>>G>4Z#@=P:
MI7L/ ^3#SSJYA_O"-Y*TX&$(YH GV[^(1YI/&%%SRLTJ\_(*P<87F,6>T""/
M+5]MTKW-%-YNHT$W0]5I1Q(F7ML8:.W;&.A/U(%_G=^ZI#$][0Y(.G[.RB!>
M_):%GTS^96:1(+3L4'H=[*.U"F9RW??&>O!Q0G6CJ12:"B@N./\//U^S58MW
MHK)\S9WT"B]45HLC=,W;IP,O5@X+1YBE"IALO+FMUA%:AE:R*DO6N":M4J,_
MH]* J3)4"20?53+=*:9+ZAI?S@':!.L"J*B;TO#(7^J]=+'F<TU6D-O=%B(#
M]GN%4P^O9$/JF!DA4%_BE>$;ZXU4X8D?^+S.4$4Q6<JS<L5]=KF4.GDK#3MI
MDD/384GA[4O%QID:7U@K$?<HQT7B=Y#$]#1?E:\O*Y- Z8HT6!&H^97LR[9M
MTNQ*=N8;J+=(#@Y><JZVI9V[U5J=%C\X/ W_ 5:5Z3]$\JY HY>Z<[)?4Y.]
M6=<J08T80DMLF5-O;L+]YB5+G?GLCM#0<3?L7)ZO<1[#:K>Y J-ML+]M\*+)
M.+QH : ]:T&D'9!A\&@Y.5V? 8TU\9;%&O-Q6(.(0)E<;JJ3923&_@T+ ;=Z
M<JJ!-'L3GYI)1KI+F^3^BT>/GSU]\F@,N;PGY&+$B[X9E=VTN0!)'>/ *9N*
M%=G'6_IF=A*8YF[J]G9.;/,+JN2[/3C?5ZQ0.YY/U9HC9%R6(938K&(AV'&]
M=+J*\_0=D-6]@$7>@T(K&EP'*C]IH1P-%UMR]+&-_7\3\N$'(7^,$GA_"?R@
M"T_5:-M#3B>\DH9).D@ 8YAZK_I]8'&-IZP$68/RO1!ORJI5SZ.DS(U0%9<J
M4+05X4T7 [:QUUKX$H-3./3+*'/!3?V,BT&FI*HS568$/+^%<8*%%,,!J$2V
M4K@*9E,K!CR4"CLZVT-#DNL6>DVW&5@5LVV->-$9, !R?FU@OACXAP%F^6!'
M ?=I!-QC[=P\YMFA^7J.Y5%PI =D6;YJJ@V4IT;5*UJPL&%IW+1%LQ,F#I,5
M%*T&&Z.?%:\0[35 ,MHP:(\H,H6!1F7KHC=5 #-7M8Z$G];4\V%,6/G0+7:^
M%#3B7)M176<-P>:H '&CC']5ZF82E$OD73:.Z98BXBE"-1*=_*V"7/@IY&,N
M%H:O8A@-F.Z<#P)>8OQK#1F9#3=!"#5)195C*7$Q5&;9E!^;QA3"<<1/L.C:
MK0-I9//]V?PECW%5I1#/VQJH;>(\5$TI!\3[3QGVT81G.7+7U-EO, A&60A^
MK=O_2H$9G9@!4E0_-@,=J"$G(SRFFB-5V+O2>CYUZ"C+' ,H"=6=4BB/.H$N
M">A?([ZU%/NT>4C#]-,)&/IS#>E4KE<(@*<WP>GLE;DT5N];#8=6U7G!46V<
M%K)2G;X(GW$R>93W(K9-+'9CBS3R-6DF-HO)68'X&":O55$D6>-#UZO6K1"H
M- L\-?1S*<T74<_SI F0+^]67.[8WV87FVMPD*N*0FDP/9XQ,R IU7&S?S=D
M\'2[OU15IWG2P,V0_,6F=5GI'!P9/&OR!&4+.:]5!JZ1HK3+-TX8^D HV!,<
MK&%$P7:H9"!0RAGUA<6FC&AL^CD!-FI*[:2$AJA4MSR9/KY1=7T:U?4O\#:
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MRE+GL"G6 Q3A:LJP:HYW*@2QP6+SBM'$BG2H]GQ%66[NRT@Q-,9+ULB1#!I
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M<2=2@X*H7IW[V]S&7;B-:WE^[HB)SZM =$"'!_Z^K$2D#TE2O&[?(T50/0O
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M/:<$#.3UW-P>0I*6;MX6<MM^ZQ&V .VU)2K;">ROWY%L8\!8EDFRU19Z;D_
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M4;<0K ?$Q;S'"_X 0\CQ5J-_VI%3;KNCOY1WP+L0$] NFDPXGLC:LG'28SX
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M71A2]L(;%IC6<;OC*3L6&!YWD; ^#>J-]I:EN]7/RY?@9_#K#_\/4$L#!!0
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M97,#XG+M,XQ[SG4!&QTC'UHD6DYU "%-LC8F[AKE.MX![ @\C_L:\3HY>K3
M1M]R[SF0O]92W_GP,S9/?+SQICUE.]XNX;44Q\*2$<%F95A0Y)\Z+[.*(<C,
MD0O,'5,<;[QSU]+G/R^]8SH9TY?I_*J&-]/G'\/X [X:7_[$<)R&9+C7%WE,
MUB3%C45P)E9RR@2^U!1@=*HXYLD_;E,5L3/TIIF1*;O @A=@1%&@3.T!R)(#
M%X(M-ED?3:-9\Z@R(_?+KZU2)[>Q4(/4R7<XFT^'J5Z3$F8?!_7\B5F%( Q+
M%+2F&F%:!U8SS%X*IQK5EUS%\;TQ9 <K]'U._U\3TN _2.ZS*?Y_9V$ZQ^GH
M*RGD=%(-\!)KFYZW4YREZ7#1EV\0&;D6-4M(:4]@2Q$0?)*0+ _2LLC)*>UV
M@KCEF[\7DK0W2]\Y W>"'22)@44CH>:C@(HH22,I0HX$S!I$$7,_I'EBR;T5
MWWL"PEWHGH=/GS"?G%;-?%LC3^+D,SX+,Z2'XD#DH"QYK9"TI?!71XIP4"?0
MZ*6,VEHT/3&G YHG<K4T7X_)$S<$^ VGI\/QPB,C]VPVI,<OF]*M-M\'LO@4
M0A8@8NT'%!4-%6$<1"&U8 F+Q;0UT^Y^[W?+J9Y-TN!:AN5&_DO2("$DAS[-
M_SF<?UQMG/S\)8W.:E^DD]D,Z?_\6_A"JF'9)4'.&XK:M[/>)"&%AN(-UZ@L
M3Z+-)8#W /N]4&]?]FQR@<-GG,Z',T+U\Y?:2A,'AMLBG55 <4+-+F 9G#:D
M 9>%3QDS8VVV/FYB^=X(M*,U&MRZ\'PRFU^<. Z,+ 9+]E XUGQ%YB $7:=/
MY95*44?1IN7X%1C?&RON;X,6%R/4IGW/KO?>/:G]+S\L-/+LZ[>/O U?ZX].
M:F?%EV$X733+I-GO['35@_\3UEV*%\//M#R/\[LPQP$16@3+&/ L#2A52%6<
M(DW.E4V,*PS=RB2W3_-I+=KW1MSCXDJ#JQM^/:OJ?U/>?%KXEN,/[\\+AV>#
MI$WBBXZ$+-.R'JR%J(R"@M$5SW)FNLU,N1'2]T:^?FS3XLJ%^^KE/.&'H,:8
M-$)2J$@G.9 <2H%$(26IA):&-D<P.\'>5X." W-N;Y8]=(N#SFG*0C,T@B%-
MR?4\*G D=28'BVXXQ206$ONNJD?VR)%MRTNVL=4A*@2ZX'LJ+]G1KMN6"MS'
M*(<@CPE*RR(I;K(N$4Y%J[Z5$<B!I$A:R*3M4WG)GCBSC2WV5EZ2>8K2%%WS
MT7R]V$-"K?($;83*T;F L<W.ZD,I+]G*:IW*2[91>8-DE=O28C7W289L@4EF
M01G'P->^%3D07F=R"K+55M?1%2 <E<MR+POMHQCV4MIL%VA/%0KW,N06&>CW
ML<*>*Q2"#X9[)\ XKT$Q[VA*C0[0.ZZE2]K9-K?R/*0*A5;\V$;Y#7A!$VD^
M2_--Z?':^"*P9(BH B@N"CC)$DC&2M#"!1;;7.!Q.ZXC\$ON:\)),_TW\$W>
MGWWZ-!INKIX0VH2"P4&P@595%B+$PA3XX"+W.3+O&]UM?CNPQ\.//BW0<[?!
M)77?3)=779Y/D_7F&B7)A4[D7:F4-3C$ M)CEK'>=V,ZQ2^=&@VN0_#]N*>]
MV*#'=,A+>&8GX[Q$-%OY01U ]=Z#=".<_?<@W=U2-\W>DYK;S MKP*%/C/ 9
M,+1L@7*:0\C* RO%\,"3LMTV-X[1]K=T(=V3Z;?1;M\%%B?_>/7^Y^>_O?@-
M9ZMM%4PY118#P9&B5FU*<'7]HY7):%G31$2WZU]O/GN_+=AZTOBD/W6U\/0^
M#C]]JEF!X_SW,,[TL0]+8,IHKHT.H%7M[:#00A!<@> Y)L."\XVN,-\(Z2&;
MOU]]-P@(GX51(,?E_4?$^>OZZ:K8.F$5JSFBJE=(<?)B??2$2SE(F%GV,4DF
M<Q,>;$+T_7AZO=JF0??&=;B68Z0+LJ:;D)NQ'68/LA\;=B#&#@;8T[2R.M&1
M,45K7+W=&FD:]?4&W=H%).LBA G6A#:;"/NFQAV[C_MFQC9Z;\"(-_./.*U%
M"//5?62I<.\]LY!,"J"LI94OTDS)K#/"ZMJ'MLT*<P/*_O>/^K+3I$\E]^AG
M5D_J75T:%XQFE@OG [V56PF**PZ^^ 19"\629[EC!X=.@>#%:[\?A^'^VNZQ
MP.P"Q*I1?P<8O>\ 70*P_SV?>YK@NA%WT%_/6SM7X$3!?+V&TAM&JQ(J#0%S
M@9BM],(5&WRG4\/C,.,MVS<]6W$+M?5LO5](4Z=GIZLX4ZMDM/,@["+M10GP
M2)!25FHA3<?B@&X7@5U^]7[C]WLK?]*'YGI>0G\)7RX!\=E9B2F!XS47*D9%
M:[G)Q,P89#0\.=W?,GKEU0_0A/?67,^C\'E=YG'Z*4SG7^OM#N?]#\G%*UYG
M\#X)\NQ<!!\5@\23=S:&('2G<_9.EER'X/ORC7:V08]%T N"XZ>S:?H89GCR
M88H+\:]#7.TY=@#9OQ/5%=[^7:S=+3G9EQGZ]L4Z@V6H4FV#",HP4TO-!#B6
M:S$1$U[27"=\IQW\A\"56_RX U%E&^WWWO=LW54_C!>6>2R@E:N5AYJ!HU43
MI&*>N9"M[]K;[."W(S6RPIVW)6VCP@:'=8ORY(O,1":ED$[&VE@OU)[\2*(Y
M$C*54!NCI63:U)1<@?'].!"[6Z%!BXP[J]QGF\K<OXDQSF]'87QYT'20J>GA
M30NI#G/LLP-9MNUGL"]+MZB):B%;+A2P2Y?!25F/3[*%Z#5%[RR0B+$HV2R!
MX:&P]XZ3J2,G[S8&;D#:;WUNW\\GZ8]Z2>;LW?O?5]5EZ%(1)8 GSX-6&-*6
M=\F#*YE<AN0]0]>$?;?"VO\!U^$MO[$]\:YF:^#A57'?E$O:68P\7K+EG%DH
M,510)'BH?2:1666<*"7R-I[>6CC?G\>WNU4:],*Z/(1HA/PZ&8=O/_F-OIJ%
MM.A=M&1V%[A-G;HM 1_&7^O!U-?#A3W8J<'JMBWLH'D,F7LHA9-/$(N$*#1%
MVT:S4+P)HE&:X%'0Z@Y'ZO"LVL8\C7:C+KHK7^S9K-;<8#2MX0*LK4T%8Q+@
M>>;@,^:()27..W;!OOU%^W=^FEIIS6Y5+RINDF6^<O#^-IGDI2KP]--H\A5Q
ME5U]21_D$B[KWQ8#109O'2\.>&8.E%*AGM\92#IP:45RPK:.Y.Z#^_MSE/9H
MYP8-%;=%O\*^NJZL _H][9K=!_]A_*U],F9'LO9@[J9;9_>2(CL9DT.2(J('
ME8A5WAD$;14/F#'JT&:;XAC)>H<7]W"YNHV5^_;^?OMS\DOX[\ET!6GEZTCC
M/2\BDSJ\KR=S$8*2"A)#;U).WF+LY/5M>,$AM[K:&VG2LX8W.GU[O^/RZH73
MDU7K\>8W7M[QWCW=?[F-]-=NP\Q,H>$L6:NU4D7X[)"'F')D@5Q\UO$VS#L0
M[+9:;;A-_/5% US!BLE1:V!%U1-V@1!MB2 +L\)Q5!0A-UF/[D)VB.M6DG(\
M"6?!E\75>;7=!TH#0:>L7>;.AC;=EA_$=2N]<JF/VU2V,5>#('N#/LZCNF 2
M2BL#,)88+2Y"@(M&D%9<%ADQM/+S;D.UK[[<39G2F]H/W57[/%N:_(@5R6<+
MM[6V)Q BDD:$(+>5- %^4??N%1%>2.M+?UF$-]]_J$V4_LPZZ4V]/6>2U@/5
M-^4*II4KV@%4[]G&&^'L/[MX5SM-6BEY;PS@D7/!9 94KI:+!E,OK C !5)D
MDGAVH=-QSC%:_I9<X;T8?AO=]AV-_QW#:/XQ4:#Z:CP[FWX+%G-!EY2)((I%
M4-PJBCZ= ,V90Y--Q*3O"K1N?<-^,X1[TOZD;]7UZ/<M0/UM\AFGX[KL\U6A
M=Q#*B\(!B[3$4O)'G:NN:"Y)!5DPI&[[*C<>_> MN)NR^AZ*ST?#;P=TP16>
M/=<0>6T+5F0]=2&W@B.+R&N'<^$Z6>WR4Q^\P>ZMH@8MMQ<M%5:"K9IWJ6),
M<@S0US8=FEQ G[V"H*)/G(*_(MK<+[,&S$,V=E\Z[K&KY>8B$.,I)BPL F(F
MAT"K "%E<@@TX[)(4T. !U)'TV#([JRRC7VJ]KX3_1[3V93>A+/FF\\W7[6G
M_>8[9+RVQ1R*(5^'7. @D]*2!Y9I#/K"'%>N9-5QB_GF2W=L<C\*L]F;LLCG
M_;:I4P1J:VG.T*40A4T2$*)W8 QC6D7A8S1-)N>U<';.QR,-YN'H;#[\C-_T
M=[X/B?E\G_+TT]E\N5WQ<YB.2>.SMSA='$N=7V0_$#Q8(:P'QX*H-]:+\_1F
M;U*RRDJEKQ^Z]96EUP?\ [3WWIE9-Q+W]F['%OE<Z2/FLQ$N-?/LZT)/R[VQ
MY+VE51EX=!R4Q-JH04HH63NTUJ84&_6&WPQJ7QO-_=.E+TT?>G.Y)_H_^[K^
M 8N=FA!UL!A(%9;3H, 8P,7H0#J9:W/\+%R;^TP:"G6H[>_>>-?O]->;_5MD
MS*]%=JEJJ0N^MA48=R \4(GLL5"B$U5WM.<A>&=K8P(?%*!1%'V)%"'P9* @
M4Y(GU$FVN5OP,'R[JZCUH=)M&S,VH-D_%Z4+J\TXIDH1SI,G(V0F<3V#(!%!
MY91<24IP;%.2> 7& 2HZ>K72I"\5M_#QZ[K_YE-5YQ)0,1(]+QPB(0"E1('(
M, +FPAWYMMZ4-KN=-Z \,KOOINJ]E[8+[9AEV@*+P9+_9PV%H<A B[H'9'D.
MH8V??62E[4TYT9\)&IR%_+Q*:J[05MG&:#QR;6C90W/>8-HC<Q3TADQLYB1X
MF[A_#9A'QH5=U;WQ6*3'+?7%T<W+X3B,TS",7HW+9'JZ<*'>3B<4=\Z_AG'&
M?YT-/]5=A!WVT^_UGITWTW>7[MI.NC!9>,]T0*[H/Q^5DJH(6O"%S;JXP;W>
MN/.=H(LGUV8;\Y-Q_GGU^&];638+0Q!9O? FU]N*ZK6#BPL(D;S=&%G2;5R
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M>JZ[&#W28C&+.H14"*4S$H)4 3@/TFC'HVQTY4$W?$\NTV:7J2^S]EC3>NL
MN8EWE2K0 >S>_:>-< _N2?5F]RZS6J]&V]?RN!&T%M8';1C$7"^VS"Q"=*E
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M(#BGD_%B1ERE0;HH5! 1F#2"XO?J!QFF( 6;D@ZN9-8FP?T&E/V[H3V8Z'K
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MS"00P65; L5"CF]IU:MO>'16W4&!_5=#KT"]P%1!Z24HEKG/K-:/T(]!I<C
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MFN_>_[XLRM6*>11<@JC=CE4(&9Q6%I+V3%B# 7V;G>E;81WA]D5SRT]:F>T
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ML=HP<Z46 X$@BB..XI %J;#JIC8TX*FIT&H!;#QW;$<:.[4Z^#2;J> I3=[
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M4BFHTC6)+IPL/+5?#P+=_"*(TR1FB%C5*;T\Y-34T3;WJL)<=RIM45_1R<*
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M"5I1<J*UH-W]?4^[E8!DF?UWM9$K+*WX,W=/Z)LX0#B(77^!!<>'GZ?'&OF
MLU/@XT/,[LO[=]A=+2O'7N,#04D:QE3X,,7,@PB)%!+*8DA9@CA+ L%3JYBY
MHQ$FN&0J@/_ZSW[L_:6":=\X=Y]!XZ6Q/R_#KX$*6],B;(!FV^=$=]X2=W^4
MT1OAGA3R5/O;TQ?V^Z0_M!5ZZ_5.VX!SA"(O]7T!$RF1VKM+#M. 2LB\.$RE
M%T>^1VQ"-$^,8?59CQ"<J3'5H3Y-R6+KH[=31)I]VU?2,[0C?5/"N88'?M
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M("^JV)_J'-;V&';$=\30KIKFS(_H1=J5>]>55.CLNI/N)BW]##3RST#-@#[
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M6(6CU,QIN2WFF6:02PIAD6,O'>_H%D^-T"](&TU,T6@J4D83&EO&US"::%)
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MMEI).R_[N%JJXXINFZ]KMMS80-S5\LON\7$Q5^M&OD]Q2I$L"(",%F:-F#-
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M$/?@/@TIXG,&_CE$B7N@#29/W-?&,.+_L&++C6G"'H4TH55(XH)#J@$T"V*
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ML,%IB34S'!U< R(H'5QL;%0ZN.;R<SJX>GV(^,O]SO.,TBPKS/\!)2D%R'
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M5XG5W[]+_F.W5 E,*XVGS']W=_27PHW:I]C5D4>#D#6=.F_,V\X;\X_JC>F
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MEMH^M?-9(>TS%PP_-;O77]A";3ZM%G/Q]%7]W/YJ3/GGC'.A>8HI8'E*&[5
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MJ>(49X(YB18/-V%J\[C6L+U>0;)J-/Z'*Q3X]PO&I2J*,@,%+BA 7!# )<=
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M6KD<#B@C-O5(4BOTAB1T$@?M:V1JGWZ;#5L;6F]8&E,3:ZM[_M%%2/N__5!
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M@W@^S/PEB*UJME8@ME\Y;+E_W.9<2K'3I'9EARHUO[M5R"%!O"##B 1 ,(8
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M%";6+O.:"0RIHXK<83B%?\A2D6(5,L$SU8Y2C+9M[A$5-Y;NAHN&KS7[$>K
MR#A!#M**BXG_/I(Y $N9$FI$))+GC+Z03(1Z90/+7+MTG(VXM5RW>K^&[S$/
M%UYO6O^G7^\)[P-^X] *?72#I@M(K_RD=!7 X J6B]LT=RW9?_"3>JGA?YK&
M(XOZ+Q;DN_?GHU7^8U'OI_QN/,7%QKC-9^MKAROL" ^6:F9)$!&Q8X,DSCM&
MN.8I0<XRP&-;)OM%6*EXL^AZW\!DN=A^9R580MFF^<+_V(>Z0RW#=HV3Q0*%
M>\6K#BE0PP6ABI=2=XG.L:2>1)!:1V]4?+1)P.&\WJ9CF/8!U5"QM2@]"'W
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M^ZE:(!D-U/@R>0:W&&"HZB,K7<V )^W*Z*HZ7M2>A';#X8O*$JBIJI>85?=
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M9S:_<0=-05$= N'&8!QDDB4VL$RBEZ 3#32D.A[< <0V^]2^#Y;NG;65E=;
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MZX1=NVD:-IKO1^<=@'2  AJ TJ?E*<Q/%@M8+C96M[0;<XX:$G49AFT,6MV
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M\O(/%/"V4[5'!R#)2((JF>+.4F(3RLIYKKQPV6O=+6/HZ;6&+=RI"I>>!=W
M4?4!_ ).9Y/T_NQ\/ONQGDRTW0*).69M(LE'0:11N 4H-X2;G(25TMA*[2<>
M(6K8:I[:AU5?VF@ 6&4X[W)^$8MJWI?+FN^HJRTO-$E-M=7$2U'*)Y4@ ? @
MIBP;!]88J2HUI'N$JF''?=>&5F_Z: !;.V7UX7IJ6N*:6TZ)3Q)].^$#"=E+
M(BE(""'0J.K413]-6ROE9$-<(ARFH)8A]Y?Y;+$8:9V#8MH1YDOF13GP/4^.
M:!JTHTI3*NM,/'Z<KD9#NP-1T!5D^ZND 8"=Q'AQ=C'Q930H(!%QO-(3?CV!
ME<*FZ>1L-E^._^O6Z\<]YD?:1Y A>,)5:6D1R\2C&!R)/BN(/&N@U6;L]<)!
MH^%F/Z =1,W[P]NMX3TMG<4WOUO-@GZ$Y<AXP..&.>("^AY2>8^>#4B2F9!X
MV%AJ19VV-X]1U6@@6]EZ[JN.%_8L_K'T_RFEQ37>PN]]>,T'\,<Y>9Y7;TZE
MESJB5PA&E:[$D003!$DL&AI#!$/94])L[-6[),K:X"EA-@"R5**BTH/%Z)2$
ME+@O:.W2BA?\ZKT/( Y^]=Y'10VX=EU>T()0+B29B5A5^$K0:'O1J-N(G,64
M$S+YWZ_>_:'B@%?O?534,NIN7"AQ Y&J\N1E9+E0*H\<-B-,DN*V#+^K55S[
M=_'JO1<@#GCUWD<[0S]!K=,J?T>/8[XI"5[=96_N%R7C/#M'262E&4O('"5%
M-9$6SP6)7JJYF_^ZPTUX=)E&$7.H1F=5Q-NR9;J.;)*T8*WAQ/)5X:2VQ K(
M)=#)01L-S+K_OKY]]M/P, 4U +DN=RTCSRVS7@0BN&,81"OT76,)K)TUZ,1F
MK66=5ZDNU#5JW Y$Q+V6$CVKIP'(/7$]'9V. HTVX2PB#YD7YR%8DC-H_$X2
MWCRSA>O^8C#DY>LQ,.M1)3U.XWJ>>Z]-KP(_3;/R*W%= #.Y;EU0XSZL\Z(U
M[\D.X_QY[L^"<(AG*@F/NM0W*4^\4Y0$(UDP5.D8!VY6=^/AHDCQJY_X>1GS
MN"TYCXXG5X(>H<IH*:/6VU'Y'!/57@5?Y^'S87J:OAO;1]D/O!L=*_X&SL3W
M4_PL6"P_^\OBI&ZY8)H+QPK9J40M7!KB:. DR\BL28RBF*J Z&%ZFJ[^/P9$
M/8A_\'N&]3[X?#&/IQ@ _V4V2Z7+XE>8_QC'ZWUA$?[)*56ZB^&^4 J(#<*0
M+%QB$! -]LE3;8_UFNX < AB:LFZ 1NTX>JJ!<:6#4=S#DQRHK611,HR8),)
M3P2D3$'XY%F=Z&\'04V7_O=PE!VE@$;,T(W.7Z_Q]\;13[XN+]+EEB4O+5,V
M):)EZ728D27\H%)P(I,W*9<B\WW,T!/K-5W*?ZP9ZE/6#9BAF]>XG\)D_'TE
MK:O-D*(16F,8JFD.:%DSNGB&99)8F4JDP%E7)W_U<;HZ(4R_((154$<#X%IW
MNKB_;S;<(,G2<R=)*.*1.8OR528TFB"BTIK*7 5<C]/5"5SF!8*K1W4T *Y'
M&,G24)> 9"=+B0JRY#F7A'K#N$H>OUO5A3H04O8%0JH?);29N_=J-I_/_B@S
M/0ZYC+SQKWNX5=Q%2T^SKM] 6%ZWR+Y"!C!)DT =(BA*>UIGT15F$?^://XL
M,8S6*[U$/43/\:]O-S_UNCTN.OS )4\D&8[,48VGJA24Z/+"0Q4S >H4&.X@
M:-@WMAZP</]=[7C!M]F7^'I?'CX[XMYG]&HO*DR'> HIB87D@)%$@RPE 0R/
M$I>(L]PSX32/JM:HA!I6XSK5X3>_W$R!^I0_S*;?O\'\K*QYI]NVB!*\M4 H
M"(<GGU<D"*4(58ZS+*B,LD[7X7TI;=/.[(&>W9F[%535N@'JHZ+@D4_KU2A5
MK1EX F""^Y22MX1%JXC$R(9XAHKW,62I3 R>UJGQJ>?4O%_55%\G72$KN%N2
M)\&6X>82R7&1E^'FE)MLN=&Z3A;W \0T:63VP<!#SLPQ F\@=+[-PBJ)&$04
M,D$D)I<G%"=4"0(%25$)ZY5TH.OT/+]/R_"(.4J]C\)E;UDWAY8;,X.15"V,
MER1I8XAD,1"K:20JIJ2T<U:P.I?#NRAJ"3G[:_I1X!PH]J$?J(K?Q2DSFPQQ
MSUS(T0JB$I1+(;#HUV7\JZ46% A@OMM[^.W/;4GOARIJUH_4&K 7Q=]>;OWM
M;9%*EC0D:W2I$^=$9H7&5%%%F#=1)$IM9G6:^#Y$S;#9I7V?,$?+NT',;':0
MU59PI5$.%AF0X 2Q+AO"K:/42244?1[4M'"^'*_G)X!S@-";@(Z?+C:I9!N#
M*;+0N9A)H;(E,K%,7,Z4J*PR\&RDLW6ZZ-ZGI2W('*+A>Z Y2MP-  :)+X;W
M_?3?QM/T^?V_?9PMMYP$W#2@K2->E:Q^+R*&A!Q(M,8+"H$+56E QDZ:ACVK
M*@"H)_$W *0/XRE\RJ]QX?'RG8_E ?1R990U9V",HP1<*.6/HA1"2D6<TQQ$
MH#%6@M$NBH9M(=.[P].'W!O%SX=R\SG?;#/PTG)I+4FT#([U:%AMF=L9F \J
M!7"QTOOK4Y0-?*KUHO\.H#I8&4.'W>^GT]D/O[Q8?!AG^!K',(VP*-R,I]_?
M74S3QMYRJH+/3!%E)![< OU&A_N/A$259(%9=[?X;T<XWFV]]E!SN()G=:4]
M-( V>8CKY.C+SWZ^G.('OW__X?.&&6=E248T1#B''H!C'IG)0*CEPELJ!7ZG
M$W2>6FE@_Z<::'J5< .'V>U#_L-5H:PVP -32+=>#8,MB64J8:Q LV3.6)Z,
MJ7*&[2!HV,[==5\7#I-Z ^#Y/)]%@+1XAP)[OUA<E-&>MQ_N1YE;$(F6";%J
M=9F*VT$E22S7@29N.![O=4*S)VEKZ?KY0 C<KU#O4Q\-(.P+G*_CSL5=/FBP
M%LIM!8=$I+*4>(9  *&LB5%RK^K<%>VBJ*7+Z7[0U(OL&\#0;=ELJUB_^"5\
M79;^M)]A'HNNOI>V-P$ 3^C""MITR(:XC"<X<XPZ88O0ZN7 =:.QI3N!?G!6
M23]#^^*WV5JS<I.YSWZ<UK=I(Y T&)0242 Q *96$&=6^?Q4VFQ-27OIY)5W
M7[,E?^HX&-44=M/6ZVW.$$LVWHT-8BP$%E1IY&T#D;D4XVOIB39,E'M]SF*=
MOD![D3GLK)3GM6'':JDY"!8W8$0E2LOE3(R,)1./)N)DUL@0<U9'@X[ELZ0J
M(BW#%)4^'YCVEG=SB'D'<'(VNY@N1R)0FY(%$E>)VV4>5<BE[WQ4 3A+DIDZ
M_7YV$#1,S>CS8><PR;?E.5T?W:LW[!+70AIQ[S3+$75M2]N0K!FQ>* 3 8H&
MB,&ICG,K.RPV3!GH,_E*QXNW,;C,MV$K?G4VOCB[<>YFJE76HCQ4)]P$3"3B
MRT[(G"8FP #N@D- LWO)3M!Q+Q4Z/8GZQ0#H9#J]\),OD-:#\$8FEDDI3!,A
MO<=3F6$H4?(I%$O,I("[Q'5[33F4@FY7F/3O#U_':*(MN+V>_8"I+_\].Y^,
MRXWM;^/I^.SB[/=I"2'FXXBA[&N_.'WE)^6G(Z,=,,B,.%6:B<2 )[EVE#!N
M7'DJ1ULM#P#=OG1T@]Z+N#Y_;JVT"<"/L^DUMS<CV/?3."^-;=[ ^K\C*TQD
M(0MBL@24,;7$)RT(RUZ[I#@X*HY 8&="ND'P1=RY/[M>6B^+?7>QO"A&?[7I
MMN\0O93(/OK)O9;+=N>A<F4_9=H(80F'TML,*!Z.6E-B0M0I&Y/01:L6=?=?
M.GOS+>JZ8/SF:]7G^7@:Q^?%02C9'F@'/N5W2(>?_ ?X^2C%P)(O Z:81'E8
M'TEPTA%F9:*,2I9SK3SSXR@?_L7Z2'0]5,KP;*ILX%YL#W[?3S^B5?CV!TQ^
MP&^SZ?)T,8HL19^"(C&LAG($3[QFG# :-0C-E-/URFH.)GOXA_'A0'ND$E\:
M8LN6_/;';"2C\#J$0!)7DL@D=1FPP @/(6MCE?=0IRK]$&J'?U ?$I^'J.Q%
MPA)Q5J;2!ZH\>*(R6"*U=RC6LOE\5$88#I#K>$*'T3O\(_W@T-Q;;4,'US=9
MQ AM<E'2R7^?)A1D>8BY3DL8>:5$I#:3'#!8E"EE8L%3XI2E >EBTNBGPIK]
MEAS^W;TG/%64=&]-+?MZ/?U]ZM=SK""]V;"VN0X]F:;5KVXR/5_/%LM%F;\=
M+2V-7W&[L)+C":+DYT$B!@+8!-EP5J\QXA&$#_^2W[.Y>TY%[H];M\;M%+Z7
M;*E^+=]#VW#S$FTD%2!Y((X%022:<.)"#"A?,%(+F7F*>YN]W>L-_\1?R^;U
M).-!@?.08S!*,L3LO"54ESFG6O@RYS22Z(,+VJE,59TLD;WSN:L^^E?TO?82
M<9MMGE_/SL[&RV)7_32]QM@:#W] U_&P9JZ/?%H/5\)=:>WI&OAZN3)PY]9Z
M#V"*Q3*P,)4QPF5^DTZ*>.$5*2V0I+316%O'6]B+S*,'9G19[+K#:#+*<\<]
M 2H#D8;A_DBQ=!AEG"OC<O)U2KCWHW/8"^%Z.+LW7Z.>]MI\"-MM,?KH%[O'
MIU>U?L_23W8_E$8=J2R]3"+DTIBI%'2Z+(FF7EBN(V,17KXU_#!;+&XML2YI
MU0ITBJ!)R<\BDAI*;/*<B!" &<5 RUH/# _1\Y*LVSZXN>^9':V-H6^]OA3-
M3+83DE]=7C4Z0[-.M=.1>%Z:($J5,"8I_;HUTD^-0%/=+5MIUPI#=^HZ7G6S
MON78(A@V?1=D>5ZP)A,:;"9XZG/B#)4$MPH*1MA LSH8#D,VN>E1>T_AX0!1
M#HV(3SF/(Z 9Q8^:S<MO7FZ;I(:4M6%H*#DODD&[&9('8L6J%,]:FSJ.L-ZU
M1&-X.$1[L]Y%V08@MH0[E[CS 1V#TFY9Z$Q"1,<]1I&$!Q$#='L(N?FI XYA
MKJ?V P0VH*87\R5Z4>5^<HY26UZ6'LLK<V@CNO4^:Y)D1BE$KH@K<,TI<*&M
M4EIT\C-Q@1L^)O[MKG^YBX*ANS/VYC3T(N*!(?(%SC<SHD^^SP'6N:^W6=KN
M'DJM*STGP'IDBE%'G BI3*BST>.)RF6G&2"=<-.9K&$.F'XT/ZNMAJ$/&K3"
M9[ \A8O%U7F)&^[]-&Z[NP'PLKF(,HP1Z1*RX:E%KFQ4S'!GH%LOO2<6&@XD
ME?0ZJR3DH0%S,IG ]U.87OXK^,GR]",L_YC-__8%]84TG9;7W/'RXJKU;73:
M2L8<25YX]+F $F]E&4P52H,EIN7=IZI=([KW67:8X^N9P%1/ 4.?<Q[/^W4X
M*)P-IJ3898J>>M*6!.<R4310S[*,5G=J,]3M'-LN.VRB8\].SV'"; $!6YOH
MLK!<)")]:1_(8T3@4HT^/)5.1.Z3[-1@L3L&!C^(#E/97:4?(+^!U;XI'=QV
M2P]H_:C&PQ#!C8A'$QE*/P]KF;1* %7=NHQW4ORMI0=6_2&*F_4AQ:'5[W_>
M(%PY*4QYC.0L./2%@B".YUCJ1EE62M)(.R6W=%/_S:4']!KZ4/_!4FP@77WK
MO:P2_7[ 9':^FC4VGQ?!K)VHZ>H=Z=OL,\S+K/=WL_EJ!/SBQBVR](Y+)71)
M]T&7JMSRV=)V%H*A(3%C5:6WR5[('S:9O4?W8SBEOFPDW[@&%38+:BR&!(93
M%#N5)/#DRP#?8#VE2L9:W5M[('_8)\<!8-<?\ _$0 / _S".,+T1]I94RL7F
M-)+@;); B1$&K8AVFH2@\:_<*K0PZ."J.LW2'R'JQ8+T4(C<&PS2C[[^__:^
MK;FM(U?W_?P75/7]\G*J',>9[5-.G+(SLVL_J?J"=EB120\I>>+]ZP^:HB1*
MIB1>5G,UF;S8$FFOU0 ^H(%N7#J 7N7(^[+&O*4&9UZLT:H 9F.J"Z3!%_*#
MA-<!)>$E/CZY' AT&Y<S;FE1@]W]<*9W@)RUY=<DIE]FTW#_R6_TTR(L^R?=
M*D8HR23%)43.2>%L*.11*ZSC>)PH#NG+-MWZ=USHN,9M &C,CB>GT0_4_^N7
MU[/+RYN+ :)A10*Y&3%@<)"$HF"0: "R]H9T$SU+7H3O9H0^=7*^\?GC(J2I
M/&?#,K<#,_6=^7YWUTQ)8# N*=KSQ7)(I5+@%9)6"7)1&<HL;)OJA*?7-&Z9
M8H.M;B#VCVUHWG_!J@333^]J-ZS%!YSB?\+ELGUR-C)'9(X</D&V.9(J.!7J
M+:22S# 5HBU;&9NGW]%9'NJ>(IP-S\\>[$LE@.SP36+6FS^_U,B@GB$Z)DU5
ME-KRHD@!+F1--EBX;*N1#&V&?6Q<3F<I28?A9SC&CVU4?IY<XN)J-L7W\7+R
M:2F/"\>5$85LK=,U_<[4-MHA&S 8M%.\?KW=I?^&AW=V23N &3F4@]T@X)XQ
MWWX*D_F_PN4UWE>"7&1A3,PR T^T[RJ1!82"'%)AA=RM:$+:+K5]RQ=V=IX^
M)%(&Y/38Z%D-BKS'_GT/X_?E8R""+P(RS#$FD(83OY(F<UCOLI+.C)3!2O_X
M1O"IFH@7W]79*<T F!F8OQTX*RN*_G$=*$Z\0ERL%Z+=M'?P2;M0? )" (5W
MQI("!&L@*LM3B5:T:@3X\MHZ"XZ&<6,&%LG8-NE5_EK;S/QZTW3KHD2)KC #
MA:D$*B@'KM ?7O""2AJ;S';E%P^?.V[CE1:VY@"^C2WRQ[<A;Z>3JTFX7'W\
M$^*%-T;59N7D@_G:E](S\-9RT#XD)X.TKFS7U/O%5XW;6:4%,(;E;@=[T*^K
M)-_[;?6FE_4J!VNE 8O-/7EYD-DG)%.8**A33!CP)A<RA4%KYIWDOLULL$-6
M/>Z@ED;[UM'$V"5D?[S&#?UW54'M:[3 #+F$2C&B*-1#]Y!0"2Z(K*W2+P=
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M[.P'%*^^S->)4,P8[YD!DQ0ANQ1.<5T1M$<$1?R1WG.[(R8>OJ&+V]I6D#B
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M@UKOND93M6J)4D94(QN53H[I#CX%CT[^<?Q3I<+.5)B/1&I9J 6W(F*YD>F
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M5WYE*F;=6SX0*3M/PRJ@<;@1-(#KHR5R_#<W!*^M@J7QHX-E^_A@;[@!+ "
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MJ&^^HO[Q4,]))%+ %4)T@:,R0!ZZ0[->:A=I!(<FQ:0!OH<R9S G8'4)-&7
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M\91LWS(D CK!B7ZC=V$XI.S<5<JPB);F<[MVO%4Q-7/9A[' T8\S%R2=/XH
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M;V-O>'!R;VUO=&EO;BYH=&U02P$"% ,4    "  'B@E3WF'J<PL[   !DP$
M'@              @ $U"@  97@T-2UF;W)M;V9P<F5X9G5N9&5D=V%R<F$N
M:'1M4$L! A0#%     @ !XH)4PM0FF3]PP$ FD@2 !$              ( !
M?$4  &5X9'@M,C R,3 V,S N:'1M4$L! A0#%     @ !XH)4]SI1-<,#P
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M,#(Q,#8S,%]L86(N>&UL4$L! A0#%     @ !XH)4Z4L=R=<=0  '6H% !4
M             ( !@T,# &5X9'@M,C R,3 V,S!?<')E+GAM;%!+ 0(4 Q0
M   (  >*"5,[D1(+D0@  "(O   0              "  1*Y P!X9VXS,3$M
M-C,P,C$N:'1M4$L! A0#%     @ !XH)4W.HY.I]"   ]2X  !
M     ( !T<$# 'AG;C,Q,BTV,S R,2YH=&U02P$"% ,4    "  'B@E39A,G
M\D8&  !#)0  $               @ %\R@, >&=N,S(Q+38S,#(Q+FAT;5!+
4!08     "P + -P"  #PT ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
